#version: 0.2
i n
t i
r e
t h
a n
e n
e r
e d</w>
o n
o f</w>
a t
r o
i n</w>
th e</w>
i t
a ti
a r
an d</w>
o n</w>
s i
a l
s t
a l</w>
o r
i c
a s
d i
e c
en t
a c
l o
in g</w>
d e
o r</w>
a s</w>
u r
t o</w>
e r</w>
w it
u l
wit h</w>
s e
o m
a m
o l
u c
e s
re s
o c
l y</w>
in e</w>
l e
en t</w>
p h
p ro
o u
p ati
c on
r i
w as</w>
d uc
ati on</w>
T h
er e</w>
v e</w>
i d
e s</w>
at ed</w>
a d
o s
v e
s .</w>
h e
p er
f f
a t</w>
i s</w>
a n</w>
i c</w>
m e
o t
a g
a p
i l
w ere</w>
ent s</w>
u s
c h
c e
i m
duc ed</w>
ti on</w>
i s
a b
t re
h y
t er
c om
t r
f or</w>
Th e</w>
p a
s u
n e
in e
o x
ec t
b y</w>
u n
pati ents</w>
e x
in duced</w>
b e
p l
re n
v er
e ff
ati on
in c
w e
e n</w>
r at
h i
a r</w>
it y</w>
m ent</w>
t er</w>
s ,</w>
p res
re as
a f
re d</w>
c ar
i f
m in
th at</w>
u t
h a
n o
c e</w>
s y
ti on
o p
g n
l i
t e
0 .
u d
l e</w>
r a
- induced</w>
m a
an t
ti c</w>
af ter</w>
tre at
m o
y .</w>
p re
v i
w h
g /
i st
at e</w>
ro u
p t
e m
th er
p or
con t
ti ve</w>
i z
u m
si on</w>
q u
ic al</w>
c l
) .</w>
e p
si gn
as e</w>
an t</w>
d o
ul ar</w>
c o
r u
m on
p o
th e
d a
b e</w>
e t
h o
u m</w>
on e</w>
g h
ur e</w>
ou s</w>
p ar
in f
d .</w>
os e</w>
re ce
i r
inc reas
no t</w>
if ic
car di
ther ap
s er
m g/
ect s</w>
an ti
treat ment</w>
g rou
res p
si s</w>
an g
sign ific
th er</w>
) ,</w>
or m
y ,</w>
e l
v ed</w>
g en
ent r
in g
i a</w>
b u
s e</w>
ar y</w>
lo w
m ic
d ru
u re
min ist
y l
hy per
ti v
c or
m or
as s
ad minist
e v
oc i
c a
ro m</w>
en ce</w>
I n</w>
t en
lo g
si on
d ur
f rom</w>
s p
o b
al ly</w>
e .</w>
re l
ti c
u ro
ass oci
lo p
u s</w>
S :</w>
pa th
eff ec
di s
th is</w>
t a
st ud
e ar
in d
eff ects</w>
re por
ar e</w>
es e</w>
tr a
b lo
us e</w>
de ve
p ot
tre ated</w>
ha d</w>
i d</w>
oc a
t ed</w>
ox ic
d ose</w>
O N
ve l
a z
t s</w>
d er
s ho
i o
deve lop
e st
ro m
th an</w>
associ ated</w>
e ,</w>
mg/ k
i th
se s</w>
su b
ti m
c ur
ac tiv
dur ing</w>
+ /
0. 0
f ol
f i
ou n
ation s</w>
cont ro
bu t</w>
m y
s c
o l</w>
resp on
ut e</w>
in j
id e</w>
ne uro
or y</w>
c y
o log
un c
l l
pot en
w ith
r an
administ r
rece i
ma y</w>
d ec
us ed</w>
v en
res ul
effec t</w>
pati ent
am ine</w>
i ti
rat s</w>
l l</w>
m ent
ren al</w>
stud y</w>
g h</w>
pati ent</w>
( 1
in ed</w>
p os
W e</w>
b o
o d</w>
ff e
en d
an c
in ter
i a
ati ve</w>
d ,</w>
be en</w>
tr an
v er</w>
+/ -</w>
therap y</w>
da y
t oxic
d y
ar di
grou p
n orm
si ve</w>
ag e</w>
es s</w>
ac t
signific ant
hi b
pres s
r on
c oca
d e</w>
fol low
es t</w>
we e
ha ve</w>
f unc
es .</w>
increas ed</w>
w he
com p
al l</w>
ation .</w>
be t
a il
al u
p i
f l
dec reas
sy n
significant ly</w>
0 0</w>
ot h</w>
ch ang
se iz
- 1
c entr
g g
u b
wh o</w>
cl in
me th
t w
l on
y ear
g i
mic ro
dru g
le vel
ac ute</w>
ic h</w>
en c
an ce</w>
administr ation</w>
n o</w>
wh ich</w>
v as
in tra
in v
at e
rece pt
ec h
su gg
am in
u di
( 2
ri s
in hib
or s</w>
grou p</w>
ag on
he m
ou t</w>
he ar
s t</w>
ffe ren
h as</w>
t ri
ab le</w>
re e</w>
f ail
id ence</w>
sho w
hi gh
di se
g l
signific ant</w>
gh t</w>
ob ser
s o</w>
p e
st udi
ve n</w>
cardi a
th ese</w>
S I
g r
d ro
g ra
dru g</w>
we en</w>
ec tion</w>
blo od</w>
develop ed</w>
bet ween</w>
re qu
ou r</w>
m pt
c ase</w>
oc ardi
an al
ul d</w>
v entr
di fferen
b oth</w>
ec tive</w>
pro te
Th is</w>
activ ity</w>
st r
me di
tran s
pa red</w>
al so</w>
s en
ine -induced</w>
sy st
wee k
de p
ventr ic
ine .</w>
f orm
f or
al l
si b
oc cur
1 .
b r
tion s</w>
i al</w>
re at
tw o</w>
ect ed</w>
rel ated</w>
o ther</w>
ure s</w>
c as
ine ,</w>
it s</w>
rat e</w>
clin ical</w>
i t</w>
m a</w>
ph en
de r</w>
d ic
com pared</w>
s ec
re c
tion .</w>
in u
ti al</w>
iz ed</w>
m an
lon g
m il
5 -
C L
mpt om
e th
es ,</w>
level s</w>
er g
tr ac
f ir
al s</w>
pl ic
n on
cardia c</w>
M E
mor e</w>
ventric ular</w>
cont inu
a st
i de
m g</w>
g e
mg/k g
t o
ol d</w>
v ing</w>
coca ine</w>
ver ,</w>
al o
p ri
SI ON
% )</w>
a in
u sion</w>
te st
lo w</w>
c lo
duc tion</w>
con centr
y p
hyper ten
R E
hear t</w>
ar i
ar ter
per i
S U
pl as
0 0
he pati
mo de
ev alu
c al
er al</w>
ec ti
d om
s ur
c ular</w>
increas e</w>
do ses</w>
si a</w>
resul ts</w>
contro l</w>
ris k</w>
C ON
se s
dep end
ep i
ou s
di d</w>
CL U
CON CLU
ti s</w>
CONCLU SION
sy mptom
m i
e -
si st
ne ph
Th ese</w>
b l
ver se</w>
se v
mon th
th i
A C
n it
re g
ch ol
an im
day s</w>
rat s.</w>
i .
y c
he mo
inc l
ch ron
com b
es the
show ed</w>
m al
recei ved</w>
treat ment
le p
ech an
blo c
do se
L T
a x
inhib it
ti g
toxic ity</w>
l ess</w>
si de</w>
my ocardi
m at
le v
u e</w>
l at
dy s
c i
il e</w>
norm al</w>
I n
su p
da y</w>
m echan
o ph
ation ,</w>
T H
it y.</w>
hy poten
follow ing</w>
path y</w>
press ure</w>
s ti
th rom
5 0</w>
ant agon
obser ved</w>
sev ere</w>
e i
2 .
func tion</w>
respon se</w>
is o
u se
T I
hi st
ac tion</w>
li ver</w>
mg/k g</w>
ven ous</w>
b as
an e
oun d</w>
ul ation</w>
o di
de ter
ar k
hy th
e d.</w>
v al
pa in</w>
incl ud
r hyth
oc y
v ul
we ver,</w>
SU LT
e d
at ing</w>
RE SULT
me as
or al</w>
de f
pl ac
an d
in al</w>
repor ted</w>
t ac
RESULT S:</w>
gra ph
ol y
po st
O D
chang es</w>
1 0</w>
il ity</w>
repor t</w>
tion ,</w>
s uc
chron ic</w>
f e
sib le</w>
recept or</w>
ri b
whe n</w>
se l
il l
us ing</w>
os t</w>
on ly</w>
d op
ind ic
k e</w>
ser um</w>
f act
m us
es tig
ic in</w>
ine -
e red</w>
t ro
comp le
' s</w>
l im
er s</w>
me an</w>
inv estig
m un
per id
myocardi al</w>
in .</w>
ME TH
pres sion</w>
l it
y m
olog ical</w>
ati c</w>
vas cular</w>
pres ent</w>
erg ic</w>
fail ure</w>
neph ro
in ,</w>
ar c
as ses
w e</w>
ous ly</w>
ad verse</w>
con vul
h or
hy dro
b ra
os ph
1 0
s ed</w>
5 %</w>
with out</w>
ce ll
t h</w>
th ree</w>
un der
bloc k
METH OD
decreas ed</w>
therap y.</w>
fi b
per io
- old</w>
y -
pro t
st er
c an</w>
th ou
in -
mechan is
p it
me t
fir st</w>
anal y
inc idence</w>
for e</w>
at ri
2 -
f requ
epi lep
E C
g lo
resp ecti
ex pos
ia .</w>
ph osph
v ari
gi ven</w>
cas es</w>
re duced</w>
w om
ab ol
tim e</w>
( P
i l</w>
a .</w>
inj ection</w>
b i
ver y</w>
d at
sugg est</w>
ad e</w>
u al</w>
sion .</w>
ar rhyth
recei ving</w>
d rom
i r</w>
m ost</w>
tion al</w>
si s.</w>
d ue</w>
u p
c at
3 .
patient s.</w>
administ ered</w>
s tim
al ph
de sc
si mil
hi gh</w>
ect ro
inf l
sen si
n er
t ing</w>
plas ma</w>
com plic
dise ase</w>
p at
in iti
ar g
im mun
comb in
as t</w>
re f
seiz ures</w>
plac e
en z
syn drom
f ound</w>
s y</w>
b le
im pro
ha vi
p r
em ia</w>
T o</w>
fl u
th ose</w>
pre vi
sion s</w>
respecti vel
hy po
ocy t
ac et
sec on
ia ,</w>
( A
an esthe
s )</w>
sho uld</w>
m it
t ot
H o
sp ec
f ind
o re
METHOD S:</w>
m ac
2 0</w>
sugg est
ent ed</w>
thou gh</w>
c ap
m er
s al
ma in
sy ch
( C
ca used</w>
sub j
h alo
year -old</w>
x im
il d
high er</w>
cardi o
we ll</w>
contro l
syst em
d ox
be havi
eff ect
com m
inf usion</w>
enc y</w>
ing s</w>
P A
intra venous</w>
duc e</w>
se qu
depend ent</w>
a ff
ei ther</w>
ent ly</w>
ad ren
per im
ce ll</w>
dise as
occur red</w>
t yp
c anc
sion ,</w>
gen er
mic e</w>
week s</w>
on ary</w>
a y
syndrom e</w>
symptom s</w>
studi es</w>
o gen
it e</w>
m ark
or ub
3 0</w>
ac id</w>
d am
simil ar</w>
the ir</w>
am p
p sych
gr am
de mon
be fore</w>
ve l</w>
re co
ou t
el ectro
ad di
d s</w>
( P</w>
h e</w>
d ra
re ac
group s</w>
pro g
si de
p er</w>
Ho wever,</w>
ran dom
norm al
no w
ce re
develop ment</w>
CONCLUSION S:</w>
bra in</w>
di ag
s om
com par
k g
C A
f t</w>
ve ly</w>
po si
en ti
e m</w>
r h
es s
in -induced</w>
at al</w>
ec t</w>
k now
A l
ne ur
lo s
drug s</w>
ic i
a ,</w>
vi e
V E
a v
k e
m ul
1 9
3 -
pro duced</w>
o ver</w>
k ine
dra w
4 -
cor onary</w>
dis continu
re ver
t ol
k ing</w>
dat a</w>
met abol
d ed</w>
en ce
m s</w>
5 0
ol e</w>
cur ren
ter m</w>
p ine</w>
ex perim
U N
m ia</w>
c hem
treatment .</w>
per form
mor ph
c ul
decreas e</w>
st at
combin ation</w>
ph y
inv ol
tot al</w>
c hemo
ure .</w>
o ver
month s</w>
in to</w>
am ide</w>
ch ild
R O
ox y
n ec
be ta
dis or
with in</w>
it y,</w>
t ox
se ver
m in</w>
ar ac
r ang
c le
low er</w>
ab ility</w>
e d,</w>
b ut
re t
um b
ti s
ro le</w>
dox orub
pre v
b ec
anim als</w>
with draw
ac h</w>
tol er
s ul
hypoten sion</w>
di st
L -
we i
suc h</w>
is t</w>
y o
4 .
i ly</w>
wh ile</w>
cardi a</w>
0.0 0
trans pl
non -
am ph
g reat
por t
r ine</w>
v alu
v al</w>
id ine</w>
ot or</w>
r at</w>
e lev
on e
( 3
u red</w>
mode l</w>
ca use</w>
1 2</w>
lo c
I t</w>
ol ic</w>
l or
ic ac
m is
ox id
mg/ m
e u
me dic
Th ere</w>
% ,</w>
br al</w>
u res
pi lo
s on
ic ally</w>
ho ur
find ings</w>
re gi
ra di
ane ous</w>
effec tive</w>
ex c
I I
v id
ar mac
f our</w>
c le</w>
th ere</w>
) -
A f
et y</w>
i p
le ft</w>
tac hy
z ed</w>
throm bo
h um
i es</w>
o per
M A
u r</w>
az ep
op en
sur g
at es</w>
uc le
t ub
dose -
o id
al e</w>
cy clo
1 -
e re
v ol
do g
t um
olog ic</w>
re as</w>
de s</w>
cat al
se t</w>
con cl
an y</w>
t e</w>
re ve
dy n
al ed</w>
ot oxic
i red</w>
5 .
eff icac
patient s,</w>
ur al</w>
d ing</w>
ent al</w>
pro long
- term</w>
a y</w>
u p</w>
d os
inf arc
re vie
m ents</w>
( S
K G
ant s</w>
halo perid
( 0.
le vel</w>
alph a
T w
concentr ations</w>
anc ed</w>
hepati c</w>
m ic</w>
1 5</w>
s af
ex peri
mode l
arter ial</w>
differen t</w>
is h
- dose</w>
v it
con di
B AC
s ing
a use</w>
RO UN
KG ROUN
BAC KGROUN
2 4</w>
da ily</w>
ap pro
meth yl
co uld</w>
c in
m ol
k in
A n
m ine</w>
prog res
pilo car
inj ur
at ory</w>
li thi
de t
arac ter
e tic</w>
y l</w>
poten tial</w>
s odi
ag ain
great er</w>
pe a
inj ec
micro gram
ing .</w>
p ac
an e</w>
O B
si s,</w>
re duction</w>
J EC
A N
ph eral</w>
d ul
Af ter</w>
im pa
ex am
pro p
bas el
again st</w>
c ol
u l</w>
in ary</w>
g en</w>
ar b
en s
0.0 5
hyperten sion</w>
ch aracter
stim ul
s a
ing ,</w>
l ab
. )</w>
l ine</w>
includ ing</w>
car b
f em
7 .
TI VE
bo d
OB JEC
o id</w>
al ter
l in
di ab
oca ine</w>
amph et
studi ed</w>
g o
OBJEC TIVE
at ten
is chem
glo mer
ad y
neur on
co ur
w ar
1 )</w>
p ul
6 -
hepati tis</w>
lo l</w>
dop amine</w>
ph armac
ur ther</w>
phy si
i ous</w>
2 0
mg/kg )</w>
6 .
( p</w>
ev idence</w>
on g</w>
i tion</w>
on ic</w>
am e</w>
o graph
p p
nit ro
reve aled</w>
pos sible</w>
n umb
BACKGROUN D
str uc
ro p
r ac
on set</w>
e ach</w>
ve ment</w>
year s</w>
prote in</w>
al ,</w>
meas ured</w>
ate ly</w>
am e
os pit
cell s</w>
beta -
prote in
pri m
en h
peri pheral</w>
centr al</w>
infl am
bod y</w>
l id
us ,</w>
N T
mon it
O n
br ady
1 ).</w>
follow ed</w>
dur ation</w>
yc in</w>
th al
iti es</w>
comm on</w>
S E
BACKGROUND :</w>
mal e</w>
th rou
l if
im port
ent an
A d
ac ti
p y
vi r
ch lor
catal ep
it ed</w>
v ac
tic s</w>
P ati
n a
o f
ll ed</w>
on t
perform ed</w>
G rou
ap p
seiz ure</w>
eu tic</w>
n ic
ad en
4 0</w>
antagon ist
A ll</w>
id enti
sodi um</w>
ri c</w>
( n</w>
poten ti
tic al</w>
s m
previ ously</w>
posi tive</w>
ad ul
c um
CONCLUSION :</w>
f low</w>
a in</w>
re ,</w>
po in
whe ther</w>
A D
Al though</w>
f ul
efficac y</w>
ge si
de x
evalu ated</w>
o d
ine ph
concentr ation</w>
chol est
wee k</w>
fl ur
t ly</w>
is m</w>
ta ined</w>
therap eutic</w>
1 ,</w>
N A</w>
y e
ma j
s ol
di vid
mg/kg ,</w>
mus cle</w>
he mor
b il
cere bral</w>
a d</w>
6 0</w>
he pat
re n</w>
l y
p oly
canc er</w>
curren t</w>
str ated</w>
c es</w>
pro po
ur ia</w>
hemor rh
enz ym
desc ri
A B
mic e.</w>
c is
stat us</w>
le u
secon d
n i
know n</w>
cardi om
cal ci
- treated</w>
ar ly</w>
an s</w>
pl e</w>
par tic
ce p
om a</w>
2 5</w>
perio d</w>
expos ure</w>
t .</w>
re duc
re cor
( N
ex pression</w>
an a
tiv ity</w>
st res
throm b
t est</w>
ear ly</w>
i. p
f en
ati n</w>
an ce
som e</w>
h ospit
ish ed</w>
child ren</w>
2 ,</w>
tox ic</w>
path y.</w>
s /
deter mine</w>
9 5%</w>
dyn am
typ e</w>
sing le</w>
r am
syst em</w>
id ne
Pati ents</w>
al .</w>
te m
k ed</w>
c oun
f ac
d ou
anti -
r ati
8 .
s hor
deter min
( D
basel ine</w>
s us
o st
S )</w>
( H
respon ses</w>
a ined</w>
demon strated</w>
az ol
hyper al
N o</w>
er .</w>
diag no
withdraw al</w>
enc ed</w>
los s</w>
con sist
N e
leu k
ac id
f urther</w>
1 00</w>
c ent
in ine</w>
numb er</w>
long -term</w>
whe reas</w>
al y
C h
z ap
oc amp
analy sis</w>
pri or</w>
ab normal
hi pp
en e
u tion</w>
mon ary</w>
l y,</w>
lit er
recept ors</w>
k idne
fi ed</w>
subj ects</w>
b o</w>
disor der
cardio vascular</w>
gl ut
m g
psych o
c ess
asses sed</w>
( 4
a th
si x</w>
i. v
c it
c er
P )</w>
seiz ures
I I</w>
re sist
P ro
pro duc
place bo</w>
hipp ocamp
de l
as si
di rec
chang e</w>
ation s.</w>
transpl ant
fi ve</w>
diseas e.</w>
bec ause</w>
convul s
al ity</w>
A c
system ic</w>
el l
includ ed</w>
A )</w>
ur inary</w>
nic ot
fact ors</w>
ep iso
ence ph
ac tive</w>
st ar
OBJECTIVE :</w>
r ap
oc h
c reat
in trac
i v
s hi
s :</w>
on e.</w>
in ten
( M
re le
mul ti
respectivel y.</w>
medi an</w>
pro b
A T
ad v
or ph
gl yc
exam ined</w>
0 %</w>
differen ces</w>
se en</w>
S T
surg er
sel ective</w>
rib ed</w>
olog y</w>
t ,</w>
stud y.</w>
ro s
he par
sur vi
e de
st ro
am ong</w>
R e
pro st
hour s</w>
hist ory</w>
hum an</w>
st ri
increas es</w>
mechanis m</w>
investig ated</w>
ti es</w>
prote ren
indic ate</w>
A M
tis su
in duc
f er
app ear
sub st
doxorub icin</w>
p ir
inf u
C om
u lo
ang io
ud e</w>
o -
min ut
bl ad
arter y</w>
w or
5 ,</w>
me n</w>
f entan
0 -
ge sia</w>
Grou p</w>
li ke</w>
- 1</w>
sensi tivity</w>
a u
sp inal</w>
cardiom yo
he ad
is ol
a w
oper ative</w>
prolong ed</w>
m m
he al
2 )</w>
resul ted</w>
sp ont
lithi um</w>
hyperten sive</w>
r it
ol -induced</w>
c ir
m en
experim ental</w>
su s</w>
ne w</w>
f ul</w>
atten u
ag e
A I
ren ce</w>
pres ented</w>
if ic</w>
- bl
otoxic ity</w>
chemo therapy</w>
l as
iz ation</w>
e l</w>
dys kine
ma xim
wom en</w>
liter at
medi ated</w>
gl uc
hydro x
f ol</w>
p le
ner v
f ic
8 -
second ary</w>
am ide
pres ent
re s</w>
pro f
contro lled</w>
e ti
E ff
% ),</w>
wei ght</w>
j u
mechanis ms</w>
sc op
ag ent</w>
maj or</w>
de press
ab s
ver sus</w>
cl on
G AB
iti s</w>
ev ents</w>
ag ent
the li
throu gh</w>
import ant</w>
calci um</w>
rat es</w>
spec ific</w>
n ucle
a ut
I C
dou ble
re st
bi op
in duction</w>
ro sis</w>
ate d.</w>
A t</w>
% ).</w>
dro me
cap sa
arrhyth mi
i ed</w>
dis c
ti co
pres su
le s</w>
am eth
frequ ency</w>
car cin
atri c</w>
ra z
syn drome
inhib ition</w>
m otor</w>
lo ro
associ ation</w>
en do
Tw o</w>
iso proteren
group s.</w>
v is
prim ary</w>
en g
dys function</w>
toxic ity.</w>
P re
ox ide</w>
N -
head ac
neuro pathy</w>
D E
s ame</w>
ster oid
p op
hem at
a k
1 4
inflam mat
cy t
pa m</w>
fem ale</w>
di ff
n ot
( E
tachy cardia</w>
ic e</w>
un der</w>
wom an</w>
ar d</w>
elev ated</w>
H B
a si
vac a
n ess</w>
er ,</w>
ati s
ab l
st and
o ro
infl u
m .</w>
alpha -
cyclo phosph
ab ly</w>
arb it
1 4</w>
ti s.</w>
pl us</w>
inflammat ory</w>
lid ocaine</w>
k al
tran si
pi vaca
comple te</w>
fib ri
con trac
con side
t al</w>
con f
res ol
experi enced</w>
ph ase</w>
or s.</w>
g u
P O
sup por
pul monary</w>
pre treatment</w>
differen ce</w>
ain ing</w>
l arg
m l
convuls ant</w>
ti l
impa ir
glo b
b ol
al one</w>
lit ax
i gn
o m</w>
k et
ag ents</w>
on i
neuro log
ta king</w>
s ;</w>
o lol</w>
1 3
u ally</w>
propo fol</w>
fibri ll
e qu
double -bl
ur ine</w>
tri al</w>
re ma
m m</w>
n ing</w>
rat s,</w>
d oc
antagon ist</w>
C on
on e,</w>
oc c
dam age</w>
9 .
repor ts</w>
o sis</w>
gr ade</w>
injur y</w>
random ized</w>
M D
place bo
in duce</w>
( -1
m b
( T
inj ected</w>
ho wever,</w>
u ses</w>
sub sequ
pres ence</w>
e pam</w>
agon ist
stim ulation</w>
S t
blad der</w>
at eral</w>
5- H
f o
u s.</w>
out com
1 2
v s</w>
c ut
x i
ac in</w>
O ur</w>
e ven</w>
diagno sis</w>
show n</w>
stud y,</w>
m ag
de g
administr ation.</w>
+/ -
res h
dynam ic</w>
dog s</w>
an emia</w>
sever al</w>
7 -
se d
ation shi
p ent
gen ic</w>
cour se</w>
amphet amine</w>
re tion</w>
hy p
C I
treatment ,</w>
ex amin
in d</w>
fail ure.</w>
n os
struc t
ot on
t y</w>
stres s</w>
ogen e
enceph alo
con tr
b ac
s in
re pe
p en
b enz
sal ine</w>
s ).</w>
D -
s o
py ri
pre dic
per f
tic ally</w>
secon d</w>
m id
infarc tion</w>
group .</w>
a re
A n</w>
follow -
1 1</w>
ye ar</w>
reac tions</w>
therap y,</w>
initi al</w>
On e</w>
pro l
ag e,</w>
rel ationshi
previ ous</w>
- related</w>
ana esthe
saf ety</w>
op io
su ff
sp ective</w>
fact or</w>
as pir
i g
effect s.</w>
ne g
s it
comb ined</w>
ab out</w>
t op
mo der
str ic
li ke
( 5
t y-
th resh
ro w
os ine</w>
ocyt open
discontinu ation</w>
is on</w>
ay ed</w>
le ast</w>
d ar
in divid
d -
conside red</w>
a ver
per sist
te d.</w>
m an</w>
li p
in tr
glomer ular</w>
cum ul
pos sib
oc ic
ob arbit
inter val</w>
ur ing</w>
func tion.</w>
pre gn
pac litax
mark ed</w>
behavi oral</w>
bas ed</w>
rang e</w>
l ym
c an
1 6</w>
par t
on d
the sis</w>
t en</w>
resul t</w>
al ine</w>
ure ,</w>
ro lim
ineph rine</w>
determin ed</w>
ag e.</w>
expos ed</w>
regi on
oc hem
mil d</w>
my o
c ent</w>
inhibit or</w>
f ree</w>
(2 )</w>
at h</w>
er y
adul t</w>
prot ective</w>
pilocar p
ell ular</w>
al s.</w>
sever ity</w>
p tion</w>
i di
g ast
evalu ate</w>
s co
high -dose</w>
cor rel
con fir
atri al</w>
in o
I V</w>
ner ve</w>
descri be</w>
demon st
v s.</w>
diab etic</w>
) ;</w>
pat ter
ap pea
ang i
activ ation</w>
P A</w>
the y</w>
impro ved</w>
epilep tic
cont rib
diag nos
b le</w>
mor t
AN D</w>
tim es</w>
rati o</w>
phen y
oph yl
haloperid ol</w>
az epam</w>
catalep sy</w>
a sis</w>
the tic</w>
pa ren
e very</w>
anal gesi
suggest s</w>
I S
en d</w>
b io
thromb ocytopen
ch loro
ex er
( L
( -
zap ine</w>
ri pt
or g
inter sti
heal th
b ro
am in</w>
d r
1 7
requ ired</w>
st e
sen s
C a
1 3</w>
revie w</w>
ol ,</w>
re tro
y n
ob tained</w>
con tra
1 5
re action</w>
im en
s h
re x
rat ory</w>
acet yl
disc us
ti zed</w>
me mb
ser oton
sul f
lym ph
ame ter
ic ill
de li
3 ,</w>
reas t</w>
i f</w>
f oc
complic ations</w>
um .</w>
2 00
t u
qu in
microgram s/
inc e</w>
0 ,</w>
ph yl
valu es</w>
lev o
1 8</w>
intersti tial</w>
M e
and /
D i
tre m
my e
m es
and/ or</w>
2 %</w>
y ro
ta k
de ath</w>
H y
obser v
invol ved</w>
ev ent
enzym e</w>
le sions</w>
io dar
rele ase</w>
ol .</w>
ment al</w>
all y,</w>
ate le
th en</w>
b reast</w>
suggest ed</w>
reco very</w>
n al</w>
fe at
1 %</w>
ri am
aly sis</w>
vi v
respon se
I V
monit or
com mon
y oun
tion s.</w>
it ing</w>
a m</w>
al ized</w>
se d.</w>
day s.</w>
al though</w>
t -
s k
e pt
E x
pl atin</w>
glyc er
b ind
ag es</w>
1 8
val pro
like ly</w>
oly tic</w>
hor mon
sign s</w>
l y.</w>
azep ine</w>
y st
l u
P ark
O n</w>
( 6
sy m
ma z
mo di
bu pivaca
nerv ous</w>
mis sion</w>
epilep tic</w>
complic ation</w>
activ ity.</w>
phen yl
mi ght</w>
i or</w>
per it
Ac ute</w>
ve ,</w>
rema ined</w>
ati vely</w>
alph a</w>
st ,</w>
ocic ep
rever sible</w>
go ing</w>
Park in
D O
n or
enh anced</w>
be ing</w>
use .</w>
sm all</w>
ro ph
( B
ri tis</w>
lo x
ic in-induced</w>
P h
A L
k g</w>
C O
wei gh
adv anced</w>
m ou
P -
1 6
tum or</w>
loc al</w>
H g
man if
en ing</w>
P T
C lin
D )</w>
tissu e</w>
p ur
e t</w>
brady cardia</w>
p ec
le .</w>
ex pl
ery th
3 %</w>
B oth</w>
ot ens
an ne
abnormal ities</w>
ve d.</w>
relationshi p</w>
ref le
pro per
pl atele
b ene
kidne y</w>
col l
as s</w>
prop ran
def ici
syst olic</w>
morph ine</w>
R )</w>
pro ce
. ,</w>
ven tion</w>
pilocar pine</w>
con duc
adren ergic</w>
seizures .</w>
hyperal gesia</w>
health y</w>
c op
W he
ser ious</w>
ac hi
ad ju
ex trac
vol um
te red</w>
i ratory</w>
or atory</w>
N S
v es</w>
mye lo
appea red</w>
st atis
par ameter
g row
do es</w>
me mor
creat inine</w>
addi tion,</w>
f -
di g
character is
tro ph
perit one
na use
desc ribed</w>
co ag
ation al</w>
r he
Th e
test ed</w>
ri l</w>
group ,</w>
re .</w>
min im
eth yl
a thi
tem por
re main
memb ran
me d
ca uses</w>
ox if
g ran
cumul ative</w>
ation s,</w>
( 7
A -
pot assi
resp iratory</w>
glut am
transi ent</w>
multi ple</w>
me ta
drug .</w>
ch anne
asses s
si a.</w>
vit amin</w>
o path
O f</w>
tub ular</w>
ri st
reco gn
minut es</w>
st ained</w>
investig ate</w>
week s.</w>
r ing</w>
graph ic</w>
con ver
coca ine-
m uc
de pres
ab dom
theli al</w>
occur rence</w>
hydrox y
um ,</w>
ev o
direc t</w>
19 9
( 8
cut aneous</w>
aff ected</w>
m ed</w>
cont aining</w>
re d.</w>
vari ous</w>
spont aneous</w>
ot yp
ex hib
n al
f r
ay s</w>
ab il
for m</w>
contr ast</w>
S E</w>
or s
par tial</w>
occ ur</w>
injec tions</w>
convul sions</w>
c y</w>
mg/m 2</w>
prev ented</w>
continu ous</w>
anesthe sia</w>
vas cul
rel ative</w>
med ical</w>
ap am
ag ed</w>
re p
manif est
bloc k</w>
0.05 ).</w>
ex ten
impro vement</w>
ri al</w>
pro v
pro duce</w>
de ath
chol in
ar th
a i
D uring</w>
( R
sho w</w>
in s</w>
identi fied</w>
H g</w>
r are</w>
l ,</w>
immun o
angi otens
C B
i.v .</w>
ei ght</w>
Parkin son
prev ent</w>
pres c
poin t
t ent</w>
anim al</w>
am iodar
se ven</w>
M T
( O
s ch
de pression</w>
a c</w>
s mo
re comm
(1 .
xim ately</w>
i tive</w>
ede ma</w>
asses s</w>
a ro
th ir
i ally</w>
( G
frequ ently</w>
dos age</w>
5-H T
ri ght</w>
l ac
survi val</w>
sign ed</w>
moder ate</w>
neuron s</w>
inhibit ed</w>
R NA</w>
4 %</w>
( +
Th ree</w>
ograph y</w>
form ation</w>
reg imen
ochem ical</w>
res t</w>
or ,</w>
meas ure
doc um
gl y
agon ist</w>
compar ison</w>
% .</w>
pot ent</w>
es tive</w>
E R
1 ),</w>
pharmac o
ameth as
ogen ic</w>
mal ign
comple te
appear s</w>
an xi
we ll
cor e</w>
ti me
suff ici
ischem ic</w>
est abl
ud ed</w>
d n
ca ffe
anc es</w>
H C
mit ted</w>
er o
abs ence</w>
2 1</w>
p an
im medi
co gn
ud ine</w>
s .
respectivel y
monitor ing</w>
com it
an d,</w>
lo com
ch est</w>
N a
pro c
im plic
w at
l ast
cle ar
proce d
flur ane</w>
increas ing</w>
halo th
h er</w>
s -
ri g
em ic</w>
ech ocardi
bind ing</w>
ane ously</w>
addi tion</w>
suggest ing</w>
neuro lep
influ ence</w>
diab et
cy sti
em ia.</w>
drug s.</w>
amin o
se x
in test
control s</w>
ot rop
medic ation</w>
k s</w>
w ide
under going</w>
syndrome .</w>
contra st,</w>
sy .</w>
l am
il tr
es s,</w>
nicot ine</w>
episo des</w>
6 %</w>
w ent</w>
s ity</w>
post -
le ad
dop a</w>
och ond
m al</w>
1 ,
of ten</w>
follow- up</w>
biop sy</w>
ti z
cep ti
th ec
protein uria</w>
di l
micro g/
m ar
amin ergic</w>
sin us</w>
hyper troph
adren oc
gener ation</w>
bo di
4 ,</w>
ogene sis</w>
ur ther
f ar
o red</w>
neg ative</w>
c ros
8 %</w>
lip id</w>
l ed</w>
um -
paclitax el</w>
def ic
volum e</w>
vi r</w>
ent am
disor der</w>
arrhythmi as</w>
P G
u sion,</w>
ox ic</w>
or s,</w>
T reat
. 0
consist ent</w>
(1 0</w>
f et
e di
inf ec
cor tico
in ic</w>
in de
func tional</w>
er s.</w>
ch all
ag l
Q T</w>
l un
t s.</w>
sensi tive</w>
appro ximately</w>
sus cepti
model s</w>
mag ne
resul ting</w>
evalu ation</w>
e p</w>
ur ac
ti l</w>
over all</w>
inc rist
hyperten sion.</w>
hospit al</w>
drug -induced</w>
cyclophosph amide</w>
at e,</w>
repe ated</w>
pa thetic</w>
om e</w>
mort ality</w>
literat ure</w>
wh om</w>
ur b
regi men</w>
recei ve</w>
re duce</w>
nephro tic</w>
ep ti
dex amethas
addi tional</w>
month s.</w>
man age
im ag
es pec
b or
anti psycho
al lo
a vir
ran ial</w>
pen icill
( I
impair ment</w>
espec ially</w>
mg/k g/
deg ree</w>
at e.</w>
ret ur
d g
S er
2 .</w>
ul arly</w>
aspir in</w>
S i
2 00</w>
ris perid
h al
av ail
vis ual</w>
subsequ ent</w>
hepar in</w>
coca ine-induced</w>
con sc
carb am
9 %</w>
us ers</w>
transpl ant</w>
press ed</w>
a de
r o</w>
dose- dependent</w>
b ri
C ardi
( 1</w>
under went</w>
potassi um</w>
post operative</w>
es tim
cy cl
ot rex
cardiomyo pathy</w>
achi e
3 )</w>
opio id</w>
m ut
arrhyth mic</w>
larg e</w>
C )</w>
A R
1 7</w>
ru s</w>
rolim us</w>
ic ul
concl ude</w>
antagonist s</w>
al co
Whe n</w>
8 0</w>
ver apam
thresh old</w>
m ,</w>
patient 's</w>
pa in.</w>
control s.</w>
a ke</w>
y cl
v om
c al</w>
alter ations</w>
acti vi
u tive</w>
s he</w>
or .</w>
mit ochond
progres sive</w>
pro phyl
platele t</w>
ore ,</w>
nec rosis</w>
do pa
4 8</w>
sk in</w>
p ected</w>
ocyt e</w>
clin ically</w>
U R
om orph
h ic
t om
stand ard</w>
memor y</w>
inhibit ors</w>
au th
I m
y ing</w>
micro scop
ex ist
attenu ated</w>
6 ,</w>
un d
suppor t</w>
he dul
chall eng
5 )</w>
D e
pl at
T R
ophyl line</w>
7 %</w>
d en
0. 5</w>
thrombo sis</w>
re current</w>
pre dn
ent .</w>
az ine</w>
( V
te en</w>
su stained</w>
he x
surger y</w>
par kin
comp oun
sp ite</w>
o z
flu oro
feat ures</w>
T )</w>
id al</w>
i.p .)</w>
b one</w>
Tw ent
H e
F urther
use ful</w>
the re
Treat ment</w>
st age</w>
sch iz
mol /
st ron
hippocamp al</w>
cy to
test s</w>
qu anti
con comit
9 0</w>
ta in</w>
initi ation</w>
ent ,</w>
d ine</w>
con sec
cogn itive</w>
am ine-induced</w>
aff ect</w>
Th us,</w>
t am
revie w
grow th</w>
an th
sc hedul
o v
er ing</w>
youn g</w>
anesthe tized</w>
p ic
manage ment</w>
g entam
frequ ent</w>
fibrill ation</w>
arc h</w>
adrenoc ept
o ff
lon g</w>
intra peritone
ut ed</w>
parkin son
nec ess
n ed</w>
intest inal</w>
complete ly</w>
R ec
neuro toxicity</w>
mon o
character ized</w>
F )</w>
rap id</w>
ment .</w>
indic ated</w>
S R
oc lon
ai m</w>
ag ic</w>
tak en</w>
path w
ad riam
ab normal</w>
suc cess
exc retion</w>
di ure
cholin ergic</w>
om e
i atric</w>
aden osine</w>
TI ON
L i
vi a</w>
sti t
perf usion</w>
isol ated</w>
anti depress
W ist
N A
ter min
statis tically</w>
pro ble
id ity</w>
hypoten sive</w>
hear ing</w>
az ole</w>
anti convulsant</w>
anal o
a or
s ),</w>
is ed</w>
cholest er
ac tions</w>
ne ut
f atal</w>
evo ked</w>
epileptic us</w>
clon idine</w>
agl and
- associated</w>
ve .</w>
s core</w>
respectivel y,</w>
pea k</w>
lab oratory</w>
h our</w>
are a</w>
SE :</w>
se g
on e-
7 5</w>
v incrist
man y</w>
as .</w>
Parkinson 's</w>
se m
meta st
immun e</w>
not ed</w>
le ,</w>
gra m</w>
N O
thrombocytopen ia</w>
thec al</w>
oxy gen</w>
neuron al</w>
inter val
f y</w>
common ly</w>
C N
ni qu
maxim um</w>
l .</w>
ho l</w>
det ected</w>
cor related</w>
repor ted.</w>
sp ecti
rever sed</w>
mi x
meth otrex
lat er</w>
er gen
p ap
ob j
ine d.</w>
conduc ted</w>
1 9</w>
ref r
n ine</w>
mon th</w>
inter action</w>
g am
consec utive</w>
viv o</w>
recor ded</w>
un til</w>
neuro path
ly ing</w>
em ergen
( 9
toler ated</w>
s li
oc on
gr ad
di ast
cardi otoxicity</w>
Ne uro
u pt
pilocarp ine-induced</w>
iz ed,</w>
i an</w>
electro cardio
el der
al -
refr act
prob ably</w>
capsa icin</w>
bet a</w>
as e,</w>
al le
I N
kg (-1
id om
ac comp
oph ren
develop ing</w>
C P
ve red</w>
resol ved</w>
headac he</w>
ch arg
ro w</w>
isoproteren ol</w>
inf ants</w>
anim als.</w>
s ing</w>
fentan yl</w>
est ro
canc er.</w>
bupivaca ine</w>
ap pe
th yro
pro m
dist urb
fail ed</w>
car e</w>
ar t
per cent</w>
i ve</w>
ect om
dose .</w>
c r
- like</w>
dop aminergic</w>
w o
subj ect
sel f-
parameter s</w>
on ucle
effect .</w>
ed ly</w>
di ed</w>
rit er
ri bu
re m
rat .</w>
mg/ d
double-bl ind</w>
diagnos ed</w>
UR PO
P URPO
-1 .
m l</w>
m RNA</w>
Clin ical</w>
sym pathetic</w>
con g
block ade</w>
aver age</w>
AI D
tion s,</w>
M )</w>
( mean</w>
seroton in</w>
mechan ical</w>
con si
K -
9 -
under lying</w>
prol act
metabol ic</w>
j ection</w>
b ility</w>
at s</w>
S e
vit ro</w>
PURPO SE:</w>
% ;</w>
nit ric</w>
ischem ia</w>
arrhyth mia</w>
schiz ophren
resist ant</w>
prost agland
mo re,</w>
GAB A
D NA</w>
perio d.</w>
individ u
war far
p ren
o lo
ble ed
sco res</w>
intra ven
di pyri
st op
propran olol</w>
dipyri dam
In tra
2 ).</w>
fe w</w>
ect ing</w>
cl u
alter n
( 5</w>
resist ance</w>
las tic</w>
accomp an
C H
level s.</w>
il l</w>
ide ,</w>
hemorrh age</w>
er b
enc es</w>
di azepam</w>
ac h
S ub
(2 .
pregn anc
ne w
li e
en al</w>
ch ed</w>
wo uld</w>
refle x</w>
no rep
tam oxif
se ,</w>
rec i
del ayed</w>
P R
refract ory</w>
le ar
ap omorph
ag g
1 00
surg ical</w>
t ech
se em
or der</w>
lun g</w>
com pl
E E
) -induced</w>
pop ul
confir med</w>
v es
pre val
per cent
conf idence</w>
chlor ide</w>
ap plic
ance .</w>
rel atively</w>
bil i
al tered</w>
L )</w>
C I</w>
lam iv
anti bodi
0.05 )</w>
y s</w>
ster oid</w>
gast ro
u ter
toler ance</w>
ti s,</w>
ref ore,</w>
nal ox
Wist ar</w>
C D
v ag
s por
Eff ects</w>
ocicep tive</w>
mark edly</w>
lo p</w>
deve lop</w>
(1 )</w>
random ly</w>
patter n</w>
effect s,</w>
diseas e,</w>
8 ,</w>
sup ple
mou se</w>
bil ateral</w>
A s</w>
2 8</w>
2 3
ve hic
stri atal</w>
ru b
h is</w>
diast olic</w>
c riter
b ile</w>
n .</w>
locom otor</w>
reg ul
om eth
be g
n g/
continu ed</w>
p raz
auth ors</w>
ac ce
7 ,</w>
2 5
tri als</w>
ol ar</w>
chol ine</w>
ar ge
0.0 00
side -
s le
partic ularly</w>
Th ir
I )</w>
z e</w>
tw ice</w>
os f
no vel</w>
gen eral</w>
correl ation</w>
8 0
vas odi
obser ved.</w>
n or</w>
hyperal gesi
eth an
diabet es</w>
de spite</w>
II I</w>
prot ection</w>
upt ake</w>
eryth ro
ind ometh
foc al</w>
am ine,</w>
C S
te x</w>
re ly</w>
activi ties</w>
2. 5</w>
valu e</w>
oxid ative</w>
behavi or</w>
Further more,</w>
trem or</w>
st ra
sion s.</w>
potenti ally</w>
ex ac
c ri
an ter
ad mitted</w>
( F
el ic
dyskine si
con sequ
am ine.</w>
activ ity,</w>
ac c
R es
P ,</w>
2 50</w>
pr us
mar row</w>
ful ly</w>
transplant ation</w>
st ate</w>
recomm end
ap paren
T E
requ ir
ne on
fol d</w>
analgesi c</w>
G F
D A</w>
inde x</w>
examin ation</w>
child ren
y r
prov ide</w>
intra thecal</w>
concomit ant</w>
us ually</w>
st re
pl ay</w>
high -
exc it
est er
dis charg
da il
t s,</w>
pheny to
otrop ic</w>
inten sity</w>
t le</w>
rap id
pre vention</w>
pre treated</w>
p as
ic ,</w>
at tri
50 %</w>
ster one</w>
glomer ul
cor tical</w>
cong estive</w>
2 4
subst anti
occur ring</w>
en e</w>
demonst rate</w>
de d.</w>
u it
physi ological</w>
ing es
in suffici
impa ired</w>
et ine</w>
benz odi
i um</w>
i es.</w>
wat er</w>
gener alized</w>
appro pri
A S
0 00</w>
su per
reci pi
phen obarbit
n =
hemo dynamic</w>
ffe red</w>
progres sion</w>
ineph r
ex tr
S he</w>
P er
se arch</w>
ne x
docum ented</w>
ap op
cor tex</w>
adren aline</w>
as th
5- F
metabol it
neurolog ical</w>
imag ing</w>
doxorub ic
adju st
S H
psych iatric</w>
ne ed</w>
exhib ited</w>
em ia,</w>
A m
tempor al</w>
outcom e</w>
oni um</w>
channe l</w>
caffe ine</w>
block ing</w>
thal am
mi gra
bas al</w>
st able</w>
neurolog ic</w>
iz e</w>
hypo kal
attri but
amiodar one</w>
Q T
vir al</w>
thir d</w>
su m
al s,</w>
SI G
r al</w>
prot oc
oc or
m as
. 00
p ub
mol ec
lif er
ide .</w>
hypo thesis</w>
E )</w>
o side</w>
m ade</w>
g est
ex cep
elev ation</w>
concl uded</w>
a -
per oxid
main tained</w>
2 2</w>
wide ly</w>
im pl
cas es.</w>
vol un
my oclon
metabol ism</w>
ep inephrine</w>
am ne
C Y
nitro prus
7 0</w>
reg ar
monit ored</w>
methyl -
ha em
a di
O R
In c
pro lifer
o ti
mid azol
wh ite</w>
symptom atic</w>
sti ll</w>
oly sis</w>
da y,</w>
at ro
R enal</w>
tech niqu
ol amine</w>
hem olytic</w>
rat e,</w>
pre -
p ose</w>
ocyt es</w>
nec ro
anti coag
F or</w>
E P
DE SIG
obj ective</w>
concl usion,</w>
Twent y-
urac il</w>
proper ties</w>
pro pi
n at
low -
co hor
am oun
1 .</w>
0.00 1).</w>
on ce</w>
am pl
in si
immun os
encephalo pathy</w>
elder ly</w>
tre at</w>
mat er
l ast</w>
decreas es</w>
car ri
vi rus</w>
stri at
rhe um
mus cular</w>
es s.</w>
disorder s</w>
di et
con duction</w>
cess ation</w>
sens ory</w>
se t
meth ad
hemorrh agic</w>
graph y</w>
an ,</w>
F our</w>
z ol
at tac
anti oxid
E n
ti ally</w>
ribu tion</w>
ne ed
id ate</w>
angiotens in</w>
y :</w>
le ad</w>
ind ,</w>
ate d,</w>
haloperid ol-induced</w>
fib ro
ep id
em bol
car bo
acti n</w>
te tra
stro ke</w>
s ince</w>
rop en
perform ance</w>
ot er
mitochond rial</w>
main ten
anti bio
B ec
5 00</w>
low ing</w>
st on
sensi tiz
s oci
reg ulation</w>
di z
bi ochemical</w>
accompan ied</w>
ab use</w>
y mptom
pharmaco kine
partic ip
in a</w>
cont ent</w>
5 %)</w>
t ure</w>
p epti
metast atic</w>
le y</w>
is h</w>
func tion,</w>
discontinu ed</w>
as es</w>
year s.</w>
ul e</w>
th reat
patient .</w>
p u
do but
H -
om a.</w>
oc ular</w>
epilep sy</w>
bol us</w>
H e</w>
mo dul
ine- treated</w>
defici ency</w>
z in
ket amine</w>
induc es</w>
hypoten sion.</w>
clo zapine</w>
verapam il</w>
se par
gen ous</w>
est radi
( p
rel ap
flu id</w>
fic ial</w>
em br
compar able</w>
E D
D 2</w>
ta ke</w>
repor t.</w>
random ized,</w>
gen e
b ic
6 )</w>
4 )</w>
j unc
high ly</w>
hyper activity</w>
discus sed.</w>
convul sive</w>
v ast
r ho
pr ag
org an
malign ant</w>
ill ary</w>
en al
def ined</w>
tachy cardia
pa in,</w>
maxim al</w>
fail ure,</w>
e y
clear ance</w>
apop to
C R
retur ned</w>
pub l
ou ab
S prag
D aw
3 5</w>
pressu re,</w>
p t</w>
symptom s.</w>
s. c
pro spective</w>
in te
dexamethas one</w>
d o</w>
Bec ause</w>
( 95%</w>
pre par
lim b
agonist s</w>
achie ved</w>
en .</w>
dog s.</w>
cle s</w>
ram idal</w>
prostagland in</w>
m ia.</w>
in dependent</w>
dep le
ca the
aut o
Daw ley</w>
DESIG N
3 0
u e-
toxic ity,</w>
star ting</w>
s ite</w>
persist ent</w>
or -
om en
gr af
coun t</w>
N MD
B P</w>
is tic</w>
hy dr
2 3</w>
) )</w>
prof ile</w>
infu sion.</w>
immunos up
hormon e</w>
di et</w>
contrib ute</w>
c h</w>
se .</w>
rapid ly</w>
preval ence</w>
pre ci
plas tic</w>
os in</w>
der iv
ab o
M R
n if
mo ve
membran e</w>
lim ited</w>
iltr ation</w>
divid ed</w>
Eff ect</w>
An ti
2 6</w>
vas o
syn ap
stre pt
injec tion.</w>
hepat oc
G )</w>
D ru
1. 5</w>
t ur
rib avir
ox i
model .</w>
b ar
ati c
appe ar</w>
tum ors</w>
si mul
remain s</w>
ph al
l ate</w>
in toxic
pharmac ological</w>
le ph
comp on
ax is</w>
w a
risperid one</w>
pro duction</w>
mainten ance</w>
inf used</w>
glutam ate</w>
aor tic</w>
star ted</w>
nitro glycer
inflam m
cis e</w>
ce f
cat ech
b rom
azep am
assess ment</w>
act ing</w>
comple x</w>
as c
DESIGN :</w>
the si
sed ation</w>
mon ke
intraven ously</w>
chang ed</w>
appropri ate</w>
A ,</w>
we ak
or ation</w>
nucle us</w>
o ver,</w>
idom ide</w>
gen e</w>
block ed</w>
M y
st ere
k .</w>
f rac
A T</w>
one -induced</w>
group s,</w>
pit uit
neut ropen
my c
cysti tis</w>
con sum
a un
4 5</w>
4 4</w>
ra m</w>
placebo -
or ally</w>
fem al
dom in
day s,</w>
cor ding</w>
P .</w>
s '</w>
meth amphetamine</w>
inf ection</w>
antagonist ,</w>
w er</w>
om as</w>
g al
di alysis</w>
cyclo spor
consc ious</w>
arc in
uro myc
the ophylline</w>
par t</w>
methotrex ate</w>
in sul
anti arrhythmic</w>
threat ening</w>
pe di
neur al</w>
in st
carcin oma</w>
0.0 1).</w>
surger y.</w>
mic e,</w>
long er</w>
inc id
dose ,</w>
bec ame</w>
F ol
si g
om et
kin ase</w>
if osf
S C
th io
struct ural</w>
p al
m u
inhibit ory</w>
S .</w>
E i
meth o
day )</w>
Hy per
volun te
p s</w>
lox acin</w>
anter ior</w>
reg res
qu ine</w>
pur pose</w>
os in
m ia,</w>
lif e-
g li
condi tions</w>
avail able</w>
Sprag ue-
us ual</w>
supple ment
phen omen
double-bl ind,</w>
cis platin</w>
b re
al one.</w>
M ore
E NT
tamoxif en</w>
rheum at
path ogenesis</w>
ma .</w>
it al</w>
immedi ately</w>
descri be
am ine-
U n
well -
seizures ,</w>
res er
pro por
indic ating</w>
experi ence</w>
cyclophosph amide
bet ter</w>
V )</w>
2 ,
carbam azepine</w>
b ul
antibodi es</w>
W h
PA TI
lo fen
de n</w>
ance ,</w>
Sprague- Dawley</w>
S cal
S -
7 )</w>
ro tox
ran s
point es</w>
B e
week ly</w>
st -
p ut
ol /
log ical</w>
is e</w>
emergen cy</w>
al b
GAB A</w>
3 2</w>
3 00</w>
suscepti bility</w>
otoxic ity.</w>
cor rec
C o
wor sen
saf e</w>
presc ribed</w>
ox in</w>
o ther
long -
lid oca
lat eral</w>
invol vement</w>
gastro intestinal</w>
consi der
compoun ds</w>
M P
2 /
possib ility</w>
amin onucle
PATI ENT
HB V</w>
sup pression</w>
literat ure.</w>
lead ing</w>
l act
haloth ane</w>
gam ma
characteris tics</w>
possib ly</w>
or th
or b
nephro pathy</w>
main ly</w>
li g
el ec
C A</w>
rati o
im b
fr action</w>
depend ently</w>
compar e</w>
as ,</w>
analy zed</w>
adrenocept or</w>
throu gh
stop p
ro x
respon sible</w>
n s</w>
levo dopa</w>
high est</w>
dyskine sia</w>
Ad minist
ic ardi
exac erb
es sen
r ation</w>
min ant</w>
le th
id s</w>
ex tent</w>
c ed</w>
The refore,</w>
test ing</w>
poin t</w>
min ,</w>
ex amine</w>
c he
aun dic
anxi ety</w>
S M
R ats</w>
More over,</w>
L ,</w>
H D
rec ent</w>
r as
prom ot
ph asi
pedi atric</w>
ocor tico
inf orm
hy pe
ere bral</w>
U /
C .</w>
4 00</w>
su d
rat e
p uromyc
lif e</w>
fi el
em b
av oid
appear ance</w>
ant in
a sia</w>
S ince</w>
up on</w>
th us</w>
reco vered</w>
pos ed</w>
norep inephrine</w>
nause a</w>
h ,</w>
fet al</w>
dys function.</w>
applic ation</w>
P las
sm all
le dg
P D
5 ).</w>
v an
ol ar
gener ally</w>
con ven
at or</w>
F ive</w>
(1 00</w>
y )</w>
sh oc
pop ulation</w>
oxy gen
op tic</w>
N G
0. 1</w>
t on
recommend ed</w>
pro vid
pr amine</w>
it ation</w>
vasodi lat
ur ic</w>
mat ure</w>
in ing</w>
en ro
be ll
administr ation,</w>
C -
reduc ing</w>
p ect
injur y.</w>
ic k
e ly</w>
I F
( 2</w>
system .</w>
rec ently</w>
pic rotox
ot en
magne si
ev id
di min
condi tion</w>
stron g
neuro pathy.</w>
e mo
an other</w>
L /
3 6</w>
3 .</w>
3 ,
- dependent</w>
t or
rang e,</w>
prolong ation</w>
neph ritis</w>
le g
f at
equ al</w>
bleed ing</w>
V PA</w>
on s</w>
nif edi
includ e</w>
fic ation</w>
endo genous</w>
amin oph
( n=
si m
sex ual</w>
ograph ic</w>
antagon ized</w>
A mon
0. 6
use ,</w>
spont aneously</w>
pro ca
occur s</w>
know ledg
dopa -induced</w>
condi tion
cl ero
ari ly</w>
anth rac
aminoph en</w>
C ocaine</w>
ser ies</w>
cl assi
P D</w>
transplant ation.</w>
ti le</w>
studi ed.</w>
sec retion</w>
phosph ate</w>
oc ript
lit tle</w>
level s,</w>
ic s</w>
alco hol</w>
2 7</w>
y si
steroid al</w>
seem s</w>
r ad
o ur
iti s.</w>
f ron
f low
er ior</w>
enal ap
thi az
rat e.</w>
pro specti
minim al</w>
intrac ranial</w>
il d</w>
excep t</w>
e jection</w>
apparen t</w>
ad ol
EC G</w>
Amon g</w>
uc in
ot oc
kg -1</w>
fac il
ear li
anti- inflammatory</w>
0 %)</w>
on al</w>
gly co
ence ,</w>
elec tr
contrac ep
cere bro
acet am
3 %)</w>
warfar in</w>
pro xim
ol an
ev ent</w>
cholester ol</w>
T -
NMD A</w>
2 9
v als</w>
rheumat oid</w>
oph ysi
month s,</w>
mo d
low -dose</w>
h all
g a
da y.</w>
ch o
ab ine</w>
0. 5
ven til
endo thelial</w>
cas es,</w>
cal cul
abo ve</w>
I ,</w>
1 /
year s,</w>
typ ical</w>
l ine
gran ulo
glut athi
epid ural</w>
EE G</w>
D es
wh ere</w>
ur g
sc ale</w>
phenyto in</w>
ot oxic</w>
hippocamp us</w>
S N
flu ox
d ent
c u
N O</w>
pu t</w>
oph il
mat ched</w>
ens ity</w>
I -
sc re
predn isol
men ing
medic ations</w>
lim iting</w>
fib rosis</w>
f am
drug s,</w>
deter i
coca ine.</w>
brady cardia
at yp
S im
simul t
sc al
ro ut
review ed</w>
puromyc in</w>
ob struc
min .</w>
l -
inter vals</w>
hyperten sion,</w>
hyper sensitivity</w>
e )</w>
deli ri
as ed</w>
w ill</w>
up per</w>
typ es</w>
s ac
prop yl
on ate</w>
ocardi al</w>
j aundic
ine mia</w>
in take</w>
identi fy</w>
ha ving</w>
g ang
dobut amine</w>
ap y
ad dic
abdom inal</w>
Plas ma</w>
8 )</w>
trans por
through out</w>
syn thesis</w>
ra ther</w>
adriam ycin</w>
ade qu
7 2</w>
tre mor
si d
re mia</w>
r ic
p .
k g/
indometh acin</w>
hypoten sion,</w>
fo ur
cor tis
A g
10 -
un i
s al</w>
r ab
quanti t
predic t
mus car
microgram s</w>
mg/kg ),</w>
mater nal</w>
li ght</w>
k ind
a reas</w>
ures .</w>
ur ia,</w>
sup pressed</w>
neurolep tic</w>
it h</w>
ful minant</w>
establ ished</w>
er s,</w>
to ge
parkinson ian</w>
is m.</w>
cohor t</w>
can n
antipsycho tic</w>
a emia</w>
OBJECTIVE S:</w>
produc es</w>
p lo
myo pathy</w>
meth od</w>
as signed</w>
H i
rat ing</w>
last ing</w>
i.v .)</w>
b asis</w>
as part
ac cording</w>
A .</w>
1 %)</w>
0. 9
rel ax
present ing</w>
om al</w>
drug ,</w>
de signed</w>
cir cul
arter i
anal gesia</w>
W ith</w>
U S
Administ ration</w>
tr ic
path y,</w>
impro ve</w>
ap pl
2 ),</w>
y g
ti vely</w>
retro spective</w>
requ i
individ ual</w>
ence .</w>
con cer
L .</w>
tac rolimus</w>
sit es</w>
re ten
lab el
individu als</w>
chem ical</w>
cell ular</w>
(A B
pituit ary</w>
oter icin</w>
ol der</w>
ne um
h om
as e.</w>
anesthe tic</w>
6 5</w>
to -
ret ino
re lev
o t</w>
life- threatening</w>
exist ing</w>
CA SE</w>
4 .</w>
un treated</w>
thrombo tic</w>
t a</w>
inf ected</w>
hum an
ca us
S ev
prol actin</w>
lamiv udine</w>
glob in</w>
dipyridam ole</w>
de oxy
ar rest</w>
' -
sup pres
nalox one</w>
h r</w>
go od</w>
describe d.</w>
cell s.</w>
pheny leph
percent age</w>
path ophysi
ma in</w>
impl ant
fer ase</w>
do w
chemo therapy.</w>
tic s.</w>
recept ors.</w>
proxim al</w>
on in</w>
gluc ose</w>
gast ric</w>
gamma -
ethan ol</w>
ate -
apy ramidal</w>
ame li
ac qu
AT P
t ex
se ly</w>
gentam icin</w>
es sive</w>
en ,</w>
af ter
ac tic</w>
L I
2 9</w>
0. 7
oc ca
m mol/
lo ad
invol ving</w>
hyper prolact
det ect
al ter</w>
agent s.</w>
Sev ere</w>
PG E
C T
( 3</w>
tri al.</w>
treat ments</w>
se ud
ri tis.</w>
requir ing</w>
necess ary</w>
infarc tion.</w>
in ation</w>
f ore
elic ited</w>
cy cle</w>
acet aminophen</w>
D S)</w>
1 50</w>
war d</w>
vascul itis</w>
respon ding</w>
mm Hg
ment ,</w>
le -
l eng
headac he
experim ents</w>
ce mia</w>
AC T</w>
week s,</w>
subsequ ently</w>
propo fol
posi tion</w>
per for
o .</w>
inges tion</w>
cir rho
atyp ical</w>
abdom y
Ser um</w>
0.00 1)</w>
valpro ic</w>
se ve
s os
re curren
muscar inic</w>
criter ia</w>
conven tional</w>
Me an</w>
region al</w>
preci pit
meas ures</w>
diff er</w>
com a</w>
co -
aw are</w>
anaesthe sia</w>
al op
Inc reas
4 %)</w>
2 4-
( group</w>
uro sem
sa des</w>
penicill amine</w>
ne o
me dul
m s.</w>
id ov
hall ucin
conver ting</w>
un it</w>
til ity</w>
patient ,</w>
midazol am</w>
kg )</w>
e me
abol ished</w>
(P <
y clo
sli gh
reduc es</w>
prev ent
oz otoc
gang li
cere bell
cardiomyo pathy.</w>
brom ocript
as al</w>
X -
3 9
stric tion</w>
s amp
region s</w>
or ity</w>
on .</w>
oc cl
anti body</w>
ti n</w>
there fore</w>
the m</w>
sus pected</w>
ri se</w>
qu es
fac e</w>
exer cise</w>
depress ed</w>
de s
ant s.</w>
7 %)</w>
19 8
0. 8
( 0.0
vaso press
osin ophil
i ved</w>
end -
contrib ut
cholest asis</w>
au g
allo dyn
2 %)</w>
rab b
nephro toxicity</w>
lac k</w>
episo de</w>
ent ly,</w>
re mo
on -
muc h</w>
migra ine</w>
cum ulation</w>
I NT
D op
Ad verse</w>
ti az
or i
mm Hg</w>
k ,</w>
cl ass</w>
children .</w>
art an</w>
ant ly</w>
ST R
On ly</w>
C M
3 ).</w>
0.0 1)</w>
ur ia.</w>
t as
spec ific
sp as
si a,</w>
response .</w>
ors ade</w>
o si
methad one</w>
iz ing</w>
depend ence</w>
deg re
ar m</w>
toxic ities</w>
pit e</w>
leuk emia</w>
hy d
hepatoc ellular</w>
comp ound</w>
anesthe sia.</w>
Des pite</w>
6 %)</w>
- -
sub cutaneous</w>
medul l
lat ency</w>
g ue</w>
H IV
H )</w>
Fol lowing</w>
0. 2</w>
vincrist ine</w>
sle ep</w>
s ar
rel ation</w>
om ycin</w>
ic -
he l
g re
fen flur
end ing</w>
1. 0</w>
( i.
p ron
n er</w>
magnesi um</w>
h und
cap top
b ir
R -
pressu re.</w>
ml /
lat er,</w>
glob ul
enzym es</w>
altern ative</w>
(2 0</w>
( 50</w>
top ical</w>
r in
pul se</w>
physi cal</w>
observ ation</w>
isoproteren ol-induced</w>
ine )</w>
diz zin
direc tly</w>
bu propi
9 9
os mol
m L</w>
fe rence</w>
estim ated</w>
ep inephr
cholest atic</w>
all y.</w>
A r
ma ,</w>
initi ated</w>
f av
dose s.</w>
diure tic</w>
desc rib
cor tex
al k
The y</w>
A s
1 2-
sud den</w>
steroid s</w>
sion s,</w>
mus t</w>
intraperitone al</w>
immun ore
b ur
aspart ate</w>
5- fluoro
vi ous</w>
ribavir in</w>
perio d,</w>
or e</w>
mix ed</w>
hist ological</w>
g ,</w>
dist ribution</w>
diff icul
arg inine</w>
Com par
(3 )</w>
need ed</w>
me tr
know n.</w>
inter fer
cy cles</w>
carbo platin</w>
ag e-
Cardi ac</w>
A P
2 6
tr as
suc cin
pre domin
hypertroph y</w>
doxorub icin-induced</w>
dos ing</w>
dam age.</w>
challeng e</w>
Pre treatment</w>
CY P
CI ,</w>
3 1</w>
( i
w all</w>
vom it
trans f
stro k
rig idity</w>
n oc
f ed</w>
antioxid ant</w>
al ol</w>
adren al
ac t</w>
ab le.</w>
w ay</w>
valpro ate</w>
si l
iso flurane</w>
is ch
investig ation</w>
il .</w>
i.p .
cros s-
cour ses</w>
carri ed</w>
L e
I g
st en
regres sion</w>
reac tive</w>
ot om
och rom
iti es.</w>
defic its</w>
cor d</w>
at a</w>
an o
amph otericin</w>
C ,</w>
trac t</w>
synap tic</w>
pro mis
f urosem
es )</w>
epilep sy.</w>
d ensity</w>
cul t
Si x</w>
2 7
vom iting</w>
ure a</w>
thresh ol
regimen s</w>
me ti
S P
ro n</w>
r y</w>
or ig
observ ations</w>
mg/ day</w>
ke le
inhib it</w>
implic ated</w>
hund red</w>
gen etic</w>
fi t</w>
d )</w>
ac cumulation</w>
U D
Q u
z idov
thi op
subject s.</w>
strept ozotoc
pro maz
physi ci
n a</w>
hyper cal
func tion
fron tal</w>
ent er
consist ed</w>
[ 3
s wit
hepati tis.</w>
find ing</w>
d ors
bene ficial</w>
ampl it
STR ACT</w>
C T</w>
5 7
ron ch
res c
recogn ized</w>
op i
on g
normal .</w>
n one</w>
kg(-1 )</w>
i b
el im
e -induced</w>
an .</w>
W OR
TE D</w>
PA N</w>
E l
D o
(+ )-
thal idomide</w>
strong ly</w>
resol ution</w>
regar ding</w>
prof en</w>
par tially</w>
norm oten
complic ated</w>
bor n</w>
block er</w>
WOR DS)</w>
UN CA
UNCA TED</w>
TR UNCATED</w>
F if
(AB STRACT</w>
un it
syn cop
subst ance</w>
publ ished</w>
ne i
ia sis</w>
glutathi one</w>
di sp
de part
MT X</w>
F -
vas ocon
ron ic</w>
pa rox
od ds</w>
molec ular</w>
gluc ocortico
extr apyramidal</w>
ev er</w>
2 8
sy ,</w>
spec tr
place ment</w>
dyskinesi as</w>
diagnos tic</w>
cl er
ad ine</w>
L V</w>
In ter
2 5-
radi o
ra rely</w>
om ic</w>
em at
di azepam
al bu
tiv en
test .</w>
shor t</w>
remain ing</w>
over dose</w>
nitroprus side</w>
micro g</w>
inform ation</w>
i.p .</w>
gra v
ca ref
W ith
Scal e</w>
H ist
sligh tly</w>
sel ected</w>
placebo- controlled</w>
olog ically</w>
intr am
clon id
aminonucle oside</w>
al g
TION :</w>
pro vi
pre ce
placebo .</w>
on ,</w>
e osinophil
Wh ile</w>
ve loc
tic ent
sp i
pres ents</w>
pregnanc y</w>
pent obarbit
nei ther</w>
min )</w>
infu sions</w>
f all</w>
activ ated</w>
0. 3</w>
( range</w>
v ant</w>
syn th
som n
re fl
metabolit es</w>
atro pine</w>
ar tic
success fully</w>
ici ans</w>
di an</w>
cer tain</w>
a ph
dil tiaz
cl onic</w>
ca using</w>
appl ied</w>
amoun t</w>
O ther</w>
C l
si ze</w>
par acetam
ot rans
neon atal</w>
l ic
il ateral</w>
hist opath
gu an
b ronch
adol es
L D
C or
4 0
4 ).</w>
y ;</w>
se s.</w>
oc arcin
manifest ations</w>
l er
g y
extrac t</w>
ex trem
ex pres
anticoag ul
amne sia</w>
al ong</w>
al most</w>
I T
-1 -
pro fi
potenti ated</w>
pl asia</w>
or rh
move ments</w>
fentan il</w>
estro gen</w>
ch ic
ameli or
MA P</w>
un usual</w>
sensitiz ation</w>
rh abdomy
it ory</w>
in ning</w>
deriv ati
3 3</w>
( 3.
samp les</w>
rever sal</w>
pron oun
par alle
o vari
lox ac
i dis
ch ar
O )</w>
- type</w>
vast atin</w>
um -induced</w>
re lie
prophyl axis</w>
pr acti
nause a,</w>
find ing
fi x
de generation</w>
d on
attribut ed</w>
T H</w>
M eth
B y</w>
ymptom atic</w>
respon ded</w>
protein s</w>
open -
lo cal
im i
G lu
Ch ronic</w>
3 7</w>
1 20</w>
ri f
p neum
n ociceptive</w>
follow- up
comple x
a )</w>
H ep
respectively ).</w>
injec tion,</w>
flu o
c .
bili ary</w>
ad ded</w>
symptom s,</w>
poly morph
mag nit
initi ally</w>
creat ine</w>
ap lastic</w>
S ign
M A</w>
I .</w>
CN S</w>
ul tras
ta il
studi es.</w>
pregn ant</w>
ost e
nifedi pine</w>
g er</w>
anti hypertensive</w>
S ,</w>
vari ety</w>
trans mission</w>
tem per
si vely</w>
inter mit
h .</w>
facil it
estradi ol</w>
essen tial</w>
dors al</w>
death .</w>
tri gg
t onic</w>
st o
phenobarbit al</w>
n ess,</w>
my el
mg )</w>
metabol ite</w>
maj ority</w>
f en</w>
b aro
IS C
A b
9 ,</w>
res on
ob ut
li po
le sion</w>
impro ve
import ance</w>
hydro chloride</w>
di ar
der ived</w>
comple ted</w>
a im
ISC US
I N</w>
F or
D ISCUS
5 5</w>
vie w</w>
vehic le</w>
treat ing</w>
stere otyp
rou s</w>
re verse</w>
pac t</w>
org an</w>
oni az
od -
is oniaz
extrac ellular</w>
exten sive</w>
di pine</w>
depres sive</w>
cathe ter
arac h
aden ocarcin
Y :</w>
1. 0
st rate
regi on</w>
prevent ing</w>
prednisol one</w>
pi ri
phosph at
per son
out put</w>
inhibit or,</w>
i bu
hemat ologic</w>
degre es</w>
cis plat
c -
bl ast
am mon
G -
F urther</w>
DISCUS SION
wh ose</w>
st in
shor t
path ological</w>
os pas
l up
ch rom
bene fit</w>
alb um
agent ,</w>
adju vant</w>
a vir</w>
M MA
ve -
test o
op tim
is ,</w>
equ i
det ection</w>
dent ate</w>
c ou
P ost
3 4</w>
thou ght</w>
reson ance</w>
plas mic</w>
pan ic</w>
op en</w>
on at
mg/kg ).</w>
he ad</w>
epi thelial</w>
drug -
capsa icin-induced</w>
b al
as e-
arrhythmi as.</w>
D is
B )</w>
t in
su ffered</w>
seg ment</w>
p id
open ia</w>
meas ure</w>
li ver
hepat otoxicity</w>
g em
enh ance
enceph al
dy ston
R A</w>
DISCUSSION :</w>
AD R</w>
0. 4
th at
sp ir
proc es
inten sive</w>
insuffici ency</w>
in es</w>
i onic</w>
fiel d</w>
experim ent
evalu able</w>
dist inc
St ud
Res ul
P C
AC E</w>
8 %)</w>
( 50
temper at
pronoun ced</w>
po or</w>
os cop
muc os
mg ,</w>
earli er</w>
a ir
U sing</w>
B lo
) /
tiven ess</w>
re mission</w>
nor adrenaline</w>
n -
mo vement</w>
induc ing</w>
g all
fac ial</w>
cl ar
catech ol
adequ ate</w>
T TI
SE TTI
F K
F .</w>
t y
reac h
o ventricular</w>
mpt om</w>
e ph
def ects</w>
at roph
anim als,</w>
a fferen
v ent
t orsade</w>
revie we
provid ed</w>
pre mature</w>
pi de
pepti de</w>
min or</w>
li th
l an
in tro
] ,</w>
S yst
3- year-old</w>
succin yl
mor b
hemo globin</w>
bar ri
b us
ation -
ab le
Thir ty-
SETTI NG
u ti
quin ol
prim arily</w>
enro lled</w>
electro n</w>
e :</w>
dig oxin</w>
curren tly</w>
consum ption</w>
M ost</w>
year s)</w>
ti d</w>
sol ution</w>
paclitax el
capsa ic
cap ac
apomorph ine</w>
anthrac ycl
ad mis
Sim il
SU RE
SU MMA
SUMMA R
R ,</w>
H ear
20 -
yl -
y pt
wa ve</w>
ru pt
pent yl
p on
log ic</w>
loc ated</w>
lo b
clin ic
cler osis</w>
beg inning</w>
anti epileptic</w>
acce ler
Resul ts</w>
AI M
ve in</w>
tic s,</w>
syndrome ,</w>
provi des</w>
mg .
differen tial</w>
ang ina</w>
alco h
adjust ed</w>
synth ase</w>
ros s</w>
q /
opath ic</w>
magne tic</w>
ex cl
enalap ril</w>
day s)</w>
benzodi azepine</w>
acetyl choline</w>
H ]
D ata</w>
5 .</w>
3 6
( AC
sulf ate</w>
rem if
pres sive</w>
pa inf
p olar</w>
mo ther
measure ments</w>
ifosf amide</w>
embr y
disorder .</w>
dic lofen
ce .</w>
c ulo
b en
amphet amine-induced</w>
adul ts</w>
R S</w>
ME A
Ad di
( range,</w>
toge ther</w>
side- effects</w>
rif amp
recipi ents</w>
re tic
quantit ative</w>
predn is
one ph
ch ild</w>
cann ab
T N
P <
MEA SURE
H .</w>
tub ul
re -
physi ologic</w>
p seud
occl usion</w>
man ner
magnit ude</w>
l )</w>
ic ular</w>
electr ical</w>
echocardi ography</w>
amin otrans
acce pt
3 8</w>
ul monary</w>
tac t</w>
t oc
sur face</w>
sion al</w>
reten tion</w>
mark er</w>
limb ic</w>
in ated</w>
human s.</w>
h and,</w>
es cal
differen ti
di ethyl
complic ations.</w>
atten tion</w>
athi op
angio edema</w>
Blo od</w>
5- year-old</w>
ve si
use d.</w>
relev ant</w>
pren atal</w>
mul ticent
le pt
interval ,</w>
im pact</w>
describ es</w>
ci meti
chloro quine</w>
c. v
be at
atri oventricular</w>
at er
N one</w>
5 4</w>
u nex
oc lop
embol ism</w>
de hydro
cal c
arth ritis</w>
anti gen</w>
an emia.</w>
20 %</w>
( N</w>
toler ability</w>
ter at
sul ph
pl ayed</w>
oti de</w>
kele tal</w>
con st
amin es</w>
-1 ,</w>
( MA
tig mine</w>
lo be</w>
lin ked</w>
ith rom
in tact</w>
gram s</w>
g s</w>
cri tical</w>
all ,</w>
ad mission</w>
a k</w>
SETTING :</w>
S D
9 %)</w>
4 2</w>
s pre
perio ds</w>
levo dopa-induced</w>
leth al</w>
le b
incl u
analy sis.</w>
agonist ,</w>
SUMMAR Y:</w>
P /
D ox
st abil
recor d
radi ation</w>
prob able</w>
ophyl l
o w
indic ates</w>
in tub
hospit al
hist amine</w>
cle ar</w>
bi polar</w>
be lie
ac tion.</w>
Si x
M P</w>
M I</w>
, 000</w>
ye t</w>
y s
tub er
ren in</w>
prog ester
pre disp
pentyl ene
olan zapine</w>
dr in
de gener
arge t</w>
antidepress ant</w>
. (ABSTRACT</w>
sup ra
press or</w>
immedi ate</w>
enc y.</w>
electro ly
di aly
de ,</w>
chang es.</w>
bupropi on</w>
van com
set t
rest ing</w>
reg ular</w>
proc ess</w>
pneum on
persist ed</w>
non steroidal</w>
medi ate</w>
fir st-
f il
et om
a ud
X )</w>
Sign ific
tor sades</w>
t arget</w>
refle x
recurren ce</w>
lear ning</w>
inflamm ation</w>
hist or
g ir
f asc
3 0-
10 %</w>
success ful</w>
m E
larg er</w>
idi opathic</w>
hour s.</w>
ectom y</w>
at ors</w>
ab les</w>
a qu
Intra venous</w>
ATP ase</w>
5 2</w>
withdraw al.</w>
studi es,</w>
per icardi
nitroglycer in</w>
hypokal emia</w>
hypo thesi
dose s,</w>
psycho tic</w>
produc ing</w>
painf ul</w>
op o
modi fied</w>
malign anc
li gi
l arge
cardi otoxicity.</w>
ap ne
C C
4 8
3 7
1 2.
0. 4</w>
w ide</w>
ul f
ther mia</w>
ri m
rhyth m</w>
protoc ol</w>
pentylene tetra
m ass</w>
intermit tent</w>
ine ster
in i
id o
hear ts</w>
fluox etine</w>
dimin ished</w>
co lo
chlor promaz
bili rub
ab stin
a sive</w>
Pre vious</w>
Ph ase</w>
P E
H IV</w>
Dru g</w>
0 )</w>
stimul ated</w>
propran olo
min ute</w>
l ing</w>
infu sion,</w>
electrocardio graphic</w>
deter m
agent .</w>
adriam yc
CS F</w>
= 0.0
wor k</w>
ul ar
ti es.</w>
shor ten
port al</w>
outcom es</w>
neutropen ia</w>
n ar
level .</w>
knowledg e,</w>
in ity</w>
identi fi
fat ty</w>
f el
er ous</w>
deliri um</w>
ane ur
R B
worsen ing</w>
su peri
schedul e</w>
reduc tions</w>
pres um
normoten sive</w>
mas sive</w>
lo fen</w>
il ,</w>
effec tiveness</w>
di hydro
Se ver
9 )</w>
1 1
( 30</w>
show s</w>
sev o
lo we
in- treated</w>
d ram
bromocript ine</w>
A p
4 50</w>
weigh t,</w>
sal t</w>
re sid
p -
normal ized</w>
amino phen
val v
super oxide</w>
ris ks</w>
meth yl</w>
globul in</w>
g ab
exc essive</w>
eti n</w>
estro gen
dist al</w>
d one</w>
biop si
benzodi azep
ac ut
L ong
A ),</w>
3 8
vac u
re stric
re li
orub icin</w>
intram us
i me
ha emo
control .</w>
at ax
ar d
apopto sis</w>
agg res
V T</w>
Ph en
O ver
C s
4- year-old</w>
(2 -
yl ate</w>
shoc k</w>
poin ts</w>
plac ed</w>
op ic</w>
li gh
enhance ment</w>
dis appeared</w>
det om
clo zap
channe l
blo od-
6- year-old</w>
5-F U</w>
time ,</w>
striat um</w>
stit ution</w>
peroxid ation</w>
ost atic</w>
n ,</w>
m um
kidne ys</w>
h r
et ax
catalep tic</w>
M ale</w>
M B
FK 50
u st
sens or
proca in
on omic</w>
o in
nephro sis</w>
mort al
me ans</w>
l ay
intrac erebral</w>
hal f</w>
e rec
dose- related</w>
de ep</w>
de .</w>
chloro thiaz
bri e
as ymptomatic</w>
S even</w>
L- arginine</w>
D H
7- year-old</w>
stand ing</w>
separ ate</w>
response ,</w>
ox idi
oc al</w>
neuropath ic</w>
lead s</w>
l is
hyp onat
heal th</w>
ex pressed</w>
ate -induced</w>
ast ro
ass ay</w>
a ther
E v
6 00</w>
5-H T</w>
- positive</w>
p um
o sis.</w>
me detom
ind in
in sti
ec oxi
disorder s.</w>
catalep sy.</w>
bra in.</w>
an ine</w>
Se iz
I L
G l
Con tro
A /
6 .</w>
ul ated</w>
tw o-
ref er
mono therapy</w>
log y</w>
jaundic e</w>
inter actions</w>
il i
gran ule</w>
form s</w>
electro encephalo
e ment</w>
aug ment
ath yro
3 9</w>
1 1.
tran sc
that ,</w>
thalam ic</w>
tachycardia .</w>
respon si
pro found</w>
ouab ain</w>
ol -
o k</w>
le d,</w>
g )</w>
fib ers</w>
fib er</w>
fi br
ere bro
epi rub
e .,</w>
chol inester
bac ter
PATIENT S</w>
El ectro
A Z
tri glycer
te d,</w>
t ob
stron g</w>
reviewe d.</w>
ren t</w>
reco ver
perfor me
pathw ay</w>
ill ed</w>
de m
cy tot
coll ected</w>
calcul ated</w>
be low</w>
an e-
album in</w>
a y.</w>
D ec
-1 0</w>
th re
subj ective</w>
propor tion</w>
o d.</w>
mg .</w>
mer ic
fl uc
dehydro gen
consc i
con current</w>
analgesi c
P V
P ),</w>
5-fluoro uracil</w>
yl ated</w>
w k</w>
sy mptom</w>
respecti vely</w>
neuro muscular</w>
is on
inv asive</w>
er v
coll ag
cit alop
ce phal
angio graphy</w>
K- 80
10 00</w>
un changed</w>
smo k
per me
ill in</w>
glomerul oneph
f oun
f iltration</w>
emb olic</w>
deple tion</w>
ar y,</w>
Ph armac
I D
A meric
A E
( W
s ot
re search</w>
prophyl actic</w>
mg/kg .</w>
ide -induced</w>
excit atory</w>
ex tra
erg y</w>
enc ing</w>
de si
cal cit
ca ud
ca ro
3 0%</w>
volunte ers</w>
ti mo
superi or</w>
stopp ed</w>
s ou
ol ig
o ,</w>
ha z
control s,</w>
ca ution</w>
block ers</w>
N- methyl-
M ul
Ei ght</w>
Ca 2
8- year-old</w>
4 7</w>
vari ables</w>
tuber culo
rang ed</w>
poten cy</w>
popul ation.</w>
hum ans</w>
hepar in-induced</w>
gen ital</w>
en s</w>
az athiop
T ,</w>
Com pared</w>
AD R
vomit ing,</w>
tic ,</w>
testo sterone</w>
ter ms</w>
ter but
spectr um</w>
ph leb
patter ns</w>
infec tion.</w>
di c</w>
cy te</w>
cur ve</w>
beta- adrenergic</w>
arg et
agg reg
S uc
R is
NS AID
Im mun
B ,</w>
met oclop
fentan yl
expos ure.</w>
abs or
P H
NO S</w>
yg d
spre ad</w>
remif entan
recept ors,</w>
microscop ic</w>
mic rom
maz en
leuk o
i ron</w>
g/ m
effect ,</w>
col chic
characteris tic</w>
analy ses</w>
am ygd
aff inity</w>
MA IN</w>
A V
ther mal</w>
s low</w>
respon sive</w>
mid d
lat ter</w>
kg ,</w>
intoxic ation</w>
hyperalgesi a.</w>
h ero
gen otyp
ful l</w>
event s.</w>
dynam ics</w>
[3 H]
4 3</w>
1 5-
weak ness</w>
tre n
th ym
sur ve
phosph or
insi pid
in h
ho od</w>
fe wer</w>
discontinu ed.</w>
der s</w>
dec line</w>
ant .</w>
al ing</w>
ad y</w>
acqu ired</w>
S O
2- year-old</w>
-1 )</w>
vas ospas
tri meth
se pt
s am
present ation</w>
pharmacokine tic</w>
ouab ain
myoclon us</w>
lim it
diff use</w>
d in
aud itory</w>
ant s,</w>
a e</w>
T en</w>
S T</w>
An im
y sm
ves sel
veloc ity</w>
s on</w>
m Glu
iz ation.</w>
ci prof
amin o</w>
U nit
T .</w>
N or
F o
D R
(1 0
tr ypt
techniqu e</w>
sli ght</w>
presc ri
post erior</w>
kin in</w>
iti s,</w>
is he
inf iltr
f le
dose- response</w>
disturb ances</w>
ant ,</w>
acid ,</w>
a sis.</w>
TION S:</w>
P L
Increas ed</w>
zidov udine</w>
uc ul
to pro
sol u
se em</w>
rever sib
resp ect</w>
re d,</w>
pro posed</w>
model ,</w>
me topro
mac roph
f ever</w>
enc ies</w>
deteri oration</w>
confir m</w>
bene f
b ound</w>
arach no
Li ver</w>
F ,</w>
C oca
3 /
3 ),</w>
2 5%</w>
ve d,</w>
th ,</w>
test ,</w>
t arget
se x</w>
se d,</w>
ques tion
prost ate</w>
po d
mg/m (2)</w>
mE q/
i on
gene sis</w>
func tions</w>
el ective</w>
demonst rates</w>
death s</w>
coca ine,</w>
cell s,</w>
asth en
al kal
ad renal</w>
acet aminophen
P P
IC H</w>
C G
5 5
0. 6</w>
( r</w>
un d</w>
th ick
qu ality</w>
micrograms/ kg</w>
lact ate</w>
h imb
dose- limiting</w>
clo se</w>
bl ind
avoid ance</w>
an tr
am ine
adv ant
administ ere
METHOD :</w>
7. 5</w>
uter ine</w>
ul tra
tro n</w>
ro se</w>
microscop y</w>
lup us</w>
ist ry</w>
hyper kal
ex clu
diar rhe
defici ent</w>
N either</w>
Ex perim
Ad riam
4 1</w>
0.0 5</w>
( e
( 4.
w ise</w>
w ild
t able
su mm
stimul i</w>
ser v
sequ el
rang ing</w>
par athyro
p. o
nephro pathy.</w>
lin es</w>
lat er.</w>
l ind
inte gr
i es,</w>
comp eti
ch ain</w>
ST UD
D F
D 1</w>
4 5
(0. 5</w>
the l
re present</w>
po i
pl ays</w>
leng th</w>
k -
he ter
grad ually</w>
epi lept
compon ent</w>
clo sely</w>
an dro
an -
acet ate</w>
P ain</w>
10 ,</w>
un known.</w>
s qu
progester one</w>
proble m</w>
patient s)</w>
oph thal
oc clu
neuro toxic</w>
iti es,</w>
intraperitone ally</w>
exc re
dose- dependently</w>
dis played</w>
cyclospor ine</w>
coun ts</w>
chron ically</w>
cerebell ar</w>
S ),</w>
HB e
B .</w>
- mediated</w>
z ole</w>
trans amin
tom ography</w>
to ok</w>
tiv ari
supplement ation</w>
short -term</w>
reg urg
phenyleph rine</w>
inhib its</w>
ine ff
expl ain</w>
er mal</w>
doc etax
cysti tis.</w>
concentr ations.</w>
ch ing</w>
behavi ors</w>
bac lofen</w>
angiotens in-
ame ter</w>
agent s,</w>
Unit ed</w>
Stud y</w>
P hy
My ocardial</w>
H R
DO X
Ch ang
A g</w>
ures ,</w>
suscepti ble</w>
side -induced</w>
se tron</w>
schizophren ia</w>
prob ability</w>
pe g
particip ants</w>
p anc
ol ip
immuno hist
f ati
end omet
em phasi
dipyridam ol
deli very</w>
cy ste
al azine</w>
U )</w>
Signific ant</w>
L- N
4 9</w>
ycl ic</w>
signific ance</w>
prolifer ation</w>
ox amine</w>
n ess.</w>
medic ation.</w>
ing ly</w>
evid ent</w>
aminotrans ferase</w>
ag grav
M M
M K-80
1 5.
(1 5</w>
val ent</w>
u me
star t</w>
se -
s w
occur red.</w>
o ural</w>
implic ations</w>
hyp ox
exc ess</w>
ec ain
condition ed</w>
INT ER
I T</w>
F rom</w>
B ased</w>
w ays</w>
tra um
tr am
sig n</w>
recogn ition</w>
quin idine</w>
proced ure</w>
partic ular</w>
ob lastic</w>
interfer on</w>
immunosup pressive</w>
enc y,</w>
do g</w>
depres sion.</w>
d s.</w>
cros s
anxi et
antin ociceptive</w>
aff ecting</w>
Sub j
P ar
ME NT
Hear t</w>
F lu
1- year-old</w>
st aining</w>
re uptake</w>
oxic ity</w>
opio id
ischem ia.</w>
is m,</w>
immuno deficiency</w>
depart ment</w>
captop ril</w>
bu lo
bec ome</w>
amplit ude</w>
amide ,</w>
ag ne
QT c</w>
ven ess</w>
vasopress in</w>
v ar
set ting</w>
sec re
pro min
par alysis</w>
investig ated.</w>
ing u
hyperprolact inemia</w>
hydro chlorothiaz
furosem ide</w>
el ect
cor responding</w>
conver sion</w>
can not</w>
barri er</w>
am id
al anine</w>
T ran
G en
F in
C P</w>
(1 -
unc lear
ul cer
th .</w>
sam ple</w>
ocy cl
ochrom e</w>
n asal</w>
is om
inf ant</w>
fenflur amine</w>
fe ren
el uc
bo y</w>
antagon ism</w>
all ergic</w>
al low
ag ain</w>
ER I
DO X</w>
Compar ison</w>
6 0
2. 0</w>
wild -type</w>
we l
tri ax
time .</w>
su mat
small er</w>
rel b
re placement</w>
phenomen on</w>
mod ulation</w>
it .</w>
intrac ellular</w>
ino relb
inf iltration</w>
id en
i .</w>
fl ut
evalu ated.</w>
determ ined.</w>
def ect
cholinester ase</w>
beg an</w>
bac k</w>
b yp
STUD Y</w>
E arly</w>
sumat ript
smo oth</w>
s.c .)</w>
ru ption</w>
p .</w>
orth ostatic</w>
mac ro
lim b</w>
l umb
in ser
ide s</w>
i ble</w>
fe ver,</w>
eph ed
enh ance</w>
dis ul
diet ary</w>
coun ter
cle arly</w>
carbam azep
ar ab
acid .</w>
L E
H ere
H ,</w>
9- year-old</w>
3 5
1 4.
yl ine</w>
vit ro
subj ected</w>
se p
sal ic
per man
paracetam ol</w>
ograph y.</w>
no w</w>
monke ys</w>
model s.</w>
le sion
hal f-
bic ucul
allodyn ia</w>
al one,</w>
stimul ating</w>
show ing</w>
sevo flurane</w>
respectively )</w>
qu e</w>
pressu res</w>
picrotox in</w>
par a
ous ly.</w>
hist ologic</w>
fact ors.</w>
appro ach</w>
aim ed</w>
T d
S D</w>
Dop pl
1 3.
us t</w>
struct ure</w>
sti l
som e
simil ar
seroton ergic</w>
prot ected</w>
mum ol/
ment s.</w>
m am
haem orrh
h ere</w>
fasc icul
ex pected</w>
embr yo
em plo
d ly</w>
alter ation</w>
a emic</w>
F e
D- penicillamine</w>
8 ).</w>
(N S
system s</w>
s low
ret inal</w>
prot ect</w>
proced ures</w>
present ed.</w>
perf used</w>
off sp
neuro trans
mo l</w>
mal form
infarc tion,</w>
ine ur
experim ent</w>
effec tively</w>
detect able</w>
bir th</w>
auto immune</w>
ar yn
S A
D 3</w>
( IC
under taken</w>
suff ering</w>
rec tal</w>
ratio s</w>
r in</w>
ph ot
oxid ase</w>
out patient</w>
ol ine</w>
lamiv ud
headache ,</w>
d d
d ;</w>
cannab in
attribut able</w>
abil ity.</w>
reach ed</w>
r e</w>
ocicep tion</w>
nicot ine-induced</w>
k ain
hospit alized</w>
gir l</w>
distinc t</w>
d an
consci ous
caro tid</w>
bu s</w>
arter ies</w>
I O
H er</w>
G r
50 ,</w>
ver sion</w>
ter al</w>
pl an
ovari an</w>
op yr
measure ment</w>
inter ven
infec tions</w>
exam ined.</w>
er -
contracep tiv
aut onomic</w>
am bul
Sever al</w>
H U
6 ).</w>
withdraw n</w>
us al</w>
tu be</w>
pro ved</w>
prev ents</w>
predic tive</w>
os ing</w>
ome tr
o vir</w>
manner .</w>
le ar</w>
is su
ig n</w>
ic ity</w>
electro physiological</w>
cycl ic</w>
capac ity</w>
b est</w>
atic ally</w>
ardi ve</w>
arachno id</w>
afferen t</w>
S ome</w>
IS O
E M
D X
( 4</w>
us ers.</w>
tic -induced</w>
retino ic</w>
phen otyp
manifest ed</w>
last ed</w>
in otropic</w>
eth in
ep e
en tial</w>
cardiom y
ax onal</w>
anti gen
R A
PR L</w>
Hy poten
H ospit
wh ole</w>
vancom ycin</w>
th or
stil be
sle ep
over dose.</w>
ma k
m s,</w>
insul in</w>
h )</w>
es oph
epileptic us.</w>
em erg
duc t</w>
cyt ochrome</w>
cross over</w>
const ant</w>
competi tive</w>
apomorph ine-induced</w>
anti tumor</w>
N )</w>
Chang es</w>
C 57
-1 0
-1 ,
+ )</w>
(2 )
ur ation</w>
tic lop
ta ining</w>
t one</w>
stilbe stro
st s</w>
si rolimus</w>
pharmacokine tics</w>
iso flur
hallucin ations</w>
group s:</w>
gem cit
g ain</w>
es :</w>
diltiaz em</w>
cas e-
anticoag ulation</w>
Ne ph
N it
C ase</w>
B M
0.05 ),</w>
( median</w>
yo himb
ti tr
ten ded</w>
t )</w>
substanti al</w>
sub cut
re presents</w>
prospecti vely</w>
pro x
op ril</w>
neuro toxicity.</w>
myocardi um</w>
morb idity</w>
mal ar
ju g
intra -
immunore activity</w>
if ied</w>
i. c.v
he at</w>
fix ed</w>
eti ology</w>
ent s.</w>
control led,</w>
CH F</w>
B P
us cit
thyro idis
thyro id</w>
tachycardia ,</w>
syn erg
sing le-
si x
o pa
nicot inic</w>
i on</w>
es ;</w>
den af
compar ing</w>
cas e,</w>
bradycardia .</w>
at es.</w>
anti cholinergic</w>
anthracycl ine</w>
ant o
ant ine
V PA
ST -
S A</w>
R ating</w>
I P
( Group</w>
vol ume
sym path
s or
rout ine</w>
po ison
os yn
optim al</w>
nephro genic</w>
medi a</w>
mark ers</w>
ine d,</w>
glob al</w>
ecti vely</w>
drin king</w>
def in
chemo therapeutic</w>
biopsi es</w>
attac ks</w>
Me dian</w>
H is</w>
C l</w>
valv ular</w>
rec tom
orph ine</w>
no de</w>
n ational</w>
mo od</w>
los s.</w>
docum ent
consequ ences</w>
cocaine- dependent</w>
cho ice</w>
cerebro spinal</w>
beat s/
ane -induced</w>
am ant
M -
A u
seiz ure
recor ds</w>
pharmac ologic</w>
perme ability</w>
o ve
ne ver</w>
m os
le thal
foun d.</w>
flu mazen
f ur
ex ce
dos ages</w>
defic it</w>
d ri
convul sions.</w>
control ,</w>
consequ ence</w>
c re
and s</w>
S event
O r
I so
Hi gh
AM E</w>
(2 00</w>
wel ve</w>
ventric le</w>
um erous</w>
ri a</w>
recor ded.</w>
pro fen
p ast</w>
ox ane</w>
metho ds</w>
medetom idine</w>
ir rit
in- associated</w>
hyper plasia</w>
headac h
glomerul i</w>
cur onium</w>
cr yst
compl ain
av oid</w>
U C
J ap
Gr ade</w>
Doppl er</w>
C57 B
4 ),</w>
stra in</w>
st em</w>
reac tion.</w>
pre lim
pap illary</w>
pa w</w>
p el
om otor</w>
morph ological</w>
m io
ine :</w>
in )</w>
ex ter
ede ma,</w>
dil ated</w>
chemo therap
amygd al
am il
am but
W e
U r
Phy si
For ty-
D .</w>
0.00 1),</w>
uti li
uni que</w>
spec ies</w>
s keletal</w>
s atis
resid ual</w>
promin ent</w>
predomin antly</w>
pivaca ine</w>
p in
ox yl
o vascular</w>
new ly</w>
n atal</w>
microm ol/
me perid
isoniaz id</w>
ing ly,</w>
hemo dialysis</w>
f ast
condi tions.</w>
behavi oural</w>
am it
al in</w>
T M
M R</w>
Long -term</w>
L o
H )
5 8</w>
5 7</w>
10 (-
( 4-
ure th
ure mic</w>
supra ventricular</w>
rema in</w>
performe d.</w>
o sis,</w>
nex t</w>
mening itis</w>
load ing</w>
l ess
ithrom ycin</w>
inf requ
fl ecain
ent ered</w>
dail y,</w>
caref ul</w>
ab le,</w>
L ith
Di fferen
D B
Com b
5 3</w>
thrombo embolic</w>
system ,</w>
sol ute</w>
prednis one</w>
phy sos
pathophysi ology</w>
olog y.</w>
me lat
le uc
k noc
intra vascular</w>
intr ad
haloperid ol.</w>
g/ d
dig it
at en
am ,</w>
M et
J an
I f</w>
Fin ally,</w>
E ach</w>
E T
2 ;</w>
to ward</w>
te mpt
sil denaf
se e
scre ening</w>
res uscit
ras h</w>
prelim inary</w>
om al
medi al</w>
lowe red</w>
lo ad</w>
l ation</w>
ir reversible</w>
inf or
hero in</w>
ed -
di p
cirrho sis</w>
chang es,</w>
can ine</w>
all -
ac ro
ac count</w>
SI AD
IV )</w>
GF -
. g
(H B
( K
y s.</w>
y ric</w>
x ameth
ver sity</w>
tu bulo
sub arachnoid</w>
stopp ing</w>
st om
sensi tiv
prospecti ve,</w>
proble ms</w>
phosph olip
mg/kg/ day</w>
me ll
man ag
intramus cular</w>
ine- associated</w>
imi pramine</w>
ill ust
femal es</w>
erythro poi
ede ma.</w>
dys function,</w>
develop mental</w>
amit ript
amide -induced</w>
V al
PA )</w>
MA T
Af ric
0. 8</w>
( 5.
valu es.</w>
temperat ure</w>
ri fic
pac ing</w>
ox antr
minut es.</w>
microgram /
mal es</w>
l ing
if ost
i el
end oc
duc t
decreas ing</w>
con sti
c lop
attenu ate</w>
ap ine</w>
antibio tic</w>
an emia,</w>
abnormal ities.</w>
S p
GABA ergic</w>
G ,</w>
( a</w>
( 40</w>
wom en.</w>
ventil ation</w>
vasocon stric
under g
ser ial</w>
sac rific
rhabdomy olysis</w>
res s</w>
requir e</w>
r amide</w>
op ulmonary</w>
olog ic
lithi um-induced</w>
ligi ble</w>
kind led</w>
id azol
h ar
f lo
eryth emat
dyston ia</w>
de v
ac ts</w>
ab use.</w>
O ral</w>
Neph ro
Grou ps</w>
youn ger</w>
vari able</w>
tivari ate</w>
schedul ed</w>
ra ised</w>
pl ast
per ox
mg/m 2/
mell it
low ering</w>
li pos
inc re
in s.</w>
in appropriate</w>
f as
docetax el</w>
diseas es</w>
discontinu ing</w>
dis mut
amide .</w>
alk alo
ac etic</w>
R et
Hep ar
G S
D N
7 ).</w>
50 -
4 6</w>
4 0%</w>
z om
transpor t</w>
ti car
threshol ds</w>
sol id</w>
soci al</w>
responsi veness</w>
respon d</w>
recept or-
pro mpt
plac e</w>
p up
on es</w>
olog y,</w>
midd le</w>
lim it</w>
inorelb ine</w>
hypothesi zed</w>
haem at
fo ot</w>
f inal</w>
discharg e</w>
dec l
cortis ol</w>
cle .</w>
bic arb
angio graph
acid osis</w>
U T
N P
L A</w>
AID S</w>
A D</w>
7 6</w>
ul c
tric yclic</w>
thor ac
shor tly</w>
s ha
prog no
produc t</w>
otom y</w>
opi ate</w>
hypercal cemia</w>
g ol
enc oun
cortico steroid</w>
continu ously</w>
blood- brain</w>
ather os
ap ar
analy sis,</w>
anaesthe tized</w>
ac u
Re ver
O -
MR I</w>
L- DO
Jan u
C ap
AM P</w>
6 7</w>
) :</w>
war r
un ilateral</w>
ty ros
suc c
sign aling</w>
re cur
press ing</w>
placebo ,</w>
it s.</w>
hyp oc
graf t</w>
follow-up .</w>
em ent.</w>
doxorubic in.</w>
creat in
cimeti dine</w>
ch i
VE N
T A
L ab
AT P</w>
0. 7</w>
0 /
(-1 )</w>
y ri
us h
ul ate</w>
tro p
timo lol</w>
th em
stimul ation.</w>
sp ac
se min
s clero
prov o
neut roph
neuropath y,</w>
mo tion</w>
medi um</w>
li gn
injur y,</w>
in hal
hyperalgesi c</w>
hemorrh age.</w>
fel l</w>
fam ily</w>
discus sed</w>
dep olar
def ect</w>
cir c
ation :</w>
R F
D ,</w>
8 7</w>
00 -
(4 )</w>
y iel
x y
st er</w>
simult aneously</w>
se l</w>
relap se</w>
re infor
praz osin</w>
plat in
ot al</w>
my asthen
mat ter</w>
ine /
id az
ia :</w>
i )</w>
hype remia</w>
ey e</w>
chlorpromaz ine</w>
S SR
S R</w>
P os
M ,</w>
INTER VEN
I L-
G .</w>
vul ner
un its</w>
tram ad
thiop ent
tetra hydro
syn thetic</w>
sp e
rest ored</w>
resp ective</w>
regimen .</w>
on azole</w>
numb ers</w>
ma x
investig ations</w>
in os
hel p</w>
establ ish</w>
elev ations</w>
diclofen ac</w>
dehydrogen ase</w>
cyto plasmic</w>
cir cum
cathe ter</w>
ati vel
antidepress ants</w>
an n
Rec ent</w>
Q RS</w>
MAT ERI
D P
CA 1</w>
C E
An g
5 6</w>
1 ;</w>
(0. 1</w>
ysm al</w>
un common</w>
stra ins</w>
shor ter</w>
rig id
rele as
refer red</w>
pre term</w>
potenti ation</w>
perman ent</w>
ocy tic</w>
ng/ ml
min oxidi
main tain</w>
inter vention</w>
inf erior</w>
increas ed.</w>
fibrill ation.</w>
elect rom
det ect</w>
cyste ine</w>
cer v
b ran
atroph y</w>
as h
arth ritis.</w>
ag it
a udi
P a
N-methyl- D-
C lo
C entr
AS A</w>
3. 0</w>
1 8.
theli um</w>
tempor ary</w>
t ardive</w>
subj ect</w>
statis tical</w>
simult aneous</w>
seve rely</w>
retro specti
pum p</w>
pa ir
omet ric</w>
mother s</w>
in somn
g on
fe ed
estim ate</w>
eff ici
d ap
correc ted</w>
consist ing</w>
ch ore
Subj ects</w>
N ine</w>
Janu ary</w>
II ,</w>
H D</w>
Anim als</w>
(O H)
vi sion</w>
un chang
ter s</w>
syn the
re mark
p H</w>
lo dipine</w>
lab et
ing est
ine ;</w>
h il
gluc o
epirub icin</w>
electrocardio gram</w>
depres sion,</w>
del ay</w>
byp ass</w>
brie f</w>
ar rest
U se</w>
S yn
N E</w>
MK-80 1</w>
M ed
L-N AME</w>
In trac
H alo
H R</w>
D el
C y
5 ),</w>
. ),</w>
( EC
yc in.</w>
ventr al</w>
v ec
un known</w>
sion -
self- administration</w>
seem ed</w>
remifentan il</w>
psycho sis</w>
pro ven</w>
pl asi
pas sive</w>
nephro sis.</w>
neg ati
methyl prednisolone</w>
low est</w>
los artan</w>
locom o
ll ing</w>
line ar</w>
indometh ac
frac tional</w>
fr ag
etom idate</w>
electroly te</w>
der ,</w>
cocaine- associated</w>
c ranial</w>
c ra
as yst
an e.</w>
] -
S ide</w>
M an
6 6</w>
5 9
. ).</w>
+/ -1
unclear .</w>
tissu es</w>
thromb in</w>
man ner</w>
lith iasis</w>
ic k</w>
hour s,</w>
fact ors,</w>
equi valent</w>
endomet rial</w>
emplo y
echocardi ographic</w>
cyclophosphamide -induced</w>
cortex ,</w>
comple tion</w>
cef triax
b )</w>
angiotensin- converting</w>
analo gue</w>
Re g
N- acetyl
F 1</w>
6 1</w>
3. 5</w>
(P T
(A D
tra ining</w>
thrombo embolism</w>
terbut aline</w>
suffici ent</w>
ser tr
se s,</w>
ri min
rad ical</w>
pro gram
praz ol
path ology</w>
on se
ol i
myoclon ic</w>
minim um</w>
level ,</w>
gli al</w>
fe a
ex tre
er 's</w>
compon ents</w>
ation )</w>
analo g</w>
al ways</w>
air way</w>
age al</w>
Sub sequ
M in
L V
I ts</w>
G T
G E
CB F</w>
1 6.
vi ron
val ve</w>
vacu ol
syncop e</w>
ser ved</w>
s well
rou gh</w>
ri tis,</w>
ret in
phleb itis</w>
pathw ays</w>
part um</w>
myo pathy.</w>
lumb ar</w>
ibu profen</w>
hydro chlor
gu ine
glomeruloneph ritis</w>
f un
f re
dog s,</w>
depend ence.</w>
de le
dat ab
chrom at
carcin oma.</w>
canc er,</w>
azathiop rine</w>
appro ach
alle vi
ac yclo
Th rom
M ic
Ei gh
( +/-
te trac
succinyl choline</w>
su xameth
sal ine,</w>
profi les</w>
op sy</w>
neo plastic</w>
mortal ity.</w>
mes na</w>
meas uring</w>
man nit
knoc k
is op
hospit al.</w>
ep tic</w>
ectom ized</w>
da un
d :</w>
cyt osine</w>
contrac tion</w>
com mun
at tempt
arrhyth mia.</w>
ap ri
amino glyco
abil ity,</w>
With in</w>
U -
SM -
L ).</w>
Hi gh</w>
He al
FK50 6</w>
Americ an</w>
(E D
vie w
sugg estive</w>
smo king</w>
pr ur
pilo t</w>
p ol
o il</w>
norep inephr
metopro lol</w>
lind ane</w>
iz ation,</w>
first- line</w>
dist ingu
diethyl stilbestro
dex tro
cerebro vascular</w>
ce ,</w>
cap illary</w>
behavi our</w>
an e,</w>
amin ophylline</w>
al located</w>
St udi
HIV -
C arb
(2. 5</w>
wide spread</w>
ut ure</w>
spec imen
sou ght</w>
pi per
panc re
obut yric</w>
n im
me gal
maz e</w>
inh aled</w>
in tak
h ap
fav or
f usion</w>
eth ambut
est er</w>
catech olamine</w>
attenu ation</w>
alg ia</w>
adenocarcin oma</w>
T ri
S ).</w>
He pati
B et
7 3</w>
7 .</w>
0. 0</w>
(2 5</w>
(+ )</w>
we l</w>
ut ing</w>
thrombo sis.</w>
ter ol</w>
subject s,</w>
so ur
shor t-
re activity</w>
prepar ations</w>
po or
physici ans</w>
peritone al</w>
mg/ d</w>
lab el</w>
hear t.</w>
expl ained</w>
correl ate</w>
con junc
circul ating</w>
bradycardia ,</w>
be ats</w>
ati tis</w>
Seiz ures</w>
P B</w>
L VE
viv o.</w>
sul piri
sc an</w>
retur n</w>
response s.</w>
protein uria.</w>
prot ects</w>
propyl thio
proces ses</w>
pres er
om a,</w>
nucle ar</w>
neuron s.</w>
necro sis.</w>
m L/
le sions.</w>
dys rhyth
dizzin ess</w>
di men
deteri or
dail y.</w>
channel s</w>
block .</w>
b is
atri ure
as p
ar ch
aff ective</w>
Pro po
Per i
P rop
Hypoten sion</w>
D ex
6 4</w>
yl )
vag inal</w>
u los
tas k</w>
sus p
relie f</w>
procain amide</w>
post natal</w>
phasi c</w>
ou s,</w>
opo i
nat ure</w>
men opa
mechanis ms.</w>
m im
leuko encephalopathy</w>
le ven</w>
f if
en viron
ect ed.</w>
derivati ves</w>
compl i
compar ative</w>
c m
aneur ys
anaesthe sia.</w>
an ol</w>
acc umb
absor ption</w>
MEASURE MENT
Cs A</w>
C M</w>
ur on
struct ures</w>
re sem
prom pt</w>
post ural</w>
obstruc tive</w>
mucos al</w>
min ocycl
kine tic</w>
in- related</w>
ifost ine</w>
iden tical</w>
hemat oma</w>
glucocortico id</w>
fi ram</w>
enh ances</w>
ecoxi b</w>
e ;</w>
der mal</w>
contracep tive</w>
concentr ation.</w>
con genital</w>
case- control</w>
at or
asi c</w>
amoun ts</w>
am b
Studi es</w>
M .</w>
7 8
4 0-
yl ation</w>
surger y,</w>
schizophren ic</w>
repor ting</w>
reg ard</w>
pos ses
poor ly</w>
paralle l</w>
oc tre
nitro -
neurotrans mit
me ly</w>
indin avir</w>
event s,</w>
ev ol
dou ble</w>
continu ation</w>
condi tions,</w>
chol ec
at tem
anti diuretic</w>
ant ed</w>
an con
al fentanil</w>
Dru g
B r
20 ,</w>
/ -
- to-
(- )-
under sto
tion ally,</w>
so ,</w>
ra ph
qu eti
predic t</w>
pap er</w>
p all
n atriure
multicent er</w>
metoclop ramide</w>
label ed</w>
intrac erebro
h er
gest ation</w>
erythemat os
em is
che mic
cat at
arter io
al do
al de
a uc
SN P</w>
PA N
Over all,</w>
N P</w>
BACKGROUN D</w>
A P</w>
8 5</w>
0. 3
vec ur
vari ed</w>
scop olamine</w>
re ference</w>
qu al
predict ors</w>
ox al
otoxic ity,</w>
om y
ocy to
occa sion
mg/ day)</w>
lithi um-
k illed</w>
iz ed.</w>
identifi ed.</w>
gentam ic
di phen
cyt es</w>
cont ribution</w>
colchic ine</w>
col on
citalop ram</w>
block ade
bilirub in</w>
ben ign</w>
arab ino
an at
Tran si
P B
G i
Dox orubicin</w>
B i
4 ,
( r
vag al</w>
v inorelbine</w>
the ophyll
significant .</w>
restric ted</w>
requi re
reac tions.</w>
of f</w>
modi fy</w>
it sel
in dependently</w>
id ine,</w>
gy rus</w>
gly ce
fol ic</w>
extre mely</w>
di ameter</w>
de mo
condi tion.</w>
comp uted</w>
clin icians</w>
calcit ri
aw a
attenu ates</w>
at el
amin obutyric</w>
alde hy
Twent y</w>
SH R</w>
PATIENT S:</w>
P sych
O 2</w>
METHOD S</w>
L ),</w>
F ancon
C F
10 )</w>
( from</w>
z ed.</w>
ur ticar
subst ances</w>
st ly</w>
s ph
res ,</w>
qu inine</w>
methyl phen
lay er</w>
hydrox y-
granulo mat
di lat
cortico steroid
comp ens
bo wel</w>
anti retro
am is
aggres sive</w>
ac cur
] .</w>
C at
C R</w>
A V</w>
5- hydroxy
0. 9</w>
( c
u sions</w>
tre x
sal ine.</w>
regul ated</w>
precipit ated</w>
prece ded</w>
perid ol</w>
paren teral</w>
myocardi tis</w>
mix ture</w>
melat onin</w>
lis in
li qu
isop ren
io hex
ific ation</w>
finding s,</w>
fas hi
en ergy</w>
embryo s</w>
e ous</w>
e ach
discus s</w>
disc rimin
collag en</w>
ciprof loxacin</w>
am .</w>
acid s</w>
O H-
C ol
7 7</w>
1. 2</w>
(p <
vis c
t ase</w>
sot alol</w>
sign al</w>
relax ation</w>
re produc
re ady</w>
potenti als</w>
ogen ous</w>
nerv es</w>
mos sy</w>
min al</w>
mGlu R
long- lasting</w>
l ide</w>
induc ible</w>
increas ingly</w>
implant ed</w>
il -induced</w>
g ad
four th</w>
excl uded</w>
del ta</w>
coag ulation</w>
cardi otoxic</w>
car nit
bio logical</w>
arrhythmi as,</w>
apne a</w>
an omal
al is</w>
Re por
Pro long
Pos sible</w>
N ar
ME TH</w>
Contro l</w>
C57B L/
6 3</w>
0.000 1).</w>
tyros ine</w>
tri als.</w>
the refore,</w>
strate gi
spas m</w>
rep olar
r al
pyri dox
neuro genic</w>
n es
mit oxantr
lipos omal</w>
it rate</w>
gre l</w>
fr act
form ul
en -
electrom yo
de sign
d s,</w>
ar ing</w>
ang ial</w>
acid -induced</w>
ac ross</w>
U ni
S ur
R .</w>
PA R
N on
E p
7 0
6 2</w>
5 9</w>
3 0,</w>
2 5,</w>
u sion.</w>
tum ors.</w>
test s.</w>
te zom
ta il</w>
substanti a</w>
stit uted</w>
sit u
sequ ence</w>
regurg itation</w>
rabb its</w>
ot otoxicity</w>
organ ic</w>
nephro toxic</w>
na prox
ishe d.</w>
inter pre
influ enced</w>
if y</w>
histopath ological</w>
exacerb ation</w>
eme tic</w>
dis semin
dem enti
de grad
cytot oxic</w>
contribut ing</w>
clo mi
baro reflex</w>
acc id
ab solute</w>
Z )</w>
Transi ent</w>
Ne w</w>
MATERI AL
M S</w>
E valu
3 4
tri al,</w>
t on</w>
t ary</w>
stop pe
sequ ential</w>
s at
ratio ,</w>
rad ic
promis ing</w>
pr inc
os ar
n umerous</w>
lesion ed</w>
hyp om
he av
he al</w>
glomer ulos
finding s.</w>
episo de
elim ination</w>
difficul t</w>
di hydroxy
contribut es</w>
combin ations</w>
but am
basel ine,</w>
ation ;</w>
ap l
ac cumul
Thir ty</w>
T welve</w>
P/ d
I s</w>
Ch in
CO 2</w>
0.0 1),</w>
(i. e.,</w>
y -induced</w>
ves sel</w>
termin ation</w>
tac rolim
streptozotoc in</w>
specific ally</w>
sc i
proper ties.</w>
produc ts</w>
phenyleph r
patient s'</w>
par as
oxygen ase</w>
out put
nit r
m atic</w>
lidoca ine.</w>
knock out</w>
i.p. ),</w>
h and
f in
en ox
en ed</w>
disorder s,</w>
determin ation</w>
d P/d
at rop
amin o-
albu min
ad junc
N ine
Here ,</w>
CO M
C yclo
C al
AIM S:</w>
6 9</w>
(P AN
trans ferase</w>
thorac ic</w>
ro d
retic ul
requi res</w>
outcom e.</w>
odi um</w>
ochem istry</w>
new born</w>
nec k</w>
menopa usal</w>
medull a</w>
inhib i
inc or
g y</w>
flow .</w>
equ ally</w>
ephed rine</w>
deriv ative</w>
consist ently</w>
compl ained</w>
bacter ial</w>
at rac
ast er
asses sed.</w>
P F
M o
In iti
C s</w>
C D</w>
(M T
war ds</w>
vast at
ton ic-
tin nit
st one</w>
sel ectively</w>
sel ec
s or</w>
pentobarbit al</w>
path ologic</w>
ond an
ne t</w>
nat ural</w>
n mol
me l
kine sia</w>
iso prost
inhibit or
ex t
encephalo pathy.</w>
electro physiologic</w>
cult ured</w>
con cent
cerv ical</w>
achie ve</w>
V -
Suc h</w>
N-methyl-D- aspartate</w>
Clin icians</w>
AR F</w>
(C B
y ).</w>
week ,</w>
ur in
ultra structural</w>
ten d
survi v
substanti ally</w>
subcut aneously</w>
su it
soci ation</w>
si ded</w>
record ings</w>
not ed.</w>
ne arly</w>
n mol/
ke y</w>
invol ve</w>
ine -</w>
i.p .,</w>
gluc uron
gemcit abine</w>
fo od</w>
fac t</w>
f ying</w>
f os
exce ed
disturb ance</w>
desc ending</w>
cortex .</w>
child hood</w>
ac idi
a :</w>
SC H</w>
O UT
E 2</w>
DE S</w>
D ep
Cardi ovascular</w>
Adriam ycin</w>
Addi tionally,</w>
5 %,</w>
00 ,</w>
(A )</w>
trans fer
tra z
termin al</w>
syndrom es</w>
survi val
second -
random ised</w>
question na
predic ted</w>
pre feren
per gol
ol s</w>
norm ally</w>
mg/m 2,</w>
ment s,</w>
local ized</w>
ling ual</w>
ine ural</w>
icac y</w>
hy bri
group )</w>
gl auc
emergen ce</w>
dismut ase</w>
der .</w>
dail y)</w>
d ate</w>
cortico steroids</w>
consi der</w>
be f
b .
attem pt</w>
antibio tics</w>
ambul atory</w>
al ready</w>
al az
administere d.</w>
ac hol</w>
Ris k</w>
Res pon
O R</w>
B -
9 6</w>
1. 3</w>
yohimb ine</w>
wh at</w>
ti es,</w>
stimul ant</w>
st a
s par
ren ess</w>
ren e</w>
progres sed</w>
po wer</w>
phosphat ase</w>
not .</w>
neuro protective</w>
neph ritis.</w>
mes angial</w>
medic ations.</w>
lor azepam</w>
inhibit ing</w>
ineff ective</w>
in ner</w>
hydrochlorothiaz ide</w>
hepati tis,</w>
fact ory</w>
exer t</w>
erec tile</w>
dissemin ated</w>
discharg ed</w>
den erv
decl ined</w>
cit rate</w>
caus al</w>
atrac ur
ate g
antipsycho tics</w>
anaesthe tic</w>
am yl
aff ects</w>
Simil ar</w>
IS O</w>
Fif ty-
Ca2 +</w>
B u
As ses
9 5</w>
9 0
6 8</w>
6 0%</w>
5-HT (1
3, 4-
1 5,</w>
( 7.
( 6.
y clin
vessel s</w>
vari ability</w>
ti ve,</w>
side s</w>
rat s:</w>
pre g
poly uria</w>
pati on</w>
path ic</w>
pac e
p <
om ime
measure d.</w>
intrad ermal</w>
inten se</w>
inhibit ors.</w>
ine 's</w>
he re
haloperid ol,</w>
gamma- aminobutyric</w>
foc i</w>
d u
contrib uted</w>
com for
bre ak
ameth ox
ad ver
T n
S af
E -
CYP 2
A ce
3 44</w>
(O R</w>
vasospas m</w>
vasocon striction</w>
trimeth op
transpor ter</w>
tonic- clonic</w>
ten sion</w>
t ment</w>
sumatript an</w>
sol ub
sec tions</w>
ro f
predisp osing</w>
poly mer
oz yg
ox y-
ni gr
mg/m (2
mal e
l af
laf ax
is ms</w>
il lo
haemo dynamic</w>
glyc ine</w>
glutam at
doxorubic in,</w>
dow n
character ize</w>
bre ath
amelior ated</w>
abnormal ity</w>
Ur inary</w>
Peri pheral</w>
P ac
N S</w>
Mic ro
M g
In hib
Centr al</w>
C lon
7 9</w>
4 /
(P R
(D E
we ak</w>
vesi cal</w>
vasodilat or</w>
var ying</w>
simil arly</w>
schizophren ia.</w>
s lic
review .</w>
prop an
pre existing</w>
pos ite</w>
other wise</w>
nephro toxicity.</w>
min -1</w>
mg/m 2.</w>
m ing</w>
in tran
in stitution</w>
in dex
ide -
hyponat remia</w>
flumazen il</w>
flow ,</w>
encoun tered</w>
ec it
disorder ,</w>
dam age,</w>
cy tic</w>
comp ris
co logy</w>
c im
analo gu
an ser
an ore
accept able</w>
V T
M on
M S
G F</w>
= 0.00
8 4</w>
6 ),</w>
5 1</w>
5 ,
1. 4</w>
(2 )-
us -
un related</w>
some times</w>
rec ru
protein uria,</w>
offsp ring</w>
obstruc tion</w>
no d
meth amphet
lymph oma</w>
lymph oblastic</w>
leuk emia.</w>
j ust</w>
insi c</w>
ill ness</w>
ho w</w>
gi ven
exhib it</w>
esoph ageal</w>
do m</w>
dex medetomidine</w>
con n
cholest asis.</w>
cas e.</w>
c ateg
anti convuls
an j
Nar anj
Ho dg
H IT</w>
Be havi
8 .</w>
2 %,</w>
(e .g
vascul itis.</w>
ther ,</w>
te tr
ste ad
ris k.</w>
retrospecti vely</w>
ran iti
r ul
pregnanc y.</w>
para dig
pace mak
ocyt es.</w>
occasion ally</w>
nucle i</w>
mechanis m.</w>
ly sos
liver .</w>
it y:</w>
insipid us</w>
inc ub
id ,</w>
i s.</w>
hippocamp us.</w>
h and</w>
g ro
et al</w>
dy st
di aph
cont in
cardi opulmonary</w>
bl ing</w>
benef its</w>
bar ic</w>
b und
an ese</w>
T ac
PA P</w>
P ri
Naranj o</w>
K et
IO P</w>
I /
Hg ,</w>
E D</w>
CB Z</w>
C e
8 0%</w>
6 %,</w>
x anth
tum our</w>
thiop ental</w>
tail -
sulf amethox
salic yl
respectively ;</w>
ra re.</w>
ot ec
osi tive</w>
os mo
o gen</w>
natriure tic</w>
mg/ day,</w>
l -induced</w>
intro duction</w>
incor por
id -
he mic
exter nal</w>
end oscop
en o
d end
calc ineur
benz o
az osin</w>
arteri os
appe ti
ana emia</w>
al er
V er
Syst emic</w>
R T
O c
NA ME
D D
B ra
An alysis</w>
7 4</w>
7 0%</w>
1 60</w>
vehic le
v in
ur rent</w>
trigg ered</w>
sildenaf il</w>
ren in-
recover y.</w>
re mis
prur it
pro st</w>
parameter s.</w>
on ol
myo si
mit ral</w>
me t</w>
mat ri
k s.</w>
im e</w>
gen es</w>
enter ic</w>
eluc idate</w>
deli ver
death ,</w>
de tail
cortico sterone</w>
con jug
chemo therapy,</w>
ana phyl
ain s</w>
M ore</w>
D L
AN CA
1 2,</w>
( 6</w>
vol t
un affected</w>
th o
suppor ts</w>
releas ing</w>
recomm end</w>
prolifer ative</w>
po w
pilocarp ine.</w>
par aly
p unc
osmol ality</w>
od rine</w>
myasthen ia</w>
man ia</w>
ir e</w>
ip )</w>
in :</w>
i ,</w>
hypercal ce
hydrox yl
hormon al</w>
glutamat ergic</w>
gest ational</w>
ge al</w>
et ing</w>
dizzin ess,</w>
cy st
cont ained</w>
compar is
clop ido
c old</w>
bal ance</w>
augment ed</w>
attac k</w>
am ycin</w>
acut ely</w>
T P
R an
R OD
Med ical</w>
HBe Ag</w>
Eff icacy</w>
9 0%</w>
9 ).</w>
8 2</w>
1. 6</w>
1 :
1 %,</w>
worsen ed</w>
w ash
ven tive</w>
tren d</w>
ti b
suit able</w>
stres s.</w>
st ep
so on</w>
scop ol
saf ely</w>
pi g
peroxid ase</w>
om yc
man ic</w>
li pide
i op
hyp no
hem olysis</w>
guine a</w>
fluox et
flecain ide</w>
fascicul ations</w>
ey es</w>
exer ci
es /
diseas es.</w>
de sign</w>
contrac tile</w>
conf oun
concentr ations,</w>
co de
caref ul
cannabin oid</w>
c och
az oc
ari pi
ar ly,</w>
am -
abstin ence</w>
ROD UC
P 450</w>
INT RODUC
HB s
CO X-
Am iodar
A L</w>
3 %,</w>
1 25</w>
(C H
year .</w>
y ch
su ic
resul ts.</w>
r af
pap aver
onol act
monit or</w>
min /
le t
label ing</w>
j oin
ing -
h n
fluo res
f uture</w>
expl an
ei gh
com pa
bil ater
bas ement</w>
antiretro viral</w>
alkal ine</w>
Saf ety</w>
S ymptom
N S)</w>
H em
F l
E leven</w>
CI :</w>
7 8</w>
5-F U
1. 8</w>
1 7.
0. 9%</w>
0. 5%</w>
um or</w>
tubulo interstitial</w>
swell ing</w>
suppor tive</w>
st ren
sim ple</w>
shorten ing</w>
sex ,</w>
s ca
repe ti
princ ip
prepar ation</w>
pre frontal</w>
patient s).</w>
parox etine</w>
opyr amide</w>
occlu sive</w>
nitr ite</w>
ml )</w>
mil li
log raf
liqu id</w>
levo dopa
in /
hyper ther
gener ated</w>
experi encing</w>
ex encephal
es ul
dyskine tic</w>
contro lling</w>
conscious ness</w>
carcin omas</w>
carb on</w>
beta- adrenoceptor</w>
antagonist s,</w>
anc es,</w>
amant adine</w>
am oxic
Th er
S G
R epe
MATERIAL S</w>
INTRODUC TION:</w>
Fif teen</w>
Dec emb
C erebral</w>
Asses s
AC TH</w>
3 ;</w>
2. 0
1 -1
(- /-
( 3-
u preg
tub ule</w>
tu mo
tri am
ti form</w>
sal butam
ra y</w>
psych ological</w>
practi ce</w>
p ine-induced</w>
om es</w>
mg/m 2)</w>
il ine</w>
id azole</w>
heav y</w>
gam ma</w>
fluo resc
exten ded</w>
erg ot
e asi
cy s
cent er</w>
az one</w>
adul ts.</w>
acet am</w>
Ther ap
Th us</w>
Rever sible</w>
O p
Heal th</w>
Drug -induced</w>
Ca (2
24- hour</w>
100 %</w>
trans -
thrombocytopen ia,</w>
striat um.</w>
sing le
secon ds</w>
sacrific ed</w>
ra re,</w>
ra -
propofol .</w>
pre pared</w>
pa fen
opio ids</w>
on going</w>
olan zap
oid s</w>
ogen icity</w>
ne ar</w>
mo bil
meperid ine</w>
medull ary</w>
lo o
large ly</w>
inf ants.</w>
id ine.</w>
gentam icin-induced</w>
fem oral</w>
exac t</w>
employ ed</w>
emis sion</w>
dis ruption</w>
der mat
cy pro
cur ves</w>
convul sion</w>
carb achol</w>
block s</w>
bicarb onate</w>
b er
at ally</w>
aryn geal</w>
anc ing</w>
al low</w>
al )</w>
adi ly</w>
ad d
Propo fol</w>
Prolong ed</w>
P K
L- NAME
AC h
( in</w>
use d,</w>
ta x
stat es</w>
sp ectro
si z
si c
see king</w>
scop ic</w>
reser ve</w>
point es.</w>
pent am
peg ylated</w>
parkinson ism</w>
knowledg e</w>
intrac or
in s,</w>
in o</w>
impair ment.</w>
i lo
i b</w>
hypo the
haz ard</w>
h ind</w>
exer ts</w>
ex cell
epinephr ine-induced</w>
e le
dram atically</w>
discontinu ed,</w>
diethylstilbestro l</w>
complic ation.</w>
circ ulation</w>
ce ph
catechol amines</w>
catal ase</w>
cardiomyo pathy,</w>
bu pren
bra ins</w>
bor tezom
au tis
at o
anticoagul ant</w>
al lograf
] )</w>
O b
Lab oratory</w>
F our
B /
7 %,</w>
5. 0</w>
year s;</w>
volunte ers.</w>
vascul ar
unchang ed.</w>
ul es</w>
tubul es</w>
tr act
tic .</w>
there by</w>
streptozotoc in-induced</w>
s.c .</w>
s ure</w>
reve al</w>
repor ted,</w>
re plic
rang e.</w>
post synaptic</w>
phosph o
ph er
pa w
p ly</w>
oph osph
oly sis.</w>
o plastic</w>
myelo ma</w>
mul tivariate</w>
los s,</w>
intr insic</w>
inter ac
fam il
ex plo
enti re</w>
enti n</w>
disul firam</w>
cor d
caus ative</w>
avoid ed</w>
anesthe sia,</w>
am ifostine</w>
alpha- methyl
ag ing</w>
ag es.</w>
SE .</w>
M I
M ),</w>
B as
Al so,</w>
A S</w>
1 A</w>
0 .</w>
( 8.
y me
under standing</w>
ud g
u ne
tumo ur
tramad ol</w>
tion )</w>
tig m
ti ve.</w>
seg ments</w>
ret ard
relap sed</w>
pati al</w>
p g/
ous ly,</w>
ogene sis.</w>
ob last
normal ,</w>
is ot
infu sion
i v</w>
form ation.</w>
fet uses</w>
ex ogenous</w>
entr y</w>
em a</w>
dur al</w>
drug -related</w>
carnit ine</w>
car r
canc er
bl un
belie ved</w>
belie ve</w>
b if
arg in
appro ved</w>
anto in</w>
ad ap
R NA
P N</w>
P -induced</w>
Mul ti
Immun o
Hospit al</w>
Evalu ation</w>
Decemb er</w>
Com ple
Chin ese</w>
C ).</w>
AM -
A A</w>
- cell</w>
(1 50</w>
( ></w>
z ing</w>
visc eral</w>
toler ated.</w>
ta st
stren g
strate gy</w>
sten osis</w>
sed ation,</w>
remo val</w>
polymer ase</w>
pentylenetetra z
patient s;</w>
on ly.</w>
nic ardi
ng/ ml</w>
na ive</w>
metr on
m ary</w>
great ly</w>
g er
evalu ating</w>
dro p</w>
deli vered</w>
degener ative</w>
contrac tility</w>
catalep sy,</w>
c rac
b red</w>
arb oxyl
apparen tly</w>
anti inflammatory</w>
adoles c
T or
S u
R el
Phen y
Na +
L- dopa</w>
Fancon i</w>
8 00</w>
0.0 1</w>
y lo
ver b
ven lafax
tra ined</w>
therap ies</w>
t ation</w>
synerg istic</w>
su fentanil</w>
si rolim
sca ven
pre fer
post partum</w>
pentam idine</w>
par ad
ou gh</w>
other s</w>
octre otide</w>
nor adrenergic</w>
neurolep tics</w>
mus cim
mitoxantr one</w>
manifest ation</w>
li um</w>
ist s</w>
impro ves</w>
hypo thermia</w>
hyper thermia</w>
headache .</w>
half- life</w>
ha ir</w>
go al</w>
gen it
epilep tiform</w>
enalap ri
em ul
diazepam ,</w>
di ffered</w>
brady kinin</w>
behavi or.</w>
allow ed</w>
W il
T oxicity</w>
T otal</w>
N ational</w>
N R
He mo
D SM-
Ch ild
AZ T</w>
9 7</w>
8 ),</w>
5-hydroxy trypt
(D O
( 60</w>
wom en,</w>
vitro .</w>
verb al</w>
tuberculo sis</w>
tri pt
st ages</w>
specimen s</w>
sim vastatin</w>
side- effect</w>
sensor ineural</w>
s ampl
r ag
progres sively</w>
proced ure.</w>
presum ably</w>
ph ases</w>
par tly</w>
p ure</w>
osmo tic</w>
oper ativel
monke ys.</w>
ml ,</w>
mannit ol</w>
labet alol</w>
ischem ia,</w>
intra operative</w>
inges tion.</w>
illust rates</w>
id .</w>
i si
hypo thalam
he i
gu ide
form ulation</w>
expres sion.</w>
examin ations</w>
ed ;</w>
deoxy chol
concer ning</w>
com pati
careful ly</w>
b arbit
analgesic s</w>
adriamyc in-induced</w>
acceler ated</w>
T B
Q -
Pro te
P e
Lith ium</w>
I U/
G P
B B
9 2</w>
3 90</w>
19 .
1. 1</w>
1 5%</w>
-1 00</w>
trans genic</w>
swit ched</w>
sub clinical</w>
st ed</w>
spec i
re combin
presc rib
potenti ate</w>
pl ant
par t,</w>
p.o .)</w>
or ing</w>
one- treated</w>
ograph y,</w>
obser ved,</w>
log istic</w>
le d.</w>
ket oro
iz es</w>
ish ing</w>
indic es</w>
id ation</w>
high- risk</w>
hemat uria</w>
group ).</w>
facilit ate</w>
f ind</w>
edi atric</w>
easi ly</w>
e a</w>
dy sp
dis comfor
del ta
colo rectal</w>
clin ic</w>
ce -
amil or
administ ering</w>
ad he
acro megal
ac coun
V as
Simil arly,</w>
O ut
H z</w>
GAB A-
C V
Bas el
AT RA</w>
A C</w>
5 8
3- 4</w>
(N MD
(MA P)</w>
( m
weigh t.</w>
week .</w>
ultras on
u tility</w>
typ ically</w>
transamin ase</w>
terat ogenic</w>
sub unit</w>
strok e.</w>
st ru
specific ity</w>
s l
r y
pro cess
placebo- controlled,</w>
pericardi al</w>
parox ysmal</w>
out .</w>
ouabain -induced</w>
on ia</w>
no dul
nitro s
necess it
mono amine</w>
mg/kg ;</w>
lign ocaine</w>
intra ventricular</w>
incid ences</w>
i.p. ).</w>
hippocamp us,</w>
experim ent,</w>
dialy sis.</w>
day ).</w>
contraceptiv es</w>
cap able</w>
c up
ax is.</w>
atheros clero
anti parkinsonian</w>
amitript yline</w>
aldehy de</w>
T T
S ec
Pati ent</w>
PGE 2</w>
Ig G</w>
ED 50</w>
D AT
A F</w>
3 %),</w>
18 0</w>
+/ -1.
( one</w>
( >
( 5-HT
zin c</w>
week s)</w>
war ran
test s,</w>
ston es</w>
stimul us</w>
sed ative</w>
s pro
r ated</w>
progno sis</w>
pre- existing</w>
per cutaneous</w>
pa re
ot opic</w>
modul ate</w>
microg/ kg</w>
metabol ism.</w>
mes enteric</w>
man .</w>
main taining</w>
locomo tion</w>
is ing</w>
inter view
inten si
id -induced</w>
hypertroph y.</w>
hemat ological</w>
he pt
function ing</w>
fati gu
ect opic</w>
ec tion.</w>
dyskine sia.</w>
don or</w>
develop ment.</w>
contr al
classi fied</w>
arrhyth mo
anti platelet</w>
anesthe tics</w>
aldo sterone</w>
ak athi
aggreg ation</w>
admis sion,</w>
abs ent</w>
S ch
Ret ro
RF -1
R ole</w>
PGE 1</w>
E uro
CY P</w>
Be fore</w>
B U
A spir
5 6
% );</w>
vent ro
ut ri
ultras ound</w>
succinyl chol
str ych
resul ts,</w>
res .</w>
refl ect</w>
opoi etic</w>
ocic ept
nit rous</w>
mut ation</w>
mo de</w>
micro M</w>
li ver,</w>
lev of
kg(-1 ),</w>
in direct</w>
ic ot
hydr amine</w>
hemorrh age,</w>
favor able</w>
fail ure
es tic
dep ri
con striction</w>
compati ble</w>
com e</w>
cl as
bra inst
ardi zed</w>
abnormal ities,</w>
S K
Rec ently,</w>
R R</w>
Pro t
OUT COM
OUTCOM E</w>
M us
H z
H ere</w>
Experim ental</w>
EP O</w>
tur no
there after
survi ved</w>
strategi es</w>
stit ute</w>
solub le</w>
si der
shi ft</w>
saf et
sac char
s one</w>
ro ute</w>
raz ole</w>
ran ulo
r un
put ative</w>
patient s),</w>
pall id
open- label</w>
month -old</w>
mode st</w>
microscop y.</w>
me tri
me flo
m ir
lisin opril</w>
initi ating</w>
ine- related</w>
immunosup pression</w>
ill ing</w>
h ind
h en
great est</w>
gen cy</w>
fun g
ep ide
endoc rine</w>
end- stage</w>
dyst onic</w>
diltiaz em
dig ox
d- release</w>
cor tic
condition ing</w>
complex es</w>
bra in,</w>
blind ed</w>
benzodiazep ines</w>
avail ability</w>
aten olol</w>
arabino side</w>
ar abine</w>
anc er</w>
adjust ment</w>
ab users</w>
[ CI
V entr
Symptom s</w>
St at
Pac litax
Nit ro
Jap anese</w>
F E
5 %),</w>
4 ;</w>
(OH) 2
( odds</w>
( U
wom en
toler ated,</w>
thyroidis m</w>
thal idom
termin ated</w>
su med</w>
stro ph
spir onolact
si s:</w>
sett ing.</w>
sept al</w>
seiz ure.</w>
ru pt</w>
ondan setron</w>
moder ately</w>
mo stly</w>
kg -1,</w>
intub ation</w>
in da
h ome
gly cemia</w>
expl ore</w>
es ).</w>
e ).</w>
dow n</w>
dis opyramide</w>
dis appearance</w>
demonst rating</w>
comp uter
comp ul
com a.</w>
centr ally</w>
ce l
calcineur in</w>
as eptic</w>
antin ociception</w>
anti viral</w>
anat om
al f
T D
ST- segment</w>
S D)</w>
P AC
Me as
M ice</w>
Le ft</w>
II I
HIV- infected</w>
H b</w>
Ev idence</w>
DX R</w>
CA 3</w>
B H
Ace t
3 %).</w>
0. 2
( i.v.)</w>
z il</w>
we ver</w>
vari ation</w>
vari abl
uter o</w>
tic -
significant ly.</w>
sertr aline</w>
proced ures.</w>
physos tigmine</w>
penicill in</w>
patient -
pa ired</w>
non- small</w>
micro angio
methylphen idate</w>
matri x</w>
mal on
ma x</w>
long- acting</w>
lidoca ine,</w>
lac tic</w>
l ac</w>
ful ness</w>
discontinu ation.</w>
diarrhe a</w>
dat a,</w>
consider ably</w>
clo sed</w>
challeng ed</w>
b ase</w>
artic le</w>
aro und</w>
ar ti
ar -
amplit u
acqu isi
Td P</w>
NSAID s</w>
LI D</w>
Hy po
De pression</w>
Assess ment</w>
AN CA</w>
14 ,</w>
1 %),</w>
0. 25</w>
( at</w>
% -
ven ti
understo od.</w>
unc er
treatment s.</w>
to wards</w>
ter .</w>
st radi
som at
sequel ae</w>
re :</w>
radio therapy</w>
prece ding</w>
praz ole</w>
pharmaco dynamic</w>
p tive</w>
ot rig
mmHg ,</w>
minut es,</w>
mam mary</w>
malform ations</w>
lo st</w>
kg ro
intoxic ation.</w>
inos it
implant ation</w>
ia )</w>
hypertroph ic</w>
hyper baric</w>
hemo dynamics</w>
haloth ane-
gon ad
g .</w>
f ar</w>
exclu ded.</w>
ester n</w>
es are
def ovir</w>
dec i
cyclophosphamide ,</w>
cul ture</w>
conf usion</w>
az ot
awa reness</w>
atax ia</w>
aspir in,</w>
ac ted</w>
a ur
M or
M any</w>
Gi ven</w>
GF R</w>
Cor onary</w>
C ent
A z
2. 4</w>
vecur onium</w>
ve di
transplant ed</w>
suppres s</w>
suppor ted</w>
s patial</w>
regimen s.</w>
recept or.</w>
reac tions,</w>
promot ing</w>
proca ine</w>
pr one</w>
p sor
oxid ation</w>
oc hemic
observ ational</w>
o tic</w>
nitro gen</w>
micro M)</w>
mic tur
mg/ day.</w>
man ip
line zol
kind ling</w>
isch aemic</w>
intr act
inter nal</w>
inter mediate</w>
ing s.</w>
imi pr
idi osyn
h loro
form alin</w>
fol low</w>
fib rate</w>
ethambut ol</w>
endo theli
en si
en anti
ecti n</w>
contro ver
contrac tions</w>
co administration</w>
cholester ol
behavi our
asp ects</w>
am ate</w>
addi tive</w>
a /
W estern</w>
Th al
T rans
Hep at
H IT
C 3
Basel ine</w>
9 1</w>
7 1</w>
5 %).</w>
4. 5</w>
2 6.
(C O
vi ro
tremor ,</w>
tion ed</w>
tion :</w>
time -
ticlop idine</w>
ter ,</w>
system atic</w>
syn thesi
si c</w>
s he
repolar ization</w>
remo ved</w>
re adily</w>
ph il
pel v
out patients</w>
otec an</w>
oc occ
normal ization</w>
neon ates</w>
meth oxy
meth amphetamine-induced</w>
man aged</w>
leng th
ibu profen
hyper ammon
hist ology</w>
hepat ocytes</w>
hemat oc
fol ate</w>
fi g
f loxacin</w>
event ually</w>
esare an</w>
erythropoi etin</w>
e /
dram atic</w>
dop amine-
de pos
contral ateral</w>
complic ations,</w>
com promis
colon y-
children ,</w>
cardio protective</w>
calcitri ol</w>
av es</w>
aqu eous</w>
aminonucle o
all ed</w>
adrenal ine-induced</w>
acyclo vir</w>
activ ation.</w>
Val pro
Uni versity</w>
Repe ated</w>
O ver</w>
N K
M agne
M ).</w>
HU S</w>
Bra in</w>
Al ter
A no
A (2
2. 3</w>
(-/- )</w>
z ine</w>
vincrist ine-induced</w>
traum atic</w>
tr ue</w>
tox in</w>
te m</w>
sib ility</w>
se c</w>
s ine</w>
ro pivacaine</w>
repeti tive</w>
recor ding</w>
qu ad
py r
psych omotor</w>
propylthio uracil</w>
prompt ly</w>
pro pafen
pilocarp ine,</w>
phen ic
on uc
omime tic</w>
olig uric</w>
n ocicept
my co
mus cles</w>
meta -
ment ation</w>
m -
lymph ocytic</w>
lo mer
lipo protein</w>
lethal ity</w>
le g</w>
j ac
intract able</w>
insti ll
in contin
fl ush
eryth ema</w>
efficac ious</w>
di phenyl
cys tic</w>
cyclospor in</w>
cou pl
concentr ation,</w>
compul sive</w>
cocaine- related</w>
coag ul
cisplat in,</w>
cis -
circul atory</w>
challeng e.</w>
cap ecit
c Tn
bupivaca ine.</w>
basel ine.</w>
az ol</w>
as alazine</w>
am phenic
am ous</w>
aden os
accumb ens</w>
R ),</w>
N ,</w>
Hodg kin
D ay</w>
Ar g
8 3</w>
1 1-
(N O)</w>
(N O
( the</w>
warran ted.</w>
ur ally</w>
thre e-
ter ious</w>
sulpiri de</w>
st as
seg mental</w>
ro ot</w>
rin one</w>
resc ue</w>
pro -
per cep
olog ous</w>
no v
mor ning</w>
micrograms/ kg/
m urine</w>
lat er
lamivud ine-
k ine</w>
insuffici ency.</w>
inhibit ors,</w>
in uria</w>
ic lo
hyperalgesi a,</w>
hydr ation</w>
gen der</w>
form ed</w>
fibr in
exer ted</w>
et op
enanti om
discharg es</w>
day s).</w>
day -old</w>
combin ation.</w>
com orb
can di
c li
block er,</w>
bicucul line</w>
antine oplastic</w>
anore x
am lodipine</w>
advant age</w>
ac k</w>
a vi
U l
Physi ci
LVE F</w>
K +
Iso proteren
Inc idence</w>
INTERVEN TIONS:</w>
Hg )</w>
H a
GS H</w>
E P</w>
D ).</w>
COX- 2</w>
A dul
ve lop
ul a</w>
tw or
ti r
t un
sup ine</w>
sulf on
slow ly</w>
shi f
s in</w>
repor t,</w>
renin- angiotensin</w>
regul atory</w>
pri de</w>
pre cur
pp m</w>
ph ent
pa ir</w>
or d
onuc lide</w>
on d</w>
ome g
nitroprus side-induced</w>
morph ology</w>
mitochond ria</w>
m M</w>
lig ation</w>
leuk openia</w>
less er</w>
know n,</w>
it s,</w>
it ,</w>
intra ocular</w>
ingest ed</w>
indic ative</w>
increas ed,</w>
ic .</w>
he im
h ab
follow-up ,</w>
fluoresc ence</w>
e ar</w>
dr y</w>
dipyridamol e-induced</w>
degrad ation</w>
de d,</w>
d ang
cult ures</w>
cra ving</w>
complain ts</w>
clonid ine.</w>
bran ch</w>
bo dy
bac kgro
b ru
ay s.</w>
as cit
ap aro
alcoh olic</w>
adoles cent</w>
Ventr icular</w>
T ak
S S</w>
S BP</w>
MD MA</w>
M T</w>
M PT
J un
In te
Grou p.</w>
G V
Fo od</w>
F atal</w>
F ).</w>
E 1</w>
7 ),</w>
5 /
2 3.
- based</w>
vac c
tiz ing</w>
t es</w>
sub -
s pl
s clerosis</w>
recipi ents.</w>
re jection</w>
prescrib ing</w>
pre operative</w>
pos t</w>
per ative</w>
pat ch
p tion.</w>
ove rex
om yo
om as.</w>
mg/d L</w>
ket ocon
iohex ol</w>
ing )</w>
inflamm ation.</w>
impair ments</w>
immunore active</w>
id ine-induced</w>
hospital ization</w>
hormon es</w>
gab ap
g an
fer ri
ex pan
epilept ogenic</w>
enh ancing</w>
dos age.</w>
dog .</w>
depress ant</w>
def ine</w>
conjunc tion</w>
classi cal</w>
cap sul
bri le</w>
b asic</w>
adrenocept ors</w>
adolesc ents</w>
abol ic</w>
W K
Rec o
R s</w>
N D
L ocal</w>
L P
In f
IC U</w>
IC RF-1
Hodgkin 's</w>
H emat
CA )</w>
C ancer</w>
AIM :</w>
6 ;</w>
6 0-
4 %,</w>
20 00</w>
2 4.
0 -1
( 8</w>
we an
vit al</w>
traum a</w>
tra di
tissu e.</w>
thrombocytopen ia.</w>
surviv ors</w>
str al</w>
stimul ation,</w>
stand ardized</w>
st ent</w>
st atic</w>
so ft</w>
side .</w>
sec tional</w>
ri gh
reli able</w>
rele ased</w>
recombin ant</w>
rat e-
rat ,</w>
provo ked</w>
prost atic</w>
prolact in
pect or
ob ses
neo plas
ne os
nar co
mut ations</w>
mor tem</w>
month s)</w>
m isoprost
lymph ocyte</w>
log raph
invol ves</w>
impro ving</w>
i -
hyper activity.</w>
high ligh
ga ve</w>
fl are</w>
exacerb ated</w>
es ),</w>
er )</w>
efficac y,</w>
e ligible</w>
di methyl
develop ed.</w>
decreas ed.</w>
de myel
cri tically</w>
cont ex
con sol
coll ap
clar ify</w>
captop ri
ca v
asth ma</w>
ass ay.</w>
analgesi a.</w>
ST Z
MT X
M orph
Inhib ition</w>
G ra
Ch ol
Al z
A ).</w>
1/ 2</w>
1 %).</w>
-1 7</w>
(i )</w>
treatment -
transf usion</w>
table ts</w>
system s.</w>
spi k
somn ol
rifamp icin</w>
regar d
regard less</w>
reduc tase</w>
ras h,</w>
radi onuclide</w>
propranolo l.</w>
pre clinical</w>
ph ere
p ine.</w>
p ine,</w>
oxy toc
osmol ar</w>
os ed</w>
om ep
o d,</w>
ne twor
n utri
my ocyte</w>
morph ine-induced</w>
ml .</w>
minoxidi l</w>
minocycl ine</w>
meth od
las er</w>
it y-
gall bladder</w>
excell ent</w>
ev ing</w>
etop oside</w>
en co
dyskinesi as.</w>
dele terious</w>
cor b
con stric
capsaic in-
ca u
c m</w>
bronch odi
atracur ium</w>
ap pa
aneurys m</w>
activ ating</w>
a er
Thir teen</w>
S pec
Re search</w>
O H
NS AI
N icot
N I
N .</w>
Hist opath
E pi
D M
CN U</w>
C ont
9 .</w>
2 A</w>
.00 1).</w>
- M
(S T
(S E)</w>
(1 9
(1 2</w>
ym pathetic</w>
vin blast
ve tir
ur able</w>
tremor s</w>
tim ul
thel ess,</w>
sup press
strok e,</w>
slic es</w>
sh am-
selec tivity</w>
rim -
re mic</w>
raz oxane</w>
presum ed</w>
post menopausal</w>
paren t</w>
o ple</w>
non selective</w>
negati ve.</w>
ne a</w>
n om
month s).</w>
meth ion
medi ating</w>
ist er
invol ve
intracerebro ventricular</w>
interval s.</w>
ic s,</w>
gre at</w>
gn os
genotyp e</w>
g ross</w>
extra vas
elim inated</w>
dy stroph
dur ation,</w>
diphen hydramine</w>
diclofen ac
capsaic in.</w>
c ran
b ar</w>
arter y.</w>
apopto tic</w>
anthrac yclin
antagon ize</w>
acetaminophen -induced</w>
S odium</w>
Pri or</w>
Pre vention</w>
Me dic
GABA (A)</w>
B ilateral</w>
An esthe
Alz heim
8 6</w>
5 ;</w>
3. 2</w>
23 390</w>
2 %),</w>
( 5-
zidov ud
weigh ted</w>
vulner ability</w>
un common
ter ti
stres s
ste ad</w>
squ amous</w>
reg ist
reas on
re al</w>
py ramidal</w>
prote in,</w>
process ing</w>
proc ess.</w>
patient s:</w>
p. o.</w>
of -
nigr a</w>
neuro n</w>
monit ore
micro som
m ec
m arg
kg -1.
ketoro lac</w>
is ation</w>
io di
insti tu
in- 1</w>
in verse</w>
ia /
hyperkal emia</w>
hyper cholesterol
home ost
hepat ocyte</w>
g ri
fact or-
experiment s,</w>
enz yme
e duc
diure tics</w>
dis co
depend ent.</w>
de struc
conside red.</w>
carbo plat
b ing
b ,</w>
appeti te</w>
a reas
Throm bo
ST Z</w>
SE ,</w>
M ethyl
K +</w>
I MP
I CA
En gl
Comple te</w>
Aspir in</w>
Ar ter
Ang io
AM I</w>
4. 0</w>
4 %),</w>
1. 9</w>
1. 7</w>
1, 25-
1 8-
0.0 2).</w>
(D A)</w>
(0. 3</w>
ta ined.</w>
suxameth onium</w>
stat e.</w>
sit u</w>
se en.</w>
s- -
s ection</w>
posi tively</w>
pl ate</w>
pl ant</w>
pathw ay.</w>
ozyg ous</w>
onucle ar</w>
ol )</w>
ogen etic</w>
nitro- L-arginine</w>
nim esul
neurotransmit ter</w>
neuro chemical</w>
metho d.</w>
manag ement.</w>
kine tics</w>
kidne y.</w>
kain ic</w>
infec tion,</w>
i m</w>
hepatoc arcin
gnos tic</w>
expos ure,</w>
escal ating</w>
dro w
diazepam .</w>
conver ted</w>
carb onate</w>
bus ulf
bef ore,</w>
aut opsy</w>
antagonist s.</w>
antagonist .</w>
ammon ia</w>
a j
With draw
V ari
SP EC
Physici ans</w>
O x
Hepar in-induced</w>
Fo s</w>
E th
De velop
Coca ine-induced</w>
8 %),</w>
6 9
-1 .</w>
- free</w>
(M D
(C Y
(3 00</w>
(0. 2</w>
y r</w>
vasodi lation</w>
unex pl
ulo x
ulc er</w>
transplant ation,</w>
transc ri
tinnit us</w>
susp ici
spec ial</w>
sour ce</w>
side ,</w>
ser a</w>
salbutam ol</w>
ro stral</w>
retro grade</w>
respon ders</w>
repe at</w>
recur red</w>
raz ol
rabb it</w>
psych os
prop ose</w>
present .</w>
phy loc
phenyl propan
ph e
person s</w>
per in
pe ople</w>
particip ated</w>
parathyro id</w>
ocyt es,</w>
ochrom ocyt
neuron s,</w>
me lan
lob al</w>
it amin</w>
infec tions.</w>
improve ments</w>
ic tal</w>
hypo thalamic</w>
g ain
fung al</w>
flut ter</w>
fibro sis.</w>
fati gue</w>
f osf
es us</w>
ep icardi
em ent,</w>
echocardi ography.</w>
desi pramine</w>
dec om
clinic al,</w>
clar ithromycin</w>
caud al</w>
bund le</w>
ate )</w>
ap ril</w>
acet azol
a sis,</w>
T o
S w
S up
R P
On cology</w>
M it
Jun e</w>
G lobal</w>
G ),</w>
Four teen</w>
E .</w>
DAT A</w>
D PA
Cat al
A M</w>
2 5.
.0 5).</w>
(1 0-
up -
traz od
tob ram
to ol</w>
tend ency</w>
techniqu es</w>
sub type</w>
stit ut
se n</w>
scal e.</w>
ro om</w>
ro les</w>
ro l
ro curonium</w>
reser pine</w>
raniti dine</w>
phosphor ylation</w>
perid one</w>
orig in</w>
onse t,</w>
necro sis,</w>
morph ine,</w>
micrograms/ kg)</w>
mel phal
literat ure,</w>
kg .</w>
k appa
it ary</w>
ir radiation</w>
individu als.</w>
in toler
identi fication</w>
hyperprolact ine
hyper lipide
heter ogene
headach es</w>
gangli a</w>
frequ encies</w>
for ced</w>
ex pect
evid enced</w>
establ ished.</w>
er ro
ei r</w>
dro xy
dilat ation</w>
de vi
dap sone</w>
cyt arabine</w>
cyclophosphamide .</w>
correl ates</w>
continu e</w>
concentr ation
compris ed</w>
colony- stimulating</w>
cep t</w>
bl ue</w>
an oid</w>
alb ino</w>
admis sion.</w>
aden omas</w>
Th eir</w>
NS CL
M echan
I P</w>
Ev ans</w>
E E</w>
Cont inu
C ),</w>
AM P
A Q
9 9</w>
8 %,</w>
5 -1
1 2)</w>
0.000 1)</w>
/ -</w>
- P
vi g
venti lat
v es.</w>
un able</w>
tr in
test ing.</w>
tachy cardi
supplement ed</w>
sub lingual</w>
stud ying</w>
stru al</w>
stat us.</w>
sig ma</w>
seve re,</w>
resuscit ation</w>
put am
predict or</w>
pre ventive</w>
pre treatment.</w>
ox ical</w>
orth otopic</w>
ol -treated</w>
ni gh
n ia</w>
mus cl
morph ologic</w>
micro injection</w>
medic ation,</w>
loc us</w>
lithi um
le f
itsel f</w>
inhibit or.</w>
influ ences</w>
im azole</w>
if or
hemo dynam
hear t,</w>
h am
grad ual</w>
glomerulos clerosis</w>
fe brile</w>
ex p
cyt os
concent rating</w>
coch lear</w>
aor ta</w>
anser in</w>
anc es.</w>
al prazol
Six ty-
Pharmac o
I S</w>
F re
Am ph
Afric an</w>
8 1</w>
3 5%</w>
2. 7</w>
2. 1</w>
.00 0
(AC E)</w>
( NT
xanth ine</w>
us ers,</w>
ul l</w>
ti d
surve y</w>
super ficial</w>
stoppe d.</w>
st ain
sist ent</w>
ri t</w>
pyri dine</w>
pod ocyte</w>
plas ma
pergol ide</w>
pa res
os por
naprox en</w>
interval .</w>
in stead</w>
im ages</w>
hepar in.</w>
g as</w>
four -
fluc tu
examin ation,</w>
ethin yl</w>
er up
endo thel
embry onic</w>
clo sure</w>
cimeti d
chrom os
cholec yst
ca use
bupren orphine</w>
arter ies.</w>
ap ical</w>
ang in
amygdal a</w>
acquisi tion</w>
a y,</w>
a defovir</w>
Six teen</w>
SR L</w>
Retro spective</w>
Parkin son</w>
N H
F em
Carb am
C ar
9 ),</w>
7 5%</w>
2 8.
1 4-
- onset</w>
(e.g .,</w>
(S E
yc in-induced</w>
y /
well- known</w>
we re:</w>
vi ol
triam te
tast e</w>
shorten ed</w>
sensitiv ity.</w>
s lop
rupt ed</w>
risperid one.</w>
rim- sulfamethox
pren atally</w>
post ulated</w>
plast y</w>
parathyro idis
multicent er,</w>
muc osi
morph ine.</w>
malon di
le ak
l ine,</w>
intra hepatic</w>
intak e.</w>
i. e.,</w>
hypertroph y,</w>
hyper calci
hepat otoxicity.</w>
g old</w>
g ated</w>
eth yl</w>
en flurane</w>
dys ph
di ed.</w>
cycl es.</w>
chron otropic</w>
ca in
bl ind</w>
antioxid ants</w>
analy zed.</w>
age- matched</w>
aff ected.</w>
addic tion</w>
V .</w>
Tor sades</w>
Prop ran
P res
I P)</w>
I ).</w>
HC V</w>
AL T</w>
A ut
A t
A U
5 '-
24- h</w>
(E E
y- state</w>
withdraw al,</w>
une vent
underg o</w>
u xim
tri azol
syn chron
sub acute</w>
si ve,</w>
rh esus</w>
reac h</w>
re striction</w>
re se
pro gnostic</w>
pneumon ia</w>
pent azoc
ot umor</w>
oper ated</w>
ome gal
oly sis,</w>
necro tizing</w>
na di
microg/ kg/
meas urable</w>
m RNA
lam otrig
ke phal
hypoc al
hypo ther
haemat ological</w>
etom id
en kephal
efficac y.</w>
e ),</w>
detail ed</w>
der m
dat a.</w>
continu ing</w>
consider able</w>
concomit antly</w>
clozap ine.</w>
cle ,</w>
cholin erg
ceftriax one</w>
carbamazep ine.</w>
cal cin
barbit ur
azol e.</w>
atro b
atel y,</w>
analy sed</w>
ab und
Ser ial</w>
L-DO PA</w>
Hg .</w>
D obut
C H</w>
= .0
7 ;</w>
7 %).</w>
3. 3</w>
2. 6</w>
- specific</w>
( <
year s).</w>
y le
v ox
unex pected</w>
un likely</w>
throm bus</w>
t ting</w>
sub mitted</w>
stereotyp y</w>
spi ke</w>
sci atic</w>
remark able</w>
ran k</w>
queti apine</w>
phyloc occ
ph ase.</w>
pacemak er</w>
or ic
op posite</w>
olo l,</w>
ol e-
ng/ m
mit omycin</w>
mictur ition</w>
loc ation</w>
lif e.</w>
k in</w>
is os
inser tion</w>
ine ).</w>
induc tion.</w>
hist ologically</w>
hap s</w>
gene tically</w>
fif th</w>
fact or.</w>
extrem e</w>
evol ution</w>
escal ation</w>
er ol</w>
eosinophil ia</w>
ent s,</w>
ec stas
diagno sis.</w>
dec arboxyl
correl ations</w>
coll ecting</w>
chlor amphenic
ceph alo
car vedi
c anal
aw ake</w>
assess ing</w>
arrhyth mia,</w>
appea red.</w>
an -induced</w>
ag es,</w>
acc ess</w>
Withdraw al</w>
Sevent y-
MEASUREMENT S</w>
I ),</w>
G R
G MP</w>
F os
F ),</w>
E ,</w>
D T
C K
B AL
Ano ther</w>
AV P</w>
A PAP</w>
5-HT(1 A)</w>
2. 2</w>
(NS AID
(NMD A)</w>
( s)</w>
( by</w>
xi let
w i
vetir acetam</w>
ver theless,</w>
ut roph
ur niqu
un responsive</w>
ular ,</w>
ul e
to urniqu
titr ated</w>
tion -
ten sive</w>
t ap
t al
t /
si ve-
ris k,</w>
relationshi ps</w>
rat ings</w>
promot e</w>
pro convulsant</w>
pre- treatment</w>
poly neuropathy</w>
peri pher
p tion,</w>
oper atively</w>
op tion</w>
oni um.</w>
on ce-
occur .</w>
non- steroidal</w>
ni ght</w>
my algia</w>
mus cle.</w>
modi fication</w>
microgram s.
medic ations,</w>
me xilet
local ization</w>
lidoca ine-induced</w>
k le</w>
it y;</w>
ino gen</w>
inhal ation</w>
ing :</w>
im oz
i. e.</w>
hyper parathyroidis
h erb
grad ed</w>
fact or
examin ation.</w>
epilep sy,</w>
end ot
dos ed</w>
dom eth
discomfor t</w>
creatin ine,</w>
concl usion</w>
concer ns</w>
con struc
compli ance</w>
code ine</w>
categ or
cardiomy ocytes</w>
ca re.</w>
c ost</w>
at ure</w>
as one</w>
arrhythmo genic</w>
aminoglyco side</w>
alter s</w>
Un der</w>
Further ,</w>
E mer
Clon idine</w>
An gi
Adul t</w>
9 %,</w>
7 /
6. 5</w>
3 7.
1 10</w>
0.0 3</w>
(E P
(A R
z o
vi gab
vigab at
un complicated</w>
ulo pathy</w>
ul tim
turno ver</w>
thyro x
thrombo sis,</w>
thrombo embol
test ed.</w>
t wit
sub stitution</w>
sub group</w>
spironolact one</w>
sig ma
sh ar
rit odrine</w>
re tri
prog est
preser ved</w>
prescri ption</w>
par ano
ophthal mo
nit rate</w>
neutroph il</w>
ne ede
n e</w>
lob ular</w>
lat encies</w>
isch aemia</w>
ir radi
inter action.</w>
inte rest</w>
im otor</w>
idiosyn cr
idaz ox
hypox ia</w>
hom ogen
hem is
gem fibro
func tions.</w>
form er</w>
fore arm</w>
erythro cyte</w>
eosinophil ic</w>
effici ent</w>
ed :</w>
document ed.</w>
di l</w>
bus pir
brainst em</w>
be y
associ ations</w>
anc y</w>
amin ophyll
V is
V O
Twenty- four</w>
S C</w>
P artic
NSAI D</w>
N C
L eu
Initi al</w>
In v
In dometh
Di ag
Comb ined</w>
Ca2 +
Ca ffe
Bet ween</w>
Amiodar one</w>
Addi tional</w>
9 4</w>
50 )</w>
3. 8</w>
2 %).</w>
13 5</w>
) ]</w>
(A N
z e
z ation</w>
w all
venlafax ine</w>
v on</w>
tw ic
trans formation</w>
ten of
t an
ser ve</w>
secre tion.</w>
sco red</w>
sc hem
rod ent</w>
recomm en
ral oxif
radic als</w>
pur pur
prote ase</w>
pro myelo
pos it
ple x
platele ts</w>
pic ture</w>
phen azine</w>
papaver ine</w>
over t</w>
orph in</w>
ometr y</w>
oid al</w>
off er</w>
neurolep tic-induced</w>
neuro transmission</w>
modi fic
mo ther</w>
mmHg )</w>
men strual</w>
lysos omal</w>
lomer ular</w>
li k
l ist</w>
immunohist ochemical</w>
ia sis.</w>
histor y,</w>
gl it
form ing</w>
echocardi o
duct us</w>
drow sin
determin ing</w>
depri v
demonst rat
cortis one</w>
compar tment</w>
breath ing</w>
beta- blocker</w>
aut ologous</w>
as corb
app ing</w>
app a</w>
ap preci
antagon istic</w>
angiograph y.</w>
al -induced</w>
acid -
a e.</w>
Sw is
S te
S /
Paclitax el</w>
PT U</w>
P ).</w>
O N</w>
L S</w>
II )</w>
I C</w>
HC l</w>
F S</w>
En do
C i
B D
A 1</w>
19 7
1 6-
, 00
(4 00</w>
ym al</w>
volum es</w>
vig il
tradi tional</w>
tion ;</w>
sha m</w>
rest ingly,</w>
resp ir
repe ate
rectom y</w>
reas on</w>
re inst
quanti fied</w>
pre medication</w>
phosph on
pathophysi ological</w>
over -
non ionic</w>
neuro psychiatric</w>
myelo id</w>
mg. kg-1</w>
metr y</w>
men .</w>
me an
l y-
isos orb
isoflur ane-induced</w>
intracor onary</w>
intra vesical</w>
intra renal</w>
inter f
interf ere</w>
ine ),</w>
indic ation</w>
in nerv
if en
i le
haemorrh age</w>
frac tions</w>
frac tion
fentanyl -induced</w>
feed ing</w>
f ing
f illing</w>
exten sion</w>
explan ation</w>
experiment ally</w>
ep o
enro l
electroencephalo graphic</w>
e x</w>
drom e</w>
diet .</w>
di ameter
develop s</w>
de af
d or
convul sions,</w>
colo r</w>
cis apri
cancer :</w>
c AMP</w>
bey ond</w>
are a.</w>
addic tion.</w>
a emia.</w>
P o
P 2
Meas ure
Hepati c</w>
He ad
B T
B NP</w>
3. 6</w>
20 )</w>
2 9.
2 7.
- opioid</w>
(A L
( two</w>
( a)</w>
z es</w>
ver te
unexpl ained</w>
underg one</w>
tremor .</w>
toge ther,</w>
terti ary</w>
ta uro
sens ation</w>
sc an
sar co
salicyl ic</w>
repor ts,</w>
re challenge</w>
protoc ol.</w>
pro arrhythmic</w>
pres yn
ph thal
or rhe
oc ur
nal trex
medic ated</w>
ly )</w>
loc ally</w>
intro duced</w>
insomn ia</w>
inosit ol</w>
inj ured</w>
infrequ ent</w>
indin avir
incid ent</w>
in ti
in t
impa ir</w>
ill ance</w>
icill in</w>
i.c.v .</w>
hybri diz
hic cup
given .</w>
ester ase</w>
direc ted</w>
detect ed.</w>
con serv
carb ox
blockade .</w>
biop sy.</w>
ar y.</w>
anti hist
anti emetic</w>
amis ul
al ve
aden o
V itamin</w>
R o</w>
PD .</w>
P G</w>
IN R</w>
Hemo dynamic</w>
E SR
Cyclo phosph
Br ady
B o
Ap pro
A ra-
2. 9</w>
(1 00
z one</w>
weigh t)</w>
throm ycin</w>
sub set</w>
stead y-state</w>
sen se</w>
ret te</w>
rem ia.</w>
re l</w>
re gener
propranolo l,</w>
promyelo cytic</w>
prob uc
princip al</w>
pri l</w>
predict able</w>
pre hen
popul ation,</w>
platin um</w>
pi g</w>
phenotyp e</w>
ol ate</w>
ob tain</w>
myosi tis</w>
multi focal</w>
mir ta
mim ic
mg/d l</w>
men ,</w>
membran es</w>
mec amyl
lamivudine- resistant</w>
lab or</w>
k i
invol un
ini b</w>
in ;</w>
id one</w>
hypokal emia.</w>
hil ar</w>
hem i
fast er</w>
f all
excit ability</w>
eff usion</w>
dur ation.</w>
di dan
dementi a</w>
dam aged</w>
d ual</w>
cyto sis</w>
cross- sectional</w>
clonid ine-induced</w>
cef ot
bac lofen
anter o
alk yl
TION AL
T op
T em
T c-
T am
RA TIONAL
Ne vertheless,</w>
Lo w</w>
Gl uc
Dis continuation</w>
DOX -induced</w>
CR F</w>
B 6
B 2</w>
AE s</w>
A min
5-fluoro urac
4 %).</w>
10 (9
- 2</w>
(5 00</w>
( b)</w>
( ME
( 9.
ucle ar</w>
swit ch</w>
sus pect
str um
str ati
stereotyp ed</w>
spro uting</w>
sh un
sec ret
rele ase.</w>
reduc ed.</w>
re perfusion</w>
qual it
per haps</w>
p imoz
osar coma</w>
neos tigmine</w>
n ox
min ).</w>
mg/kg/ day)</w>
lim its</w>
k ne
k appa</w>
instill ation</w>
incl usion</w>
hi p</w>
hemat opoietic</w>
granulomat ous</w>
glucuron ide</w>
gangli on</w>
feat ure</w>
f ast</w>
f .</w>
exam eth
ex change</w>
d ulox
d ot
d ).</w>
criter ia.</w>
controver si
citalop ram
ci ga
beta- D-
baro receptor</w>
b allo
arrest .</w>
amilor ide</w>
aler t</w>
acu ity</w>
V F</w>
TN F-
PO RT
P oly
Na Cl</w>
LI CA
L am
IMP LICA
II I,</w>
F K</w>
Di se
D (2)</w>
Com p
CD 4</w>
8- OH-
1 1,</w>
, 2
(P GE
(P D)</w>
y ),</w>
volume ,</w>
use fulness</w>
triglycer ide</w>
thick ness</w>
stere ot
sensor imotor</w>
sensi tized</w>
rul ed</w>
response s,</w>
reas ons</w>
re pair</w>
re bound</w>
rat es.</w>
provid ing</w>
previ ously.</w>
piper az
pepti des</w>
paras ympathetic</w>
p em
oxytoc in</w>
oxi b</w>
oper ation</w>
ocyto sis</w>
neutroph il
n g</w>
myel inated</w>
mix t
iz ine</w>
iz ations</w>
ist r
isoproteren ol.</w>
iop amid
involun tary</w>
injec tions.</w>
indic ations</w>
inclu des</w>
in adequate</w>
improve ment.</w>
imb al
hyper plasi
hematoc rit</w>
granulo cyte</w>
gabap entin</w>
fatigu e,</w>
facilit ated</w>
es cap
epide mio
elic it</w>
ectom y.</w>
dysrhyth mi
duc ts</w>
dis abl
crac k</w>
conf usion,</w>
concentr ation-
compoun ds.</w>
cell s/
bodi es</w>
bif id
behavi or,</w>
assess able</w>
aripi prazole</w>
anti cancer</w>
ang u
al ization</w>
age en
ab rupt</w>
Ver apam
SIAD H</w>
Qu in
P ath
P 2</w>
O C</w>
N MS</w>
L i</w>
Isoproteren ol</w>
Intra thecal</w>
IF N</w>
I fosf
HBe Ag
GT N</w>
E lev
8 9</w>
8 8</w>
4 8-
2 40</w>
1 3-
/ kg</w>
(1. 5</w>
yiel ded</w>
vi de
ul y</w>
tri als,</w>
tiv ation</w>
tib ular</w>
survi ving</w>
st and</w>
spl en
separ ated</w>
sc inti
s we
s per
ru gad
rigid ity.</w>
rest ra
resist ance.</w>
regimen ,</w>
pseud o
practi ce.</w>
phe ochromocyt
oxygen ation</w>
oro facial</w>
or in</w>
modul ating</w>
modi fi
model s,</w>
milli on</w>
meflo quine</w>
ma ke</w>
lab or
junc tional</w>
join t</w>
in ating</w>
fle xi
f al
exist s</w>
exist ence</w>
erythematos us</w>
electroencephalo gram</w>
dist rib
difficul ty</w>
diarrhe a,</w>
deple ted</w>
demo graphic</w>
cyt openia</w>
cyclo oxygenase</w>
cr amp
contex t</w>
con currently</w>
com a,</w>
chloro qu
cephal ospor
carr ageen
c alled</w>
c )</w>
bronchodi lat
ate ment</w>
anxiet y,</w>
anti thrombotic</w>
ant ly,</w>
andro gen</w>
alpha- adrenergic</w>
ag ranulo
ac tion,</w>
T G</w>
S ing
S hor
S P</w>
P seud
Multi ple</w>
Meth amphetamine</w>
Inter national</w>
F act
EM G</w>
E :</w>
Dep art
DL IN
Cap sa
C a</w>
Arter ial</w>
3 '-
2- adrenoceptor</w>
(1. 0</w>
(+/- )-
( up</w>
( n
( control
yle stradi
wor k
warr anted</w>
w ing</w>
ves '</w>
vehicle -treated</w>
valu es,</w>
utroph il</w>
uc asi
transc ript
therap y:</w>
the se,</w>
t or</w>
summ ary,</w>
ste at
st .</w>
sc ans</w>
res ection</w>
repor ts.</w>
recru ited</w>
recommen ded.</w>
recept or
re plac
pro gram</w>
pp ed</w>
potenti ates</w>
poison ing</w>
picrotox in-induced</w>
pi ratory</w>
physici an</w>
perio dic</w>
nov o</w>
neuro toxicity,</w>
monitor ing.</w>
methyl dopa</w>
meth orph
mellit us</w>
lymph ocytes</w>
lo l.</w>
lo l,</w>
lin k</w>
limb s</w>
lep tic</w>
k er
ir rig
ine ly</w>
in strum
ifor m</w>
id s,</w>
gene ic</w>
flur bi
fluoro quinol
exencephal y</w>
en large
e en</w>
dist ress</w>
differenti ated</w>
diaph rag
depend ing</w>
cyto kine</w>
cy cle.</w>
correc tion</w>
conjug ated</w>
concer n</w>
col itis</w>
chang e.</w>
carcin ogenesis</w>
c ot
assess ments</w>
ass ays</w>
asc ending</w>
angio graphic</w>
an d.</w>
amoxic illin</w>
amiodar one.</w>
alop ec
albumin uria</w>
advant ages</w>
adoles cent
Thal idomide</w>
T ol
T est
RO S</w>
P R</w>
MEASURE S:</w>
L evo
K )</w>
Inte restingly,</w>
In duction</w>
Im pro
IMPLICA TIONS:</w>
I R</w>
High -dose</w>
Gra ves'</w>
G u
C is
9 8</w>
8 6
6 /
2 -1
2 +/-
17 5</w>
100 ,</w>
(L V)</w>
(HB V)</w>
x .</w>
w aves</w>
ur k
ur idine</w>
um- dependent</w>
tur nal</w>
toxic ology</w>
thereafter .</w>
subst rate</w>
striat um,</w>
str al
solu tions</w>
so deoxychol
sion :</w>
ro t
ro dent
resem bling</w>
relev ance</w>
rel im
receptor- mediated</w>
propor tional</w>
propafen one</w>
ph ore
ne u
metri c</w>
meth oxy-
met ab
meas ures.</w>
me m
like li
lig ands</w>
le sions,</w>
l /
j er
j ec
investig ating</w>
in ver
in do
im mu
ill ic
gy nec
glyce mic</w>
g rel
for ce</w>
f at</w>
extrem ity</w>
ex pressing</w>
event .</w>
ept ogenic</w>
ent or
enox apar
diseas e:</w>
depos its</w>
day ),</w>
consider ation</w>
clon azepam</w>
char t</w>
block ,</w>
beats/ min</w>
be aring</w>
as ti
anti cataleptic</w>
analy ze</w>
amelior ate</w>
al gi
RE PORT
P ot
N on-
ME DLIN
MD D</w>
II .</w>
HC T
F 2</w>
Dec reas
D s</w>
Compar ative</w>
Ca(2 +)</w>
B rugad
B ac
Au stral
9 /
2 1-
1 40</w>
0. 15</w>
(C NS)</w>
(50 )</w>
zol pide
yr -old</w>
yl )-
yc in,</w>
viv o,</w>
ul t
tw ent
troph ic</w>
tro pine</w>
thiopent one</w>
th an
sus pen
su sta
ser ocon
rof ecoxib</w>
rit on
rigid ity,</w>
rec all</w>
r ine.</w>
pyridox ine</w>
prote in-
phenylephr ine-induced</w>
path y:</w>
os c
ophthal mic</w>
op ositive</w>
om at
methotrex ate.</w>
macroph age</w>
m on</w>
lithi um.</w>
le x
l s</w>
l aparo
isopren aline</w>
inter ference</w>
immu ne
ic in,</w>
ic es</w>
hypno tic</w>
hydroxyl ase</w>
h ome</w>
gluc os
gi ving</w>
fil am
epti de</w>
end- diastolic</w>
emul sion</w>
emerg ent</w>
eme sis</w>
e al</w>
dis per
coupl ed</w>
compens atory</w>
cholester ol,</w>
augment ation</w>
at ter
asyst ole</w>
ar ds</w>
anesthe si
allograf t</w>
ag itation</w>
Tak en</w>
Syn drome</w>
Subsequ ent</w>
St atis
S al
RATIONAL E:</w>
Prot ective</w>
L ;</w>
ICRF-1 87</w>
I M
H C</w>
GABA A</w>
E ch
C E</w>
C C</w>
Behavi oral</w>
B P)</w>
As sociation</w>
8-OH- DPA
3 8.
2, 3,
(P E
(8 0</w>
( grade</w>
us )</w>
tion ally</w>
thir d-
sy -
suspici on</w>
sub stituted</w>
stat us,</w>
smok ers</w>
sel y,</w>
seiz ure,</w>
scaven g
s lower</w>
rout inely</w>
ro ten
refl ected</w>
reach ing</w>
re placed</w>
rang e:</w>
posi tion.</w>
popul ations</w>
piri form</w>
ph enter
percep tion</w>
pen ile</w>
partic i
pan curonium</w>
on co
oc ci
n ociception</w>
mut ant</w>
mucos a</w>
model ing</w>
mg ),</w>
mal e,</w>
loxac in,</w>
kidne y,</w>
kg ),</w>
j udg
it ud
intra thec
infarc t</w>
indic ator</w>
incid ence,</w>
in patient</w>
ia ;</w>
hyd ram
hepar in,</w>
h ost</w>
grav is</w>
fo s</w>
fibrill ation,</w>
experi ences</w>
evalu ation.</w>
epi thelium</w>
enzym es,</w>
electromyo graphic</w>
e modi
dow n-
domin ant</w>
decarboxyl ase</w>
de position</w>
cr uc
cour se.</w>
complic ating</w>
clomi pramine</w>
chemotherap y-induced</w>
ch ec
bro ad</w>
bl ed</w>
aver aged</w>
asyst ol
ap tic</w>
anomal ies</w>
anc iclo
agonist s.</w>
agit ation,</w>
agg er
accid ental</w>
Vis ual</w>
U p
Swis s</w>
Ran dom
RB V</w>
Propran olol</w>
P ren
Mus cle</w>
L-DO PA
L id
Inv estig
Immuno hist
I r
Hyper tension</w>
HBs Ag</w>
G A
F 344</w>
D a
Con comit
Ch lor
9 ;</w>
7 %),</w>
6- hydroxy
5. 5</w>
3 3%</w>
1 30</w>
(2 50</w>
(- )</w>
( <</w>
' ,
year ,</w>
week -old</w>
vir t
ventil ated</w>
ut aneous</w>
ur ine.</w>
trop onin</w>
tim ing</w>
tic ity</w>
ti dine</w>
th ro
target ed</w>
sur ro
sub types</w>
sal ine-treated</w>
ra ise</w>
prophyl axis.</w>
profi le.</w>
proble m.</w>
present ation.</w>
predomin ant</w>
pre ference</w>
polymorph ism</w>
per t
pea ked</w>
parad oxical</w>
pa ediatric</w>
ox ide,</w>
oscop y</w>
ol ed</w>
ob vious</w>
o- occlusive</w>
nucle otide</w>
noc turnal</w>
metron idazole</w>
metoclop ram
man ,</w>
macroph ages</w>
likeli hood</w>
intran asal</w>
inhibi tion.</w>
inda c</w>
inclu ded.</w>
idiosyncr atic</w>
i az
hex ameth
guide lines</w>
gluco se,</w>
gangli onic</w>
g all</w>
fore brain</w>
fl un
feat ures,</w>
ex ist</w>
epicardi al</w>
enzym atic</w>
ene di
end ocardial</w>
emo tional</w>
dic hloro
demon str
datab ase</w>
cross- over</w>
clopido grel</w>
cirrho sis.</w>
cere br
carb on
ca uti
atri pt
at es,</w>
arg atrob
ar y-
antibodi es.</w>
am -induced</w>
allow s</w>
ag on</w>
activi ties.</w>
ab or
Whe reas</w>
W T</w>
V R
T GF-
St ates.</w>
Sp ont
S we
S ta
S ep
Qu anti
P rim
P ilo
P RE
NA C</w>
M arch</w>
LT )</w>
L Y
L A-
I A</w>
Halo peridol</w>
G B
Develop ment</w>
Clo zapine</w>
C r
9 3</w>
6 %).</w>
5-HT 1A</w>
5 +/-
3 A
3 9.
2 2.
0.00 1</w>
.0 1).</w>
(V PA)</w>
( IV)</w>
x yl
wash out</w>
val id
unit raz
u si
tw o
trigg er</w>
ter fen
survival .</w>
stimul atory</w>
st ay</w>
st av
sp ina</w>
small -cell</w>
sive- compulsive</w>
sion ;</w>
sed ation.</w>
sat uration</w>
ro d</w>
ri tic</w>
reduc ed,</w>
ran dom</w>
r ich</w>
qu ick
py raz
pup s</w>
promot ed</w>
pro thrombin</w>
pro genit
pre dis
pentylenetetraz ol</w>
par anoid</w>
p h</w>
ow ing</w>
one uro
ni gro
neutropen ia,</w>
muscim ol</w>
mitochond ri
mil dly</w>
microgram s)</w>
manif est</w>
malignanc ies</w>
ma king</w>
lymph oma.</w>
lat ent</w>
ip si
investig ation.</w>
gram .</w>
glauc oma</w>
fos car
fl unitraz
excep tion</w>
erythro id</w>
episode s.</w>
ens ory</w>
eff or
diabet es.</w>
defin ite</w>
decreas ed,</w>
dat e,</w>
d ental</w>
coun tri
classi c</w>
ch il
cephalo th
catal eptogenic</w>
c ,</w>
busulf an</w>
bilater ally</w>
as alaz
all- trans-
aden oma</w>
acid osis,</w>
accompan ying</w>
ac he</w>
ac e
Whe ther</w>
WK Y</w>
Th ere
St ates</w>
S tro
S ou
R T</w>
O A
Neuro toxicity</w>
N al
L ow
L M
In tr
H V
G er
Fem ale</w>
F ir
Emer gency</w>
Dop amine</w>
Depart ment</w>
D ys
D exameth
Ca ucasi
B CNU</w>
Alzheim er's</w>
AD V</w>
A N</w>
3. 7</w>
2 b</w>
1 2.5</w>
(S D)</w>
(1 )-
w al
under stand</w>
trac ted</w>
trac heal</w>
thym idine</w>
tempor ally</w>
techniqu e.</w>
sud den
sto p</w>
steroid s.</w>
star ted.</w>
sodi um,</w>
sit es.</w>
ser ies.</w>
rever ses</w>
rem ia,</w>
reinst atement</w>
region s.</w>
questionna i
punc t
produc tion.</w>
prehen sive</w>
pos ure</w>
ple ural</w>
phenyl but
phenyl )
ph ase,</w>
pector is</w>
p ill
output ,</w>
or =
one )</w>
ob es
non- selective</w>
new bor
nalox one.</w>
monitore d.</w>
micro g)</w>
memor y.</w>
male ate</w>
linezol id</w>
levof loxacin</w>
isosorb ide</w>
in ergic</w>
illic it</w>
ho wever</w>
hemo glob
hab it
foc us</w>
femal es.</w>
experiment s.</w>
epinephr ine.</w>
ecti ous</w>
differenti ation</w>
diagno sis,</w>
dev oid</w>
depend ent,</w>
ch ymal</w>
calcit onin</w>
c- fos</w>
b in
aut om
ang inal</w>
ad ic
accoun ted</w>
ab ec
Un like</w>
U .</w>
S tre
S ter
L E</w>
K (+)-
J uly</w>
H E
H A</w>
G- CSF</w>
ET -1</w>
EP S</w>
E Na
Con ver
Ce f
CYP -induced</w>
C ro
Anti -
Angi otens
Ad en
A H
8 /
6- week</w>
13 %</w>
1- adrenoceptor</w>
1- 2</w>
0.05 ,</w>
(7 5</w>
( all</w>
vitro ,</w>
ves tibular</w>
verapam il.</w>
ur i
um p
ul l
trimethop rim-sulfamethox
tourniqu et</w>
toc oph
ti vi
t rough</w>
sub sided</w>
su m</w>
spac e</w>
sot al
single -bl
sin us
s op
reversib le.</w>
rel ated.</w>
reinfor ce
reac tion,</w>
re a</w>
preval ent</w>
pre -</w>
praz os
polymorph isms</w>
persist ence</w>
ox carb
over load</w>
out flow</w>
or adi
one- associated</w>
odi pine</w>
ocur ar
occa sional</w>
nephro calcin
mon onuclear</w>
max )</w>
malondi aldehyde</w>
malar ial</w>
malar ia</w>
m t
m )</w>
leuc ov
l amin
l ),</w>
ketocon azole</w>
issu e</w>
isot retino
io do
indomethac in.</w>
in tolerance</w>
in adver
im mobil
glo bus</w>
fibro blast
facil itation</w>
ethyl ene</w>
estim ates</w>
ent ly.</w>
enlarge ment</w>
e f</w>
design .</w>
defect s.</w>
d- amphetamine</w>
cour se,</w>
corticosteroid s.</w>
consti tu
computer ized</w>
compa red.</w>
chang ing</w>
ca ine</w>
blun ted</w>
analo gs</w>
amiodar one,</w>
am ic</w>
altern ate</w>
alcoh ol
U S</w>
TR PV
T e
Syst olic</w>
Subsequ ently,</w>
Stre pt
Sec ond
Respon se</w>
Pren atal</w>
P ulmonary</w>
N-acetyl cysteine</w>
M B</w>
L os
IN D
Fol low-
F A</w>
E X
DB A/
D NA
BAL B/
B ri
Ab normal</w>
AC TH
6 0,</w>
6 ,
6 %),</w>
50 6</w>
3 50</w>
3 3
2 1%</w>
10 ).</w>
(S N
(L D
( medi
( i.p.)</w>
y s,</w>
well- tolerated</w>
vomit ing.</w>
ven ile</w>
upreg ulation</w>
under li
uncer ta
un like</w>
trin itrate</w>
trans mis
thromb oxane</w>
surve illance</w>
stat es.</w>
slop e</w>
significant ,</w>
sequel ae.</w>
salic ylate</w>
rest oration</w>
relax ant</w>
recipi ent</w>
ra i
r ant</w>
pur po
psor iasis</w>
pro ve</w>
pr ac
physos tigm
ol one</w>
ol e
oclon al</w>
no dos
nicot ine.</w>
n af
myelo suppres
my algi
methion ine</w>
metab otropic</w>
leth arg
ishe d,</w>
inter national</w>
inten s
initi ated.</w>
in sp
in bred</w>
in active</w>
impro ved.</w>
ili ary</w>
i x
he at
group ),</w>
frequ ency,</w>
follow s:</w>
fibro sis,</w>
fea sibility</w>
f f</w>
extravas ation</w>
expl oratory</w>
epileptic us,</w>
electro physi
dos ing.</w>
dis closed</w>
demonstrat ed.</w>
cyto kin
coun ter</w>
consol idation</w>
chore a</w>
bortezom ib</w>
ass ayed</w>
arth ro
ar ms</w>
administere d,</w>
activ ation,</w>
abl ation</w>
ab use,</w>
a emia,</w>
V en
Tam oxif
S )-
P =0.0
MB F</w>
L O
Hist ological</w>
H yp
H T
H 2
Follow- up</w>
Ex posure</w>
Comb ination</w>
CI PA
B 12</w>
Au g
2 5)</w>
17 %</w>
13 ,</w>
12 %</w>
0 ).</w>
(M R
(G SH
(C P
(C M
(A T
( including</w>
wor king</w>
well .</w>
ur sodeoxychol
unit .</w>
thick ening</w>
swit ching</w>
stimul ate</w>
sti ff
sign s,</w>
sev ent
ses sions</w>
sel ection</w>
sco res,</w>
repeate dly</w>
psych otropic</w>
precur sor</w>
por phy
plac ental</w>
phenobarbit al,</w>
perform ance.</w>
p ,</w>
oxid ant</w>
ou ter</w>
ot otoxic</w>
os uxim
organ ization</w>
op ri
od enal</w>
obses sive-compulsive</w>
nox ious</w>
nmol )</w>
nephro lithiasis</w>
neede d.</w>
necro tic</w>
misoprost ol</w>
mil d,</w>
mexilet ine</w>
membran ous</w>
lip ids</w>
lab ell
l angu
ing s,</w>
incontin ence</w>
hypom agne
hyd antoin</w>
g anciclo
fluores ce
fl ic
fav our
f illed</w>
expan sion</w>
ex agger
ethyl -
estic ular</w>
escap e</w>
ep sy</w>
endoscop ic</w>
double -
dopa .</w>
dist ribu
di ent</w>
demo graph
def er
confoun ding</w>
combin ing</w>
cerebell um</w>
cel ecoxib</w>
brady cardi
br achi
bal anced</w>
ati d
anim al
an x
amb uc
allo geneic</w>
aff or
adjunc t</w>
ac y</w>
T yp
Sp inal</w>
Sevent een</w>
R V
Prote inuria</w>
Pro spective</w>
M al
L T</w>
K I</w>
Indometh acin</w>
In flu
In de
IL -1
G lomerular</w>
Fre y</w>
For ty</w>
Del ta
D ue</w>
Cardi otoxicity</w>
C57BL/ 6
AU C</w>
AD )</w>
8. 5</w>
4 5%</w>
2 2%</w>
- 2
(i i)</w>
(C S
( or</w>
( 6-
year s),</w>
ye li
weigh ts</w>
vincrist ine.</w>
vari ations</w>
vari ant</w>
tumour s</w>
til t</w>
thi or
se mi
scal e,</w>
sar coma</w>
ri s</w>
region .</w>
re activation</w>
prostagland ins</w>
poison ing.</w>
phent olamine</w>
phenomen on.</w>
perox is
path ogenetic</w>
par ts</w>
par ti
paclitaxel .</w>
p ene
org ans</w>
op y
olo m
non invasive</w>
my osin</w>
mon oclonal</w>
modific ations</w>
m us</w>
leg s</w>
lamotrig ine</w>
isopren al
interven tions</w>
interpre ted</w>
inter medi
ing 's</w>
in ate</w>
im mature</w>
im idazol
ha emodi
gest ation.</w>
expres sion,</w>
en ough</w>
electro shock</w>
distrib uted</w>
dextro methorph
depress or</w>
de -induced</w>
consider ing</w>
con flic
compromis ed</w>
co- administration</w>
cardi otoxicity,</w>
c esarean</w>
b p
b er</w>
b and</w>
avail able.</w>
av age</w>
atrop ine,</w>
as ked</w>
as e)</w>
an ion</w>
amin ation</w>
alve olar</w>
akathi sia</w>
aim s</w>
ag re
acetyl cholinesterase</w>
ac etin</w>
a ;</w>
W ar
W H
SI S:</w>
S y
Reco very</w>
Rec urrent</w>
R P</w>
R N
Pro g
Pheny to
PO -
P- SM
P =
Or gan
O HD
Nicot ine</w>
High er</w>
Hepati tis</w>
Eigh teen</w>
Ech ocardi
Dobut amine</w>
Differen tial</w>
D- penicill
D ip
Continu ous</w>
Caffe ine</w>
CB 1</w>
B Z
AL F</w>
A 2</w>
7 ,
3. 4</w>
2. 8</w>
16 ,</w>
16 %</w>
(i. c.v
(P =0.0
(L VE
( greater</w>
yl line</w>
ventilat ory</w>
us age</w>
ur red</w>
tub ocurar
tobram ycin</w>
sympath omimetic</w>
suppor ting</w>
stres s,</w>
ste p</w>
sensitiz ation.</w>
sco re.</w>
satis factory</w>
safet y,</w>
respectively ),</w>
regurg it
recommend ations</w>
propofol ,</w>
pre cise</w>
plic ations</w>
phenomen a</w>
phen az
p s
oxygen ase-
ove mb
ovemb er</w>
oni um,</w>
ol ith
n ur
n ing,</w>
modul ates</w>
micro dialysis</w>
mg/kg/ day,</w>
mening itis.</w>
lac king</w>
ki log
kg(-1 ))</w>
impair ment,</w>
im ine</w>
idazox an</w>
hyper activity,</w>
hour s)</w>
highligh ts</w>
hel p
gal act
g ar
foc used</w>
exhib iting</w>
excre tion.</w>
estrogen s</w>
er a</w>
ep t</w>
end ed</w>
electro graphic</w>
electro convulsive</w>
elder ly.</w>
diar rho
di al</w>
de -
cyclo hex
cruc ial</w>
cri sis</w>
cor p
cont ents</w>
condi tion,</w>
bleed ing.</w>
blad der.</w>
bi osyn
attempt ed</w>
aspir in.</w>
as es.</w>
anxi olytic</w>
antidepress ants.</w>
andro gen
an s.</w>
an ic</w>
albu terol</w>
adrenoc or
] ).</w>
V ,</w>
Th ose</w>
S tr
R ap
Prim ary</w>
Pharmac ological</w>
P l
N orm
Meth ad
M es
IN G
Head ache</w>
Euro pe
CP P</w>
C ases</w>
Ad ren
Ac cording</w>
8 %).</w>
6 7
3. 9</w>
20 1</w>
10(9 )/
0.00 5).</w>
(-1 ))</w>
( with</w>
( 5-F
( +/-</w>
wor l
ver .</w>
vasodilat ation</w>
valu able</w>
urticar ia</w>
urk inj
tum ors,</w>
treat ed,</w>
transplant .</w>
transi tional</w>
transfer red</w>
succ ess</w>
stri king</w>
st rat
st atin</w>
sal v
s lowing</w>
ru s.</w>
retri ev
res um
recogn ize</w>
publ ic</w>
protoc ols</w>
pro long</w>
predic ting</w>
precipit ating</w>
pow er
posses s</w>
polymorph ic</w>
phospholip id</w>
phen olate</w>
phen acetin</w>
perio perative</w>
pentylenetetra zol
partic ular,</w>
pal sy</w>
pal pit
p tions</w>
oli go
occur red,</w>
o edema</w>
non specific</w>
nitro fur
neu tr
neph ritis,</w>
n ic</w>
mu g/
minim ize</w>
mi gr
mg/ 100</w>
membran e-
mark eting</w>
m ot
lithium- pilocarpine</w>
l ad
l ).</w>
ine mia,</w>
incub ation</w>
incorpor ation</w>
imag ing.</w>
ic al
i.c.v .)</w>
hydrochlor ide,</w>
human s,</w>
hn 's</w>
graph y.</w>
glycer yl</w>
g/m 2</w>
fle x</w>
fentanyl .</w>
exacerb ate</w>
environ mental</w>
eff e
ect able</w>
e sis</w>
dis soci
dexamethas one-induced</w>
denerv ation</w>
den se</w>
del ay
defic its.</w>
de red</w>
cran i
cent ers</w>
carvedi lol</w>
capecit abine</w>
but yl
bradycardi c</w>
blo t</w>
backgro und</w>
atax ia,</w>
arth r
ant -induced</w>
analogu es</w>
amne sic</w>
amin id
all y-
al lowing</w>
agonist s,</w>
W om
V incrist
TI CIPA
TICIPA NT
T er
Spont aneous</w>
Seiz ure</w>
REPORT :</w>
Pre -
PT Z</w>
PT H</w>
PAR TICIPANT
P N
N B
M ild</w>
M PA</w>
L ip
H S</w>
D ),</w>
Co operative</w>
9. 5</w>
8 ;</w>
6. 7</w>
4. 8</w>
3. 1</w>
3- week</w>
2- chloro
19 -
15 )</w>
0.0 2</w>
(H R)</w>
(1 2.
( both</w>
volt age</w>
vit amin
ventro lateral</w>
ven o-occlusive</w>
vacc ine</w>
us -induced</w>
ultim ately</w>
ulcer ative</w>
ty pe
tri phosphate</w>
trazod one</w>
trans dermal</w>
top otecan</w>
terbut al
t esticular</w>
surro un
struct urally</w>
speci men</w>
si st</w>
sh ap
schedul es</w>
re war
re presented</w>
re generation</w>
rap amycin</w>
raloxif ene</w>
ra sid
questionna ire</w>
proper ty</w>
program med</w>
proble ms.</w>
pro be</w>
present ation,</w>
pod ocytes</w>
plan ned</w>
pl aqu
pharmac ology</w>
pentylenetetra zole</w>
pene tr
pat ch</w>
p mol/
outcom es.</w>
os .</w>
offsp r
off ers</w>
nod ular</w>
new er</w>
myelo suppression</w>
mortal ity,</w>
morph ine-
month ly</w>
mmHg .</w>
min er
min ),</w>
melphal an</w>
manner ,</w>
mam mal
mal es,</w>
m (-
lograph y</w>
lit er</w>
le vetiracetam</w>
langu age</w>
k s,</w>
itud inal</w>
irrit ation</w>
ip rasid
intramus cul
ine d-release</w>
in ium</w>
ic in.</w>
ia -
i setron</w>
hybridiz ation</w>
histopath ologic</w>
h ol
fol inic</w>
flush ing</w>
fl ick</w>
fib ers.</w>
fen o
f ly</w>
explo red</w>
excre tion,</w>
epinephr ine,</w>
dro pped</w>
diagno ses</w>
des ferri
depend s</w>
deliver y.</w>
comorb id</w>
chromat ography</w>
chlor per
che lat
cer vi
cardiomy ocyte</w>
brachi al</w>
ax im
ation -induced</w>
as tic</w>
ari es</w>
arach id
apl asia</w>
amne sia.</w>
ame ly</w>
alter ing</w>
alpha- tocoph
aggrav ated</w>
adjust ing</w>
X ,</w>
Wom en</w>
We e
T a
SE )</w>
Psych iatric</w>
N ovember</w>
N T</w>
N F-
N AD
METH -induced</w>
LD L</w>
L- argin
IND ING
II I-
F INDING
E A</w>
Dise ase</w>
Di ab
D et
D Z
AC )</w>
A trial</w>
9 %).</w>
6. 0</w>
6- month</w>
5- year</w>
4- week</w>
2- 3</w>
2 9%</w>
2 4,</w>
10 .</w>
1 +/-
0. 5,</w>
-1 2</w>
(I F
(C R
(B P)</w>
week s).</w>
weak ness,</w>
vigil ance</w>
vari ants</w>
v oxamine</w>
u z
triglycer ides</w>
triglycer ide
tra u
titr ation</w>
thrombo phlebitis</w>
the -
t ing.</w>
studi ed,</w>
spar ing</w>
s ole</w>
ron eph
ri um</w>
reg ularly</w>
recept or,</w>
re th
rac heal</w>
r ine-induced</w>
pseud otumor</w>
progres s</w>
predisp ose</w>
phenyl )-
per sist</w>
parkinson ism.</w>
ot ri
or ic</w>
olog ies</w>
ochem istr
occa sions</w>
oc il
nephro pathy,</w>
nadi r</w>
n io
n ative</w>
mo ving</w>
mo bility</w>
microg/ kg)</w>
micro gram</w>
methyl- 4-
metabol ism,</w>
meta- analysis</w>
mes sen
mem ant
mechanis ms,</w>
mecamyl amine</w>
m ural</w>
kne e</w>
kg ).</w>
k age</w>
ju venile</w>
isoproteren ol,</w>
isom ers</w>
inf er
incre mental</w>
i.v .).</w>
hype remic</w>
ho t</w>
herb al</w>
g .
flurbi profen</w>
fashi on.</w>
ex tub
es mo
en larg
dulox etine</w>
dox azosin</w>
diff ers</w>
dex razoxane</w>
deterior ated</w>
defici ency.</w>
cyto plas
correc t</w>
cor ne
catheter ization</w>
cardio genic</w>
canal icular</w>
bifid a</w>
ax on
atri zo
ati tis,</w>
antine utrophil</w>
antigen s</w>
antero grade</w>
add ress</w>
ad ding</w>
activ ate</w>
accept ed</w>
a w</w>
X .</w>
War far
W or
Verapam il</w>
U rine</w>
S elective</w>
R h
O X
O F</w>
NP Y</w>
MEDLIN E</w>
MD MA
M aj
L D</w>
ICA L</w>
G M
Europe an</w>
Electro n</w>
Dexameth asone</w>
Del ayed</w>
Cro hn's</w>
C ]
C NS
Appro ximately</w>
4. 6</w>
3 +/-
18 ,</w>
18 %</w>
1, 000</w>
1 0.
1 -</w>
-1 7
(H C
(G F
(0. 25</w>
( total</w>
( t
( relative</w>
( day</w>
( 7</w>
x )</w>
vari ate</w>
us h</w>
urkinj e</w>
ulc ers</w>
tri me
tis :</w>
thromb olytic</w>
ter m,</w>
tas k.</w>
t os
streng th</w>
sin o
se mia</w>
scopol amine-induced</w>
reticul um</w>
retic ulo
reflex es</w>
rec re
overex pression</w>
ovari ectomized</w>
osmol al
nucle oside</w>
nitroglycer in-induced</w>
n amely</w>
myocardi um.</w>
mou se.</w>
molec ules</w>
mo tility</w>
mmol/ L</w>
men tioned</w>
medic ine</w>
m u</w>
li b
jaundic e.</w>
ipsi lateral</w>
ip en
involve ment.</w>
inter leuk
immunosup press
immun ological</w>
hear ts.</w>
gener al
fib res</w>
f a
exceed ed</w>
examin ing</w>
estradi ol
eluc id
effe rent</w>
ed ull
dose )</w>
dis play</w>
dihydroxy phenyl
dihydro -
digit alis</w>
di az
dex fenfluramine</w>
describ ing</w>
def en
cont act</w>
comparis ons</w>
clonid ine,</w>
clear ance,</w>
ch amb
caffe ine.</w>
ca strated</w>
bu ffered</w>
bl ack</w>
ast atin</w>
as sist
ap o
anti malarial</w>
amis ole</w>
aminonucleo side-induced</w>
achi eving</w>
a ine</w>
VT E</w>
V II
Throm b
TNF- alpha</w>
Re duction</w>
Pilo car
PG I
PARTICIPANT S:</w>
P neum
P E</w>
Neuro logical</w>
MEASUREMENT S:</w>
Influ ence</w>
Impro vement</w>
Hem orrh
FINDING S:</w>
F entan
E A
Do se-
Da ily</w>
D P</w>
D A
Conver sely,</w>
Catal epsy</w>
Brugad a</w>
B ar
7. 4</w>
3/ 4</w>
1. 25</w>
1 1%</w>
- negative</w>
) ).</w>
(R R</w>
(P =
(M M
(5-F U)</w>
ventil ation.</w>
ve red.</w>
variabl es.</w>
val s
v o
us p
unc lear</w>
ud ing</w>
u ment</w>
typ e.</w>
tum or.</w>
tot ally</w>
to o</w>
tic -like</w>
syndrom es.</w>
susta ined-release</w>
suppres ses</w>
success ful
si s;</w>
sever ity.</w>
sep tic</w>
sclero der
rifamp in</w>
rever sing</w>
require ments</w>
replic ation</w>
regul ating</w>
rec t</w>
queti ap
ques tion</w>
psychos timul
presyn aptic</w>
plasma phere
pilocarp ine-treated</w>
pi gs</w>
pericardi tis</w>
per oxide</w>
par ameter</w>
op yri
ont ine</w>
ologic ally,</w>
ol g
off ending</w>
oblast oma</w>
nodul es</w>
multi -
mic ro</w>
mer cap
lo be
le t</w>
le a
inter act</w>
inst ances</w>
ic ally,</w>
ic al,</w>
hr .</w>
histor ies</w>
hemorrh ages</w>
haloth ane.</w>
glutam ic</w>
glucocortico ids</w>
gener al,</w>
gen der,</w>
form in</w>
excit ation</w>
eth osuxim
essen tially</w>
erg oline</w>
end ocardi
enc es.</w>
en i
ecti ve.</w>
each .</w>
diseas es,</w>
dis ability</w>
diet ,</w>
diabet es,</w>
di atrizo
depriv ation</w>
concl u
co done</w>
cle ft</w>
cl a
chloramphenic ol</w>
caud ate</w>
carcin ogenic</w>
carbamazep ine,</w>
c ing
bro ad
be ag
b uc
b rou
b .</w>
ax ial</w>
atript an</w>
asth matic</w>
approach es</w>
anti- HB
am i
ac ous
abstin ent</w>
[ 4-
Therap y</w>
T r
T C</w>
Second ary</w>
SPEC T</w>
S el
R o
Post operative</w>
P en
P RO
P I
O .</w>
Nine teen</w>
NT G</w>
N a</w>
Maj or</w>
M M</w>
Lith i
Lam iv
K+ -
HCT Z</w>
F isch
F i
CL IN
C o-
Bi ochemical</w>
An t
AZ T
AN F
7 5
4. 4</w>
4. 2</w>
2 a</w>
2 1,</w>
19 %</w>
1. 4
1- year</w>
1 16</w>
0 ),</w>
/ d
-1 ),</w>
) -</w>
) ),</w>
(A M
(2 4</w>
(0. 1-
( three</w>
( control</w>
( but</w>
( SIAD
( 0-
z iprasid
volun tary</w>
ver tig
uro thelial</w>
trimeth aph
triamte rene</w>
tran s</w>
symptom at
summ ar
sul indac</w>
sham- operated</w>
sensitiv ity,</w>
scre ened</w>
risperid one,</w>
ri z
reduc tion.</w>
pyr ro
putam en</w>
prurit us</w>
proper ties,</w>
profi le,</w>
pro motion</w>
posit ron</w>
por al</w>
plant ar</w>
phosph odi
perf usion.</w>
parameter s,</w>
p ris
operativel y,</w>
open ia,</w>
omegal y</w>
olog ists</w>
ocyt oc
nor tript
non- Hodgkin's</w>
nimesul ide</w>
nigro striatal</w>
nicardi pine</w>
networ k</w>
neoplas ms</w>
narco tic</w>
n ocicep
mono therapy.</w>
mo fe
m ox
m c
loo p</w>
leuk ocyte</w>
kain ate</w>
k ept</w>
ir regular</w>
iopamid ol</w>
intra uterine</w>
integr ity</w>
insuffici ency,</w>
inf ectious</w>
in ess</w>
hyd roneph
hy pot
hallucin ations,</w>
h inal</w>
grow ing</w>
gl and</w>
gl and
gemfibro zil</w>
fraction ated</w>
fen ol
exten sively</w>
exclu sively</w>
exagger ated</w>
end omy
emphasi zes</w>
ecstas y</w>
ec h</w>
diure sis</w>
diseas e-
di pi
di oxide</w>
develop ed,</w>
destruc tion</w>
defect s,</w>
cryst all
cou gh</w>
conduc t
comple ment</w>
clas ses</w>
cerebr i</w>
brou ght</w>
bri dg
break through</w>
bo th.</w>
bleed ing,</w>
be at</w>
b. w
b. i.
ax on</w>
at r
as sum
ant rol
amitript yl
amin es,</w>
alprazol am</w>
alph a,</w>
adjunc tive</w>
adequ ately</w>
adenocarcin omas</w>
acut e,</w>
acetazol amide</w>
Y -
V e
Tamoxif en</w>
Stro ke</w>
Six ty</w>
Re gi
Partic ip
O P
Nephro toxicity</w>
L arg
I B
Di azepam</w>
Co x</w>
Ch loro
CLIN ICAL</w>
CA D</w>
C57BL/ 6</w>
Ara- C</w>
A(2 A)</w>
A R</w>
5. 3</w>
2 8%</w>
0.0 4
0.0 3).</w>
0 %,</w>
(i. e.</w>
(PAN )</w>
(C A
( approximately</w>
( L-NAME
yo to</w>
yl thio
ycl in</w>
vulner able</w>
vincrist ine,</w>
vigabat rin</w>
vari ance</w>
utili zation</w>
ur ide</w>
uc t
triazol am</w>
treat ed.</w>
th y
te l
t ative</w>
syndrome :</w>
sulph asalazine</w>
sub thalamic</w>
strych nine</w>
ste ady</w>
som atic</w>
significant ly,</w>
side- effects.</w>
separ ation</w>
scre en</w>
sch o
sal ine-
rodent s.</w>
rac emic</w>
psycho sis.</w>
protein s.</w>
propofol -induced</w>
pro s
pregn an
power ful</w>
popul ation-
phylococc us</w>
per ce
pe th
patter n
patient- controlled</w>
oter ol</w>
orig inal</w>
ord ination</w>
or y,</w>
onse t.</w>
on ly,</w>
ologic al,</w>
ol d,</w>
ocy s
ob tained.</w>
nod al</w>
nit ren
min (-1)</w>
microsom al</w>
microangio pathy</w>
micro vascular</w>
mg ).</w>
metho hex
le pro
label ,</w>
l enal
kg -1)</w>
ir respective</w>
insi ght</w>
injec tions,</w>
inflamm ation,</w>
in- releasing</w>
in um</w>
in put</w>
in complete</w>
hypothesi ze</w>
hormon e-
gen ce</w>
fluc onazole</w>
f action</w>
es tion</w>
draw n</w>
do ses
distingu ish
daun orubicin</w>
com position</w>
character ization</w>
chang e,</w>
catat onia</w>
carb ach
canc ers</w>
c GMP</w>
bupivaca ine,</w>
bor der
blad ders</w>
bing e</w>
behavi ors.</w>
azepam ,</w>
ation ).</w>
atid yl
ascorb ic</w>
as sumed</w>
as es,</w>
ar ub
ar ity</w>
anti ci
anatom ical</w>
amphet amine,</w>
activ ator</w>
acous tic</w>
acet yl</w>
acc o</w>
ac yclin</w>
V P
UN E
T orsade</w>
SK F</w>
Pe ak</w>
Particip ants</w>
M N
M /
Ket amine</w>
K yoto</w>
H T</w>
G s</w>
Eigh ty-
DE X</w>
D ose</w>
Concomit ant</w>
Cent er</w>
CD 4
C urrent</w>
C hemo
C S</w>
Brady cardia</w>
ADR -induced</w>
A ne
A k
8 5%</w>
2 -</w>
0 %).</w>
-to- treat</w>
(T ax
(EE G)</w>
(2 ))</w>
( RO
z ym
z olom
wor se</w>
withdraw n.</w>
we dg
virt ually</w>
viro logical</w>
verapam il,</w>
valid ated</w>
v es,</w>
uni ver
ul in</w>
thyrox ine</w>
thiaz ide</w>
ther n</w>
the sia</w>
test ing,</w>
tamoxif en.</w>
tachycardi as</w>
t y.</w>
suic ide</w>
succ essive</w>
solu tion.</w>
ses sion</w>
secret ory</w>
ron ate</w>
retard ation</w>
re absorption</w>
rat es,</w>
qu er
pro chlorper
pregnanc y,</w>
precipit ate</w>
potassi um,</w>
po real</w>
pi perid
perin atal</w>
percent )</w>
parox et
pares thesi
pare sis</w>
par i
p ass
ox ide.</w>
other .</w>
ot e</w>
or din
oph an</w>
once- daily</w>
om ing</w>
ocytoc lastic</w>
ocy te
nucle oti
ni acin</w>
necess ary.</w>
mit te
metabolit es.</w>
metabol ized</w>
man u
man ia.</w>
m sec</w>
lop urin
leuk aemia</w>
judg ed</w>
it er
isotretino in</w>
isol dipine</w>
induc tion,</w>
index ,</w>
immunosup pres
im ipen
ic s.</w>
i. t.</w>
i p</w>
hypokal emic</w>
homeost asis</w>
hei ght</w>
haz ards</w>
gluc agon</w>
erythro cytes</w>
end point</w>
emphasi ze</w>
effec tive,</w>
ed ar
ec hol</w>
dos age,</w>
dis sociation</w>
descri ption</w>
deliri um.</w>
defin itive</w>
dat es</w>
d ac
coun t,</w>
comm ence
combin ation,</w>
clu ster</w>
ciga rette</w>
calci um-
calc ification</w>
ca dian</w>
block ers.</w>
biop sy,</w>
bi om
ber ate</w>
benzodiazep in
ax ons</w>
artic les</w>
arteri ol
ap o</w>
anti thyroid</w>
angio edema.</w>
an al</w>
amisul pride</w>
amiodar one-induced</w>
adul tho
acetyl salicylic</w>
ab sc
[ 2-
Y MDD</w>
W B
V N
Ul tra
Ser oton
R V</w>
Pro st
PO )</w>
Nal ox
M axim
Leu k
K ap
Increas ing</w>
HB I
H um
G D</w>
Fact ors</w>
E stro
E R</w>
De li
DSM- IV</w>
Carbam azepine</w>
CYP2 C
BU N</w>
AN P</w>
99 m
6. 1</w>
4. 7</w>
3 2%</w>
2- receptor</w>
2 8-
2 4%</w>
14 )</w>
1 7-
(1 ,
( range:</w>
vac cin
uni versity</w>
un controlled</w>
um )</w>
ul ph
u g
trac he
toxic ity:</w>
toler ate</w>
tob acco</w>
them .</w>
termin als</w>
tenof ovir</w>
t ly,</w>
synthesi zed</w>
sup pressing</w>
sulph ate</w>
strept omycin</w>
stimul i.</w>
stat e,</w>
sp in
sp ent</w>
sion )</w>
scop y</w>
sco re,</w>
salv age</w>
s cor
s );</w>
review s</w>
reinfor c
regar ded</w>
rai ses</w>
radi ological</w>
r s</w>
r ine,</w>
qu ite</w>
qu ar
ps ori
pres erv
predisp osed</w>
possib le.</w>
po oled</w>
plex us</w>
pi rox
phenyto in.</w>
phenobarbit one</w>
pentazoc ine</w>
pent amid
pat ent</w>
pancre atitis</w>
oxygenase- 2</w>
ost atin</w>
orb ital</w>
ont al</w>
non fatal</w>
need s</w>
need le</w>
necessit ating</w>
micro liter
medi ates</w>
leucov orin</w>
l ic</w>
interfer on-
ing ;</w>
inde sine</w>
il st</w>
id ed</w>
i.v .,</w>
i ox
hypoc ap
hiccup s</w>
hemo dialysis.</w>
head -
guan ine</w>
glut amine</w>
gamma- glutam
g ic</w>
fluoresce in</w>
fea sible</w>
failure :</w>
exten d</w>
evalu ations</w>
dose :</w>
disturb ances,</w>
dep end</w>
def ined.</w>
cycl ine</w>
cour ses.</w>
conserv ative</w>
commun ity</w>
commun ic
co incid
cir cu
cTn T</w>
bu ff
bre ast
bra in-
blind ness</w>
ble .</w>
b ab
aw ak
apopto sis.</w>
antibodi es,</w>
amil ton</w>
alkyl ating</w>
addic ts</w>
a red</w>
Valpro ic</w>
T oxic</w>
Sur vi
Sing le</w>
Sim ult
ST N</w>
S urg
S oci
S m
S CH
Re duced</w>
R est
Per sistent</w>
P ent
O lan
Nine ty-
Neuro leptic</w>
Mon it
K(+)- ATPase</w>
IL- 6</w>
IF N-
H ol
H LA-
H AM-
H 2</w>
G astro
F unc
ENa C</w>
E ven</w>
E ry
Caucasi an</w>
Ca ref
CH F.</w>
C K</w>
Aug ust</w>
AT P-
7. 0</w>
7 50</w>
6 7%</w>
5-HT (2
2 3%</w>
2 %.</w>
10 4</w>
1. 5
1 );</w>
, "</w>
(c )</w>
(S H
(C s
zolpide m</w>
z er
w ast
volume .</w>
verte bral</w>
vel y.</w>
vehic le.</w>
vaso active</w>
v ocal</w>
ureth ral</w>
ur ine,</w>
underli e</w>
ultrason ography</w>
u ation</w>
tri ge
treatment ;</w>
treatment -related</w>
trans mural</w>
tob er</w>
to ,</w>
threshol d.</w>
thou gh
tauro chol
tachy arrhythmias</w>
ta m</w>
stra ins.</w>
stav udine</w>
squ are</w>
some what</w>
sever ity,</w>
se leg
respon der
relie ved</w>
relap se.</w>
recre ational</w>
re d-
protein uric</w>
proces ses.</w>
por tion</w>
phospho kinase</w>
pelv ic</w>
par ac
paclitaxel -induced</w>
paclitaxel ,</w>
p ra
oxal i
ow n</w>
out -
omep razole</w>
ol factory</w>
occur ren
naltrex one</w>
my ocytes</w>
my alg
muscl es.</w>
micro sph
meth y
memor y,</w>
ma de.</w>
low ,</w>
lo vastatin</w>
leak age</w>
larg est</w>
jac ent</w>
isom er</w>
inser ted</w>
inj ecting</w>
infrequ ently</w>
ill ness,</w>
i.v .),</w>
i NOS</w>
hypokal emia,</w>
hepat otoxicity,</w>
glyc opyr
form ation,</w>
flu voxamine</w>
fl av
fibr in</w>
fashi on</w>
expos ures</w>
exhib its</w>
endomy ocardial</w>
en su
en cour
echocardi ograph
dys plasia</w>
doc ument</w>
disper sion</w>
dis appeared.</w>
de sensitization</w>
day ;</w>
com prehensive</w>
collap se</w>
co ffe
co er
co ated</w>
cla vul
ciprof loxac
ci es</w>
chil d.</w>
c .</w>
beta- blocking</w>
b ed</w>
ay na
auto antibodies</w>
areas .</w>
an ionic</w>
an em
an abolic</w>
aminotrans fer
amin es.</w>
am ylo
alpha-tocoph erol</w>
alpha ,
acidi c</w>
a ure
a ,
Vari ous</w>
V i
U RE
Tac rolimus</w>
Sta phylococcus</w>
S V
Quanti tative</w>
Pre gn
Or th
O xy
Magne tic</w>
M 2</w>
In jection</w>
Histopath ological</w>
H amilton</w>
H F</w>
GAB A)</w>
Caref ul</w>
Cal ci
CC K-
An a
Alter ations</w>
AD R-
AD HD</w>
A pril</w>
A S)</w>
5. 6</w>
3 6.
3 3.
3 00
2. 5%</w>
2- adrenergic</w>
14 %</w>
0.0 2)</w>
0. 75</w>
0. 2%</w>
.00 1)</w>
- containing</w>
(P C
(O R
(3 )
(2 ),</w>
( serum</w>
( less</w>
yri dam
wh ole-
vis u
valu e.</w>
v ary</w>
un mas
ule us</w>
tr us
top ir
thi azol
testo ster
system ically</w>
similar .</w>
shoc k.</w>
seve re.</w>
se ts</w>
sat ur
sar com
ro pi
rheum atic</w>
rex cit
require ment</w>
refl ecting</w>
prop ensity</w>
progres sion.</w>
proce dural</w>
prepar ations.</w>
pl ain</w>
pin do
phenyto in,</w>
parano ia</w>
p inal</w>
ox etine</w>
ol ateral</w>
oc om
ob ia</w>
nor mo
nephro toxicity,</w>
n ull</w>
n mol</w>
n ess
myel in</w>
myco phenolate</w>
mut ants</w>
month .</w>
mirta zapine</w>
mg/m l</w>
metabolit e,</w>
met allo
messen ger</w>
mechan ically</w>
me an,</w>
m atic
m ast</w>
ly sis</w>
lign oca
is radi
interval s,</w>
insuffici ent</w>
in- based</w>
id s.</w>
hydro cortisone</w>
hepat otoxic</w>
glyc os
foscar net</w>
form al
flunitraz epam</w>
fact or,</w>
epi theli
enti ty</w>
encephalo pathy,</w>
ect ed,</w>
dur ations</w>
dro ps</w>
dro peridol</w>
dop amine,</w>
dobut amine-induced</w>
distingu ish</w>
disor i
disabl ing</w>
dipi vox
diltiazem ,</w>
describe d,</w>
de trus
d re
d ol
d enti
cycl ase</w>
cra v
clin ici
circul ation.</w>
chemotherap y-
characteris tics,</w>
cefot et
catheter s</w>
cat s</w>
cain ide</w>
buspir one</w>
bupivaca ine-induced</w>
block ers,</w>
benz yl
behavi or
be d
b ot
atro genic</w>
ati ve,</w>
atherosclero tic</w>
aster n</w>
ar a-
anxiet y.</w>
anx io
ant ec
ang le</w>
ameli oration</w>
age- related</w>
ad jacent</w>
] ),</w>
[ 95%</w>
Z )-induced</w>
VPA -induced</w>
V 1</w>
Twenty- six</w>
To ge
Therap eutic</w>
T ime</w>
T CD
Suc cess
Ser ious</w>
R ayna
Post -
Over all</w>
Oc tober</w>
O u
O ,</w>
Neuro logic</w>
Ne on
Meth otrex
K idne
IV ,</w>
I GF-
Gen eral</w>
Fisch er</w>
F etal</w>
Experim ent</w>
Dip yridam
Di rect</w>
DF O</w>
D il
Cyclophosph amide</w>
Com plications</w>
Child ren</w>
At ten
8. 0</w>
4. 1</w>
4 '-
20 /
2, 3-
2 %;</w>
18 )</w>
1, 25
(T d
(OH)2 D3</w>
(L V
(E M
(4 5</w>
(1 0%)</w>
( GABA
ycl ine</w>
x ,</w>
vastat in,</w>
vasoconstric tor</w>
v inc
u sional</w>
transf er</w>
the- counter</w>
target s</w>
surroun ding</w>
sup port
strong er</w>
ster ile</w>
ser um,</w>
ser i
satis faction</w>
sal iv
saf e,</w>
rupt ure</w>
rou gh
rest ore</w>
recor d</w>
prim ing</w>
pregnanc ies</w>
preferen tially</w>
pharmac ologically</w>
ph aryngeal</w>
pallid us</w>
open- label,</w>
om yeli
od y</w>
ocys tis</w>
occi pit
o grams</w>
nar row
mus cle,</w>
mou th</w>
monke y</w>
migra ine.</w>
memb ers</w>
mechanis m
mater ial</w>
manu fact
low .</w>
lig and</w>
li ving</w>
lef t-
lan sop
k D
jug ular</w>
invol ved.</w>
intub ation.</w>
intrathec ally</w>
in ability</w>
ill ness.</w>
il -
hypercalci uria</w>
hype rexcit
hil us</w>
hex iline</w>
here in</w>
hei gh
har m
haloth ane,</w>
gram ,</w>
glyco l</w>
fibrill ar</w>
femal es,</w>
f urther
f ish</w>
f ,</w>
examin es</w>
enkephal in</w>
en ium</w>
en flur
disul fir
disori ent
dis h</w>
depend ence,</w>
dam s</w>
d ens
cros s</w>
corne al</w>
con cept</w>
clo t</w>
cisapri de</w>
cing ulate</w>
cholecyst o
chlor ambuc
cap ill
ca th
c ad
bru ary</w>
azol e-induced</w>
aut oradi
aut op
attempt s</w>
attac ks.</w>
ati ve.</w>
arth ritis,</w>
arteri olar</w>
argatrob an</w>
arachid onic</w>
ar ri
ar m.</w>
applic ation.</w>
antibio tics.</w>
anti sense</w>
anti cholinerg
ane ously.</w>
ane ous
all-trans- retinoic</w>
all y)</w>
acid osis.</w>
Twenty- three</w>
Twenty- five</w>
Tol er
Success ful</w>
Sep tem
S L</w>
Regi onal</w>
Re view</w>
P s</w>
P K</w>
NS ).</w>
MT D</w>
MD A</w>
L IS
K O</w>
J o
Ifosf amide</w>
ISO -induced</w>
IF O</w>
H is
Gl ut
F requ
F ran
Differen ces</w>
D ou
CG P</w>
C an
B rom
AR S</w>
A G</w>
7 0-
6 +/-
5. 2</w>
4. 9</w>
30 )</w>
3- hour</w>
2- year</w>
2 25</w>
2 1.
100 -
1 st</w>
1 1)</w>
1 %.</w>
0.0 3
0 %),</w>
(MT X)</w>
(EC G)</w>
(3 ,
( L-
( 9</w>
yst ag
ye lo
wat er.</w>
vol vement</w>
vis its</w>
vascul itis,</w>
valpro ate.</w>
v ic
utili zed</w>
un stable</w>
ub ular</w>
ton gue</w>
th is,</w>
th -
te mo
table t</w>
synthe sis,</w>
sw im</w>
sur fac
succinylchol ine-induced</w>
stom ach</w>
spe ech</w>
sinus oidal</w>
sign als</w>
ser um.</w>
sept um</w>
second- line</w>
schedul e.</w>
s arc
rhyth m.</w>
reversib ility</w>
reten tion.</w>
ret ar
respir ation</w>
reli ably</w>
reac ted</w>
radi ographic</w>
quick ly</w>
quantit atively</w>
pyri d
prov oc
prolong ing</w>
progenit or</w>
pro tracted</w>
prefer red</w>
pre treatment,</w>
pre -treated</w>
performe d,</w>
pathw ays.</w>
pathophysi ologic</w>
ot otoxicity.</w>
ors '</w>
orig in.</w>
opy ram
ol ;</w>
ococc al</w>
obarbit al</w>
non- small-cell</w>
nitros amine</w>
neuro psychological</w>
neuro degenerative</w>
nalox one,</w>
myelo ma.</w>
mucosi tis</w>
mu -opioid</w>
move ments.</w>
mm 3</w>
ml/ min</w>
mil rinone</w>
metast ases</w>
medi ator</w>
manip ul
mammal ian</w>
malignanc y</w>
long itudinal</w>
kal emia</w>
insipid us.</w>
ingest ing</w>
indomethac in,</w>
inc i
immunohist ochemistry</w>
immuno globulin</w>
immune -mediated</w>
i ed.</w>
hydro gen</w>
hor iz
haloth ane-induced</w>
haem olytic</w>
gu n</w>
group ;</w>
g/d l</w>
fo ot
fluoro uracil</w>
flun ar
flu phenazine</w>
flu or
et ,</w>
er ic</w>
epti d
endot racheal</w>
enantiom ers</w>
doxorubic in-treated</w>
diz ocil
distinguish able</w>
diet s</w>
de ep
day s),</w>
dP/d t
d B</w>
cytot oxicity</w>
cou gh
cont ent,</w>
consti pation</w>
cocaine- exposed</w>
clopido grel
cisplat in.</w>
chemic ally</w>
c ure</w>
bur ning</w>
bo th,</w>
bi phasic</w>
beta- blockers</w>
atic ,</w>
as ymptom
aro tid</w>
antici p
anti convulsive</w>
ann ab
aneurys ms</w>
amphet amine-
aggrav ation</w>
af in
adren o
ab er
a b</w>
Y )</w>
Wist ar-
W -
W )</w>
U ,</w>
T ic
Survi val</w>
Stat us</w>
S A)</w>
R em
Prop ylthio
PT Z
P rin
P ositive</w>
Neon atal</w>
N- nitro
Mul tivariate</w>
Measure ments</w>
MM P-
M idazol
M em
Lid ocaine</w>
In volvement</w>
Hum an</w>
Hg ;</w>
H SP
D ays</w>
CYP2 D
C ur
Anim al</w>
Ac tivation</w>
5-hydroxytrypt amine</w>
4 4
3 8%</w>
2 -induced</w>
(p =0.0
(S SR
(O R,</w>
(AD R)</w>
(5 %)</w>
(2 ,
( IS
z on
wh ilst</w>
wh ic
vi si
visi t</w>
vesi cular</w>
uncommon .</w>
ud 's</w>
tri ple</w>
transi ently</w>
time -dependent</w>
til ide</w>
thi obarbit
temo zolom
te tan
te ach
synthe sis.</w>
survival ,</w>
sur al</w>
suc rose</w>
sub units</w>
strok es</w>
stres sed</w>
strati fied</w>
strat um</w>
st ability</w>
sph inc
sp le
sit es,</w>
si lon
si an</w>
sertr al
serocon version</w>
reversib le,</w>
rese arch
requi red.</w>
radio immuno
rabb its.</w>
quanti fy</w>
pyrro lid
pre medicated</w>
post ulate</w>
pol yp
phenyl -1,
perio ds.</w>
per oxy
path ogenic</w>
particip ate</w>
paralle l-
paradig m</w>
p ens
p =
oxcarb azepine</w>
over- the-counter</w>
out ,</w>
ot o
ophosph ate</w>
operativel y.</w>
on it
om as,</w>
oli po
ol ab
ogene sis,</w>
od ine</w>
ochemic ally</w>
neg atively</w>
n R
morph one</w>
miner al
mg/ 24</w>
mer open
medi ators</w>
malignanc ies.</w>
mRNA s</w>
m L
lithi um,</w>
levodopa .</w>
lev amisole</w>
le sion.</w>
kilog ram</w>
it rac
intracerebro ventric
inter ruption</w>
intak e,</w>
inh er
ine- containing</w>
induc ed,</w>
indic ators</w>
in- dependent</w>
in tim
in sen
hypo glycemia</w>
hyperprolact in
hydrochlor ide.</w>
gre en</w>
gran isetron</w>
gener 's</w>
ganciclo vir</w>
fract ure</w>
famil ial</w>
exer cis
ex amp
esoph ag
ery thromycin</w>
epilept ogenesis</w>
entr ant</w>
enrol led.</w>
enoxapar in</w>
eng e</w>
ed -dose</w>
ectom y,</w>
dist res
discontinu e</w>
dimen sional</w>
dig ital</w>
di deoxy
dextromethorph an</w>
devi ation</w>
delta -
decom pens
d antrol
concentration -dependent</w>
con ce
common ,</w>
com mer
co administered</w>
circum st
caus ality</w>
carcin oma,</w>
brie fly</w>
bir th.</w>
bac k
atheros clerosis</w>
aryn g
anti hyperalgesic</w>
anti bod
anthracyclin es</w>
amelior ates</w>
allodyn ia.</w>
al te
add res
acid s,</w>
[CI ],</w>
We gener's</w>
U .
TH E
R I
Out come</w>
OD )</w>
Nalox one</w>
N im
M ay</w>
Le w
Lamiv udine</w>
L H</w>
L AD</w>
J )</w>
In fusion</w>
INTERVEN TION:</w>
HC C</w>
H A
G Y
G T</w>
Fe bruary</w>
F L
F ANF
Ex tr
Ex amination</w>
Electro cardio
Con sider
CA -
C /
A 2A</w>
9 00</w>
9 +/-
7 +/-
19 ,</w>
13 )</w>
10 -1
1. 3
0. 1%</w>
-1 6</w>
(i.c.v .)</w>
(I N
(H D
(6 )</w>
(0. 5-
( "
wom an,</w>
weigh ing</w>
vinblast ine</w>
ventric les</w>
usp id</w>
tubocurar ine</w>
transi tion</w>
toxic ities.</w>
tic ed</w>
thrombocytopen ic</w>
terfen adine</w>
tacrolim us.</w>
sudden ly</w>
sub groups</w>
su be
strych n
stitut es</w>
sten osis.</w>
son 's</w>
sit e.</w>
shar p</w>
scor ing</w>
scal es</w>
sarco plasmic</w>
sal me
ro ta
ris k
reve als</w>
ret e</w>
resul t
resist ance,</w>
reser pine-induced</w>
recover y,</w>
re mor
re ad
prop ag
promot er</w>
practi tion
po ol</w>
plic ation</w>
pl us-
phenylpropan olamine</w>
peroxis ome</w>
peri vascular</w>
pe d
partici pation</w>
part uri
output .</w>
op a</w>
ob lo
nor adrenal
ni gra
neutropen ia.</w>
neuro blast
modi fying</w>
mg/d l,</w>
method s.</w>
meth imazole</w>
ment ed</w>
m 2</w>
lex y</w>
labor ator
l ;</w>
ket amine,</w>
inver sely</w>
inter neurons</w>
incre ment</w>
in- resistant</w>
in -</w>
in ).</w>
hypo thyroidism</w>
hypertroph ied</w>
hyper tonic</w>
hyper thyroidism</w>
hydr alazine</w>
hospital ization.</w>
h is
h abil
h ).</w>
group s;</w>
graf ts</w>
gen e-
gemcit ab
gain ,</w>
g adol
fre ely</w>
f ru
extrac ts</w>
experim ent.</w>
excre ted</w>
es tin</w>
ergot amine</w>
erg ol
er adic
epid ermal</w>
enalapri l.</w>
en tic</w>
el ing</w>
dox y
dil uted</w>
didan osine</w>
dev ice</w>
det ecting</w>
dem and</w>
deci sion</w>
de b
cytokin es</w>
cycl es,</w>
confir ms</w>
conf ined</w>
compoun ds,</w>
collag en
col on</w>
co st-
ch es</w>
catal y
bortezom ib
blockade ,</w>
beag le</w>
azot emia</w>
az ithromycin</w>
az ide</w>
asth ma.</w>
ar ,</w>
am en
all ergy</w>
al /
Typ e</w>
T ).</w>
T ),</w>
Statis tical</w>
Septem ber</w>
SO D</w>
S ex
Rh abdomy
Rap id</w>
R adi
Pneum ocystis</w>
P TH
P IL
M ark
L C
In stitute</w>
Gen er
G o
D (3)</w>
Con sequ
Com mon</w>
Ch aracter
Calci um</w>
B6 C3
Ane mia</w>
AT )</w>
AC E
> /
55 ,2
1. 5%</w>
0.000 1),</w>
- matched</w>
- 3</w>
(P B
(C D
(5 )</w>
(1 1.
(1 -1
(0. 4</w>
( an</w>
( GABA)</w>
we t</w>
w id
volt age-
vessel s.</w>
us :</w>
up- regulation</w>
un known,</w>
un detectable</w>
tuberculo sis.</w>
transcri ption</w>
ton ,</w>
tis m</w>
til ity.</w>
tac tile</w>
t ing
system atically</w>
suspen sion</w>
suspect ed.</w>
sup pl
stimul ates</w>
steroid -induced</w>
somat ostatin</w>
similar ities</w>
si as</w>
short- acting</w>
sep sis</w>
sed ated</w>
retriev al</w>
ret y
rest less
resc entic</w>
recogn ized.</w>
re d
quin pi
pseud olith
prote in.</w>
prost acyclin</w>
promot es</w>
population- based</w>
pharmaco dynamics</w>
persist ing</w>
patter n.</w>
paralle led</w>
par s</w>
over l
op tical</w>
on to</w>
om o
occipit al</w>
obser ve</w>
ob ese</w>
norepinephr ine,</w>
non- specific</w>
neuro physiological</w>
neph rin</w>
move ments,</w>
ml/ min/
mimic king</w>
midazol am,</w>
micro mol</w>
mic ron
memant ine</w>
mak es</w>
mEq/ L</w>
m O
load ed</w>
lif e
l ut
jaundic e,</w>
iodi x
intra- arterial</w>
imb ic</w>
ic ter
i sed,</w>
hyp oxic</w>
hor n</w>
histopath ology</w>
hepar an</w>
haemorrh agic</w>
gran ular</w>
glit azone</w>
g p</w>
g ative</w>
frequ ency.</w>
fluores cent</w>
fluctu ations</w>
femal e,</w>
favour able</w>
f it
exerci se.</w>
exam ic</w>
eu tical</w>
ep silon
en ing.</w>
en e,</w>
ell a</w>
duc tal</w>
droxy progesterone</w>
dox ep
differenti ate</w>
detrus or</w>
dend rit
de tri
cysti tis,</w>
con sumed</w>
con s
commence ment</w>
clear ance.</w>
chol ang
cannab is</w>
atroph y.</w>
atri a</w>
arterio venous</w>
arteri es,</w>
are a,</w>
appear ing</w>
aneur ysm
al lopurin
al is
agranulo cytosis</w>
agonist .</w>
adul ts,</w>
accur ate</w>
ac ne</w>
a ir</w>
U/ L</w>
Twenty- two</w>
TH C</w>
TA M</w>
Sever ity</w>
S ymptomatic</w>
S ]
S 1</w>
Repor ts</w>
Repor t</w>
Rayna ud's</w>
Pro phyl
P C</w>
N-acetyl -
M ater
L- dopa-induced</w>
Ig M</w>
I GF
HD L</w>
H ).</w>
GV HD</w>
Elev ated</w>
E m
Do ses</w>
Coca ine-
C s)</w>
C CR
Bu propi
Bo NT
BACKGROUND /
B6C3 F1</w>
B R
Angio edema</w>
8. 4</w>
55,2 12-
5. 8</w>
4 50
3A 4</w>
2. 5,</w>
10 1</w>
1 0.0</w>
-1 6
(R B
(P< 0.05).</w>
(P D).</w>
(NSAID s)</w>
(D F
( normal</w>
( Q
yl ]
wat er-
w anted</w>
vi sion,</w>
ventric le.</w>
urac il-induced</w>
unc ture</w>
un toward</w>
u ren
twic e-
transf u
transc ranial</w>
tra st
tid al</w>
thromboembol ism.</w>
thiobarbit uric</w>
the mo
thal lium</w>
terat ogen
teach ing</w>
suic idal</w>
su los
stress -induced</w>
sti tu
sion- free</w>
seizure -induced</w>
seizure -
se )</w>
schiz o
s. (ABSTRACT</w>
s ati
rest .</w>
reproduc ible</w>
recogn ised</w>
re ne
rat )</w>
radi al</w>
qu i
prurit us,</w>
prot ect
prog estin</w>
pri ap
pre neoplastic</w>
pot ently</w>
pi l</w>
phosph atidyl
phenobarbit al.</w>
ph ag
perox ides</w>
per m
per form</w>
p olar
out side</w>
otom y.</w>
ot roph
omyo si
omeg alo
oly sacchar
ol e,</w>
o ffered</w>
nephrocalcin osis</w>
neph rectom
n isoldipine</w>
mou se,</w>
modul atory</w>
mineral ocortico
min ;</w>
mim ic</w>
micrograms/ ml</w>
microgram s,</w>
mg/d )</w>
mercap to
m sec
los art
lo st
lo g</w>
liver s</w>
limit ed.</w>
lethal ity.</w>
l aryngeal</w>
l -treated</w>
k an
j aw</w>
it y
inter rupted</w>
infu sions.</w>
inform ed</w>
in activation</w>
in ),</w>
illust rate</w>
il ater
hyperprolactine mia.</w>
horiz ontal</w>
high- grade</w>
high- frequency</w>
hepatocarcin ogenesis</w>
help ful</w>
he avi
gra dient</w>
glucos aminid
glomerulos clero
fin ally</w>
extrem ities</w>
expres sions</w>
ethin ylestradi
et ric</w>
escal ated</w>
entor hinal</w>
elev ated.</w>
electro phore
el at
ed )</w>
dos ing,</w>
differen tially</w>
di ed,</w>
deli berate</w>
de s.</w>
dar k</w>
dan azol</w>
d itary</w>
cyt omegalo
cor d.</w>
consti pati
circum flex</w>
cir cadian</w>
ci par
ci lost
che wing</w>
cephaloth in</w>
cent er.</w>
cause s.</w>
catat on
carri er</w>
c il
bronch ial</w>
brom ide</w>
azol e,</w>
ation ),</w>
astro cytes</w>
ap olipo
antipsycho tics.</w>
anticonvuls ants</w>
and -
anaphyl actic</w>
amphet amine.</w>
alpha- 2</w>
al gesia</w>
al fentan
administr ations</w>
ad ine.</w>
ac r
abs orb
] ;</w>
Y M
Wistar- Kyoto</w>
WH O</w>
V AS</w>
Twenty- one</w>
T rial</w>
T oxic
S ensi
S ed
R S
Pre vi
Physi cal</w>
PA ,</w>
P S</w>
P I</w>
O H</w>
Na (+
NO -
My oclon
Mor ris</w>
Monit oring</w>
Li ght</w>
L at
Kidne y</w>
H ),</w>
Gen etic</w>
Gastro intestinal</w>
G I</w>
Fif ty</w>
F as</w>
F ail
F D
Engl ish</w>
ESR D</w>
E F</w>
DE S
D TI
Co gn
Chol est
CP -induced</w>
Afric an-
Aden osine</w>
8-OH-DPA T</w>
5 4
4 2%</w>
4 00
25 ).</w>
2 6%</w>
100 ,000</w>
1. 6
0.0 1,</w>
- evoked</w>
- a</w>
(P V
(NS CL
(6 %)</w>
(5-HT )</w>
(2 0%)</w>
(1 1</w>
(1 ,</w>
( as</w>
yn uren
ye 's</w>
whic h,</w>
ven a</w>
us -like</w>
ureth ane-
unevent ful</w>
twit ch</w>
trimethoprim-sulfamethox azole</w>
tric uspid</w>
treatment s,</w>
third- generation</w>
therap y;</w>
theophyll ine-induced</w>
them sel
sub cortical</w>
st ers</w>
spectr al</w>
sol v
sol ely</w>
six th</w>
single- agent</w>
sil ent</w>
secre ting</w>
se tr
se di
se ar
se -induced</w>
schizo affective</w>
sc at
ro bus
robus t</w>
ric h
regist ered</w>
re aring</w>
re al-
quad ri
provo ke</w>
prot ecting</w>
probuc ol</w>
point s.</w>
pirox ic
phosphodi esterase</w>
phenylbut azone</w>
peth idine</w>
person ality</w>
p ran
over dose,</w>
open- field</w>
occlu sion.</w>
o vir
neutropen ic</w>
neuro trophic</w>
n ystag
n on</w>
n am
myo pathy,</w>
molec ule</w>
min (-1
metabolit es,</w>
mellit us.</w>
mark et
m o</w>
lym ph</w>
loxac illin</w>
lithium -treated</w>
le de
irrig ation</w>
io d
intrac arotid</w>
intoxic ated</w>
inte resting</w>
insomn ia,</w>
injur ies</w>
indic ated.</w>
incub ated</w>
in patients</w>
impa i
il lede
ifosf amide-induced</w>
if edi
identi fying</w>
i ons</w>
i i)</w>
i an
hyperparathyroidis m</w>
here ditary</w>
glyco protein</w>
function ally</w>
flu x</w>
fal cipar
f ro
excl usion</w>
erup tion</w>
enco ding</w>
en cy
em iz
effec tive.</w>
eff lu
edi c</w>
dysrhythmi as</w>
dyskinesi a,</w>
diphenyl hydantoin</w>
differen c
develop ment,</w>
de tox
d ),</w>
cy clop
cord ance</w>
consequ ent</w>
concentration- time</w>
con sul
clozap ine,</w>
cl imb
chromos ome</w>
candi date</w>
c ally</w>
bur st</w>
blad der,</w>
beta- carb
b asi
aure us</w>
atrop ine.</w>
atri um</w>
assi st</w>
ascit es</w>
ar n
ap or
anti micro
anaesthe sia,</w>
an olic</w>
alle le</w>
al gesi
af il</w>
acyclo vir
acromegal ic</w>
accur acy</w>
a id</w>
[CI ]</w>
TM P-SM
T ou
T im
T UNE
Su stained</w>
Si rolimus</w>
SU B
SUB JEC
ST )</w>
S kin</w>
S W
S .
Respon ses</w>
PP I</w>
PA ),</w>
On ce</w>
Nephro tic</w>
Na use
NSCL C</w>
NSAID s.</w>
N ifedi
Mo der
Mater nal</w>
M otor</w>
M orphine</w>
M D</w>
Levo dopa-induced</w>
In divid
I tal
Halo th
H un
Glu R
Fail ure</w>
E ),</w>
Diag nos
Decreas ed</w>
De x</w>
D ig
Capsa icin</w>
Ca Cl
C d
BB B</w>
B one</w>
B cl
Anti convulsant</w>
Anesthe sia</w>
An xi
Ag )</w>
AN G</w>
A TION:</w>
7- N
50 %,</w>
4 3%</w>
2 8,</w>
199 5</w>
17 beta-
16 )</w>
12 5
0.00 1,</w>
-1 ).</w>
(S D</w>
(HB s
(E D)</w>
(A P
(A I
(1 7.
(1 6.
(1 5.
(0.0 5</w>
( d
( +/
yiel d</w>
wom an.</w>
w an
upt ak
ul atory</w>
uc h
toler able</w>
tol u
theophyll ine.</w>
test ed,</w>
t ).</w>
sw im
stereot y
stabil ized</w>
sk in.</w>
sit ting</w>
sino atrial</w>
signific ance.</w>
si um</w>
si s
shif ted</w>
sclero sis.</w>
scan ning</w>
ropi um</w>
rof ecoxi
rhabdomy olysis.</w>
respon d
regul ate</w>
re vascular
re b
random ised,</w>
r a</w>
progres sing</w>
pro ic</w>
pressu re
preferen tial</w>
posses ses</w>
po ses</w>
plas ticity</w>
picrotox in,</w>
phospholip ids</w>
phen el
per -
pea k
pari etal</w>
par at
or poreal</w>
oph asic</w>
open ing</w>
ol ec
nocicept ors</w>
nicot ine,</w>
neuro ten
ner ve.</w>
myoclon us,</w>
myelo genous</w>
monitor ing,</w>
modul ated</w>
min eral</w>
midd le-
micro g,</w>
mg/d L,</w>
me themo
me pivacaine</w>
maxim ally</w>
mac ular</w>
lor at
loc k
lif e,</w>
li pop
le n</w>
lamivud ine.</w>
labet al
l ate-
l amp
k es</w>
it em
ind ed</w>
inadver tent</w>
improve ment,</w>
im mobility</w>
ide )</w>
id azine</w>
i. m.</w>
hyd rate</w>
hexameth onium</w>
hem e</w>
gra des</w>
gr and</w>
ga it</w>
g/ kg</w>
g ained</w>
frag ments</w>
formul ations</w>
form e</w>
for tun
fluoxet ine.</w>
fentanyl ,</w>
feat ures.</w>
exp and
enzym es.</w>
embry o</w>
el l</w>
ear ly-
e ver
e ating</w>
dyston ia.</w>
dyn orphin</w>
drowsin ess</w>
don epe
do fe
dipivox il</w>
di lu
dexamethas one.</w>
detri mental</w>
derivati ve,</w>
del ine
deaf ness</w>
cypro hept
cryst als</w>
conn ective</w>
conduct ance</w>
coffe e</w>
ce tin</w>
cas es)</w>
bro mo
border line</w>
biop sy-
bicarb on
be gun</w>
b um
b im
az ine,</w>
ay s,</w>
auth ors'</w>
ation /
ati ves</w>
asth matic
asc ribed</w>
ari ju
anti muscarinic</w>
anti body
anaesthe ti
amplitu des</w>
allevi ate</w>
al ce
aggrav ate</w>
adv ised</w>
administ er</w>
adi c</w>
ac illin</w>
ac cent
abund ance</w>
[3 5
[ 1,
U K</w>
Top ical</w>
T MA</w>
St and
SUBJEC T
Rec om
Re ye's</w>
QT -
Pheny leph
P rom
P oin
Op io
Olan zapine</w>
O l
Nor th</w>
Na+ ,
N M
N 2
IC R</w>
Hol ter</w>
Hemorrh agic</w>
HBs Ag
G ).</w>
E astern</w>
Dox orub
Differen t</w>
DP H</w>
Com mitte
CD4 +</w>
Al tered</w>
A F
: 1</w>
9 %),</w>
8 +/-
5- day</w>
5 %
37 8
23 39
2 :</w>
199 8</w>
10 8</w>
10 ),</w>
1. 7
1. 0,</w>
1 15</w>
0.00 5)</w>
0.00 2).</w>
-- a</w>
(9 5</w>
(4 %)</w>
(3 3%)</w>
(1 4
( five</w>
( and</w>
( [
wi se,</w>
week s'</w>
warr ants</w>
w ound</w>
us ti
ur nal</w>
un predictable</w>
un ilater
u ous</w>
tri al
treatment :</w>
tissu es.</w>
ti ve
ti li
thir ds</w>
there after</w>
ter one</w>
ter azosin</w>
tail- flick</w>
t able</w>
system s,</w>
sub unit
sub dural</w>
su fentan
ston es.</w>
somnol ence</w>
sk in,</w>
siz e,</w>
sevo flur
ser ves</w>
sal t-
saf er</w>
s c</w>
ro le.</w>
result ant</w>
res cu
ren al,</w>
remark ably</w>
refer ral</w>
re habil
r ation
pur ified</w>
protoc ol
prolong ation.</w>
progres sion-free</w>
pri mat
pri lo
pr ick</w>
potenti al.</w>
post- operative</w>
post operatively</w>
platin um-
plas ma.</w>
phen e</w>
pap illede
oxy codone</w>
orrhe a</w>
on es.</w>
omyc in,</w>
om edi
olanzap ine,</w>
ol d)</w>
off -
ocytopen ia</w>
oca in
oc ellular</w>
o protective</w>
no ticed</w>
neuro surgical</w>
neuro genesis</w>
neuro degeneration</w>
ne vir
n- propyl
min us</w>
mg/ day).</w>
macro scopic</w>
m(- 2)</w>
m /
leg e</w>
las s</w>
kappa B</w>
it ect
ip p
ip ex
initi s</w>
in directly</w>
ill nes
if er
hyperther mia.</w>
hyper -
hemo dialy
guan idine</w>
gi ve</w>
fol lic
fil gr
fig ures</w>
fail ing</w>
f ist
extrac ted</w>
exercis ed</w>
ethin ylo
et ary</w>
estrogen -induced</w>
episo dic</w>
endothel in-1</w>
em pt
electrocardio grams</w>
ele ments</w>
el y,</w>
ec tion,</w>
ec lamp
dysp nea</w>
dys plastic</w>
dys arth
do pam</w>
dis ru
dimin ish</w>
determin ant</w>
der ang
depolar izing</w>
defic its,</w>
de s,</w>
cy an
complex .</w>
com pression</w>
cohor ts</w>
clo fib
cholest asis,</w>
channel s.</w>
c ne
bl ast</w>
bicucul line,</w>
b rety
b atter
aut oph
atel y.</w>
at ors.</w>
assess ment.</w>
arter itis</w>
arch itect
anti py
anthracycl ine-induced</w>
amoxic ill
alcoh ol,</w>
agre ement</w>
adrenocor tic
aden ylate</w>
act ually</w>
ach loro
acetyl chol
ac y
ab ly,</w>
[35 S]
Z .</w>
Tic lop
Thirty- five</w>
Th ough</w>
THE SIS:</w>
T ax
Simult aneous</w>
Scal e,</w>
SSR I</w>
S H</w>
Ris peridone</w>
R LS</w>
Qu es
Phenyto in</w>
PC R</w>
P rac
P DE
Nor plant</w>
NG -
Methad one</w>
MA P,</w>
M K
I schem
I M</w>
Hist ologic</w>
HB V-
H PL
H O
H 1</w>
Flu oro
Fentan yl</w>
E nal
Dru gs</w>
Deli rium</w>
Cogn itive</w>
Ca(2 +
C57BL/6 J</w>
Amph et
AS T</w>
AMP H</w>
A G
: 00</w>
8. 9</w>
6. 9</w>
5. 1</w>
5- fold</w>
5 alpha-
5 4-year-old</w>
4 8%</w>
3- year</w>
2- week</w>
2 n
2 7%</w>
199 0</w>
10 7</w>
1- methyl-4-
0.0 8</w>
0.0 4</w>
)- positive</w>
(S )-
(H Be
(A DR
(50 %)</w>
(2 5%)</w>
(1 4</w>
(1 3</w>
(1 20</w>
( TI
( QT
( 0,</w>
y sti
w k.</w>
ver tical</w>
vel y,</w>
vasodi l
vals artan</w>
val ence</w>
v ity</w>
urg ent</w>
un less</w>
un altered</w>
u ma
tum ori
trige minal</w>
tre ad
transmis sion.</w>
tr un
toler ance.</w>
tiv es</w>
tissu e,</w>
thre e
th ing</w>
test ).</w>
ten der
tem po
taurochol ate</w>
tas ks</w>
tam sulos
t ar
t :</w>
syncop al</w>
stereoty pi
sten o
stabil izing</w>
spec ies.</w>
sign s.</w>
ro om
relim inary</w>
rele ase,</w>
rel ate</w>
reinforc ing</w>
r ule</w>
ques tions</w>
punc ture</w>
propor tions</w>
prompt ed</w>
pro j
present ,</w>
pre mat
potenti ating</w>
poten cies</w>
port un
pin acidi
phot o
phenyl -
phen yl</w>
perce ived</w>
pelv is</w>
paraly sis.</w>
p ontine</w>
ou s.</w>
otrop in-releasing</w>
oten tial</w>
oper ating</w>
olo l.</w>
offspr ing.</w>
norepinephr ine.</w>
norepinephr ine-induced</w>
no ea</w>
neurotrans mis
neuro peptide</w>
necess arily</w>
nause a/
mod al
mod afin
microgram/ kg/
met formin</w>
medi a.</w>
mechanis m,</w>
me droxyprogesterone</w>
marg inal</w>
man age</w>
lu minal</w>
lith iasis.</w>
lipop olysacchar
ligh t-
life time</w>
leuko encephalopathy.</w>
leg ia</w>
l ing.</w>
kidne ys.</w>
ket o
k ing.</w>
isradi pine</w>
iso propyl
intro duc
inter fe
instrum ented</w>
in stituted</w>
impl ants</w>
impair s</w>
imbal ance</w>
im idaz
ic os
ic e.</w>
ic ally.</w>
i bility</w>
i atrogenic</w>
hyper glyce
hom ozygous</w>
histor ical</w>
gra vi
gentamic in.</w>
g/d L</w>
g insen
fibro tic</w>
extrac tion</w>
ext inc
ex ec
ethan ol.</w>
estradi ol-induced</w>
eosinophil ia,</w>
environ ment</w>
enti ally</w>
endo thelium</w>
electro des</w>
effici ency</w>
ec ho
e NOS</w>
dy e</w>
document ation</w>
distinc tive</w>
discharg e.</w>
dil ution</w>
degener ation.</w>
daun orub
counter acted</w>
cord ingly,</w>
conven i
contraceptiv es.</w>
consum ption,</w>
conduc ted.</w>
common .</w>
coll ection</w>
cne mi
classi fication</w>
chemic als</w>
char co
ch ill
calc ific
bu terol</w>
bronch ospas
ble s</w>
be d.</w>
ax is,</w>
auto regulation</w>
ate :</w>
arub icin</w>
anxio genic</w>
anti globulin</w>
antagonist )</w>
angio plasty</w>
angio genesis</w>
angin a.</w>
an ia</w>
amine -</w>
alkalo id</w>
age -</w>
after depolar
adver sely</w>
abil ities</w>
VII a</w>
T est</w>
S equ
S G</w>
Rel ative</w>
Pl atele
Parkinson ism</w>
Parkinson ian</w>
P reliminary</w>
P otential</w>
P or
P M</w>
O cular</w>
N /
M yo
M yelo
M PO-
Iso flurane</w>
IC H.</w>
HD .</w>
F ind
F R
Ex pression</w>
E G
D VT</w>
D R</w>
D M</w>
Consequ ently,</w>
Con vul
CE :</w>
CB (1)</w>
C reat
B 6</w>
B ).</w>
An g</w>
ACh E</w>
A ll
A -induced</w>
99m Tc-
78 8</w>
7. 1</w>
6- tetrahydro
6 5%</w>
6 -1
5. 4</w>
4 3-year-old</w>
4 +/-
3. 0
2- amino-
2 20</w>
2 10</w>
17 )</w>
15 ).</w>
12 ).</w>
1. 73</w>
0.0 2
.0 5)</w>
- ,</w>
) .(ABSTRACT</w>
(T M
(R A)</w>
(H R</w>
(A Z
(1 99
( to</w>
( s
( TH
( ISO
vehic le,</w>
vasodilat ory</w>
vag otomy</w>
v indesine</w>
typ e,</w>
twent y-
trigg ering</w>
transamin ases</w>
tim es,</w>
therap ies.</w>
the ore
th r
terat ogenicity</w>
techniqu es.</w>
tamoxif en
t ently</w>
synthe tase</w>
synap ses</w>
suscepti bil
stoppe d,</w>
steroid s,</w>
spe ed</w>
spas ms</w>
sodi um.</w>
shoc k,</w>
sho ul
seleg iline</w>
sc ra
roten one</w>
resol ved.</w>
requ est
rel ated,</w>
region ,</w>
rec t
re pair
re entrant</w>
radi ologic</w>
r p
r ,</w>
r )</w>
protoc ol,</w>
prost en
prolact inemia</w>
progno sis.</w>
pressu re-
post- treatment</w>
plast y.</w>
plasi a.</w>
plas min
piperaz in
pimoz ide</w>
picrotox in.</w>
phenyl-1, 2,3,
phenyl-1,2,3, 6-tetrahydro
phen o
phen acet
pharmaco therapy</w>
p.o .,</w>
p yl
p ith
ox ot
ot onic</w>
org est
omorph ic</w>
omeg a-
oly tic-
obstruc tion.</w>
o pathy</w>
nit rit
nim odipine</w>
ng/ml ,</w>
myo glob
min ip
micrograms/ kg,</w>
micrograms. kg-1.
microg/ m
metron idazol
metr y.</w>
me eting</w>
manip ulation</w>
ly sine</w>
lo dip
ligi ble.</w>
lat ano
lab or.</w>
k ynuren
j usti
iv )</w>
ister nal</w>
is m
investig ators</w>
intramuscul arly</w>
interview ed</w>
interven tion.</w>
inten tional</w>
infec tions,</w>
in ulin</w>
ia -induced</w>
hyper glycemia</w>
headach es.</w>
grow th.</w>
graph y,</w>
gra y</w>
gluco se-
ge l</w>
ga p</w>
fing er</w>
fi ve-
fel t</w>
falcipar um</w>
erythematos us.</w>
erg ic,</w>
en rich
el y.</w>
echocardi ography,</w>
dy scra
du odenal</w>
down regulation</w>
discrimin ation</w>
determin ations</w>
desferri oxamine</w>
des methyl
dermat omyosi
derm atitis</w>
demonstr ation</w>
del ays</w>
dec ano
dec ade
death s.</w>
dP/d t</w>
d p
cy nom
corp us</w>
controversi al.</w>
cont ain</w>
charg e</w>
cardio ver
carb oxy
caffe ine,</w>
ca use.</w>
biom ark
b ind</w>
arterios clero
aripi prazol
ap parat
alpha )</w>
allevi ated</w>
all- trans</w>
af en
adv oc
ad d</w>
ab users.</w>
a the
a kine
a ).</w>
Vas cular</w>
Up on</w>
TRPV 1</w>
Sy mptom</w>
STZ -induced</w>
S L
Rhabdomy olysis</w>
Q- T</w>
Pen icill
PG -
PA C</w>
P urkinje</w>
P H</w>
P )-induced</w>
Nit ric</w>
NO S)</w>
Midazol am</w>
M 1</w>
Lithi um-induced</w>
Larg e</w>
L ong</w>
L im
L ev
L F
L C</w>
Jo hn
Intra peritoneal</w>
I sol
I s)</w>
H or
H ence,</w>
G nR
Fe w</w>
Experim ents</w>
Diagnos tic</w>
D S</w>
Ca2+ ]
CO X</w>
C r</w>
C lass</w>
Bupropi on</w>
Brom ocript
As soci
AM PA</w>
8 0-
6-hydroxy dopamine</w>
5 8-year-old</w>
5 5%</w>
4. 3</w>
4. 0
3 6%</w>
3 5-year-old</w>
3 20</w>
2. 5
2 +</w>
199 3</w>
15 -1
12 3</w>
10 5</w>
10 2</w>
1 :</w>
1 -1.
0.0 7</w>
0.0 6</w>
0. 5-
) =
(medi an,</w>
(SIAD H)</w>
(GSH )</w>
(ED 50</w>
(C I)</w>
(A U
(1 4%)</w>
( Z
( CL
z en</w>
weigh t/
ver sus
ver age</w>
vasopress or</w>
vas omotor</w>
vag ina</w>
us cular</w>
ure a,</w>
uncommon ,</w>
ular -
tubul es.</w>
tren ds</w>
trans verse</w>
ti lit
thromb i</w>
thalam us</w>
ter rit
ta z
t .)</w>
supple ments</w>
supple mental</w>
sulfon yl
steat osis</w>
st ent
spik es</w>
somat os
smok ing,</w>
smo ked</w>
sil on</w>
sic kle</w>
si s)</w>
sal ts</w>
rod ents</w>
retar ded</w>
res or
region s,</w>
reco vered.</w>
reason able</w>
re modeling</w>
r able</w>
py rex
prot on</w>
prot ection.</w>
propor tion
prof es
proced ure,</w>
prednis one.</w>
pr amine.</w>
post mortem</w>
poly dip
point es,</w>
pig s.</w>
phenylpropan ol
ph or
path ies</w>
pair s</w>
p et
oxot remor
oste osarcoma</w>
os omal</w>
ore r</w>
op portun
one :</w>
olg us</w>
ogen s</w>
nitroglycer in,</w>
nifedi pine.</w>
new -onset</w>
neur itis</w>
nause a.</w>
myelo peroxidase</w>
multi forme</w>
mon grel</w>
molec ul
mofe til</w>
mit ript
min -1)</w>
mil l</w>
midazol am.</w>
micro glial</w>
metho d,</w>
methamphet amine-
meth icill
mellit us,</w>
mark et</w>
mal es.</w>
lu oro
laparo tom
ix is</w>
isoflur ane.</w>
intraven ously.</w>
infiltr ate</w>
increas e.</w>
in distinguishable</w>
immun ost
immun oblo
id opa</w>
hypothe sis,</w>
hyperammon emia</w>
headach es,</w>
hand ling</w>
graf t-
glut ar
gastro cnemi
fol lowe
fir ing</w>
fenflur amine,</w>
fast ing</w>
extr ap
expos ure
exam ple</w>
eti ologic</w>
ethosuxim ide</w>
et opo
episo de.</w>
endotheli um-dependent</w>
endo plasmic</w>
efflu x</w>
dystroph y</w>
down- regulation</w>
don ors</w>
dom peridone</w>
dis opyram
dipyridamol e-
defer oxamine</w>
dang erous</w>
cytoplas m</w>
cytomegalo virus</w>
cyclop ent
cyclo oxygenase-2</w>
curren ts</w>
criter ia,</w>
cramp s</w>
clo fibrate</w>
cli o
clavul anic</w>
chol e
chlor prop
characteris tics.</w>
cent ri
cardio respiratory</w>
calci um,</w>
c ro
c rescentic</w>
c id
biosyn thesis</w>
ballo on</w>
azepam .</w>
ast emiz
assist ed</w>
arterios us</w>
aro usal</w>
ar ray</w>
ar m,</w>
antibio tics,</w>
anorex ia</w>
anesthe tics.</w>
analo g
amine /
am ine)</w>
alopec ia</w>
alkal i</w>
al i
adap tive</w>
ad ine,</w>
acceler ation</w>
ab normally</w>
ab en
a -induced</w>
a ),</w>
Wh ite</w>
VO D</w>
V an
T- cell</w>
T 2-
T 1</w>
S ud
S qu
R if
Ques tion
P PA</w>
P =0.00
Ob j
O P</w>
Moder ate</w>
Magne sium</w>
MI B
M i
M CT</w>
Low -dose</w>
Long -
L ate</w>
K ,</w>
In vent
I mi
I denti
I U</w>
I R
I .
Hy dro
Hospit al,</w>
Hear ing</w>
H LA</w>
G entam
G O
Find ings</w>
Extr apyramidal</w>
DF P</w>
D ic
CI P</w>
C ir
C K-
Bri ef</w>
Aut opsy</w>
Ac cordingly,</w>
AQ P
ADR s</w>
A )
4 6
200 2</w>
199 9</w>
199 7</w>
17 ,</w>
0. 50</w>
. "</w>
) .
(S BP)</w>
(P G
(N M
(CH F)</w>
(C T)</w>
(7 )</w>
(1 5%)</w>
( no</w>
( max)</w>
( VE
" )</w>
zer o</w>
x en
warfar in.</w>
vi ability</w>
versus -
vasoconstric tion.</w>
v oid
uro thelium</w>
urb an</w>
un necessary</w>
u lop
u ate</w>
two- stage</w>
tw ard</w>
trimethop ri
top ically</w>
ti ter</w>
thyroidis m.</w>
thior idazine</w>
therap y-
tetr ap
t one.</w>
t ocain
suggest ed.</w>
stabil ization</w>
spor adic</w>
sit e,</w>
shun t</w>
sex es</w>
se e</w>
salme terol</w>
restra ined</w>
rem ote</w>
refl ects</w>
real- time</w>
ram i
ra emia</w>
r s
r d</w>
publ ic
pt s</w>
protein s,</w>
propi onic</w>
prolactin oma</w>
pro per</w>
pro lol</w>
prepar ation.</w>
phil ic</w>
pheny leth
peroxid ation,</w>
perform ing</w>
pentobarbit al-
paracetam ol-induced</w>
pap ill
pancre atic</w>
p mol
p e</w>
ot ep
oste o
ophthalmo logic</w>
op tions</w>
ometr y.</w>
ocy ste
occ u
o sides</w>
not able</w>
non- competitive</w>
nio tic</w>
nephro sis,</w>
ne ocor
ne bul
n M)</w>
multi ple
mu st
mod ality</w>
minim ally</w>
microg/ kg,</w>
mg/m2/ day</w>
mg/kg/ d</w>
methamphet amine.</w>
mes ylate</w>
ment ally</w>
maz epam</w>
mater i
m iti
m ariju
m M)</w>
lipo ic</w>
j un
it em</w>
ish es</w>
intr apl
interpre tation</w>
inter ictal</w>
influ enz
infiltr ation.</w>
increas e,</w>
implic ate</w>
immuno fluorescence</w>
immun opositive</w>
im at
if ens
ic ulation</w>
ibuprofen ,</w>
hypo phosphat
hypo album
hypercalce mic</w>
hospit als</w>
hospit al,</w>
heterogene ous</w>
heter ozygous</w>
heavi ly</w>
heal ing</w>
glycopyr ro
gad odi
g avage</w>
fle x
fib ron
fat al
fall s</w>
exceed ing</w>
evo ke</w>
event ,</w>
evalu ation,</w>
eti ologies</w>
eti l</w>
esmo lol</w>
erg ot</w>
enzyme -
eno ic</w>
eno graf
em .</w>
ecti ve,</w>
diphen hydram
differen t.</w>
dex tr
denerv ated</w>
demyel inating</w>
dehydrogen ase,</w>
de form
day s;</w>
cynom olgus</w>
cum in</w>
cu ff</w>
cop i
contr ary,</w>
cont ent.</w>
clinic .</w>
cle ared</w>
circ uit
cholec ysti
cervi x</w>
centri lobular</w>
cav ity</w>
cauti ously</w>
catat onic</w>
cat abol
carri ers</w>
cardi ac
cann ul
c ab
broad -
batter y</w>
b ular</w>
az os
ar te
ar ising</w>
apop lexy</w>
anxiet y-
antidepress ants,</w>
anticoagul ation.</w>
angiotens inogen</w>
analgesic s.</w>
amygdal a,</w>
amne sia,</w>
ammon ium</w>
alter ations.</w>
after ,</w>
affor ded</w>
afferen ts</w>
activ ates</w>
act in
act .</w>
acetyl -
[ 14
Z ),</w>
X ),</w>
Twenty- seven</w>
TI ON</w>
Sed ation</w>
SO UR
R ates</w>
Prost agland
Pregn ant</w>
PT U
P ub
P raz
O F
M CA</w>
L it
L QT
Isol ated</w>
Intrac erebro
Im port
Im medi
IN H</w>
F C</w>
E V
E LIS
DO CA-
Co A</w>
Ci prof
Ca ution</w>
BALB/ c</w>
BACKGROUND/ AIMS:</w>
Anxi ety</w>
An tin
Al so</w>
Al ph
A P-
A ED
9 6
6. 2</w>
5. 7</w>
4 9
4 5-year-old</w>
4 1%</w>
4 0,</w>
4 %;</w>
1. 8
1 4-year-old</w>
- derived</w>
(r =
(Td P)</w>
(T B
(H R
(H IV)</w>
(C V
(C G
(2 00
(2 0-
(1 9%)</w>
(1 /
( age</w>
women )</w>
weak ness.</w>
we en-
var ic
valpro ate,</w>
vacuol ization</w>
v oc
ut ropen
upreg ulated</w>
un desi
un acceptable</w>
u sion-
tr abec
tot al,</w>
tiz an
tion ).</w>
therap eu
tak en.</w>
ta urine</w>
t y,</w>
t welve</w>
t ors</w>
syncop e.</w>
super sensitivity</w>
sulph asalaz
suff er</w>
succin ate</w>
sub tle</w>
stom ach
ste ato
sphinc ter</w>
son iaz
slow ed</w>
sleep ing</w>
sevent h</w>
ser ies,</w>
sear ched</w>
schizophren ia,</w>
scaven ger</w>
s inu
rout es</w>
retin ol</w>
retic ular</w>
ren z
re organization</w>
prof il
prochlorper azine</w>
press in</w>
predic tion</w>
precipit ation</w>
posi tion,</w>
popul ations.</w>
po orer</w>
pneumon ia
pituit ary-
pic t
phosphor ylated</w>
person -
per hexiline</w>
pa per
pa in-
p 53</w>
os ensi
ori s.</w>
on orgest
omyc in-
oca proic</w>
oc cul
ob ic</w>
o gram</w>
no vel
no ti
nitroglycer in.</w>
nitro gen
neurolep tics.</w>
n ing.</w>
myoclon us.</w>
morb id</w>
mon ophasic</w>
migr ation</w>
mg ;</w>
metoclopram ide.</w>
methyl prednisol
methotrex ate-induced</w>
methotrex ate,</w>
metallo protein
melan oma</w>
medi ation</w>
meas ures,</w>
me .</w>
marg in</w>
manifest ations.</w>
man dat
mO sm
m idine</w>
low- density</w>
lop ri
lit ter
lis uride</w>
lenal idomide</w>
lad der</w>
labell ed</w>
k P
j ump
iso forms</w>
iodix anol</w>
intra hippocampal</w>
interac tions.</w>
infusion )</w>
inf ants,</w>
inde d,</w>
inclu de
in- converting</w>
immun ologic</w>
im age</w>
ifosf amide.</w>
hypercalce mia.</w>
hype remia.</w>
hydroxy chloroquine</w>
hydrox yl</w>
hy ste
ger iatric</w>
g ).</w>
fre e
frac tion,</w>
fibrin olytic</w>
feed back</w>
fav or</w>
extrac orporeal</w>
expl oration</w>
eti ological</w>
episode s,</w>
ens ure</w>
end- systolic</w>
em ph
electro de</w>
electro chemical</w>
edull ary</w>
dri ve</w>
doxorubic in-
dis rupted</w>
dil ation</w>
diagno sed.</w>
di verse</w>
di bular</w>
dendrit es</w>
cypro terone</w>
cre am</w>
conn ected</w>
comm encing</w>
com es</w>
clar ithrom
cholecysto kinin</w>
char ts</w>
catechol aminergic</w>
beta-D- glucuronide</w>
be than
be ating</w>
autis m</w>
ate d;</w>
ar y
apopto sis,</w>
antin uclear</w>
ann ual</w>
aneur ysmal</w>
an emic</w>
amygd alo
altern ating</w>
alter ations,</w>
alpha- methyl-
al ip
adrenocept or-
adrenal ectomized</w>
activi ties,</w>
acetaminophen .</w>
ac ral</w>
ac onit
ab using</w>
[3H] -
W IN</w>
Vincrist ine</w>
U ro
TR H</w>
T rem
T D</w>
Seroton in</w>
SD ,</w>
S Y
Pro b
Par tial</w>
PE T</w>
OH DA</w>
Nitro glycer
Ne utropen
N umerous</w>
N F
Mul ticent
MPT P</w>
M il
LD H</w>
L if
K ore
K (+)</w>
John son</w>
Immedi ately</w>
I soniaz
I s
Hepar in</w>
HBI G</w>
H g/
Gluc ocortico
G M-
F ish
Ex c
Ep inephrine</w>
En h
D ap
D 2
Committe e</w>
Col lege</w>
C erebro
Bet a-
B A
B 1</w>
AR T</w>
ADR .</w>
A PA
8- week</w>
7 00</w>
6- OHDA</w>
3 1,</w>
29 ,</w>
2/ 3</w>
15 6</w>
0. 1,</w>
(i ii)</w>
(e g,</w>
(LVE F)</w>
(I O
(B )</w>
(A E
(1. 0
(- )
( mean,</w>
( for</w>
( f
( IV
ziprasid one</w>
with in-
wh o,</w>
well- documented</w>
wedg e</w>
wall .</w>
volunte er</w>
viro logic</w>
v )</w>
ureth ane</w>
unclear ,</w>
ud in</w>
u ated</w>
trypt ophan</w>
trans l
tran examic</w>
toler ant</w>
toler ance,</w>
threshol d,</w>
thi on
th us,</w>
tetrac ycline</w>
target ing</w>
t es,</w>
t amp
tamp on
stat ins</w>
sodi um-
shoc k
sett ings</w>
self- reported</w>
second- generation</w>
schedul e,</w>
safet y.</w>
s oun
ru v
riton avir
ribavir in-induced</w>
rhabdomy olysis,</w>
retino pathy</w>
resol ve</w>
regener ative</w>
ral gi
quar tile</w>
pt h</w>
psycho sis,</w>
prosten ol</w>
prolifer ating</w>
proces sed</w>
prim idone</w>
pre cor
pneumon ia.</w>
ple as
plasmin ogen</w>
plac ent
pl ay
pith ed</w>
person al</w>
peripher ally</w>
per ind
pathw ay,</w>
p s.</w>
os al
orth op
orph anol</w>
ore s</w>
or i</w>
or ally,</w>
opyri dine</w>
olanzap ine.</w>
ol em
ochond rial</w>
oc e
nitren dipine</w>
ng/ml .</w>
ng/ml )</w>
neuro behavioral</w>
nes tic</w>
nephro n</w>
naf c
mt DNA</w>
modul ator</w>
ml .
mil d.</w>
middle- aged</w>
micro injections</w>
mg/ L</w>
methyl enedi
methoxy- 4-
meth amine</w>
membran e.</w>
memb er</w>
manufact ure
mal ai
m apping</w>
lipo proteins</w>
lin ing</w>
li um-
leuk emia,</w>
j e
it y)</w>
it es</w>
issu es</w>
iso form</w>
ir in
intr ap
intensi ties</w>
inf ant.</w>
ineff ective.</w>
immunohist ochemistr
im olar</w>
ide al</w>
id osis</w>
id ity.</w>
i tic</w>
hyperther mia,</w>
hyperammon emic</w>
hy dra
head- up</w>
haloperid ol
glauc oma.</w>
given ,</w>
g yr
frag mentation</w>
for ward</w>
flut amide</w>
fir st
f az
excl uding</w>
exam ined,</w>
eti d
emerg ed</w>
electroly tes</w>
earli est</w>
e .g
dy ses
dur ing,</w>
drug- free</w>
dom ain</w>
disturb ances.</w>
discus sed,</w>
disco vered</w>
disc rete</w>
di urnal</w>
de pth</w>
cryst al</w>
counter act</w>
cor d,</w>
contr act
continu es</w>
consum ption.</w>
complic ation,</w>
coer uleus</w>
co sts</w>
clozap ine-induced</w>
climb ing</w>
clear .</w>
cl am
chromat ography.</w>
chlor ide,</w>
children :</w>
ch y
cephal or
ce ased</w>
cat echol</w>
captopri l,</w>
ca emia</w>
c ame</w>
bilirub in,</w>
bicucul l
benz tropine</w>
bec oming</w>
baclofen .</w>
b ial</w>
b asis.</w>
az ine.</w>
atten ding</w>
atic .</w>
appro xim
apomorph ine.</w>
antec ed
antagon izes</w>
annab in
anesthe tiz
an kle</w>
amin ocaproic</w>
amethas one</w>
alpha-methyl dopa</w>
alkalo sis</w>
agl ate</w>
aer os
admis sions</w>
act ,</w>
accumb en
ac ne
a str
a p</w>
Y oun
VPA .</w>
U. S.</w>
U nex
Soci ety</w>
SE R
Rever sal</w>
Res piratory</w>
R A.</w>
Question na
Q X</w>
Prog res
Pre dic
PAN -induced</w>
PA .</w>
PA -
O ne
NG F</w>
ND I</w>
Morph ological</w>
Min ocycl
M as
Lit tle</w>
L oc
L ine
Intracerebro ventricular</w>
Increas es</w>
In formation</w>
Immunohist ochemical</w>
G ly
G em
Flu mazen
Ex er
E C</w>
Dis ul
D AT</w>
Con tr
Col chic
CD -1</w>
CA SE:</w>
C Y</w>
B W
B O
Amph otericin</w>
African- American</w>
Acet yl
A- I</w>
> or=
7. 8</w>
7- day</w>
6. 3</w>
6 5-year-old</w>
6 3%</w>
6 00
5 6-year-old</w>
5 %.</w>
38 39
3 -1
2 3-
2 1)</w>
2 ',
17 0</w>
14 5</w>
14 17
10 %,</w>
1. 5-
1-methyl-4- phenyl-1,2,3,6-tetrahydro
1 14</w>
0.0 4).</w>
/ A</w>
-1 4
- independent</w>
(e.g .</w>
(2 2</w>
(1 7</w>
(1 4.
ze tim
zetim i
xyl azine</w>
wor th
weak ly</w>
w ild</w>
vi sible</w>
versus- host</w>
ventil ation,</w>
val ves</w>
val idity</w>
ure -
uma b</w>
tur n</w>
trime ster</w>
tri fluoro
tread mill</w>
tran yl
trac er</w>
tom ographic</w>
to sis</w>
tion ing</w>
ti um</w>
thym ic</w>
that :</w>
thal as
temperat ure,</w>
ta per
t rou
t ality</w>
syncop e,</w>
swit ch
suppress ants</w>
succinylchol ine.</w>
struct ures.</w>
stimul ants</w>
six ty-
side )</w>
sed ent
se of
seof ul
sarc olem
sampl ing</w>
s low-
s "</w>
ron edar
righ ting</w>
rhyth m,</w>
rever ted</w>
reten tion,</w>
reproduc tive</w>
repor te
ren ch</w>
remis sions</w>
remis sion.</w>
rem oxi
re presenting</w>
rat :</w>
quer cetin</w>
purpur a</w>
promaz ine</w>
pro meth
precor dial</w>
peroxy nitrite</w>
perf usion,</w>
pect oris.</w>
patter n,</w>
pas e-
par val
par am
p ine
otrop in</w>
or ally.</w>
opioid s.</w>
op re
omep razol
om a:</w>
neg ligible</w>
mo re
mil der</w>
mil d-
migra ineur
methylphen id
methemo glob
methad one.</w>
mes n
mat ous</w>
manag ing</w>
lorat adine</w>
lin king</w>
lev onorgest
lay ers</w>
lamin a</w>
ket amine.</w>
kD a</w>
itrac onazole</w>
it uit
isot onic</w>
intraven ous
intens ity,</w>
inten ded</w>
infarc tions</w>
incre ments</w>
improve d,</w>
immunosuppres sion.</w>
imipr amine,</w>
imag ing,</w>
im ple
if ep
ifep rist
ic o
hypocal ce
hypo phy
hyper sensitivity.</w>
hyper kinesia</w>
hour .</w>
hospital ization,</w>
high .</w>
high ,</w>
hepar in-
harm ful</w>
ha m</w>
gli oblastoma</w>
gen icity</w>
g m</w>
g ating</w>
fro zen</w>
flunar izine</w>
fiel ds</w>
fibroblast s</w>
fibrill ary</w>
fenol dopam</w>
fat al.</w>
fasc iculation</w>
factor- alpha</w>
f oci
experi ence.</w>
ex piratory</w>
etomid ate.</w>
er y</w>
equ ili
end points</w>
en ing,</w>
emerg ing</w>
em pir
ed ing</w>
dyston ia,</w>
dis section</w>
din itrate</w>
dihydro pyridine</w>
diethyl nitrosamine</w>
diclofenac ,</w>
dialy s
di azep
deoxy corticosterone</w>
defen se</w>
dantrol ene</w>
cu los
cor n</w>
copi es/
convuls ing</w>
compris ing</w>
complete ly.</w>
compar t
clinici an</w>
cirrho sis,</w>
cho sen</w>
charco al</w>
challeng es</w>
cardio version</w>
cardi otoxic
carb idopa</w>
car ry</w>
capsaicin- evoked</w>
capecit ab
can des
cTn I</w>
bus ulph
be pri
be .</w>
avail able,</w>
aug ment</w>
at um</w>
asti m</w>
ant ar</w>
ant adine</w>
an is
am niotic</w>
am nestic</w>
age )</w>
adrenocept ors.</w>
adolescent s.</w>
ac tions.</w>
ac ill
abstin ence.</w>
[ Ca2+]
Z ,</w>
Y or
V P</w>
Twenty- nine</w>
The ophylline</w>
T2- weighted</w>
T ai
T X
Sup pression</w>
Sex ual</w>
SSR Is</w>
S ulf
S S)</w>
S OD
S -related</w>
Q D</w>
Prophyl actic</w>
Pro l
PRE TA
PR L-
P< 0.001).</w>
P2 X
Ox id
Ne gative</w>
Na +</w>
Mor tality</w>
K+- ATPase</w>
Inde x</w>
In din
Ig A</w>
INTER PRETA
Hypo kalemia</w>
Hyper sensitivity</w>
Hy droxy
H P</w>
H ER
H E</w>
G SH
G -induced</w>
E r
E N
Dou ble
Dop a</w>
Diag no
Diab etic</w>
DOX .</w>
DN F</w>
D- amphetamine</w>
D uration</w>
Com pan
Child ren
C l-
BM T</w>
B ody</w>
Acet aminophen</w>
A A
8 9
8 8%</w>
7. 3</w>
6 3-year-old</w>
4 9.
3 80</w>
3 1%</w>
2n d</w>
200 1</w>
200 ,</w>
20 .</w>
2 6,</w>
12 2</w>
12 00</w>
12 .</w>
10 9</w>
10 6</w>
1 -induced</w>
0. 3,</w>
- /-</w>
(p =
(ST Z)-induced</w>
(SH R)</w>
(S R
(N a
(MR I)</w>
(DE S)</w>
(9 %)</w>
(10 (-
(1 7%)</w>
( 0</w>
zym e</w>
worl d
whe re
ver s</w>
ven s-
vens- Johnson</w>
vacu olar</w>
ursodeoxychol ic</w>
uncer tain</w>
tw o,</w>
transcript ase</w>
tra it</w>
tolu ene</w>
to remif
tho rough</w>
thalidom ide.</w>
ta in
swim ming</w>
stabil iz
st ret
st ain</w>
specti ve,</w>
spec ulate</w>
somnol ence,</w>
solu tion,</w>
situ ation</w>
serv ice</w>
seg ments.</w>
ro cur
ris ing</w>
ribavir in.</w>
reviewe d,</w>
ret te
ren dered</w>
remain der</w>
relie ve</w>
rel in</w>
reinforce ment</w>
rehabil itation</w>
regul ates</w>
re mitted</w>
rac lopri
r ing
r -
quinol ones</w>
quanti ty</w>
qualit atively</w>
qualit ative</w>
py ruv
pseudolith iasis</w>
propofol -
prim ate</w>
pot ence</w>
posi tive,</w>
plan ch
phot on</w>
phenter mine</w>
phen oxy
ph ine</w>
perio dic
perform ance,</w>
pan cytopenia</w>
pal ate</w>
p g/m
p )</w>
ox o-
opioid -induced</w>
ophthal m
op posed</w>
one- third</w>
one ;</w>
on cology</w>
ol im
obj ect</w>
nortript yline</w>
nor -
nom ifens
nitrofur antoin</w>
nitro sou
neuroten sin</w>
n ous</w>
myo fibrillar</w>
minut es)</w>
mid -
micro gli
mic e:</w>
mg/m 2).</w>
mg/ d.</w>
mg. /
metho do
me fen
mas k</w>
lun gs</w>
lium- 201</w>
lin es.</w>
iso enzyme</w>
ip olar</w>
intra arterial</w>
integr ated</w>
insp ired</w>
innerv ation</w>
ing i
ine- evoked</w>
induc ed.</w>
individu als,</w>
in sensitive</w>
imidazol ine</w>
ifosf amide,</w>
hyperprolactin aemia</w>
hyper locomotion</w>
hydroneph rosis</w>
high- performance</w>
hemat uria.</w>
habit ual</w>
h lor
graft- versus-host</w>
gene- related</w>
g/ day</w>
g ),</w>
furosem ide.</w>
for ty-
fe ver.</w>
fam oti
fam ili
extra hepatic</w>
exten sor</w>
exce ed</w>
et oric
est rous</w>
epsilon -
en ic</w>
em ,</w>
earli er.</w>
dyskinesi as,</w>
dist en
digit alis
diff usion</w>
diarrho ea</w>
dexamethas one,</w>
derivati ves.</w>
dec re
cyt open
culos keletal</w>
cop per</w>
contra indicated</w>
consequ ences.</w>
confir ming</w>
con stitute</w>
compromis e</w>
compoun d,</w>
comparis on,</w>
chem istry</w>
che lation</w>
categor ies</w>
cas es),</w>
carri es</w>
capsul es</w>
capsaic in,</w>
ca re,</w>
bi di
beta 2-
bec omes</w>
b /
av o
ati tis.</w>
arth ralgi
arteriol es</w>
arrest ,</w>
aor ta
anticoagul ants</w>
anorex ia,</w>
analy ses.</w>
an te
alkal in
agon ism</w>
age ment</w>
adhe rence</w>
ab use
a per
a kinetic</w>
[ SD
Z n</w>
Warfar in</w>
Ven ous</w>
U F
Trem or</w>
Thrombo tic</w>
Tac hy
T A</w>
Sud den</w>
Ste vens-Johnson</w>
Stand ard</w>
SH R.</w>
S ul
S tri
Rif amp
Q )</w>
Prac ti
Per io
PT X</w>
PK C
PH T</w>
PA N-
P ediatric</w>
Ne ur
Nause a</w>
N ig
M ar
Li -
Intr alip
In duced</w>
IC P</w>
I- II</w>
Hepat ocellular</w>
Hemat ologic</w>
Halo perid
H S
H D-
G ram
G R</w>
Func tional</w>
E pid
DE S-
DBA/ 2</w>
D an
D S
Contro lled</w>
Consider ing</w>
C utaneous</w>
C um
C s.</w>
C oc
C 3</w>
ANCA -positive</w>
AD M</w>
A ra
9 0-
8. 3</w>
6. 4</w>
6 8-year-old</w>
6 7-year-old</w>
5-H I
5 3-year-old</w>
5 24
5 00
5 -10</w>
4 7-year-old</w>
3 60</w>
3 %.</w>
29 )</w>
20 ).</w>
14 2</w>
13 6</w>
13 3</w>
10 3</w>
10 /
1 12</w>
0.0 2),</w>
0. 12</w>
.0 1)</w>
(p =0.00
(P< 0.05)</w>
(NO S)</w>
(N E)</w>
(MT D)</w>
(M I)</w>
(CS F)</w>
(A OR</w>
(2 5-
(1 :
(1 6</w>
( hazard</w>
( days</w>
( average</w>
( adjusted</w>
( 8-
( 0.00
warr ant</w>
veloc ities</w>
variabl es,</w>
v ect
ust ine</w>
uni variate</w>
uncerta in.</w>
un recognized</w>
un if
un fractionated</w>
transpl ants</w>
transf usions</w>
tivi ties</w>
termin ating</w>
te leph
te -
taper ing</w>
ta ined,</w>
t ing-
sw ol
sur ge
suffici ently</w>
sub stitu
stre am</w>
stiff ness</w>
step wise</w>
step -
spac e.</w>
sp ray</w>
sirolim us.</w>
side- effects,</w>
ser ially</w>
seoful v
se ven
run ning</w>
riz atriptan</w>
rist ol-
ristol- My
ristol-My ers</w>
risperid one-induced</w>
ri vas
resul t,</w>
resem bled</w>
re started</w>
re distribution</w>
re challenged</w>
raniti d
random ization</w>
r hi
quinol one</w>
quin idine,</w>
pyraz in
psych i
prilo caine</w>
present ations</w>
pre eclamp
pr act
potassi um-
pop ular</w>
platele t-
planch nic</w>
pl ate
perind opril</w>
peri ventricular</w>
path ology.</w>
p- chloro
p il
p ass</w>
p =0.0
ox et
over use</w>
ost ri
osc ill
orb it
or =</w>
oph armac
om asti
olytic- uremic</w>
of ur
ococc us</w>
ochemic al,</w>
occl uded</w>
non- invasive</w>
non competitive</w>
nodos um</w>
nigr al</w>
ng/ mL</w>
neutr al</w>
neuropath ological</w>
n um
multi drug</w>
mou th,</w>
month s;</w>
mono therapy,</w>
mon omorphic</w>
modafin il</w>
mmol/ l</w>
mio sis</w>
min d</w>
micro L</w>
me trex
me q/
mb le</w>
manifest ing</w>
lup us-like</w>
los ses</w>
limit ing.</w>
limb s.</w>
leuk emic</w>
lepro sy</w>
le i
lei omy
jec tions</w>
is ox
irradi ation.</w>
intr at
ini i</w>
inhibi tion,</w>
influ x</w>
in struc
in put
in 's</w>
impai red.</w>
hyperlipide mia</w>
hyper nat
hyper bilirub
hy pop
hom ocyste
hist one</w>
glomeruloneph ritis.</w>
gener ate</w>
gall stones</w>
form ,</w>
flow s</w>
fl up
fix ed-dose</w>
filgr astim</w>
fe lodipine</w>
exist ed</w>
ev ening</w>
estradiol -17</w>
erro r</w>
equi potent</w>
equ imolar</w>
epidemio logical</w>
ep silon</w>
enti rely</w>
enox acin</w>
enc ies.</w>
emphasi zed.</w>
el uting</w>
ec gon
e jac
dp /d
doxy cycline</w>
dos ages.</w>
disturb ed</w>
discus sion</w>
diaphrag m</w>
dend ritic</w>
deliri um,</w>
d- tubocurarine</w>
cycl ing</w>
cont ains</w>
construc ted</w>
consist s</w>
concl usions</w>
con fig
col um
clo x
clio quin
clam p</w>
citalopram .</w>
cirrho tic</w>
ce ton,</w>
cath ep
carcin ogenicity</w>
carb oxyl
car inii</w>
calcul ated.</w>
cal bind
bum in</w>
bul bar</w>
brady kinesia</w>
bl urred</w>
bio log
beta- end
beta 1</w>
avo ide
autis m.</w>
attenu ating</w>
attac k.</w>
atracur i
atherosclero sis.</w>
at tained</w>
at or.</w>
ast ric</w>
as certain</w>
arti ficial</w>
anti dot
an a</w>
amygdalo id</w>
amide s</w>
am isol
alpha -</w>
allopurin ol</w>
alf a-
aldo ster
al ive</w>
act ual</w>
ac it
ac cordance</w>
ab str
[ OR
Z e
VPA ,</w>
Ultra structural</w>
Twenty- eight</w>
There fore</w>
T- wave</w>
T c</w>
T BP
Syst em</w>
Swe dish</w>
Sprag ue</w>
SOUR CE
S tim
S le
R i
R ,
Prol actin</w>
Prin ceton,</w>
Phen yl
Phen obarbital</w>
PR A</w>
NMD A-
N o
N J)</w>
Min oxidi
Met oclop
MT )</w>
M g</w>
M O</w>
LV F
LT G</w>
LD 50</w>
L-DOPA -induced</w>
K .</w>
Im pres
Im paired</w>
I/ II</w>
I bu
I D</w>
Hz )</w>
Ho wever</w>
H en
H /
Gl u</w>
GM- CSF</w>
GB M</w>
G L
F rench</w>
F as
F /
E S</w>
Do se
Dipyridam ole</w>
D RE
D G</w>
Cum ul
Compan y,</w>
Ci meti
Cef triax
CT /
CG RP</w>
C l,</w>
B ristol-Myers</w>
B lock
B enz
B F</w>
Az athiop
Anti arrhythmic</w>
An th
Ag e</w>
Ad ju
AT 2</w>
A UC
A P)</w>
A K
A E</w>
9 7
8 -1
7 6%</w>
7 3-year-old</w>
7 -1
6. 8</w>
6 6%</w>
5 9-year-old</w>
5 7%</w>
5 6%</w>
5 50</w>
30- year-old</w>
3 5.
3 2
200 -
2- 4</w>
19 )</w>
16 5</w>
15 ),</w>
13 2</w>
13 ).</w>
1 50
1 13</w>
1 1.5</w>
- controlled</w>
) -1-
(i e,</w>
(SE ).</w>
(OH)2 D
(OH) (2)
(3 0%)</w>
(2) 17
(+/ +)</w>
( Y
( 0
% /
y el
warfar in-associated</w>
vertig o</w>
ure ly</w>
unilater ally</w>
unchang ed,</w>
ulcer ation</w>
ul inum</w>
tuberculo us</w>
trigg ers</w>
treatment- emergent</w>
trans port
trans forming</w>
to genic</w>
tilit y,</w>
theophyll ine,</w>
tamsulos in</w>
ta p</w>
swol len</w>
support .</w>
supplement ation.</w>
sup ras
sup ply</w>
sulf adi
spi ro
somatos ensory</w>
sol ved</w>
sleep .</w>
sl udg
situ ations</w>
single -dose</w>
si s-
scinti graphy</w>
sacchar in</w>
s.c .
s of
row n</w>
riton avir</w>
relationshi p.</w>
recru it
record s.</w>
reat h</w>
re si
rat s;</w>
rat s)</w>
punct ate</w>
pu pil</w>
psori atic</w>
promis e</w>
prolong ation,</w>
profen ,</w>
pressu res,</w>
pren olol</w>
pre cl
post operatively.</w>
polymorph ous</w>
poly myositis</w>
poin t.</w>
plas tin</w>
pheochromocyt oma</w>
pert urb
particip ating</w>
panc reas</w>
pa uc
p al</w>
over activity</w>
ov an
outcom e,</w>
ous -
oste op
osmolal ity,</w>
orb ent</w>
omat ous</w>
om b
olog ic,</w>
ob sc
nucle us.</w>
non- ionic</w>
non oliguric</w>
nifedi pine,</w>
negati ve,</w>
ne l</w>
nar row</w>
myocardi tis.</w>
myo pathic</w>
my dri
mon ophosphate</w>
minut e,</w>
minim izing</w>
microg/ mL</w>
mes en
me ter</w>
man ual</w>
mal formation</w>
load ,</w>
lisin opri
le ak</w>
kin ase,</w>
it ari
intr ag
intoler ant</w>
influ encing</w>
individ ually</w>
in- like</w>
in otrop
in al,</w>
ico plan
ic )</w>
ibuprofen .</w>
ib b</w>
hypo vol
hyperten si
homogen ates</w>
hi r
hex achloro
hepat ocytes.</w>
hemoglob in,</w>
hemat uria,</w>
hem olysis.</w>
h ot
gri seofulv
gr al</w>
glomerul i.</w>
gland ular</w>
gentamic in,</w>
gain .</w>
fol i
flu id.</w>
fibr e</w>
fet us</w>
f usi
f resh
ey es.</w>
exerci se-induced</w>
examp le,</w>
exacerb ates</w>
erec tion</w>
epo prostenol</w>
enc es,</w>
emph asis</w>
electr ically</w>
doxep in</w>
double-bl inded</w>
dopa ,</w>
dizocil pine</w>
discrimin ate</w>
dis c</w>
dip lop
difficul ties</w>
diazepam -induced</w>
di ver
depart ment.</w>
defic it
daun omycin</w>
cyt es.</w>
cy cle,</w>
creatin ine.</w>
conscious ness.</w>
comple ting</w>
com posite</w>
col lateral</w>
cocaine- seeking</w>
cl ind
cimetid ine.</w>
chlorambuc il</w>
cel ecoxi
catheter .</w>
cas pase-
cap s
bur sts</w>
broad- spectrum</w>
beta- receptor</w>
bet ween-
be fore
bas olateral</w>
avoid ing</w>
aur a</w>
ator vastatin</w>
atax ia.</w>
aspir ation</w>
arter y,</w>
appropri ately</w>
apar t</w>
anteced ent</w>
antagon izing</w>
anat omic</w>
an )</w>
amp icillin</w>
ami k
am ox
alpha 2-
algesi c</w>
al end
agonist )</w>
ad ural</w>
acetaminophen ,</w>
ac alce
aber rant</w>
a em
We b
TH P</w>
T W
Stud y.</w>
Scal e.</w>
STZ -
SE M)</w>
S h
S B
R g
Oxid ative</w>
Organ ization</w>
Nifedi pine</w>
NSCL C.</w>
N E
Man agement</w>
M elat
M I.</w>
Li ke
L- Dopa</w>
L ack</w>
Jap an.</w>
Intrac ranial</w>
In dian</w>
I D)</w>
Haloth ane</w>
HV A</w>
H I
H CO
Flu oxetine</w>
Fl uc
F DA</w>
Ery thro
E O
Do gs</w>
DN A-
D oc
Cumul ative</w>
Cap top
CP Z</w>
CI -
C och
BH T</w>
Anth rac
AI N</w>
A qu
A gg
A :</w>
9. 2</w>
9 %;</w>
8. 7</w>
7 4-year-old</w>
6 4%</w>
6 %;</w>
5- az
4 9-year-old</w>
4 7.
4 7%</w>
3 7%</w>
3 5,</w>
3 2.
3 1.
3 %;</w>
2 B</w>
15- 45
12- lead</w>
1 1).</w>
1 %;</w>
0. 8%</w>
0. 13</w>
- in</w>
- exposed</w>
(R R
(EP S)</w>
(E R
(D H
(AR F)</w>
(A LT)</w>
(8 %)</w>
(1 ),</w>
( dd
zidovud ine.</w>
z af
xim e</w>
wor k-
wh en
ver ified</w>
vasospas m.</w>
vasodilat ing</w>
vascular ,</w>
van illo
vacuol es</w>
use s.</w>
ultras oun
two fold</w>
transi ent,</w>
tran sp
tib ial</w>
thrombo plastin</w>
thir ty-
test )</w>
tas k,</w>
tamoxif en,</w>
tac h
t ness</w>
t ent
symptomat ology</w>
sym metr
sulf ox
sulf hydr
sulf asalazine</w>
su perim
stric t</w>
star tle</w>
stain ing.</w>
st age,</w>
spre ad
splen ic</w>
sple en</w>
sp ine</w>
small ,</w>
sit y-
single-bl ind</w>
similar ity</w>
sign al
ser opositive</w>
sep sis.</w>
semi -
s.c .,</w>
s planchnic</w>
s car
ros s
ri es</w>
retard ation,</w>
resum ption</w>
restric tive</w>
replac ement.</w>
ren ovascular</w>
reli eving</w>
regul ation.</w>
reac he
re appeared</w>
ras h
rang es</w>
quinpi role</w>
quanti fication</w>
pup illary</w>
pul sati
provoc ation</w>
prot amine</w>
prolifer ation,</w>
progres sion,</w>
pro arrhythmia</w>
pris ingly,</w>
predis position</w>
prazos in,</w>
pr am
post transplant</w>
posi tive.</w>
plasmaphere sis</w>
perfor ant</w>
percent ,</w>
per c
peak -dose</w>
pal li
p ill</w>
p estic
ox ide-
oste omyeli
ost om
os ,</w>
oper ation.</w>
open- chest</w>
on es,</w>
of loxacin</w>
od ol
octre oti
oci al</w>
o plas
nor floxacin</w>
non hematologic</w>
non cardiac</w>
neuro endocrine</w>
neon ate</w>
nec rop
mumol/ kg</w>
mon ocyte</w>
moder ate-
moder ate,</w>
mg/m(2 ),</w>
mg/ d,</w>
methohex it
mes alazine</w>
membrane- bound</w>
mechanism (s)</w>
measure ments.</w>
mat uration</w>
malignanc y.</w>
malform ations.</w>
mal ine</w>
loxac in-induced</w>
long- standing</w>
lo z
l ution</w>
l li
l aryng
iodi de</w>
intraven ously,</w>
intracerebroventric ularly</w>
ing ),</w>
ine- based</w>
immunosuppress ant</w>
immun ocyt
imipr amine.</w>
im mer
identifi able</w>
ib i</w>
ian -like</w>
i. m
hypothalam us</w>
hypocal cemia</w>
hyperexcit ability</w>
hype remia,</w>
hybri d</w>
hom ovan
high light</w>
hepati tis
hel d</w>
hear t-
guan eth
gr ap
glucocortico id-induced</w>
glit az
gastrocnemi us</w>
gamma-glutam yl
g et
furosem ide,</w>
frac tion.</w>
fluoxet ine,</w>
extrem ities.</w>
expand ed</w>
excl ude</w>
eu than
eth oxy
es citalopram</w>
enlarg ed</w>
enc ap
en ge
em ptive</w>
el ,</w>
e a,</w>
dop amine.</w>
diatrizo ate</w>
di am
demyel ination</w>
de man
dd I</w>
d .)</w>
d -induced</w>
cyt arab
cor responded</w>
consum ing</w>
consci ous,</w>
compoun d.</w>
compl aining</w>
col lo
co ordination</w>
co ordin
chloro procaine</w>
chloro -
child ho
chamb er</w>
chall enge
centr e</w>
candi dates</w>
ca ver
c oc
c ity</w>
but ,</w>
bromocript ine.</w>
blo od.</w>
biopsy- proven</w>
bi v
beta x
ben cl
ballo on
azol ine</w>
at or,</w>
ascit es,</w>
as y</w>
as par
arb azine</w>
ar sen
ar ms.</w>
appreci able</w>
apolipo protein</w>
anticip ated</w>
anti histamine</w>
anti fungal</w>
angiograph y,</w>
ane ously,</w>
analgesi a,</w>
aminotransfer ase,</w>
am ibi</w>
albu min,</w>
aff initi
af loxacin</w>
adriamyc in-treated</w>
adreno receptor</w>
ad duct
accur ately</w>
ac up
ac erb
abnormal ity.</w>
ab rupt
a etiology</w>
[Ca2+] i</w>
Web ster</w>
W eight</w>
W R
VN B</w>
Un til</w>
Un fortun
Thirty- six</w>
Td P.</w>
T ra
T 3</w>
Sur ve
Squ ibb</w>
Sou th</w>
Signific antly</w>
Sequ ential</w>
SOURCE S:</w>
R enograf
R TI
Prostagland in</w>
Previ ously</w>
Pre- treatment</w>
Praz osin</w>
PGI 2</w>
P gp</w>
P 1</w>
Out comes</w>
Ou ab
Obj ective</w>
Nitro prus
Neutropen ia</w>
Na (+)</w>
NT S</w>
N '-
Multicent er</w>
Met abolic</w>
Mes na</w>
Mechan isms</w>
MR P2</w>
MIB G</w>
M od
M ental</w>
M c
Like wise,</w>
Li ke</w>
II I.</w>
Hg ).</w>
Ha emo
HIV -positive</w>
H ipp
H L</w>
GY KI</w>
Flumazen il</w>
F ul
Ex acerb
Epid ural</w>
E AC
Diagno sis</w>
DRE SS</w>
DNA ,</w>
D-penicill amine.</w>
D X</w>
D A-
Con sistent</w>
Cis platin</w>
Ch est</w>
CYP2D 6</w>
CA P</w>
C ho
C arcin
C PA</w>
Bar r</w>
B W</w>
B -induced</w>
Angiotens in</w>
Angiotens in-converting</w>
Ana esthe
Adriam ycin-induced</w>
Ab s
AB T-
A ER
>/ =
9. 4</w>
9. 3</w>
9 -1
80 1</w>
8 3%</w>
7 3%</w>
7 %;</w>
6. 6</w>
50- year-old</w>
5 8%</w>
5 4%</w>
3- PP
3 rd</w>
3 A</w>
2 2,</w>
16 ).</w>
15 00</w>
1. 0%</w>
1 20
0. 6%</w>
0. 16</w>
0. 10</w>
(V T)</w>
(T R
(PR L)</w>
(P D
(P B)</w>
(N =
(H AM-
(G P
(F K
(DO X
(C R)</w>
(A TR
(1 1%)</w>
( which</w>
( cumulative</w>
( SI
( METH
( 7.5</w>
( 7-
' .</w>
% ]</w>
yl ic</w>
year -
y ed</w>
y e</w>
x in</w>
weigh t-
weigh ed</w>
w ri
ver m
ventric le,</w>
ve ins</w>
vastat in.</w>
vascul ature</w>
vag otom
vag in
ur aemic</w>
up .</w>
unex pect
undesi rable</w>
trast uz
transpor ters</w>
tra in
thal lium-201</w>
tetrahydro cannabin
tetrac aine</w>
ter ans</w>
t .
supple ment</w>
sumatript an.</w>
sulf ate.</w>
studi ed:</w>
stro ke
stead ,</w>
stand ard
six -
si s).</w>
sett ing,</w>
sens ations</w>
self- administration.</w>
se st
s cler
rupt ured</w>
respon ds</w>
rel ating</w>
reg ained</w>
ratio .</w>
quin one</w>
question ed</w>
pul ses</w>
pub er
propag ation</w>
pro drug</w>
pri v
prescri ptions</w>
pregnan cy
post treatment</w>
porphy ria</w>
phosph oro
phenter m
per tin
per one</w>
pel le
peg interferon</w>
pe ti
path olog
paren chy
par ap
pap illo
or y.</w>
or aph
or an
opo rosis</w>
oni um-induced</w>
ol ing</w>
ol in</w>
ol ic,</w>
oin tment</w>
occ up
nur sing</w>
nicot ine-
newbor ns</w>
neuropath ies</w>
nerv es.</w>
neon ates.</w>
ne a,</w>
mumol/ L</w>
mul tic
micro l</w>
micro l)</w>
mg/m2/ d</w>
methylenedi oxy
ment ary</w>
me si
mar row
ma y,</w>
ma pro
m as</w>
m ang
ly ;</w>
leuk ocytoclastic</w>
leuk em
latano prost</w>
ker at
ish ment</w>
iox aglate</w>
intra striatal</w>
intoxic ation,</w>
inten tion
insi di
inhibitor -induced</w>
inflam ed</w>
infiltr ates</w>
ine- 3-
ine mia.</w>
implant ation.</w>
immun ocom
im poten
im ply</w>
ill ic</w>
ild en
i 's</w>
hypomagne semia</w>
hypo plasia</w>
hyperplasi a,</w>
hypercalce mia,</w>
hyper kine
hour ly</w>
hist ochemical</w>
high er,</w>
heterogene ity</w>
hepat omegaly</w>
har ve
guine a-
gravi s.</w>
go rous</w>
gi t</w>
gest ation,</w>
genotyp es</w>
gene sis.</w>
g ingi
foun d,</w>
formal in-induced</w>
flexi on</w>
fist ula</w>
fe eling</w>
f und
est ram
es -
enalapri l,</w>
embry os.</w>
embol ism.</w>
elim inate</w>
elev ated,</w>
el ast
ede ma
ect op
ec onomic</w>
e zetimi
e in</w>
dys function
drug 's</w>
dra w</w>
dimen sion</w>
diab e
dexamethas one-treated</w>
determ ined,</w>
design ,</w>
depend ency</w>
degener ation,</w>
def ective</w>
de smo
d 4
cy tidine</w>
criter ion</w>
countri es</w>
corticosteroid s,</w>
confir me
comp et
common est</w>
col onic</w>
coincid ed</w>
coch le
cilost azol</w>
characteris ed</w>
caud ate-
cat arac
cardio protection</w>
carboplat in,</w>
caffe ine-induced</w>
c ation</w>
bri um</w>
brety lium</w>
bir th
bind ing,</w>
barbitur ate</w>
bac te
aug ments</w>
ass ays.</w>
ass ay,</w>
arthr algia</w>
arteriosclero tic</w>
arterio graphy</w>
approach .</w>
app ed</w>
apomorph ine,</w>
ap ular</w>
ap s</w>
analogu e,</w>
anaestheti sed</w>
amp ut
amp icill
all .</w>
agon istic</w>
age ;</w>
age :</w>
aff ili
adhe sion</w>
adenocarcin oma.</w>
acid )</w>
absc ess</w>
a re,</w>
Z -
U L
Toge ther,</w>
Thirty- two</w>
Th iop
TN )</w>
TCD D</w>
T -induced</w>
Surg ical</w>
Str uct
St age</w>
S ilden
S c
S C)</w>
Reco gn
Random ized</w>
PF C</w>
P SA</w>
P O</w>
O V
Nig er
NS ),</w>
NO AR
NF- kappaB</w>
N ec
Mg (2
MPO- ANCA</w>
MA )</w>
M MP
Lip id</w>
J ,</w>
Import antly,</w>
HBeAg -positive</w>
H P
GP i</w>
G TN
G F)</w>
Fos -
F ocal</w>
F ab
Exacerb ation</w>
Ex cept</w>
Enal april</w>
EE G.</w>
Double -bl
Dic lofen
DR G</w>
DO PAC</w>
DESIG N</w>
D BP</w>
Cyclo spor
Con centr
Comp uted</w>
Cardi omyo
Can ad
CA .</w>
B us
Amin o
A(2 A)
A pop
A ff
A )-
9. 7</w>
8. 8</w>
8. 6</w>
7-N I</w>
7 9%</w>
60- year-old</w>
55,212- 2</w>
5. 9</w>
5-F luoro
5 th</w>
5 5-year-old</w>
40- year-old</w>
4 7
4 6-year-old</w>
4 4%</w>
30- min</w>
3- h</w>
3- fold</w>
3 7-year-old</w>
3 6-year-old</w>
24 )</w>
200 4</w>
200 3</w>
2 3-year-old</w>
2 2-year-old</w>
2 2)</w>
1: 1</w>
199 4</w>
19 6
18 ).</w>
15 4</w>
14 .</w>
12 9</w>
1- receptor</w>
1 19</w>
1 11</w>
) ].</w>
(Tax ol;</w>
(S P
(S HR
(P L
(M B
(D X
(Cs A)</w>
(4 0%)</w>
(3) H]
(2 2%)</w>
(2 0
(1 000</w>
( six</w>
( chi
( 5-FU
" .</w>
when ever</w>
well- recognized</w>
wean ing</w>
wat er)</w>
warfar in,</w>
wan n</w>
ventro medial</w>
valpro ate-induced</w>
v oric
v ice</w>
utili zing</w>
ure ter
un wanted</w>
un iform</w>
un affected.</w>
ulo pathy.</w>
twice- daily</w>
twent y</w>
triam cin
trem ulo
trans mit
tract us</w>
tr amine</w>
thr ice</w>
thio guanine</w>
them ,</w>
tend on</w>
temozolom ide</w>
te g
tac rine</w>
t ris
t ing,</w>
synerg is
sulf ate,</w>
subcut aneous
sub endocardial</w>
sp on
sol itari
siz e.</w>
sign al-
sic k
sh are</w>
sed ati
secre tion,</w>
sco res.</w>
scat tered</w>
sar coma.</w>
ronedar one</w>
ron tal</w>
ric ket
ri ses</w>
rewar ding</w>
rese mble</w>
res h</w>
renz ep
remo val
relim b</w>
reflex .</w>
re present
re challenge.</w>
quinol ine</w>
psychos ocial</w>
prolifer ation.</w>
profes sion
pro thrombotic</w>
practition ers</w>
potenti al,</w>
possib il
poly drug</w>
play ing</w>
placebo -treated</w>
pil si
physostigm ine.</w>
phleb itis.</w>
phenyl alanine</w>
phent ol
pharmac eutical</w>
percent ),</w>
pe op
patch es</w>
pa ins</w>
pa in-related</w>
p amid
over come</w>
other s.</w>
ot an</w>
orig in
opi ates</w>
one ).</w>
olig uria</w>
ob taining</w>
o estrogen</w>
neuroblast oma</w>
nal bu
n ose</w>
myelo pathy</w>
myalgi as</w>
muscl es,</w>
mou th
morph ologically</w>
month ,</w>
mo tiv
mmol/ kg</w>
mixt ures</w>
mineralocortico id</w>
micrograms/kg/ min</w>
micro cephal
mg/m(2 ))</w>
mg/d l)</w>
mg/d L.</w>
mg. kg-1.
melat on
mal a
mac ulop
ma st
lun g,</w>
load .</w>
lit ers</w>
levo bupivacaine</w>
lat e,</w>
las go
lasgo w</w>
large -
lac tam</w>
l ar</w>
kind ling.</w>
iter pen
investig ation,</w>
inj ectable</w>
initi ation.</w>
ini um-
ing re
inc o
in- mediated</w>
in in</w>
impl ant</w>
ifosf amide
ic /
hypocap nia</w>
hyperkal aemia</w>
hypercholesterol emia</w>
hyper triglyceride
hydroxy- 3-
hydroxy but
high- density</w>
hemodynam ically</w>
hemo dilution</w>
hear ts,</w>
hap lo
hallucin ations.</w>
gli bencl
gl um
general ised</w>
gen es.</w>
gall stone</w>
fol d)</w>
flu ids</w>
fl an
fibron ectin</w>
extinc tion</w>
examin ations,</w>
ex ci
ever olim
eu phor
eth ane</w>
erro rs</w>
eptid ase</w>
enti ty.</w>
endomet ri
enco ded</w>
en e.</w>
en e-
eme togenic</w>
electr on-
dro ph
dose- effect</w>
donepe zil</w>
docum ents</w>
disturb ance,</w>
dis s
diaz oxide</w>
diaph ore
dex medetom
der s,</w>
depart ments</w>
dementi a.</w>
defect .</w>
de d-release</w>
cytot oxic
cypro mine</w>
cre ated</w>
cop e</w>
confir m
compa res</w>
comm enced</w>
co enzyme</w>
clear ances</w>
cisplat in-induced</w>
cin acalce
catalep sy
cardio selective</w>
carb im
bo th
ble omycin</w>
bio availability</w>
beta ,</w>
backgro un
bab ies</w>
b reath</w>
b am
ax illary</w>
ax etil</w>
avir in</w>
ativel y,</w>
aster ixis</w>
aspir in-
asp ect</w>
as :</w>
areas ,</w>
antin ocicep
antibod y,</w>
anti anginal</w>
angiograph ically</w>
anesthetiz ed,</w>
an odine</w>
an ide</w>
an and
aminophyll ine.</w>
aminophyll ine,</w>
allodyn ic</w>
ain -
ain ,</w>
aggreg ates</w>
ag glut
ag al</w>
affiniti es</w>
af f</w>
accumul ated</w>
acceler ate</w>
ac ar
a e,</w>
[SD ]</w>
Ze al
Wee k</w>
Thirty- three</w>
TN F</w>
TH )</w>
TB ARS</w>
T umor</w>
T ime
T en
T S</w>
T 4</w>
Sch wann</w>
SUBJECT S:</w>
S ot
Ran iti
RB C</w>
R ib
Propo fol
Pot assi
Pa CO2</w>
PP H</w>
PB N</w>
PAN -treated</w>
P 450
O LT
Nitroglycer in</w>
N-nitro sodi
N- methyl
MM F</w>
LE V</w>
L- type</w>
J aundic
In di
IV .</w>
ISO -treated</w>
II -
IGF- I</w>
ID 50</w>
I T)</w>
Hipp ocamp
HC V-
H M
Ex peri
Estro gen</w>
Electro physiological</w>
E PO
E F
E (2)17
Disul firam</w>
Dis or
Dex razoxane</w>
DES- exposed</w>
D ist
D PD</w>
Con current</w>
Co- administration</w>
Car bo
CP K</w>
CB D
C riter
C X
C G</w>
Austral ian</w>
Americ ans</w>
Am ifostine</w>
Am B</w>
99 m</w>
9. 8</w>
9. 0</w>
8. 1</w>
7, 8-
6 8%</w>
6 1-year-old</w>
5 2%</w>
4- fold</w>
4 2.
4 2-year-old</w>
25- year-old</w>
2. 8
2. 5-
1- 3</w>
1 6-year-old</w>
1 5-year-old</w>
1 17</w>
00- mg</w>
0.0 5%</w>
0. 17</w>
(SN P)</w>
(N -
(I L
(H IT
(6 00</w>
(4 4%)</w>
(3 5</w>
(1 3.
(1 2.5</w>
(1 2%)</w>
(0. 5
( v
( aged</w>
ym panic</w>
yl ]-
x -
wor sen</w>
wh y</w>
week )</w>
wean ling</w>
wast ing</w>
war m</w>
void ing</w>
vinblast ine,</w>
vascul at
vacu ous</w>
us age.</w>
ure teral</w>
unif orm
uc h</w>
toxic ities,</w>
ting- enzyme</w>
tim es.</w>
ti t
thi x
thalam us,</w>
ter s.</w>
te icoplan
tap ered</w>
tail- tremor</w>
sympath o
suppres sion.</w>
superim posed</w>
successful .</w>
sub o</w>
sub chronic</w>
stom atitis</w>
stand ar
st aff</w>
spik e-
sp ot
sotal ol,</w>
sor afen
so gest
sirolim us,</w>
si al
short -</w>
shap e</w>
sh rin
sett ings.</w>
sest amibi</w>
sequ in
separ ately</w>
sel enium</w>
sc ot
s me
rp 2</w>
rhi z
rest ,</w>
res tim
remis sion,</w>
regimen s,</w>
recurren ce.</w>
re in
radi olab
r one</w>
pro tr
pro mi
prescri p
pre gab
practi ce,</w>
prac tic
plus- maze</w>
pleas ant</w>
pinacidi l</w>
phosphon o
persist s</w>
persist ently</w>
per phenaz
pentobarbital- anesthetized</w>
parkinson ian-like</w>
paren ts</w>
paren chymal</w>
paras it
parallel- group</w>
p ane
pane l</w>
ox on</w>
ox az
orthop edic</w>
orth o
or bidi
oph il</w>
on 's</w>
ol imbic</w>
nutri tional</w>
nucle us,</w>
not e</w>
nitroprus side.</w>
nic oran
neuro active</w>
necessit ated</w>
ne omycin</w>
ne l
ne ar-
nausea/ vomiting</w>
n g)</w>
n as
myelosuppres sion,</w>
myelo dysplastic</w>
mus culoskeletal</w>
monke ys,</w>
mo id</w>
micro M,</w>
mg/m(2 )/
mg/m(2 ).</w>
mg/ day),</w>
mg/ K
methyl ene</w>
met for
meropen em</w>
meflo qu
measure d,</w>
manag ement,</w>
man ic-
maculop apular</w>
macro lide</w>
m oc
long- term,</w>
lip id-
lik re
letharg y,</w>
larg e,</w>
lact ation</w>
l d</w>
l at</w>
kind s</w>
it alop
isoprenal ine-induced</w>
isoniaz id.</w>
isoniaz id-induced</w>
irradi ated</w>
intrapl antar</w>
intim al</w>
interfe res</w>
intens ity.</w>
inher ited</w>
indinavir .</w>
in yl)
in sec
immunost aining</w>
imat inib</w>
ide n</w>
hypothe ses</w>
hyponat remia.</w>
hyperther mic</w>
hyperglyce mia,</w>
hyper reflex
hydr ation,</w>
hr ,</w>
hormon e.</w>
homovan illic</w>
hepar in
haz ard
h /
gy rus.</w>
graf ting</w>
gonad al</w>
glycopyrro late</w>
glutam ate,</w>
glucosaminid ase</w>
genotyp ed</w>
g um</w>
g el
fiel d,</w>
fib rous</w>
fail s</w>
fac ility</w>
extrap ol
ex pen
etoric oxib</w>
eti ology.</w>
estim ation</w>
essen ti
ere bell
erebell ar</w>
enro ll
enrich ed</w>
end- tidal</w>
en abl
electroly tes,</w>
elect ric</w>
effor t</w>
ed ly,</w>
echocardio gram</w>
e f
dysph ag
drug s:</w>
document ed,</w>
dizzin ess.</w>
disorder :</w>
discontinu ation,</w>
discontinu ance</w>
dis solved</w>
dipyridamol e.</w>
didan os
di one</w>
dextr an</w>
determin ants</w>
den si
defin it
defici ency,</w>
decano ate</w>
de sogest
de bil
dd C</w>
day time</w>
d one.</w>
d /
cy ano
cr ypt
cou mar
conver ting-enzyme</w>
control ;</w>
continu ed.</w>
conscious ness,</w>
com orbidi
colchic ine-induced</w>
cogn ition</w>
clioquin ol</w>
chron ic,</w>
channel s,</w>
categ ory</w>
carr ying</w>
cann ula</w>
canc ers.</w>
but yl-
busulph an</w>
bur n</w>
bronchodilat or</w>
bol uses</w>
blo tting</w>
blo od,</w>
betax olol</w>
behaviour .</w>
be it</w>
b un
b a
azol e-
audi ogenic</w>
ato prost</w>
ation -related</w>
aten olol,</w>
ass ay
arthr alg
antipsycho tics,</w>
anti serum</w>
antagon ised</w>
angin a,</w>
anaphyl axis</w>
an uric</w>
alpha (2)-
albu ter
al beit</w>
adriamyc in.</w>
adrenal ine.</w>
adeno virus</w>
activ ity;</w>
acetyl cysteine</w>
[35S] TBP
[ (3)H]
Yor k</w>
With out</w>
Wil son's</w>
Thirty- eight</w>
T x
T MP
T J
Sub st
St ate</w>
SA H</w>
S S
S F
Rel ationshi
RB Cs</w>
Prom pt</w>
Pre clinical</w>
Ph osph
Per icardi
PTU -induced</w>
PIL O</w>
PG- 9</w>
P lac
P i
One -
O I
Nor thern</w>
N P)</w>
N C</w>
Mit ochondrial</w>
Methotrex ate</w>
Melat onin</w>
Measure ment</w>
M- mode</w>
Los s</w>
Li Cl</w>
L ess</w>
L M</w>
K A</w>
Invent ory</w>
Intrac erebral</w>
Inter action</w>
IS P</w>
II I)</w>
IC V</w>
HBV- DNA</w>
G ranulo
G M</w>
FE V1</w>
F uture</w>
F at
Exer cise</w>
Ex tensive</w>
EX P
EC G,</w>
E po
E B</w>
Do x</w>
Do es</w>
Di ff
D (1)</w>
Contro ls</w>
Clo zap
Cl )</w>
Chloro quine</w>
Carbam azep
Captop ril</w>
CYP 3A4</w>
CH D</w>
C oun
Bromocript ine</w>
Block ade</w>
Bac lofen</w>
B or
B IS</w>
Ak t</w>
AQ P2</w>
AID S-related</w>
A plastic</w>
7. 7</w>
7- nitro
7 2-year-old</w>
6 9%</w>
5 2-year-old</w>
5 1%</w>
4 -1
3839 3</w>
3- day</w>
3 H-
3 9-year-old</w>
3 70</w>
3 4-year-old</w>
3 4%</w>
3 2)</w>
3 -</w>
2, 000</w>
2 2-
14 4</w>
13 9</w>
1,25- dihydroxy
0.0 3)</w>
- interstitial</w>
,00 0/
(W K
(T D
(N S)</w>
(IC H)</w>
(AC h
(2. 0</w>
(2 7.
(2 6</w>
(2 3</w>
(1 8</w>
( non-
( mean
( di
( defined</w>
( d)</w>
( alpha-
zidovud ine,</w>
yr )</w>
youn g,</w>
yn thetic</w>
yl )</w>
wor ds</w>
wor d</w>
wid ening</w>
week s),</w>
wa ve
w rit
w k
vinc a</w>
vi sion.</w>
vi able</w>
vanillo id</w>
van ishing</w>
us er</w>
unit s/
unex posed</w>
unevent ful
un myelinated</w>
un de
umb il
ular ly,</w>
ug inos
u ter</w>
typ es.</w>
tum or-
trimethaph an</w>
triamte rene
tri c</w>
tocain ide</w>
ticlop idine-induced</w>
ti ters</w>
ther l
themsel ves</w>
the ory</w>
thalidom ide-induced</w>
temperat ure.</w>
taz idi
suxameth onium.</w>
susceptibil ity.</w>
suppress ant</w>
suppres sive</w>
suppl ied</w>
sugg estion</w>
sub threshold</w>
stimul i,</w>
stereotyp ic</w>
steno ses</w>
sour ces</w>
si es</w>
shif ts</w>
self- report</w>
seizure -like</w>
sed ating</w>
sec tion.</w>
se mis
semis ynthetic</w>
s.c .),</w>
ro ot
righ t-
review ,</w>
resem bles</w>
re min
re jec
radio therapy.</w>
radio active</w>
r ings</w>
r .</w>
questionnai res</w>
provid ers</w>
priap ism</w>
pre ven
poin t,</w>
po t</w>
piper azine</w>
phyl axis</w>
phenylephr ine.</w>
pheno thiaz
persist ed.</w>
periodic ally</w>
peri portal</w>
pent oxif
particip ants.</w>
pan cur
p es</w>
ox yp
ous ness</w>
otep a</w>
osteop oro
oste oporosis</w>
osal ic
organ ophosph
one ),</w>
om ycin.</w>
of ,</w>
ocy an
obj ec
objec tives</w>
nucle i.</w>
noti ce
non sustained</w>
non significant</w>
no tion</w>
neutrophil s</w>
neurotransmit ters</w>
neuro cognitive</w>
ne sted</w>
ne ostri
mye lography</w>
multic entr
mol ar</w>
modifi es</w>
mmHg ;</w>
ml ).</w>
mit ting</w>
min i
min -1,</w>
mimic ked</w>
mid odrine</w>
micrograms/ ml,</w>
micrograms/ ml)</w>
mg/d l.</w>
mg/ l</w>
metast asis</w>
membran es.</w>
me glum
m er</w>
ly s
lu men</w>
low ers</w>
long est</w>
log -
lipopolysacchar ide</w>
limb s,</w>
lim itation</w>
lik ely.</w>
li ve</w>
lev amisol
laparotom y</w>
kin ase-
kal likre
k- alkali</w>
is ons</w>
intrac isternal</w>
interleuk in-
insti lled</w>
insi gh
insec tic
inhibitor )</w>
infu sions,</w>
infarc ted</w>
individu al
ind ole</w>
in- of-
in oc
ill u
ill ain-
il s</w>
hypother mic</w>
hypothalam ic-
hypomagne sem
hydrochlorothiaz ide,</w>
hr s</w>
his ti
hemodynam ics,</w>
hemis phere
hear t
h u
gynec ologic</w>
gly bur
glomerulosclero sis.</w>
gest od
ger m</w>
g k
g aug
form .</w>
follow ing:</w>
fo relimb</w>
flex or</w>
fl ud
fix ed-
fibr inogen</w>
fib ers,</w>
ferri tin</w>
f resh</w>
extra -
extr adural</w>
exten ded-release</w>
expres s</w>
ethan ol-induced</w>
eth yn
et .</w>
estram ustine</w>
establ ished,</w>
es cent</w>
es c
equi val
epsilon- aminocaproic</w>
epilep sy
ep omedi
ens or
encephal itis</w>
encap sul
emb ran
elder ly,</w>
el ed</w>
dys functions</w>
drug- drug</w>
drowsin ess,</w>
dou b
dofe tilide</w>
digox in.</w>
dextro se</w>
detox ification</w>
depres sion
depolar ization</w>
deple tion.</w>
dele tion</w>
de fl
cytos kele
cur cumin</w>
cu t</w>
conce pt
con stitutes</w>
comp uter</w>
commer ci
com posed</w>
coca ine's</w>
coag ulopathy</w>
cholecysti tis</w>
ch ick
cephalor idine</w>
carb imazole</w>
calcul i</w>
but ylated</w>
bis ulf
bind s</w>
bic al
bical ut
beta-carb ol
basel ine)</w>
azathiop rine.</w>
attac ks,</w>
asystol e.</w>
as ym
arri val</w>
arrhyth m
ardi ac</w>
anti bacterial</w>
analo g,</w>
amylo id</w>
amino )
am lodip
am bi
alte red.</w>
all ing</w>
alf a</w>
ag oraph
afterdepolar izations</w>
affili ated</w>
aer uginos
adultho od.</w>
acro le
achie ved.</w>
abund ant</w>
ab used</w>
a -like</w>
X -induced</w>
VE GF</w>
V /
V ).</w>
Un ilateral</w>
Tri meth
Tri als</w>
Tou rette
Tai w
T P</w>
T :</w>
Sur prisingly,</w>
Spec ific
SH R
S- transferase</w>
S ensory</w>
S CL
S B-
S -induced</w>
Re actions</w>
Random ized,</w>
R -induced</w>
Questionna ire</w>
Poin tes</w>
Pharmaco kinetic</w>
Pati ent
PGE (2)</w>
PA ).</w>
Orth ostatic</w>
On set</w>
Ob serv
O -induced</w>
N-nitrosodi ethyl
N K</w>
My co
Mem ory</w>
Maxim al</w>
MTX ,</w>
MP EP</w>
MENT AL</w>
MA ,</w>
M eni
Lo g
L ang
L Y</w>
L EC
K ing
K D</w>
K Cl</w>
Jaundic e</w>
Investig ation</w>
INTERPRETA TION:</w>
I F</w>
Hun ting
Hem olytic</w>
HIV -1</w>
HD L-
HD ,</w>
HC H</w>
H al
H V</w>
H AL
GnR H</w>
Gem cit
Ful minant</w>
Forty- six</w>
F SG
Epi lep
EXP ERI
EXPERI MENTAL</w>
E MB
Doxorub icin-induced</w>
DSM- III-
DBA/ 2
Cur ren
Cor tical</w>
Clin ically</w>
Cholest atic</w>
Cardiomyo pathy</w>
Ca +
CM V</w>
CM F</w>
C ell</w>
C O</w>
C N</w>
B ladder</w>
B K</w>
Am antadine</w>
Addi tion</w>
ANCA -associated</w>
AM PH
A verage</w>
A tropine</w>
A O
A ;</w>
8. 2</w>
8 4%</w>
70- year-old</w>
7 7
7 6-year-old</w>
6 9-year-old</w>
6 7.
6 2%</w>
50 %.</w>
5-fluorourac il.</w>
5-az acy
5-HT 1
5-FU .</w>
5-FU -induced</w>
5- amin
5, 7-
5 3%</w>
40 )</w>
4 th</w>
4 80</w>
4 5,</w>
4 1-year-old</w>
4 %.</w>
3 :</w>
3 2-year-old</w>
2', 3'-
2 );</w>
199 6</w>
199 2</w>
16 4</w>
13 8</w>
12- week</w>
10(- 5)</w>
1. 9
1. 3%</w>
1-methyl-4-phenyl-1,2,3,6-tetrahydro pyridine</w>
1- week</w>
1- hour</w>
1- h</w>
1, 0
1 8-year-old</w>
1 7-year-old</w>
1 24</w>
0. 20</w>
0. 14</w>
- fed</w>
- activated</w>
, 0
(NM S)</w>
(H U
(H R),</w>
(H IV
(GF R)</w>
(F D
(D M
(AZ T)</w>
(AU C)</w>
(A d
(3, 4-
(2 7%)</w>
(2 6.
( seven</w>
( four</w>
w t</w>
w indo
windo w</w>
vari es</w>
valpro ex</w>
v .</w>
uro logical</w>
uptak e.</w>
under took</w>
un usually</w>
un bound</w>
umbil ical</w>
typ es,</w>
tro pon
trimethopri m</w>
tric ho
tri phasic</w>
tri mox
tranyl cypromine</w>
transcript s</w>
toxic osis</w>
toxic ological</w>
thyroidis m,</w>
three fold</w>
thio per
tempor arily</w>
te mazepam</w>
tachy arrhythmia</w>
surg ically</w>
struct ur
steroid -
stereotypi es</w>
stere o
step s</w>
st or
st ing</w>
spectro phot
solv ent</w>
sol e
si zed</w>
sha red</w>
ses sions.</w>
ser ologic</w>
sequ ences</w>
sensitiz ation,</w>
self- administered</w>
selec tiv
sedent ary</w>
second s.</w>
scho ol</w>
sc rat
sc )</w>
rout e.</w>
ro su
rivas tigmine</w>
ris k-
retro bulbar</w>
request ed</w>
repair .</w>
relax ants</w>
rel y,</w>
regres sed</w>
reflex ,</w>
re ple
re ar
ration ale</w>
radi ograph
pu er
prot otyp
propranolo l-induced</w>
propi onate</w>
prolong s</w>
prol ide</w>
profession als</w>
prof oun
procain amide,</w>
pra vastatin</w>
poly uria.</w>
poly neuropathy.</w>
poly amine</w>
pindo lol</w>
pill s</w>
pi renzep
phosph ate.</w>
phen ir
pertin ent</w>
perit on
percent ages</w>
per son</w>
per ic
pentylenetetrazol e-induced</w>
pentobarbit al.</w>
pentobarbit al-induced</w>
pentamid ine.</w>
pe floxacin</w>
pattern s.</w>
path ies.</w>
paraly zed</w>
papillede ma</w>
pall idal</w>
pa in:</w>
p =0.00
p 38</w>
over dosage</w>
or ies</w>
oph ageal</w>
oper able</w>
oneuro pathy</w>
one al</w>
ondan setr
om on
olog ist</w>
olec ular</w>
olar yn
off "</w>
ocon vul
oc ap
observ ation.</w>
o proliferative</w>
nystag mus</w>
nucle i,</w>
no reth
nitroprus side,</w>
nif ied</w>
neuropath y:</w>
neph ron
nat ur
narrow ing</w>
na ec
myocardi um,</w>
mul tivari
morph ometric</w>
month s),</w>
mo re.</w>
minip um
mid line</w>
micromol/ L</w>
microangio pathic</w>
micro M).</w>
micro M),</w>
mic ,</w>
mg/m l)</w>
metopro lol,</w>
metabol izing</w>
mes yl
medi ast
me tic</w>
maz e.</w>
mat ur
mark ers,</w>
manic- depressive</w>
m ifeprist
m e</w>
lumb os
loo ked</w>
li sted</w>
li osis</w>
leuk ocytes</w>
leg al</w>
le ver</w>
late- onset</w>
lansop razole</w>
l ess.</w>
l es.</w>
kg ;</w>
k Hz</w>
junc tion</w>
jer ks</w>
ituit ary</w>
ipex ole</w>
investig ational</w>
interview s</w>
insul t</w>
ino si
inges tion,</w>
ine- like</w>
incorpor ated</w>
in one</w>
im pulse</w>
il /
ic v</w>
ia sis,</w>
hyper insul
hydroxy- 2-
hydroxy urea</w>
histor y.</w>
halothane- anesthetized</w>
h ous
h ard</w>
h ),</w>
glutathi one-
gingi val</w>
gentamic in-treated</w>
gangli a,</w>
gadol inium</w>
g estive</w>
g ar</w>
fusi dic</w>
ful filled</w>
fle st
fea sib
fact ,</w>
facilit ates</w>
expect ed,</w>
et odol
erythropoi esis</w>
er s:</w>
er ase</w>
epilept ogenesis.</w>
epi di
epidi dy
ent ec
emphasi zed</w>
elucid ated.</w>
elev ation,</w>
electrocardio gram.</w>
ecgon ine</w>
ec lo
e g
e droph
dyscra sias</w>
drug- resistant</w>
drin k
dra in
disturb ance.</w>
dist or
dist ance</w>
diltiazem .</w>
digit oxin</w>
diff ering</w>
diclofenac .</w>
dialys ate</w>
de ta
d otal</w>
coun ts,</w>
cortis ol-induced</w>
control s)</w>
cont ribu
cont ext
constipati on,</w>
conn ection</w>
conflic t</w>
conf er</w>
com promi
coll icul
co w
co efficient</w>
circu it</w>
chloroqu ine-induced</w>
chloro ethyl
chlor diazep
challeng e,</w>
ch oro
ch arge
cerebell um.</w>
cef azol
cau tion.</w>
carboplat in.</w>
capsaicin- sensitive</w>
byp as
but orphanol</w>
bupren orph
brady kin
br ush</w>
bo ys</w>
beta-end orphin</w>
bet amethasone</w>
benzodiazepin es,</w>
bef radi
beats/ min.</w>
basi lar</w>
b.i. d.</w>
b os
atten tion-
ation s;</w>
ate d:</w>
aspir in-induced</w>
aro x
antihist amines</w>
antidepress ant
anti le</w>
anore xi
angio grams</w>
angi ect
analog ous</w>
an in</w>
alpha- 2b</w>
alpha (1)-
allodyn ia,</w>
agranulo cyto
agit ation.</w>
aff ected,</w>
adv is
ad al
acu ity,</w>
acti vely</w>
absorb ed</w>
absor ption.</w>
abec arn
a pro
] o</w>
Zeal and</w>
Z idov
Z D
V SD</w>
V CR</w>
Un it</w>
URE S:</w>
U/ L,</w>
Toler ance</w>
Ticlop idine</w>
Thromb ocytopenia</w>
There after,</w>
Th at</w>
Tem poral</w>
Tachy cardia</w>
TM S</w>
T re
T issue</w>
T CA</w>
Subj ective</w>
Sub cutaneous</w>
Ster oid</w>
SY N
SYN THESIS:</w>
S pir
S o
S in
S ,
Prote in</w>
Prot ection</w>
Potassi um</w>
Platele t</w>
Pilocar pine</w>
Phenyleph rine</w>
Par t</w>
PAN .</w>
PAN ,</w>
P ic
P PAR
P CR
Oc tre
Ne therl
NK 1</w>
N er
N CT
Mg SO
ME L</w>
Los artan</w>
Lo wer</w>
Lew is</w>
LE .</w>
L is
L P</w>
L N
L AM</w>
K ing's</w>
Inde ed,</w>
Im pression</w>
I K
Hyper prolactinemia</w>
Here in,</w>
HU S.</w>
HC .</w>
H2 O</w>
Gu illain-
G H</w>
Fir st,</w>
Enh anced</w>
En d-
ER K</w>
E stradi
E GF</w>
Dil tiaz
Det ail
De ath</w>
D SE</w>
D MT
D L-
Cy t
Convul sions</w>
C PT
C -induced</w>
Bu t</w>
Bu pivacaine</w>
Ap plication</w>
Anesthe si
Ab out</w>
AM P-
AID S.</w>
A/ J</w>
A x
A typical</w>
A sian</w>
A AP</w>
8 6%</w>
7-nitro inda
6 4-year-old</w>
5-HT 3</w>
5-Fluoro uracil</w>
5 8.
5 7-year-old</w>
4- amin
4 8,</w>
4 6.
3-PP P</w>
3- 5</w>
3,4- dihydroxyphenyl
26 ).</w>
2. 0%</w>
17 ).</w>
14 9</w>
12 6</w>
1. 5,</w>
1. 4%</w>
0.05 ;</w>
0.00 1;</w>
0.0 9</w>
0. 30</w>
0 ;</w>
.00 1),</w>
-M ei
-1 /
)- associated</w>
) ],</w>
(RO S)</w>
(P< 0.01).</w>
(P F
(M PT
(H IT)</w>
(FK 50
(D SM-
(D R
(CY P)-induced</w>
(AT P)</w>
(8 0%)</w>
(7 %)</w>
(4 1%)</w>
(3 6%)</w>
(3 )/
(3 %)</w>
(2 9%)</w>
(2 4%)</w>
(2 1%)</w>
(2 ).</w>
(2 %)</w>
(1 6%)</w>
(0.0 1-
(0. 7
( about</w>
( X
( 5,</w>
( '
ym ph
yiel ding</w>
y ocardial</w>
with dre
well ,</w>
week ly.</w>
warfar in-related</w>
vol emic</w>
vi rus.</w>
ver ing</w>
vel s</w>
vasodilat ors</w>
urin alysis</w>
urethane- anesthetized</w>
univer sity-
un reported</w>
un diagnosed</w>
ultra structure</w>
ub i
u es</w>
tubulo -interstitial</w>
trou bl
trau ma.</w>
topir amate</w>
tom ography,</w>
to- moderate</w>
to id</w>
tion ),</w>
thi otepa</w>
tenof ovir
teleph one</w>
tel angiect
techniqu e,</w>
tax ol</w>
syndrom es,</w>
swe ating</w>
suspect ed,</w>
sulfox imine</w>
sulfhydr yl</w>
sub scale</w>
sub cellular</w>
streng th
stra in,</w>
st ell
st asis</w>
spectro scopy</w>
side s.</w>
si ve.</w>
short ness</w>
seroton in,</w>
ser ine</w>
sequin an</w>
se ter</w>
scleroder ma</w>
scaveng ing</w>
sampl ed</w>
rest less</w>
respon der</w>
res ectable</w>
represent ative</w>
reduc tion,</w>
reco ver</w>
rec ur</w>
reac t</w>
re tained</w>
rate -induced</w>
rat ropium</w>
rac e,</w>
quin oxal
quin ine-induced</w>
quanti ties</w>
propo sed.</w>
program .</w>
prof ylline</w>
produc tion,</w>
procain amide.</w>
proc ou
proc ess,</w>
pro pri
preserv ation</w>
prednis one,</w>
predis poses</w>
post ure</w>
poly uria,</w>
plas ma,</w>
pituitary- adrenal</w>
pide mic</w>
phylococc al</w>
ph ed
paw -
pauc ity</w>
parturi ents</w>
parkinson ism,</w>
pares thesia</w>
par g
pa in
pa id</w>
oxali platin</w>
oxali plat
other ,</w>
os a</w>
op e</w>
omo dul
ologic ally.</w>
oligo dend
oligodend ro
olaryn g
observ ation,</w>
obes ity</w>
ob vi
o edema,</w>
not ably</w>
not ,</w>
neuro toxic
neuro protection</w>
n M</w>
multicentr e</w>
morph ic</w>
mo i
ml -1</w>
mil l
migraineur s</w>
microscop y,</w>
micrograms/ ml.</w>
microg/ rat)</w>
micro -
mg/m 2),</w>
methy ser
methad one-
megal oblastic</w>
mat ching</w>
market ed</w>
m oun
lysos omes</w>
ly so
lut e
lumbos acral</w>
line arly</w>
limit s.</w>
letharg y</w>
lear ning,</w>
lan -Mei
kin d</w>
kidne ys,</w>
ket o-
ke t</w>
k er</w>
k Hz
jump ing</w>
j o
itsel f.</w>
it ance</w>
isoniaz id,</w>
isoflur ane,</w>
iso -
isch aemia.</w>
irin otecan</w>
ir t
ip ratropium</w>
invol ved,</w>
investig ator</w>
intoler able</w>
inter view</w>
inter acts</w>
inter -
intention -to-treat</w>
int ent
insigh ts</w>
inosi ti
ind ap
inclu sions</w>
in izing</w>
in ess,</w>
immunos orbent</w>
im potence</w>
im ide</w>
ifen pro
if entan
ide s,</w>
id )</w>
ia -like</w>
hypot on
hyperkal emia,</w>
hyper cap
hydro morphone</w>
hum oral</w>
hr )</w>
hot -
hept ano
hemi paresis</w>
hemat oma.</w>
hem olytic-uremic</w>
gyr us,</w>
gynec omasti
grow th,</w>
grap h</w>
granulo cytopenia</w>
gram s.</w>
gl ands</w>
g ross
func tions,</w>
follow s</w>
fol d,</w>
fluoroquinol ones</w>
flu vox
ff -
fet us.</w>
ezetimi be</w>
ey e.</w>
ess ation</w>
ere 's</w>
eradic ation</w>
epo etin</w>
enantiom er</w>
en erg
emplo ying</w>
em ents</w>
elic its</w>
eff usion.</w>
e leven</w>
e icos
dys regulation</w>
drug -dependent</w>
dri ven</w>
dose -</w>
diure tics.</w>
dist ant</w>
dissoci ated</w>
din it
diameter ,</w>
den ied</w>
del usions</w>
debil it
de tach
de hydration</w>
de fibrill
datab ase.</w>
da zole</w>
cy r
coun sel
conver sion.</w>
context ual</w>
con nec
compens ated</w>
compar ison
col later
co vari
clon us</w>
clo tting</w>
cli pp
citalopram ,</w>
circu its</w>
cir cl
ciprofloxac in.</w>
chem oconvul
cent ,</w>
cauti ous</w>
cau tions</w>
catheter ization.</w>
cataton ia.</w>
cat s.</w>
cas es).</w>
captopri l.</w>
calci um.</w>
cal f</w>
ca sts</w>
c- Fos</w>
brady arrhythmia</w>
bio assay</w>
beta- blockade</w>
benzo yl
benef it.</w>
az ine-induced</w>
az ana
ate d-
at azana
associ ation.</w>
ar ise</w>
ar is
ar ial</w>
ar ate</w>
appea red,</w>
app ly</w>
antipsycho tic-induced</w>
antimicro bial</w>
anti- arrhythmic</w>
anti thrombin</w>
angio gram</w>
angio genic</w>
amplitu de,</w>
amphet amines</w>
am rinone</w>
alpha- adrenoceptor</w>
all erg
all enge</w>
al cit
al as
ag in
adjust ments</w>
acti ve,</w>
ac .</w>
abol ish</w>
a x</w>
a rom
[14 C]
Youn g</w>
X ).</w>
W A
Valpro ate</w>
Unfortun ately,</w>
Thirty- one</w>
Test o
Tax ol</w>
TT P-
T F
T 2</w>
Silden afil</w>
SC s</w>
S tra
S ar
S AM
Reg ular</w>
Recogn ition</w>
Pro spective,</w>
Par ad
Par acetam
PD ,</w>
PA /
P< 0.05).</w>
P r
P he
Op tic</w>
O tot
Na +/
NP C</w>
NG- nitro-L-arginine</w>
NCT 00
N ot
Meni ere's</w>
Maxim um</w>
Mark ed</w>
Le vels</w>
L HR
L CT</w>
Ischem ic</w>
Intralip id</w>
Inf ants</w>
In tensive</w>
Immunohist ochemistry</w>
IC )</w>
Hyper tensive</w>
Hyper cal
Hg ),</w>
Hepat otoxicity</w>
HIT .</w>
H u
H ET
H )-
Gl yc
GABA ,</w>
G lasgow</w>
G AD
Frequ ency</w>
Fi bro
Fe wer</w>
Fancon i's</w>
Exc essive</w>
Ep o</w>
ED (50)</w>
EC Gs</w>
E tom
Doc etax
De ep</w>
DZ R</w>
DOCA- salt</w>
DO PA</w>
DO CA</w>
D on
D IC</w>
D I
D C
Cap ecit
C u
C essation</w>
C :</w>
BT X</w>
B asal</w>
Ap omorph
Al co
Abs ence</w>
AP L</w>
AD AM
AC h</w>
AC S</w>
A ge
9 3
86 44</w>
8 7
7 7%</w>
7 5-year-old</w>
6- OHD
6 2-year-old</w>
50 00</w>
5-HT 2</w>
5 HT
4 9%</w>
4 6%</w>
3- month</w>
3 4.
3 3-year-old</w>
3 1-year-old</w>
25 %,</w>
24 h</w>
200 6</w>
2. 9
2. 6
2- fold</w>
2 C</w>
2 7-year-old</w>
2 7,</w>
2 6-
2 3)</w>
17beta- estradiol</w>
15-45 13</w>
1417 16
14 ),</w>
12 8</w>
12 1</w>
10- year</w>
1 A
1 0.5</w>
)- treated</w>
(PAN )-induced</w>
(P< 0.001).</w>
(P P
(HC V)</w>
(EM G)</w>
(CY P)</w>
(C I
(B B
(7 5%)</w>
(2 1</w>
(1 8.
(1 ).</w>
(1 )
(0. 3
(-1 ),</w>
(+ )
z ine,</w>
yl- L-
withdre w</w>
week s;</w>
wal king</w>
w t)</w>
vul gar
vis ed</w>
ve /
ve )</w>
vaccin ation</w>
uter o.</w>
usion- weighted</w>
us sis</w>
us ate</w>
us -associated</w>
uromyc in</w>
ur ic
un successful</w>
un restrained</w>
un anesthetized</w>
u lography</w>
troubl es
triamcin olone</w>
tri ple
tri phosphatase</w>
tri az
tremor s,</w>
treatment )</w>
tre t
tret ino
transi t</w>
transcri p
trans mitted</w>
tract .</w>
trac tion</w>
topir am
tizan idine</w>
tion /
ti p</w>
thereafter ,</w>
therap y-induced</w>
ther .</w>
testoster one,</w>
ter s,</w>
ter med</w>
ter -
ten d</w>
tech ne
te d
tax an
tampon ade</w>
ta ins</w>
t ly.</w>
synap tos
symmetr ical</w>
susp ect</w>
supras pinal</w>
supplement s.</w>
subst rates</w>
subst ance
sub sets</w>
ston es,</w>
stit uting</w>
ster nal</w>
stell ate</w>
spro ut
spec ulated</w>
spec ies,</w>
spe ech
sol itary</w>
smok ers.</w>
sludg e</w>
significant ).</w>
side s,</w>
shap ed</w>
seroton in-
sec )</w>
se arch
sarcom as</w>
s.c .).</w>
s. go
rota rod</w>
ri a,</w>
restra in
reser p
relap sing</w>
regurgit ation.</w>
regul ar
refract or
recur ring</w>
recogn i
recipi ents,</w>
reas ,</w>
re ward</w>
re model
re flux</w>
raph e</w>
rap am
raclopri de</w>
r in,</w>
r ar
quetiap ine.</w>
propi on
progest ogen</w>
princip ally</w>
prescri bed.</w>
pre- test</w>
prazos in.</w>
poly ethylene</w>
pi v
physi ology</w>
phy to
phospho inositi
phosphat ase,</w>
phenotyp es</w>
phenel zine</w>
phen id
phen ad
ph as
pg/ ml</w>
peroxid ation.</w>
pentylenetetraz ol-induced</w>
penetr ation</w>
pem ph
pathw ays,</w>
paroxet ine.</w>
palli ative</w>
oxidi zed</w>
oxal ate</w>
over flow</w>
out patients.</w>
ot subo</w>
ot ox
osalic ylic</w>
os ity</w>
ori es,</w>
organ s.</w>
ophthalm op
op ini
op ac
onco log
on om
on itrate</w>
on -induced</w>
ol e.</w>
of ovir</w>
occur ,</w>
oc ol
o- called</w>
o himb
normal ized.</w>
non- diabetic</w>
non- NMDA</w>
nitrogen ,</w>
ni ff
nephro toxic
nat urally</w>
n ine
myoglob in
my ocytes.</w>
must ine</w>
mu g</w>
mon onitrate</w>
mode stly</w>
mitochondri a.</w>
mit otic</w>
mirta zap
mg/kg/ day.</w>
mg/ day;</w>
meth oxamine</w>
medull a.</w>
medi um-
mc g/
manipul ations</w>
malar ia.</w>
m ad
lute inizing</w>
loxac in.</w>
loxac ill
locomo tion,</w>
litter mat
lic king</w>
lib it
li ves</w>
levodopa ,</w>
leu prolide</w>
length ening</w>
leg ic</w>
lea f</w>
le aves</w>
lac ked</w>
it y).</w>
ir rel</w>
investig ates</w>
intest ine</w>
intent -to-treat</w>
intensi fied</w>
inst ability</w>
injec tion)</w>
initi ate</w>
infu sional</w>
in-of- four</w>
in- hospital</w>
in es.</w>
import ant.</w>
implic ations.</w>
il ity,</w>
ic l
hypother mia,</w>
hyponat raemia</w>
hypom ania</w>
hyperten sion:</w>
hyperlipide mia,</w>
hype re
hydrox y</w>
hydro lysis</w>
hydro cephal
hydr alaz
hyd anto
hy pos
hy al
hind limb</w>
high er.</w>
haemo dynamics</w>
haem olysis</w>
group :</w>
gross ly</w>
gri p</w>
granulomat osis.</w>
grad u
gk 1
gen der
g -
function ing.</w>
fru sem
follic ular</w>
flan k</w>
fin aster
fif ty-
faz od
factor ial</w>
f ai
exec utive</w>
excit otoxic</w>
ex foli
estro genic</w>
ere s</w>
equili brium</w>
enzyme- linked</w>
endothel in</w>
endoc annabin
ence :</w>
encapsul ated</w>
en cainide</w>
elim in
elev ation.</w>
eigh t-
effec tiven
echocardio grams</w>
ech o</w>
e min
e "</w>
drug -associated</w>
dou bled</w>
dose- dependent,</w>
distribu tion,</w>
distingu ished</w>
dismut ase,</w>
discus ses</w>
discharg e,</w>
dis proportion
dis position</w>
differenc es.</w>
di git</w>
des flurane</w>
derivati ves,</w>
der gic</w>
deple tion,</w>
demograph ics,</w>
decreas e.</w>
decompens ated</w>
dec ided</w>
dec ade</w>
de mic</w>
dang er</w>
crani otomy</w>
countri es.</w>
cortico ster
contraceptiv es,</w>
contrac tility.</w>
continu ous-
cont amin
conjunc tiv
conf used</w>
comparis on.</w>
commerci ally</w>
comm is
com ycin</w>
col itis.</w>
cohor t.</w>
coca ine-</w>
co- administered</w>
clo b
clob az
clinic ally.</w>
cl usion</w>
cimetid ine,</w>
chole lithiasis</w>
chlorprop amide</w>
chlor thal
ch i</w>
cere bri
cell -
cefot ax
cef tazidi
carcin ogen
carbox ylate</w>
capill aries</w>
c ations</w>
c at</w>
c am
bupropi on.</w>
bu met
bronch opulmonary</w>
bridg ing</w>
break down</w>
bor der</w>
block er.</w>
biv olol</w>
beta 2</w>
benzodiazepin es.</w>
behavi orally</w>
bacter io
b oun
avoide d.</w>
atroph y,</w>
ate /
at ab
asymptom atic.</w>
asthen ia</w>
assum ption</w>
applic ation,</w>
ap noea</w>
ap ir
anxi oly
anti- epileptic</w>
an op
am ine-treated</w>
allograf ts</w>
all yl
al :</w>
aggrav ates</w>
ag astr
aeros ol</w>
adduct or</w>
ad ducts</w>
ad d-
acet ate.</w>
accumul ation.</w>
accoun ting</w>
acc ru
[35S]TBP S</w>
Z n
Y ohimb
V T,</w>
V T)</w>
V L
Un der
U G
Treat ment
Thirty- four</w>
TUNE L</w>
Strept ozotoc
Stim ulation</w>
Sign s</w>
Sensi tivity</w>
SE NT
R- 27
R it
R ac
R 1</w>
Pot enti
Per fusion</w>
PTH r
PC B</w>
P- 450</w>
P ituitary</w>
P S
P M
P CA</w>
Opio id</w>
NS .</w>
Myoclon us</w>
Minoxidi l</w>
Mas sive</w>
MTX .</w>
M id
M ain
M CA
Log istic</w>
L-NAME ,</w>
L ov
L 2</w>
L );</w>
K ),</w>
Ital ian</w>
Intra -
Initi ally,</w>
Inf arc
Im mediate</w>
III B</w>
Hodg kin</w>
Haloperid ol-induced</w>
H US
G E</w>
G AD</w>
G 2</w>
Forty- eight</w>
Fl ecain
F V
Eigh ty</w>
ED .</w>
EC G.</w>
EAC A</w>
E B
Dex medetomidine</w>
DB S</w>
D atab
D :</w>
Colchic ine</w>
Children 's</w>
Chemo therapy</w>
Ca(2+ )-
CT .</w>
COM T</w>
CN U
CI )</w>
C oma</w>
C hem
C TR
C D)</w>
C 1</w>
Br d
BD 10
B re
B DNF</w>
Associ ated</w>
Antin ociceptive</w>
An aly
Alter n
ATP ase,</w>
AR F.</w>
AL L</w>
AC .</w>
A I</w>
A A)</w>
A -treated</w>
9 8
9 2%</w>
7. 2</w>
7 8%</w>
7 6
7 2%</w>
7 1%</w>
6, 7-
6 8
6 1%</w>
58 26
5. 0
5 9%</w>
5 2
48 6</w>
4 8.
4 30</w>
4 3.
4 3-
3 9%</w>
3 8-year-old</w>
3 5-
200 7</w>
20 %,</w>
2. 7
2 9-year-old</w>
2 70</w>
2 3,</w>
2 2
2 1-year-old</w>
19 ).</w>
16 7</w>
16 .</w>
13. 5</w>
11. 8</w>
10 %.</w>
1. 7%</w>
1. 6%</w>
1,25- (OH)2D3</w>
0.00 3).</w>
0. 19</w>
.000 1).</w>
-1, 3-
-1 3
- J
- 0.
, 8
(p H</w>
(P E)</w>
(P A
(ISO )-induced</w>
(IS O)</w>
(IO P)</w>
(E T
(C a
(C K)</w>
(C F
(B UN
(ATR A)</w>
(A ED
(7 0</w>
(2 3%)</w>
(1 5-
(1 3%)</w>
(0.0 1</w>
(0. 15</w>
( max
( groups</w>
( especially</w>
( LT
zaf ib
yclin es</w>
work- up</w>
wor k,</w>
wi der</w>
well- established</w>
well ing</w>
w /
ven tional</w>
vasospas m,</w>
vas culo
val id</w>
un remark
un pleasant</w>
ultrason ography.</w>
ular- weight</w>
ul tr
ud itory</w>
u sions,</w>
tum or
tubul es,</w>
trun k</w>
troubles ome</w>
tro glitazone</w>
trau ma,</w>
transplant ation:</w>
trabec ular</w>
ton gu
to phore
time ly</w>
ti gh
thior idaz
thiopent al,</w>
theore tical</w>
ter ing</w>
tender ness</w>
te tro
te ,</w>
t ari
t adal
synergis tically</w>
susp ended</w>
struct ured</w>
stri ps</w>
stilbestro l</w>
stereotyp y,</w>
sten osis,</w>
st u
st ores</w>
st ated</w>
squ irrel</w>
sole us</w>
sleep -
simult aneously.</w>
sim ply</w>
seve re
ses ophageal</w>
sensi tivities</w>
seizures ;</w>
seizures :</w>
scal p</w>
s o-called</w>
s a</w>
ry anodine</w>
ro si
ro pivaca
ri l
retro peritoneal</w>
ren sic</w>
remo ph
relax ation.</w>
reache d.</w>
reac tion
re- exposure</w>
re produced</w>
rate- pressure</w>
rate /
rate )</w>
ram ad
rac e</w>
quantit ated</w>
pyri midine</w>
pyrex ia</w>
pyl ori</w>
pros thetic</w>
propylthio urac
prop oxy
proble ms,</w>
pro enkephalin</w>
prepar ations,</w>
pract olol</w>
poly uric</w>
pneumonia e</w>
plaqu e</w>
pic ardi
phosphor us</w>
phosphon ates</w>
phenylpropanol amine.</w>
phenylephr ine,</w>
phenomen on,</w>
phen olic</w>
pharmac y</w>
peroxid ase,</w>
perio ds,</w>
per mitted</w>
patient ),</w>
path ologically</w>
path ogenesis.</w>
pare sis,</w>
pal sy.</w>
pa i
p H,</w>
oxygen .</w>
oxygen ,</w>
over doses</w>
outcom es,</w>
ouabain .</w>
osin ophil</w>
osar com
optim um</w>
oper ations</w>
oper ation,</w>
om e-
olog ist
ocyto sis.</w>
ob st
ob iliary</w>
nor mother
non- treated</w>
non- fatal</w>
non toxic</w>
non pregnant</w>
nigh t
ng/m L.</w>
nevir apine</w>
nalox one-
na ph
n ings</w>
n ar</w>
n ACh
mul tiv
muc ous</w>
mox on
morph ology,</w>
mono aminergic</w>
molec ular-weight</w>
mobil ization</w>
mo tivation</w>
ml/ kg</w>
mir ro
min ority</w>
mild- to-moderate</w>
mil rin
microg/kg/ min</w>
mg/kg );</w>
methamphet amine,</w>
meth icillin</w>
mes olimbic</w>
mes artan</w>
mer its</w>
medi um.</w>
me ,</w>
mas s,</w>
malai se,</w>
los ing</w>
loc i</w>
lobe m
limit ations</w>
li ability</w>
leuk open
lat ency,</w>
lamivud ine,</w>
lac king.</w>
l um
kg(-1 ).</w>
kg -1.</w>
ket anserin</w>
k a
je jun
inv ari
intraperitone ally)</w>
interven tion,</w>
interac tions,</w>
inst ance</w>
insipid us,</w>
infiltr ation,</w>
inf antile</w>
indo l</w>
ind u
in ib
impair ing</w>
im p
if ied.</w>
identifi ed,</w>
id ine
ici ally</w>
hyperkal emia.</w>
hyper thyroidism.</w>
hyper plastic</w>
hyper kinetic</w>
hydro ly
hot- plate</w>
hom ogene
hind paw</w>
hemat opoi
heat -
health y,</w>
he rent</w>
he re.</w>
hazard ous</w>
haemodi alysis</w>
h arm</w>
gy naec
guan osine</w>
group ed</w>
griseofulv in</w>
glucose- 6-
gi ant</w>
gemfibro z
furosem ide-induced</w>
ful l-
frequ ently,</w>
frequ ent,</w>
four ,</w>
form ulated</w>
fluoroquinol one</w>
flav on
fl at</w>
fir st,</w>
feno fibrate</w>
f ex
f ear
f air
exist ent</w>
exencephal ic</w>
evalu ates</w>
et es</w>
establ ishment</w>
ery throm
erv ical</w>
er m
epidemio logic</w>
encoun te
en sis</w>
en il</w>
elic iting</w>
electrophysi ology</w>
electromyo graphy</w>
effor ts</w>
eff ac
ed ed</w>
ec tiveness</w>
e tra
drug- seeking</w>
dro perid
dor sol
disease- free</w>
diseas ed</w>
disc rep
dis par
diazepam -
diameter s</w>
detail s</w>
derm atitis,</w>
dem eclo
deliver y,</w>
death s,</w>
de son
dan azol
d ronedarone</w>
cyprohept adine</w>
cy sts</w>
cros ses</w>
cran io
cr ude</w>
cough ,</w>
cortic otropin-releasing</w>
convul sion.</w>
contribu tions</w>
consol id
consec u
conjunc tivi
concentr ated</w>
compli ance.</w>
complex ity</w>
complex es.</w>
complex ,</w>
complain t</w>
com pres
cocaine- kindled</w>
coca ethylene</w>
coagul ation.</w>
co st
co existing</w>
clopidogrel .</w>
cl amp
circum feren
cinacalce t</w>
chol angi
chlorpromaz ine-induced</w>
chemotherapy- naive</w>
challeng ing</w>
cep tion</w>
celecoxi b,</w>
cause s,</w>
cat ar
carrageen an</w>
carcin ogen</w>
car til
capsul e</w>
cannabin oids</w>
canc ers,</w>
cab ergoline</w>
c ue</w>
c rest</w>
bromocript ine,</w>
bre ak</w>
brady kine
bod y.</w>
bis phosph
bind ing.</w>
bim atoprost</w>
bepri dil</w>
behaviour s</w>
behavior al,</w>
be ,</w>
balloon ing</w>
autis tic</w>
atten tion.</w>
atten tion,</w>
at ing,</w>
asi a.</w>
asc icul
are sis</w>
architect ure</w>
ar s</w>
appro val</w>
applic able</w>
apne a.</w>
aper ta</w>
antioxid ant,</w>
antibio tic,</w>
anti tumour</w>
anti tuberculous</w>
anti eme
anthracyclin es.</w>
analgesic ,</w>
anaesthe tics</w>
an s,</w>
alpha 7</w>
alpha 1-
allevi ating</w>
albumin uria,</w>
akathi sia,</w>
agit ated</w>
adrenoceptor- mediated</w>
administr ation;</w>
adi pose</w>
aden ine</w>
addic tive</w>
acup uncture</w>
acromegal y</w>
accumul ate</w>
accomp any</w>
ac in.</w>
ac counts</w>
abdom en</w>
a kinesia</w>
Z P</w>
Wor ld</w>
Wh it
WB C</w>
W est</w>
V T.</w>
V AN
V ),</w>
URE :</w>
U PD
U L-
Th yro
Th i
T ardive</w>
T S
T AS
Sm all</w>
Sle ep</w>
Sec on
SC r</w>
Repor ted</w>
R T-
Pro found</w>
Post operatively,</w>
PTZ -induced</w>
PRO C
PROC ED
PRE SENT
PAC AP</w>
P D)</w>
OUT CO
OUTCO ME
O phthal
O S</w>
O CD</w>
O ),</w>
Ner ve</w>
NS F</w>
N ).</w>
N (G
N(G )-
Mo vement</w>
Mechan ical</w>
MEASURE :</w>
MA .</w>
M ac
M E</w>
Li -treated</w>
L or
Kap lan-Mei
K d</w>
K 1</w>
IT S</w>
II IN
Heal th
HPL C</w>
H :</w>
H (2)
Ger man</w>
Gentam icin</w>
G ol
Forty- five</w>
Fir st</w>
Fifty- two</w>
F urosem
F r
F ab</w>
Echocardi ography</w>
EP I</w>
ELIS A</w>
Diltiaz em</w>
Di ethyl
Det ection</w>
D yst
D os
Con gestive</w>
Cerebro spinal</w>
Cal c
CP .</w>
CG I-
CCK- 8-
C u</w>
C italop
C erebellar</w>
C D-
C CNU</w>
Behavi oural</w>
B ene
Azathiop rine</w>
Atten uation</w>
AT 1</w>
AL A-
AD .</w>
AC ,</w>
A(2A) R</w>
A uditory</w>
A ri
A part</w>
A b</w>
A F-
9. 1</w>
9 4%</w>
8 8
8 2%</w>
8 0,</w>
7 9
6 -induced</w>
524 66</w>
50 ),</w>
5-HI AA</w>
5 H-
5 6.
5 6,</w>
5 3
5 1-year-old</w>
30 ).</w>
30 ),</w>
3. 3%</w>
28 ).</w>
24 7</w>
23 2</w>
2, 4-
2 8)</w>
2 50
2 +
198 8</w>
13 1</w>
12 5,</w>
12 ),</w>
10- 20</w>
1 1),</w>
0.00 2)</w>
0.0 3),</w>
0. 25,</w>
0 2</w>
-1 00
(i. t.)</w>
(V AS)</w>
(PGE 1)</w>
(N A
(DO X)</w>
(CB F)</w>
(AN CA
(A ra-
(8 6%)</w>
(8 5</w>
(2 2.
(14 )
(1 8%)</w>
(1 7
( non
( maximum</w>
( mGluR
( inter
( after</w>
" ,</w>
yri dox
yohimb ine.</w>
yl ,</w>
wh it
we ster
wester n</w>
water- soluble</w>
war d.</w>
wall s</w>
wa reness</w>
w est</w>
w as,</w>
w ake</w>
volunte ers,</w>
vitamin osis</w>
viol ent</w>
vide o-
vi anolic</w>
ver atro
vast ating</w>
valv ulopathy</w>
us ;</w>
ursodeoxychol ate</w>
uro lithiasis</w>
up- regulated</w>
up ,</w>
unit ,</w>
under taken.</w>
unde restim
unc ular</w>
um /
u odenal</w>
two- dimensional</w>
tri ed</w>
tra in-of-four</w>
toremif ene</w>
top o
toler ability.</w>
tissu es,</w>
timo lol.</w>
timo lo
til mic
tico ag
ther mo
tetrac hlor
t -term</w>
synerg ism</w>
survi ved.</w>
sugg es
stereotyp y.</w>
sten osed</w>
steato hepatitis</w>
stain ing,</w>
sta phylococcal</w>
st able.</w>
small -
simul ated</w>
sider oblastic</w>
si veness</w>
sen sus</w>
secon d,</w>
se en,</w>
samp le.</w>
saf e.</w>
s niff
s ?</w>
rhyth ms</w>
rhyth mic</w>
reve aling</w>
resuscit ated</w>
resum ed</w>
restless ness,</w>
remoxi pride</w>
relationshi p,</w>
recurren ces</w>
re feren
re construc
qu il
qu arter
psor iasis.</w>
protein ur
prophyl ac
prop yl</w>
produc ts.</w>
proble m,</w>
prob able.</w>
previ ously,</w>
pregab alin</w>
predomin ance</w>
pre operatively</w>
pow der</w>
post- transplant</w>
pneumon ia,</w>
placebo )</w>
pilsi cainide</w>
pide mio
pi al</w>
phleb itis,</w>
phenotyp ic</w>
pert ussis</w>
per phenazine</w>
per ia
pentoxif ylline</w>
penicill amine.</w>
pemph ig
partic les</w>
parad oxic
paracetam ol.</w>
para ventricular</w>
pamid ronate</w>
pal mit
pai red-
p eptic</w>
oxantr one</w>
ox ine</w>
oto acoustic</w>
oscop ic</w>
os up
org as
or )</w>
open- angle</w>
one- half</w>
olig onucle
oli pidemic</w>
ol us</w>
off ic
ocyto sis,</w>
occul t</w>
occu pati
occl usion,</w>
obes ity,</w>
o esophageal</w>
o athe
o )</w>
numb ness</w>
nomifens ine</w>
neuro -
ner ve,</w>
nephro lithiasis.</w>
neph rectomy</w>
nafc illin</w>
n ally</w>
myosi tis.</w>
myasthen ic</w>
mus cle
morb idity.</w>
mor ic
mono amine-
mmHg ).</w>
ml/ 100</w>
mitochondri a,</w>
minoxidi l.</w>
midazol am
micrograms/ m
mi anserin</w>
mg/kg )-induced</w>
mg/d L).</w>
metrex ol</w>
methohex ital</w>
methemoglob inemia</w>
met al</w>
mesen chymal</w>
mening eal</w>
medic ally</w>
me pivaca
maxim um-
manifest ations,</w>
mandat ory</w>
magnit u
macroph ages.</w>
lo metrexol</w>
lithium /
lig and
lidoca ine-
li ved</w>
leuk openia,</w>
leu kin
leg .</w>
left- sided</w>
lansop razol
kan amycin</w>
k now</w>
iz otan</w>
itsel f,</w>
item s</w>
intub ation,</w>
interfer ing</w>
insomn ia.</w>
inform ation.</w>
infarc tion:</w>
in version</w>
in completely</w>
import ant,</w>
import ance.</w>
imipen em
il it
il -based</w>
icter ic</w>
ia ).</w>
hypox emia</w>
hypo physi
hyperplasi a.</w>
hyper phosphat
homocyste ine</w>
hist ology.</w>
hist ology,</w>
hepar in-associated</w>
hemat omas</w>
heigh ten
h id
h ence</w>
glut eth
gluco se.</w>
gluc onate</w>
gen otoxic</w>
gadodi amide</w>
ful l
fre e-
fract ures</w>
fol d.</w>
fluc loxacillin</w>
flo sequinan</w>
flecain ide.</w>
first -dose</w>
filam ents</w>
fenflur amine-
fascicul ations.</w>
facilit ating</w>
f rank</w>
f osin
f lox
f issu
ext ent,</w>
expect ancy</w>
estradi ol,</w>
essenti al.</w>
epomedi ol</w>
epide mic</w>
eosinophil s</w>
entec avir</w>
ent an</w>
endotheli um-
endocardi tis</w>
ell s</w>
electroencephalo graphy</w>
educ tal</w>
educ ation</w>
ec tions</w>
e osinophil</w>
e asy</w>
duc ts.</w>
dorsol ateral</w>
diseas e;</w>
discrimin ative</w>
dis playing</w>
diplop ia</w>
dimen sions</w>
digox in,</w>
differen ce.</w>
di l,</w>
det ection.</w>
der ly</w>
depend ed</w>
deoxychol ic</w>
deoxy glucose</w>
densi ties</w>
demograph ic,</w>
delta 9-
deline ate</w>
decreas e,</w>
de vastating</w>
datab ases</w>
dac arbazine</w>
d "</w>
cytos keletal</w>
cur ative</w>
cu e-induced</w>
cortis ol,</w>
convuls ants</w>
contrac tions.</w>
contrac ted</w>
contrac epti
consecu tively</w>
conflic ting</w>
com promising</w>
cohor t,</w>
cocaine- treated</w>
co- trimox
co- infected</w>
co vered</w>
clinic opath
cisplat in-based</w>
chromat ograph
cholester ol.</w>
children 's</w>
chec ked</w>
cess ation.</w>
cef uro
cathep sin</w>
categor ized</w>
catechol amine-induced</w>
catabol ism</w>
cas c
casc ade</w>
carb en
capac ity.</w>
candes artan</w>
c ister
but yn
bu deson
br ation</w>
bl astic</w>
bio logic</w>
beta-carbol ine-3-
beta- 1</w>
beats/ min,</w>
be hind</w>
barri er.</w>
barbitur ates</w>
b y-
b li
b end
aver age,</w>
aten olol.</w>
ate ),</w>
at om
aripiprazol e.</w>
ari s.</w>
ar ms,</w>
appl ying</w>
antipy re
antigen ,</w>
anticoagul ated</w>
angio edema,</w>
anesthe tic.</w>
anesthe tic-induced</w>
anesthe tic,</w>
an ec
an ast
amisul pri
amik acin</w>
am s</w>
alu min
alpha 2</w>
all- cause</w>
all er
alend ronate</w>
alcoh ol.</w>
al an
al .,</w>
agonist -induced</w>
age- dependent</w>
adriamyc in,</w>
adrenal ectomy</w>
administr ated</w>
aden osis</w>
ad op
act oid</w>
acet ate,</w>
accumben s.</w>
ac ri
ac in,</w>
abor tion</w>
ab ated</w>
Y ,</w>
Vas o
V ol
Ul tras
T um
T ramad
T OF</w>
Stri atal</w>
St ar
Specific ally,</w>
Spec ific</w>
Shor t-term</w>
Sevent y</w>
SER CA
S- adenos
S (+)-
Rest ing</w>
Relationshi p</w>
R ing
R I</w>
Qu inine</w>
Progres sive</w>
Plac e
PP E</w>
PN D</w>
PG s</w>
PC P</w>
PA NS
PA F</w>
P uromycin</w>
P -treated</w>
Ouab ain</w>
O LT</w>
O D</w>
O CT</w>
Norm al</w>
NT E</w>
My ocardi
Mod ulation</w>
Minocycl ine</w>
Micro scopic</w>
Mechan ism</w>
Man ia</w>
MR I.</w>
M rp2</w>
M odi
M ex
M en
M N</w>
M IT
M C</w>
M C
Lov astatin</w>
LT ,</w>
LP S</w>
LD L-
L ind
L E)</w>
K 2</w>
J .</w>
Investig ations</w>
Intra operative</w>
Individ ual</w>
In j
In dependent</w>
Identi fication</w>
IV -
IL- 1</w>
I P),</w>
I :</w>
Hypoten sive</w>
Hyp onat
HIV /
HC Q</w>
HA ART</w>
H ex
H R,</w>
H A)</w>
GR 13
GR13 89
GABA- ergic</w>
G GT</w>
Forty- two</w>
F B
Experi ence</w>
Eth anol</w>
Eth ambut
Estro gen
Engl ish
Electro encephalo
EM LA</w>
E pidemio
E ligible</w>
E .
Double-bl ind</w>
Dig oxin</w>
Diab etes</w>
Di etary</w>
DTI C</w>
DNA .</w>
DE N</w>
Cor relation</w>
CON TE
CH F,</w>
CF R</w>
C er
C elec
C are</w>
C B</w>
BP C</w>
B ro
B raz
B ic
B en
Ari pi
An ticoag
Amphet amine</w>
Amiodar one-induced</w>
AM L</w>
A wareness</w>
9. 6</w>
9 3%</w>
7. 9</w>
7 5,</w>
7 4%</w>
6- keto-
6 6-year-old</w>
6 6-
6 4
6 -</w>
5-amin osalicylic</w>
4 8-year-old</w>
4 5-
30 %,</w>
3 00,</w>
200 5</w>
200 4.</w>
200 3,</w>
200 2.</w>
20- year-old</w>
20 ),</w>
2- h</w>
2 1),</w>
198 7</w>
17 2</w>
15 1</w>
15 /
14 ).</w>
13 ),</w>
12- month</w>
12 /
11 %,</w>
10- fold</w>
10(- 9)</w>
10(- 6)</w>
10 ;</w>
1 1/
1 -10</w>
00 0
0. 3%</w>
0. 11</w>
. ;</w>
-to- beat</w>
-1 5</w>
-1 1</w>
(control )</w>
(WK Y)</w>
(S OD)</w>
(P O
(P =</w>
(NSCL C).</w>
(N D
(M C
(L-NAME )</w>
(L DH
(IN R)</w>
(C T
(C )</w>
(A V)</w>
(7 0%)</w>
(6- OHD
(6 0%)</w>
(5 8%)</w>
(3 8.
(2 9</w>
(1 9.
(1 5
(0. 3-
' ,</w>
zol e,</w>
yel low</w>
x am
wri thing</w>
withdraw n,</w>
weigh t).</w>
we re,</w>
war ning</w>
war m
w all,</w>
vulgar is</w>
vul g
viol ence</w>
vincrist ine-treated</w>
vic tim
verm ectin</w>
ver ify</w>
vect or</w>
ve in.</w>
vasoconstric tive</w>
vancom ycin.</w>
val er
vag us</w>
uro th
uro logic</w>
up ward</w>
up or</w>
unexpect edly</w>
understo od,</w>
um :</w>
ultr af
trop ane</w>
tremulo us</w>
transf usion.</w>
trans duction</w>
ti schem
ti line</w>
ti ght</w>
thromboembol ism,</w>
thromb olysis</w>
therap ies,</w>
th in
tetrahydrocannabin ol</w>
tetrac a
terbutal ine.</w>
tacrolim us,</w>
tachy arrhythmias.</w>
t ations</w>
summar ize</w>
summ ation</w>
subcutaneous ly)</w>
sub convulsant</w>
stric tly</w>
strept oz
strategi es.</w>
ster ic</w>
star ted,</w>
standard -dose</w>
st rom
st em
st age.</w>
spin al-
sph ing
spec ified</w>
spas ticity</w>
spas m.</w>
sp ind
somn ambul
sleep ,</w>
sion ).</w>
single-bl ind,</w>
similar ,</w>
si ll
sex -matched</w>
ses sion.</w>
serocon ver
sequ entially</w>
self- limited</w>
sc ol
scol io
sar alas
s ent</w>
ro flu
rifamp icin.</w>
reversib ly</w>
reticul ata</w>
responder s.</w>
resol u
res sion</w>
regurgit ation,</w>
rect us</w>
record ings.</w>
pyruv ate</w>
pyri mid
pul sed</w>
pul se
psychostimul ant</w>
propyl ene</w>
prim ed</w>
premat urely</w>
precur s
pre pulse</w>
post marketing</w>
posi tive
pl au
phosphoinositi de</w>
phosph ate-
phenylbut az
phen cycl
ph ere</w>
perfor ation</w>
per oneal</w>
pepti dergic</w>
pem oline</w>
patient ).</w>
parval bumin</w>
parathyro id
param etric</w>
paraly sis,</w>
palpit ations</w>
pac ing.</w>
p. m.</w>
p ame
ox o
ox ide
ox amine.</w>
oti tis</w>
ot olaryng
orig in,</w>
organ isms</w>
or n
opioid s,</w>
one /
on azole.</w>
om es.</w>
ol l
ol d.</w>
off set</w>
od ular</w>
occur s.</w>
occup ancy</w>
occa sions,</w>
ob ac
o s</w>
num er
not ed,</w>
nit rates</w>
nigra .</w>
nigra ,</w>
neuron es</w>
ner 's</w>
necess ity</w>
ne fazod
nat ure.</w>
naprox en,</w>
n ad
myocardi tis,</w>
myel in
mus ,</w>
mucos a.</w>
monitore d,</w>
modi um</w>
mod al</w>
moc lobem
mm ,</w>
mm )</w>
ml/ min,</w>
micro vesicular</w>
mg/d L)</w>
methyl ation</w>
met am
mer captop
mechan o-
measure ments,</w>
mar k</w>
man n</w>
main tained.</w>
mac aqu
mGlu R</w>
mEq/ L.</w>
m s)</w>
m ist
m Glu</w>
m ;</w>
low- osmolar</w>
low- molecular-weight</w>
low- grade</w>
lor acar
lo op
ll ect
levo thyroxine</w>
lep ir
labell ing</w>
lab our
l a
j ud
iti n</w>
isom erase</w>
irrit ability,</w>
ion ized</w>
involve ment,</w>
intub ated</w>
intran e
intermit tently</w>
interleuk in</w>
ine mic</w>
index .</w>
ind ole
incontin ence.</w>
include d:</w>
in- 2-
in s
in osine</w>
implic ating</w>
immun omodul
ime l
imag es.</w>
ile um</w>
ide a</w>
ide -treated</w>
hyperparathyroidis m.</w>
hyper ton
hyper polar
hyper glycemic</w>
hyper coagul
hormon es.</w>
hi m</w>
hex y
hex idine</w>
hemo static</w>
hand -
ha ir
h in
h and.</w>
h ;</w>
great er.</w>
glutathi one,</w>
glomerul us</w>
gener ation,</w>
gall -
g/m 2/
g az
g ate</w>
fur azol
four .</w>
fo rensic</w>
flu id,</w>
fiel d.</w>
fi ed.</w>
fe ar</w>
favor ably</w>
fav our</w>
far ,</w>
famili ar</w>
famil ies</w>
fair ly</w>
ey es,</w>
exc ret
examin ations.</w>
ex ud
ex pon
ethyl ]-
ethinylo estradiol</w>
ethinylestradi ol</w>
estim ating</w>
ery the
epirub ic
ep tive</w>
ep s</w>
end or
encephal y</w>
en ec
empt ying</w>
electrophore sis</w>
electrocardio graphy</w>
effect s;</w>
effect s:</w>
ec tr
each ).</w>
dyses thesia</w>
dy l</w>
drug ;</w>
dro ple
drain age</w>
doxorubic in/
double-bl inded,</w>
dop amin
dom ains</w>
diure tics,</w>
disorient ation</w>
discharg es.</w>
dis charge
dis cer
differen ce,</w>
di um</w>
detect ed,</w>
des at
dermatomyosi tis</w>
degener ating</w>
defic it.</w>
deep -
dec lining</w>
dec ay</w>
de pot</w>
de ad</w>
dam ental</w>
dam ages</w>
d ine,</w>
d ated</w>
cyclospor ine.</w>
cyclo -
cut ane
cross- reactivity</w>
cros sed</w>
coun ted</w>
cor respond</w>
conveni ent</w>
consider ations</w>
consi st</w>
conjunctiv al</w>
conf usional</w>
conduc t</w>
concer ned</w>
complain ts.</w>
compens ate</w>
commun ity-
combin ations.</w>
com at
clo su
clin ics</w>
cl es.</w>
cis- RA</w>
chlor phenir
chlor ide.</w>
childho od.</w>
chem opre
character ized.</w>
ch ing,</w>
ch ance</w>
cent ro
cent ers.</w>
cef am
cefam and
cataly tic</w>
cardio vascular,</w>
car mo
ca val</w>
c ages</w>
bromocript ine-induced</w>
bo x</w>
ble ph
bl ac
bin ant</w>
bi us</w>
beta- CC
benzo [
bend roflu
beg in</w>
be zafib
be long
be l
bal ance,</w>
autoph ag
auth or</w>
ate ;</w>
atax ic</w>
astemiz ole</w>
ari um</w>
ara- C</w>
ar in</w>
apparat us</w>
ano rec
ane )</w>
analy ses,</w>
an k
alpha-methyl dopa.</w>
allevi ation</w>
al oxif
al c
aggres sion</w>
after load</w>
after discharge</w>
adv ance
addres sed</w>
addic ts.</w>
ad duct</w>
acti ve.</w>
acromegal y.</w>
ac compl
ac cess
abrupt ly</w>
a prot
a PT
[ CI,</w>
Z R</w>
Y .</w>
Wil c
W R-27
V ir
V inorelbine</w>
V CM
U nified</w>
Trimeth op
Toxic ities</w>
Tourette 's</w>
TE )</w>
TD P</w>
Stat es,</w>
St ress</w>
Shor tly</w>
SSR I
SCH 23390</w>
S um
Rem ifentan
Reg ist
Recom binant</w>
Rec ently</w>
R at</w>
R )-
Q R
Q ,</w>
Propylthio uracil</w>
Pro cain
Pre dn
Post mortem</w>
Phenyl propan
Path ological</w>
PRESENT ATION:</w>
PO 2</w>
PE G-
P- glycoprotein</w>
P T</w>
P -1
Ol der</w>
O (2)</w>
Nim esul
Na+, K(+)-ATPase</w>
N is
Min im
MATERI AL</w>
M er
Line zol
LVF X</w>
LM W
L-argin ine,</w>
L DA</w>
Kaplan-Mei er</w>
K CC
Isoniaz id</w>
Indin avir</w>
Increas e</w>
Im pair
IN )</w>
IL-1 beta</w>
IGF -1</w>
Hist ologically,</w>
Hippocamp al</w>
Haemo dynamic</w>
H T)</w>
H 3</w>
GABA (B)</w>
G c-
Flecain ide</w>
FK50 6.</w>
FANF T</w>
Euro pe</w>
En dom
El ectr
EC )</w>
E S
Diclofen ac</w>
Detail ed</w>
Delta 9-
De mo
D- 2</w>
Criter ia</w>
Col l
Coca ine-associated</w>
Coc E</w>
Co omb
Character ization</w>
Cat ech
Carbo platin</w>
Carbamazep ine-induced</w>
CS F)</w>
CONTE X
CN I</w>
CA D.</w>
C ;</w>
B y
B up
B le
B art
Analy ses</w>
An algesic</w>
Ag e,</w>
AZT -treated</w>
AS ).</w>
AR B</w>
AN OV
AL A</w>
AD P</w>
A v
9 2
8 th</w>
8 %;</w>
7 7-year-old</w>
7 3
6- di
6 6
6 5-
59 4</w>
50 %)</w>
5-HT (2)</w>
5- di
5 4.
5 %;</w>
4- 6</w>
4 7,</w>
4 5.
4 4-year-old</w>
3. 3%)</w>
3- mercapto
3 ',
25 6</w>
200 7,</w>
200 6.</w>
200 5.</w>
2- 5</w>
2 8-year-old</w>
2 7-
2 15</w>
19 1</w>
19 0</w>
17 1</w>
15 9</w>
14 th</w>
14 3</w>
13 .</w>
12 7</w>
11 ;</w>
1. 3-
1. 2-
1. 2%</w>
1 50,</w>
1 3-year-old</w>
1 0.0
0.05 );</w>
0.00 1);</w>
0. 45</w>
-1. 5</w>
-1 H-
-1 ;</w>
-1 8</w>
- 2-
(W H
(T T
(T P
(R )-
(PGE 2)</w>
(P< 0.001)</w>
(METH )</w>
(MD A)</w>
(L ID)</w>
(L ID
(IC 50</w>
(I P)</w>
(HU S)</w>
(HBs Ag)</w>
(HBe Ag
(G B
(G -
(D B
(CB Z)</w>
(A V
(50 ,</w>
(5. 0</w>
(5- 20</w>
(4 5%)</w>
(3 6</w>
(2 /
(1 25</w>
(1 0,</w>
(1 %)</w>
(0.0 3</w>
(0. 75</w>
( within</w>
% ])</w>
z ones</w>
ylestradi ol</w>
y rate</w>
weak er</w>
wal k</w>
w ol
w k,</w>
w av
voric onazole</w>
vis it.</w>
vehic le-
ve ;</w>
vasopress in.</w>
vasodilat or,</w>
v ine</w>
us -related</w>
urticar ia/
uro theli
ur ium</w>
uniform ly</w>
un ipolar</w>
ultras onic</w>
uc to
tu be.</w>
tro methamine</w>
tric ycl
tre tin
transi ent.</w>
tran quil
tox ins</w>
tor r</w>
ton 's</w>
to- severe</w>
time- course</w>
tigm ine,</w>
ticlop idine.</w>
ti ag
thio l</w>
the ade
th en,</w>
th emia</w>
ter t-
ter g
ten ance</w>
tel mis
te le
te ar</w>
tax ane</w>
tar tr
tachycardi c</w>
t es
t ;</w>
syst ole</w>
sulf oxide</w>
sugges tions</w>
streptoz oc
step- through</w>
spon dy
spi perone</w>
speech ,</w>
speci al
sp ect
sli t</w>
six teen</w>
situ ation.</w>
sirolim us-
sign alling</w>
sic k</w>
shrin kage</w>
shoul der</w>
shar ply</w>
ser ving</w>
ser ological</w>
sed -
scop y.</w>
sclero sis,</w>
scler osing</w>
sc an.</w>
satur ated</w>
satis fac
s kele
s gk1
rot ational</w>
ris o
ribavir in,</w>
rib onucle
reticulo cyte</w>
rest oring</w>
responsi ven
relie f.</w>
rel ations</w>
reci pit
rec ently,</w>
ras h.</w>
rar a</w>
radiolab eled</w>
radioimmuno assay</w>
rac em
rabb its,</w>
quetiap ine,</w>
quadri ple
pyridox al</w>
py el
pyel oneph
py e
pur inergic</w>
pul mon
pseudo ephedrine</w>
promis ed</w>
prolact in-
prolact in,</w>
produc ts,</w>
proces ses,</w>
proced ures,</w>
priv an</w>
pres ently</w>
prece de</w>
pre therapy</w>
prac tical</w>
pr o</w>
possib le,</w>
poly cy
plate a
piroxic am</w>
pin prick</w>
pic a</w>
perio d
perc enti
per iden</w>
peop le.</w>
pent agastr
pe liosis</w>
paralle l,</w>
par tum
paper ,</w>
paired- pulse</w>
pacemak er.</w>
p.o .).</w>
p 24</w>
oxy butyn
ox azepam</w>
over active</w>
oton ia</w>
osi 's</w>
orrh ag
or phenad
ong st</w>
oneuro tic</w>
omyc in-induced</w>
omon as</w>
obser ve
o sid
o pathy.</w>
nutri tion</w>
numb er,</w>
nucleoti des</w>
nortript yl
non convulsive</w>
nocicept or</w>
nocicep tion.</w>
nmol ),</w>
nitrofur anto
ng/m L,</w>
neurotransmis sion.</w>
neurolep tics,</w>
neuro developmental</w>
nel fin
necess ary,</w>
nec k,</w>
ne y</w>
nalbu phine</w>
n- 3</w>
n ation
myelosuppres sion.</w>
minut e)</w>
mini ature</w>
min i-
mill ilit
mil k</w>
mil k-alkali</w>
midazol am-induced</w>
microgram/ ml</w>
micro injected</w>
micro g.</w>
micro circulation</w>
mi befradi
mg/ min</w>
mg/ m</w>
method s,</w>
methad one,</w>
meth im
mes o
meperid ine,</w>
men orrhag
mediast inal</w>
medi um
me g
me dox
medox om
maximum- tolerated</w>
mariju ana</w>
main stay</w>
mac rom
mGluR 5</w>
mEq/ L)</w>
lymph oid</w>
lu k
lox y
lip id
lin es,</w>
ligh theade
lib id
leuc ocytoclastic</w>
lear ned</w>
le x</w>
le sion,</w>
l ings</w>
l essen
l es,</w>
l and</w>
kg(-1 ).
k ly</w>
iz er</w>
isoproteren ol-treated</w>
isoproteren ol-
ip ),</w>
intraperitone ally,</w>
intrad uodenal</w>
intrac ardiac</w>
interval :</w>
interac tion,</w>
inter ventricular</w>
inter leukin
inte lli
inte llect
insul in,</w>
institu tion.</w>
ing "</w>
infusion ;</w>
in noc
import antly,</w>
implic ated.</w>
implant able</w>
impl ying</w>
impair ment
immobil ization</w>
imipen em</w>
il )</w>
ifen sive</w>
id arubicin</w>
ic ity.</w>
ic a</w>
i. d.</w>
i gral</w>
hyponat remia,</w>
hypercholesterol emia,</w>
hyp olipidemic</w>
hydroneph ro
hour s).</w>
her ni
hemis phere</w>
he re,</w>
ham ster
haemorrh age.</w>
h aled</w>
gu ide</w>
glomeruloneph ritis,</w>
glomerul i,</w>
gli osis</w>
gener ic</w>
gener ating</w>
gen e.</w>
gaug e</w>
gar lic</w>
g odi
g ide</w>
frag ment
for sk
flu phenaz
fl atten
filam ent</w>
fic ation.</w>
fibrin olysis</w>
fenflur amine.</w>
fen bu
fatigu e.</w>
fall ing</w>
f loxacin,</w>
f ine</w>
exten ding</w>
expos ures.</w>
expl ains</w>
experi ence,</w>
exfoli ative</w>
exerci se,</w>
excret ory</w>
exc ised</w>
ex po
everolim us</w>
etomid ate,</w>
eti ology,</w>
ergot amine/
erec tions</w>
enzyme ,</w>
encephal ic</w>
ell ar</w>
eff usion,</w>
ect o
e.g .</w>
e gal
e NO
dyn es/
dro p
dose- dependent.</w>
diss ected</w>
direc tion</w>
differenti ating</w>
diagno sed,</w>
di valproex</w>
di e</w>
desmo pressin</w>
des loratadine</w>
der s.</w>
deple ting</w>
demonstr able</w>
defin ition</w>
de tail</w>
de position.</w>
de m</w>
de )</w>
dat e.</w>
dap tom
d- aspartate</w>
d- amphetamine-induced</w>
d a</w>
cyr rhiz
cu es</w>
crystall uria</w>
crav ing,</w>
coupl ing</w>
control )</w>
contra st-
contr ary</w>
continuous- infusion</w>
cong es
config uration</w>
comb ined,</w>
comat ose</w>
cogn iti
clinic ally,</w>
clind amycin</w>
cisplat in-
cis atracurium</w>
circul ation,</w>
chromos omal</w>
chore oathe
cholin omimetic</w>
cholang itis</w>
chol ine-
chlorothiaz ide</w>
chelat ing</w>
chang ed.</w>
ch on
cephalospor ins</w>
cells/ micro
cell s)</w>
ce fac
ce as
caspase- 3</w>
cardiotoxic ity:</w>
cardiom egal
carcin omas.</w>
ca ve
ca str
c ure
c ial</w>
c all</w>
bupropi on,</w>
buff er</w>
bu min
bot ulinum</w>
block age</w>
biolog ically</w>
beta- lactam</w>
beta 4</w>
benzo ate</w>
before .</w>
b es
az ithrom
az ido
autom atic</w>
atroph ic</w>
astro glial</w>
asthmatic s</w>
as )</w>
arboxyl ic</w>
aqu apor
apri de</w>
approxim ate</w>
applic ations</w>
appl ied.</w>
apar t.</w>
antigen -positive</w>
anticonvuls ants.</w>
analy z
ana emia.</w>
ana emia,</w>
an uria</w>
an hydr
an :</w>
an -treated</w>
aminoglyco sides</w>
amide )</w>
am ongst</w>
al istic</w>
agne tic</w>
agit tal</w>
advoc ated</w>
administr ation:</w>
adap tation</w>
acut e-
acne .</w>
acid :</w>
acetam ,</w>
access ory</w>
accent uated</w>
absor ption,</w>
a i</w>
W ol
Unex pect
Tre ated</w>
Thrombo sis</w>
Thirty- seven</w>
Testo sterone</w>
Test s</w>
Tem por
Td p</w>
TB I</w>
T NS
Seventy- five</w>
Se x</w>
ST S</w>
SN P-induced</w>
SIAD H.</w>
SH R,</w>
SE LEC
S wit
S NA
Reg istry</w>
Recom m
RV LM</w>
R ech
R apam
R aloxif
R U
R AMP
Pseud otumor</w>
Propylthio uracil-induced</w>
Plas modium</w>
Pilocar pine-induced</w>
Pent azoc
PTHr P</w>
PG F2</w>
PE .</w>
P an
P MS
P DA</w>
P B,</w>
P 400</w>
Otot oxicity</w>
Or g</w>
O T
Non steroidal</w>
Nitroprus side</w>
Neuro pathy</w>
Neur onal</w>
Na+ ,</w>
NT 69
NSAID s,</w>
NR H</w>
Myelo suppression</w>
Min or</w>
Micro injection</w>
Metoclop ramide</w>
Medic ines</w>
Man nit
Main tenance</w>
MA MP</w>
M en</w>
Long- Evans</w>
Lif e-
Le vetiracetam</w>
LI D
L- NOAR
L s</w>
L R
Kap osi's</w>
Inter view</w>
Individ u
In stead,</w>
Immun osup
IC 50</w>
Hor mon
High -
Here in</w>
He modi
HIT T</w>
HD ).</w>
Guillain- Barr</w>
Gc- globulin</w>
G d-
G al
Fran ce</w>
Fluoro -J
F orm
F ib
F K-
F F
English -
English- language</w>
Electrocardio graphic</w>
El derly</w>
Echocardi ographic</w>
EC T</w>
EC S</w>
E 2-induced</w>
Dose- response</w>
Disor ders</w>
DOX ,</w>
DMT U</w>
DE NA</w>
D MI</w>
Cy A</w>
Con ventional</w>
Coch ran
Co administration</w>
CONTEX T:</w>
CK- MB</w>
C- fiber</w>
C MR
C Cl
Bup ren
B reast</w>
B F
B ),</w>
Alzheim er</w>
Al most</w>
Al fentanil</w>
AM CA</w>
ADR -treated</w>
AD E</w>
AC E-
AC -
AB R</w>
= .
9. 9</w>
8 7%</w>
7. 6</w>
7. 5,</w>
7. 5%</w>
7-nitroinda zole</w>
7- OH-
7 1-year-old</w>
6- TG</w>
6 J</w>
6 3
5-azacy tidine</w>
40 %,</w>
4- year</w>
4- 5</w>
3 ]</w>
3 2-
29 ).</w>
28- day</w>
21- day</w>
200 7.</w>
200 2,</w>
2 60</w>
2 16</w>
16 8</w>
15 .</w>
15 %,</w>
14- day</w>
14 8</w>
14 1</w>
10 ,000</w>
10 (6)</w>
10 (3)/
1. 0-
1, 3-
0.000 1</w>
0.000 0
0. 24</w>
0. 2,</w>
.0 5),</w>
-1 3</w>
- square</w>
, 11-
(control ),</w>
(TB AR
(T GF-
(PT U)</w>
(P )</w>
(O R)</w>
(NSCL C)</w>
(NS AI
(M K-80
(E SR
(CO X)</w>
(B M
(A DH
(9 0%)</w>
(9 /
(5 3%)</w>
(5 ,
(4 8</w>
(4 /
(3 8%)</w>
(3 5.
(3 5%)</w>
(3 3</w>
(3 1%)</w>
(3 0-
(1. 2</w>
(1 0)</w>
(0.1- 1</w>
( peak</w>
( measured</w>
( h
( J
( 90</w>
zol mitript
z otoc
yr ,</w>
youn g
yn ic</w>
yl)- 2-
y "</w>
women ;</w>
war nings</w>
w iden
voltage- dependent</w>
viv o
veratro l</w>
ver -
vasculat ure.</w>
v il
university- affiliated</w>
un premedicated</w>
un g</w>
ultra -
ulcer ogenic</w>
ul i
u gh
trimeth adi
tr y</w>
tob ac
tinnit us.</w>
thy ron
the less</w>
thalidom ide,</w>
thalas semia</w>
ten ds</w>
teg mental</w>
te li
tail- cuff</w>
surger y:</w>
sulphasalaz ine.</w>
struct ure.</w>
strong est</w>
stri k
strik ingly</w>
st ents</w>
spir al</w>
sorafen ib</w>
sor ption</w>
sl ice</w>
single- photon</w>
sing le,</w>
sensitiz ing</w>
see k</w>
second- degree</w>
schedul es.</w>
sal ine)</w>
s.go v</w>
rul line</w>
rosu vastatin</w>
ro und</w>
ro lip
rolip ram</w>
ril men
rifamp icin-induced</w>
ri bo
revascular ization</w>
ret initis</w>
ret ard</w>
reser ve.</w>
reser pine.</w>
res our
res ected</w>
reproduc ibility</w>
repor t:</w>
removal .</w>
rejec tion,</w>
regul ation,</w>
ref rac
recover ing</w>
recogn izing</w>
rec ent
reat er</w>
reas ses
raz ox
ran spor
rami pri
r t
r d
quin ine.</w>
quin idine.</w>
qu ater
putam en,</w>
pup ils</w>
pt osis</w>
psori atic
procain amide-induced</w>
proble matic</w>
pro line</w>
pro jection</w>
pro grams</w>
preser ve</w>
pres cho
prefer able</w>
predic ts</w>
pr amine-induced</w>
poten c
potassi um.</w>
post ul
polyp eptide</w>
point s,</w>
pod ocytes.</w>
po )</w>
platele ts.</w>
platea u</w>
placebo ;</w>
piv otal</w>
pimoz ide,</w>
picardi al</w>
pi thelial</w>
physici ans.</w>
phosphor yl
phospholip ase</w>
phenomen a.</w>
phen procou
phen idate</w>
pharmacokine tics.</w>
pharmacokine tics,</w>
peria qu
pentobarbit al,</w>
patient s);</w>
paresthesi as</w>
pancre atitis,</w>
paclitaxel -
pa rous</w>
oxy acetic</w>
ox ime</w>
out- patients</w>
oun ds</w>
ouabain -treated</w>
ou pl
ot op
oste ogenic</w>
oscop y.</w>
osar coma.</w>
os ulf
opath ology</w>
one 's</w>
on ov
on )</w>
om er
ol mesartan</w>
od en
ocy anine</w>
ocor tical</w>
occa sions.</w>
oc arb
obstruc tion,</w>
obst etric</w>
observ ations.</w>
ob io
ob enz
o urinary</w>
o therapy</w>
non human</w>
non diabetic</w>
non depolarizing</w>
noc ifensive</w>
no ise</w>
nit rate/
nicardi pine-induced</w>
neuro imaging</w>
ne tilmic
n g.
multivari able</w>
more over,</w>
modul ators</w>
mo ti
mit omycin-
mis sed</w>
mid brain</w>
microsph eres</w>
micrograms/ kg),</w>
microgli a</w>
micro tubule</w>
micro g.
mic rom</w>
mg/kg/ min</w>
mg/d L),</w>
methylenedioxy methamphetamine</w>
methad one-induced</w>
meth oc
meth iodide</w>
meth ach
metabolit e.</w>
mesn a,</w>
men )</w>
membran e,</w>
mefen amic</w>
max ,</w>
mas seter</w>
manifest s</w>
manage able</w>
mal ari
magnesi um,</w>
macroph ages,</w>
m s).</w>
m mol</w>
lymph aden
lun g
loz enge</w>
lor azepam.</w>
liter )</w>
lin kage</w>
lignoca ine.</w>
li p</w>
levonorgest rel</w>
le )</w>
lac ks</w>
l ine.</w>
l ick
ke ep</w>
ke d,</w>
ka olin</w>
ist os
isol ation</w>
is th
is let</w>
intrac aver
insectic ide</w>
injur ious</w>
inf ant
ind ocyanine</w>
in yl</w>
in operable</w>
in herent</w>
implic ation</w>
immun ity</w>
illnes ses</w>
idi l</w>
id ity,</w>
ia c</w>
hyste rectomy</w>
hypothe sis.</w>
hypothalamic- pituitary-adrenal</w>
hypo plastic</w>
hypo kine
hous ed</w>
hour ,</w>
homeost asis.</w>
her pes</w>
hepat obiliary</w>
hem olysis,</w>
hem ip
he rence</w>
harve sted</w>
haemo globin</w>
h app
h ands</w>
gynaec ological</w>
guinea- pig</w>
gu t</w>
granulo cy
glyco gen</w>
gam bling</w>
gall- bladder</w>
gal ant
g ases</w>
further ,</w>
fun damental</w>
fore ign</w>
flumazen il.</w>
fibro blast</w>
fib rom
ff- Parkinson
ff-Parkinson -
ff-Parkinson- White</w>
fet uses.</w>
fenol dop
failure ;</w>
extub ation</w>
exist .</w>
exacerb ations</w>
ex chang
evol ved</w>
ev ul
ethan ol,</w>
estrogen ,</w>
es sively</w>
es '</w>
epitheli um.</w>
episo de,</w>
ep ing</w>
enzyme .</w>
entor ial</w>
ent ering</w>
en graf
en comp
employ ed.</w>
eme sis.</w>
embryo pathy</w>
elev ate</w>
electrocardio gram,</w>
el se
each ,</w>
e- like</w>
e ye
e y</w>
e tretin
e ther</w>
e ligible.</w>
e h
e b
dysrhyth mic</w>
dysp ep
dysarth ria,</w>
dys plasia.</w>
dys lipide
doxorubic in-related</w>
down ward</w>
dom perid
dom inal</w>
disorient ation,</w>
dis col
dis ability.</w>
dimin ishing</w>
differen tly</w>
dideoxy cytidine</w>
detect able.</w>
destruc tive</w>
day s'</w>
dap son
dail y).</w>
cyto static</w>
cyt es,</w>
cutane a</w>
cot ranspor
cortico striatal</w>
correc tly</w>
correc ted
corp uscular</w>
cor on
control le
con vol
commer cial</w>
cogn i
co infected</w>
co incident</w>
clox acillin</w>
chlorpromaz ine,</w>
chlor al
chi ef</w>
chemoconvul s
cerebell um,</w>
cer amide</w>
cent res</w>
cell ular
ceftriax one.</w>
cefazol in</w>
cardiomyo path
carboxyl ic</w>
carbon ate.</w>
carbamazep ine-induced</w>
carb onic</w>
bru ising</w>
bodi es,</w>
block er
bleed s</w>
ble omycin,</w>
bio logy</w>
bicucull ine-induced</w>
bi guan
bi ge
ber g</w>
barri er,</w>
baclofen ,</w>
ba ical
autoph agic</w>
aut osomal</w>
ate -dose</w>
ate -dependent</w>
at ors,</w>
as /
arthralgi as</w>
arthralg ia,</w>
arth ri
arterios us.</w>
ar is</w>
apne a,</w>
antiretro vir
anti- emetic</w>
anti malari
anti arrhyth
antagon ism.</w>
ant op
anne xin</w>
anim al.</w>
androgen s</w>
andro genic</w>
amygdal a-
ampl ified</w>
amelior ating</w>
altern atives</w>
alpha, beta-
alpha 2
aller gi
adv ise</w>
adi pon
aden oma.</w>
acr ynic</w>
acid- base</w>
acid s.</w>
abs ent.</w>
[ n</w>
[ corrected
Wil m
U ),</w>
Toge ther</w>
TT P</w>
TI MI</w>
T MP</w>
Sin us</w>
ST- T</w>
SN C
SD ).</w>
S ide-
S ci
S 9
Ris perid
Rec ur
RE M</w>
RB F</w>
R s)</w>
R ep
R S)</w>
Quin idine</w>
Qu eti
QT- prolonging</w>
Pseud omonas</w>
Pre ventive</w>
Potenti ation</w>
Pic rotox
PT )</w>
PL D</w>
P ap
P W
P P</w>
P IIIN
P CO2</w>
Op tim
Octre otide</w>
O m
Nine ty</w>
Nim odipine</w>
Ne w
Na+ -
Na -
NT -
NS ,</w>
NO S
NM S.</w>
NA G</w>
N2 O</w>
N-acetyl- beta-D-
N Y
N ,
MR S</w>
MA O</w>
MA O-
MA C</w>
M n
M K</w>
M 5</w>
M -1</w>
Lim ited</w>
Lew y</w>
LI D.</w>
L- carnitine</w>
L H-
L 6</w>
L 1</w>
K now
In voluntary</w>
Impair ment</w>
Im pact</w>
Ig E</w>
IT B</w>
I ]
I E
Hypercal cemia</w>
Hyper algesia</w>
Ha emat
HR T</w>
HLA- DR
HET E</w>
HAM- D</w>
H U</w>
H B</w>
H 2-
Gener alized</w>
GABA B</w>
G reater</w>
G re
Fish er</w>
FK50 6-
F olic</w>
Etom idate</w>
E(2)17 G</w>
E K
E (2)</w>
Dose- limiting</w>
Di privan</w>
De si
De f
DSM-III- R</w>
D s)</w>
D Y
D -1</w>
Creat inine</w>
Con version</w>
Con cer
Compar isons</w>
Ch E</w>
CT A</w>
CM .</w>
CI =
CA ,</w>
C57B l/
C ros
C hi
C ana
C CB
Bor tezom
BoNT /A</w>
Bcl -
B io
B ay</w>
B aro
B :</w>
Ar rhyth
Ant agonism</w>
Anesthesi ologists</w>
Am p
Alco hol</w>
Ab dominal</w>
ATP- sensitive</w>
AN F</w>
AB P</w>
A udi
A ten
A TIONS:</w>
A PD
A AF</w>
A (1)</w>
9 5
8 97</w>
6- fold</w>
6 6.
6 5
5 5.
5 5-
48- hour</w>
4 4.
4 20</w>
39 ,</w>
3. 9
3. 8%</w>
3. 0,</w>
3 5)</w>
3 40</w>
3 000</w>
2339 0,</w>
23 %,</w>
200 6,</w>
2. 4
2 7)</w>
2 6)</w>
2 28</w>
2 1.</w>
199 1</w>
18 3</w>
16 2</w>
15-1 788</w>
15 55</w>
14 7</w>
14 6</w>
13 7</w>
13 4</w>
125 I-
12- year-old</w>
10- year-old</w>
10- day</w>
10(9)/ L</w>
1. 1-
1 13
1 1-year-old</w>
1 0.9</w>
1 0.6</w>
1 0.2</w>
0.00 8).</w>
0. 22</w>
0. 18</w>
0. 12
-1. 0</w>
-1, 2-
-1 4</w>
- A</w>
- 4-
- -</w>
(W T)</w>
(V i
(ST Z)</w>
(S M
(S ):</w>
(P N
(M P
(L AD)</w>
(HBs Ag
(H V
(D N
(D D
(CH F).</w>
(C y
(Ad riam
(A RF
(8 5%)</w>
(6 3%)</w>
(5 2.
(3 9%)</w>
(3 7%)</w>
(2 0%</w>
(100 %</w>
(1-1 3)</w>
(1 9</w>
( increased</w>
( incidence</w>
y ol
xam oterol</w>
writ ten</w>
where by</w>
week ly,</w>
wat er,</w>
w in
volume tric</w>
vol ar</w>
vir us-
vesi cles</w>
ver s
vasodil ation.</w>
vac iz
v afloxacin</w>
ush ing's</w>
us ),</w>
uro dynamic</w>
ur gency</w>
unmas ked</w>
uncerta in,</w>
un resectable</w>
un ineph
um ;</w>
ul nar</w>
ul ic</w>
ucin do
u wol
u ve
u pri
tw o.</w>
trin it
tri meta
trastuz umab</w>
transplant ,</w>
trans thoracic</w>
trans itory</w>
tramad ol,</w>
trache a</w>
tol ter
tobac co
tic s:</w>
thym us</w>
thre e,</w>
thre at</w>
though ,</w>
thir st</w>
thioper amide</w>
the ta</w>
tetra zol
territ ory</w>
terbutal ine,</w>
ter m.</w>
tacrolim us-induced</w>
ta zol
t -induced</w>
t 's</w>
symptom atic,</w>
sur pris
suppres sion,</w>
super vision</w>
sulpiri de,</w>
sulfamethox azole</w>
sulfadi azine</w>
sulf asalaz
sul ind
subst ances.</w>
sub mucosal</w>
su t
ster ior</w>
sten otic</w>
st ran
spread ing</w>
spont aneously.</w>
specimen s.</w>
spas tic</w>
spar floxacin</w>
sp ra
sp ong
sotal ol.</w>
soci o
smo ke</w>
small -dose</w>
sion -induced</w>
simul ating</w>
sh am
sep ti
self- administration,</w>
self- administer</w>
seizure -related</w>
sedi ment</w>
scopol amine,</w>
sampl es.</w>
sal vianolic</w>
s one-induced</w>
s l</w>
s av
s agittal</w>
rough ly</w>
rifamp ic
ri lu
retur ning</w>
reth ral</w>
restrain t</w>
resol ved,</w>
requ is
remoph or</w>
relap se,</w>
reinfor ced</w>
regres sion.</w>
rectom y.</w>
recipi ent.</w>
recipi ent
re produce</w>
re entry</w>
re acting</w>
rat s).</w>
ra uwol
ra c</w>
r t-
r in.</w>
r CBF</w>
quad rant</w>
pulsati le</w>
publ ished.</w>
pu st
protocol s.</w>
prophyl axis,</w>
promot ers</w>
prometh azine</w>
prog ab
proc al</w>
pro inflammatory</w>
pri ma
presum ptive</w>
present ed,</w>
pregnan olone</w>
pot ent,</w>
posses sing</w>
por t</w>
poly cystic</w>
pneumon itis</w>
plat form</w>
plant ation</w>
pl an</w>
piri de</w>
pine al
person- years</w>
periaqu eductal</w>
per oxidative</w>
pepti de,</w>
pemphig us</w>
pec uli
paw .</w>
patch y</w>
pass ed</w>
partici pat
paradig m.</w>
p.o .),</w>
p mol</w>
oxotremor ine</w>
oxi b
ox prenolol</w>
over night</w>
out bred</w>
ouabain -
organophosph or
or ally)</w>
opioid ergic</w>
on yl</w>
ometr y,</w>
omal ac
om edull
ol e-induced</w>
off '</w>
of en
oce le</w>
occur s,</w>
oc eptive</w>
ob tained,</w>
normoten sion</w>
non- pregnant</w>
non ischemic</w>
nitrosou rea</w>
ng/m L)</w>
neuropath ies.</w>
neurolog ically</w>
networ ks</w>
nerv es,</w>
nephrectom ized</w>
nalox one-induced</w>
n ical</w>
n ary</w>
myo globin</w>
myalg ia,</w>
mu tism</w>
mu mol</w>
mou se)</w>
moti f</w>
mother s.</w>
month s'</w>
mono amines</w>
moderate- to-severe</w>
mo ro
ml ),</w>
mifeprist one</w>
microgram .
mi as</w>
mg/kg/ day).</w>
mg/ 70</w>
metr y,</w>
metopro lol.</w>
methoc tramine</w>
meth i
meth azol
metast ases.</w>
meta- analysis.</w>
mes angi
mening itis,</w>
me et</w>
me -
maz indol</w>
maz e,</w>
mat ine</w>
macro li
mOsm /
m ur
lymph oma,</w>
lymph adeno
ly ).</w>
losart an.</w>
lo fex
lip ids,</w>
life- threat
li tis</w>
level s;</w>
lea ving</w>
lat ency.</w>
laparo scopic</w>
lact ate,</w>
laborator y,</w>
l- N
l es
l av
kin ase.</w>
ith m</w>
ip ).</w>
ion tophore
iod inated</w>
intra ventric
intermedi ate-
interferon- alpha</w>
inter cellular</w>
integr ation</w>
insul ts</w>
instruc ted</w>
initi ated,</w>
inhal ation.</w>
ing ).</w>
inf ective</w>
ine a</w>
induc er</w>
index es</w>
indap amide</w>
ind welling</w>
inci sion</w>
in significant</w>
immunomodul atory</w>
immunohistochemistr y.</w>
immunocom promised</w>
immunoblo tting</w>
immuno globul
im idazole</w>
il -treated</w>
if ying</w>
ide :</w>
id ine-
ic y</w>
ic ity,</w>
ic h
i as</w>
hypother mia.</w>
hypoten sion:</w>
hypo perfusion</w>
hypo glyce
hypercholesterol emia.</w>
hyperbilirub inemia</w>
hydrochlorothiaz ide.</w>
hydr ation.</w>
hist ochemistry</w>
hepati tis:</w>
hepat ocytes,</w>
hematoc rit
heighten ed</w>
health care</w>
haemorrh age,</w>
h -1</w>
gu ided</w>
granulomat osis</w>
granulo ma</w>
gran ules</w>
graf ting.</w>
gluteth imide</w>
gestod ene</w>
genit ourinary</w>
gen e,</w>
gabap ent
g/ min</w>
g/ kg)</w>
g av
g ;</w>
fund us</w>
fresh ly</w>
frag ment</w>
four- point</w>
four teen</w>
followe d.</w>
foci .</w>
foc using</w>
flut ter.</w>
flur ane-induced</w>
flu -like</w>
fatal ities</w>
fat ality</w>
fat al,</w>
famoti dine</w>
facilit atory</w>
fac e,</w>
f ut
f iltr
exter na</w>
explo red.</w>
explan ations</w>
exceed s</w>
event ual</w>
eu gen
ethan ol
et h</w>
estrogen -
erg onov
ere d.</w>
er obic</w>
epi rac</w>
epi gastric</w>
ephed rine.</w>
enter ocol
ent ally</w>
enrol led,</w>
enc ies,</w>
en sed</w>
en profylline</w>
en demic</w>
em poral</w>
electro -
eigh th</w>
effac ement</w>
ectop y</w>
ecti vely,</w>
e pl
e ase</w>
dysrhyth mia</w>
dy sur
down stream</w>
dog s)</w>
docetax el
dis plays</w>
dis odium</w>
dis cour
direc tional</w>
diphenhydram ine,</w>
dimin ution</w>
digox in-induced</w>
diaphrag matic</w>
diagnos ing</w>
dex fenfluramine,</w>
develop .</w>
deterior ation.</w>
depri ved</w>
depres s</w>
dementi a,</w>
def ined,</w>
de x</w>
day -
d ,
cytoskele ton</w>
cytos olic</w>
crav ing.</w>
cranio facial</w>
coun ting</w>
cost- effective</w>
cortic es</w>
convul sion
contra sted</w>
cons ent</w>
confirm ation</w>
conduc tion,</w>
con stituted</w>
con sensus</w>
compon ents.</w>
compli ance,</w>
complete .</w>
comple ted.</w>
colum n</w>
co- treatment</w>
co ding</w>
co d
cm ;</w>
clomi pramine.</w>
clomi phene</w>
clarithrom ycin.</w>
cis- retinoic</w>
circl ing</w>
chon dro
cho ose</w>
chlorpromaz ine.</w>
chloral ose</w>
cerv ic
cent er,</w>
catechol amines.</w>
catechol amines,</w>
catal ase,</w>
cas t</w>
carcin oid</w>
capac ity,</w>
cad aver
cadaver ic</w>
ca use,</w>
c res
c iclo
c age</w>
bri mon
body -
blun t</w>
bl ind,</w>
bicarbon ate.</w>
bic yclo
beta- hydroxylase</w>
beta- adrenoceptors</w>
ben ser
behavi ors,</w>
beat -to-beat</w>
be vaciz
bal ance.</w>
b asis,</w>
azot emia,</w>
azos in,</w>
avi an</w>
atracuri um.</w>
ation s:</w>
ate -treated</w>
asth ma,</w>
ast at
aro se</w>
argin ine-
arc ot
arachno idi
anxiety- like</w>
antidepress ant,</w>
anti phospholipid</w>
anti migraine</w>
anser in,</w>
anorec tic</w>
angi oneurotic</w>
angi itis</w>
anast om
analy sed.</w>
an y,</w>
aminoglyco side-induced</w>
am ifost
alpha 1</w>
alpha -1</w>
alopec ia,</w>
allo steric</w>
all y-induced</w>
al "</w>
again .</w>
ag ra
aeruginos a</w>
adultho od</w>
adrenal ine,</w>
addic tion,</w>
ad ec
ad ds</w>
achie vement</w>
acetyl transferase</w>
accompl ished</w>
ac ade
able ;</w>
a e)</w>
Zidov udine</w>
Z O
Z ).</w>
Yohimb ine</w>
X- A</w>
Wol ff-Parkinson-White</w>
Wilm s'</w>
W al
Ve terans</w>
Unexpect edly,</w>
U A</w>
Tw o-
Toler ability</w>
Th en</w>
Tempor ary</w>
TN S</w>
T u
T LP
T LE</w>
Syn cope</w>
Strept ococcus</w>
Statis tically</w>
Sot alol</w>
Side- effects</w>
ST AT
SR S</w>
SH Rs</w>
SH ,</w>
SC -
S mo
S ensor
S em
S e</w>
S core</w>
S P)</w>
Rib avirin</w>
Res er
Rech allenge</w>
Rec or
Re duc
Rapam ycin</w>
RA 0
R- R</w>
R y
Pseud o
Predic tors</w>
Phy sos
Pharmaco kinetics</w>
PR S</w>
PF 4</w>
P ul
P ergol
P arox
P ON
OUTCOME :</w>
O Cs</w>
Ne ural</w>
Na(+ )/
N- methyl</w>
N eu
N RA0
Myocardi tis</w>
Myo pathy</w>
Methyl phenidate</w>
MT .</w>
MP O</w>
MENT :</w>
M ZR</w>
M I,</w>
M G</w>
Leuk openia</w>
Lab et
LHR H</w>
L-NAME .</w>
Kore an</w>
Ket ocon
Imi pramine</w>
Im proved</w>
IV ).</w>
II ),</w>
I T-
HI P/
H 2-receptor</w>
Go od</w>
GS K
GABA .</w>
GA P-
G ran
G rad
Furosem ide</w>
Forty- one</w>
Fluc onazole</w>
F s</w>
F O</w>
Ev ent</w>
Epi leptic</w>
Endo thelial</w>
El ect
ER K
EE Gs</w>
ED TA</w>
EC 50</w>
E osinophil
E ar
Docetax el</w>
DP CP
DF P-induced</w>
D yn
D y
Curren tly,</w>
Concentr ations</w>
Cochran e</w>
Clin ically,</w>
Centr e</w>
Calc ineur
CS F.</w>
CO (2)</w>
CF U-
CD 8
CBD CA</w>
CB D</w>
C- reactive</w>
C lop
C .
Ble eding</w>
Bcl -2</w>
BT X-A</w>
B ut
B is
Aut o
Apop tosis</w>
Anti oxidant</w>
Ant ine
Am ne
Am lodipine</w>
Ad v
AZT -induced</w>
AT P,</w>
AR CH</w>
AO AA</w>
AM ,</w>
A symptomatic</w>
A cyclo
A K</w>
A F.</w>
= .00
9 0,</w>
8 1%</w>
7- fold</w>
7 %.</w>
6. 0
50 /
5- methyl
5 9.
4- day</w>
4, 5-
36 ).</w>
30- day</w>
30 %.</w>
3, 5-
3 3)</w>
24 3</w>
200 0.</w>
2. 3
2 1).</w>
2 '-
199 4,</w>
19 80</w>
19 4</w>
10(- 3)</w>
1- 4</w>
1 h</w>
1 20,</w>
1 0.4</w>
0.5 2</w>
0.000 5).</w>
0.000 1,</w>
0.00 4).</w>
0.0 1
0. 28</w>
0. 1-
.0 1),</w>
-10 ,11-
-1 8
- n-propyl
- drug</w>
- 7</w>
- 0.4
, S)-
+/ +</w>
)- related</w>
(p< 0.05).</w>
(S V
(S OD
(S A
(R P
(R ,S)-
(P =0.00
(NSAI D)</w>
(MA )</w>
(I D
(HBe Ag)</w>
(H b)</w>
(FK50 6)</w>
(D P
(C PK
(Adriam yc
(A SA</w>
(A F)</w>
(8 1%)</w>
(7 3%)</w>
(7 /
(50 -
(50 )=
(5 7%)</w>
(5 2%)</w>
(4- fluoro
(3 0
(3 ),</w>
(2 8%)</w>
(2 5
(1- 7)</w>
(1 6
(1 0.
(+/- )</w>
( without</w>
( gamma-
zon is
zon a</w>
zol e.</w>
y t
y 's</w>
xim al</w>
x ia</w>
world wide</w>
wor k.</w>
with ,</w>
wei gh</w>
wa y.</w>
w hi
vis it,</w>
vi gorous</w>
vi d</w>
vessel s,</w>
vecur onium.</w>
vastat in-induced</w>
vasodilat ation.</w>
vasoconstric tion,</w>
vari able.</w>
v inorelb
us ).</w>
ure ter</w>
ur ished</w>
ur ap
ur aemia</w>
under -
um ab
u y
tun nel</w>
tro glitaz
triglyceride s,</w>
tri hexy
trihexy phenid
treatment ).</w>
traz ol</w>
transp eptidase</w>
transmis sion,</w>
trans duc
toxic ity;</w>
toc olytic</w>
to uch</w>
to ols</w>
time ;</w>
ti um-
ti ous</w>
thyron ine</w>
therap y)</w>
ther to</w>
tempo l</w>
t s:</w>
t s)</w>
synchron ous</w>
sy ring
surviv ors.</w>
subst ances,</w>
str ab
stitut ed.</w>
stimul us.</w>
stat in-
st able,</w>
spinal- epidural</w>
spi king</w>
sper mat
spar te
so .</w>
smok ing.</w>
sl urred</w>
sertral ine,</w>
sel dom</w>
scrat ching</w>
scopol amine.</w>
scolio sis</w>
sci enti
scal es.</w>
sar izotan</w>
sar coma,</w>
s.c. )-induced</w>
s ound</w>
s er</w>
ru n</w>
rop ini
room .</w>
rom yo
rofecoxi b.</w>
ro le,</w>
rit od
risk- benefit</w>
rilu zole</w>
rh initis</w>
ret ina</w>
resol ving</w>
resist ance
requis ite</w>
ren oprotective</w>
recommend ation</w>
recent -onset</w>
rec ti
re tin</w>
re perfusion.</w>
rat entorial</w>
rat 's</w>
rami pril</w>
radioimmuno assay.</w>
radio activity</w>
r f
r TMS</w>
questionnai re.</w>
quater nary</w>
qu it
purpo se,</w>
pum p.</w>
pulse less</w>
psycho pathology</w>
psycho active</w>
psych opharmac
pseud o-
prob es</w>
prob enec
pri ate</w>
preser ved.</w>
prescri be</w>
prepar ation,</w>
prefer ring</w>
prednisol one.</w>
pre mixed</w>
pre conditioning</w>
pr amine,</w>
post- training</w>
posi tivity</w>
pos tischem
polymorph onuclear</w>
polycy themia</w>
pol lic
po ison</w>
physostigm ine,</w>
phot oph
phosph ate,</w>
pheochromocyt oma.</w>
phenotyp e.</w>
ph an</w>
pg/ mL</w>
pentobarbit one</w>
pent ol
penicill in-
pea ks</w>
pea king</w>
patient :</w>
path ology,</w>
pare sis.</w>
pac ked</w>
pa the
pa st
p o</w>
p ad
ouabain ,</w>
otroph ic</w>
oti fen</w>
ot e
osteomyeli tis</w>
orn ith
orig inating</w>
orbit of
or tic</w>
opportun ity</w>
ophil ic</w>
oper ant</w>
opath y,</w>
op ent
on ec
on "</w>
omeprazol e.</w>
omedull in</w>
ome ga
omat osis</w>
olo l-induced</w>
ol ution</w>
ograph ically</w>
ocyt uria</w>
och ol
occupati onal</w>
obses sive</w>
obser ver</w>
o glyc
nucle ol
noradrenal ine,</w>
no urished</w>
no otropic</w>
no des</w>
nitro tyrosine</w>
nitren dip
nicoran dil</w>
nevir ap
ne bivolol</w>
natur alistic</w>
nat ure,</w>
naprox en.</w>
n- Whit
n s.</w>
n ia,</w>
my o-
mut ation.</w>
mucosi tis,</w>
moxon idine</w>
morphine- dependent</w>
mon om
mo genic</w>
mmol/ L)</w>
mm /
ml/min/ 100</w>
mit tent</w>
minocycl ine-induced</w>
minipum ps</w>
minim al-
min(-1 ),</w>
mim ics</w>
mil lis
millis ec
migra ine,</w>
microcephal y</w>
mg/m L</w>
methyser gide</w>
methyl dopa.</w>
methicill in-resistant</w>
methamphetamine- dependent</w>
metam iz
melan oma.</w>
medic ine.</w>
medi ated.</w>
materi al.</w>
mat ch</w>
mark ers.</w>
man ia,</w>
man 's</w>
malform ations,</w>
m argin
ly tic</w>
low- risk</w>
low- protein</w>
low er,</w>
long term</w>
log- rank</w>
lo us</w>
lo r</w>
lo bul
limit ed,</w>
lig ation-induced</w>
libid o</w>
li ve
levamisol e.</w>
leuk otri
l ing,</w>
iz ations.</w>
iv ocal</w>
iti s:</w>
is ometric</w>
is ob
is ms.</w>
inv asi
intracor tical</w>
interval )</w>
integr al</w>
insidi ous</w>
inser tion.</w>
injur ies.</w>
injec tion
ingre dient</w>
ing eal</w>
ing -induced</w>
inde ed</w>
inadver tently</w>
in- sensitive</w>
in ase</w>
in appropriately</w>
im pul
il legal</w>
il ing</w>
il ic</w>
ia ),</w>
i ome
hypo glycemic</w>
hypo activity</w>
hyperprolactine mic</w>
hydroxy ure
hormon e,</w>
high -</w>
hi therto</w>
hex a
heter ozyg
he aled</w>
haloth ane
gynecomasti a</w>
guaneth idine</w>
gram s,</w>
go t</w>
gn ath
gir ls</w>
gi ves</w>
ge u
ge fit
gaz e</w>
g/ d</w>
g o</w>
furazol idone</w>
function ing,</w>
frequ ently.</w>
frequ ency
frequ encies.</w>
form oterol</w>
form al</w>
fo od-
fo etal</w>
fluoxet ine-induced</w>
flexi ble</w>
fl uroth
first- time</w>
find ing.</w>
finaster ide</w>
femal e.</w>
fe et</w>
fa il</w>
f ain
ey e,</w>
extrapol ated</w>
expl or
evul inic</w>
evol ving</w>
etopo side,</w>
etodol ac</w>
ethambut ol-induced</w>
eth al</w>
estradi ol.</w>
establ ishing</w>
ept or</w>
epilep tics</w>
epi andro
enzym ic</w>
endot ox
end arte
end ,</w>
en thix
empir ical</w>
emin ence</w>
electro cortico
ed- onset</w>
ec hi
e sis.</w>
e at
dystroph y.</w>
dysarth ria</w>
dynes/ cm
du oden
dose- dense</w>
dos ages,</w>
dog ,</w>
disopyram ide.</w>
dis ulf
dis placement</w>
dipyridamol e,</w>
dimin ishes</w>
digox in-
differenti ation.</w>
diff usion-weighted</w>
diag nose</w>
dextro amphetamine</w>
dex amphetamine</w>
dex am
dexam fet
develop s.</w>
deterior ating</w>
desi re</w>
dermat ologic</w>
deg ran
deficit /
deficit/ hyperactivity</w>
decre ment</w>
dec a
debilit ating</w>
de qu
de acetyl
day (-1)</w>
d ine-induced</w>
cyst oscopy</w>
cyclospor ine,</w>
cyclopent yl
crac k
counter acts</w>
coun ts.</w>
coun t.</w>
cor responds</w>
controversi al</w>
control s;</w>
contrac tility,</w>
constric ted</w>
confirme d.</w>
conduc tion.</w>
con curren
commis sural</w>
coll ected.</w>
co herence</w>
cm /
clozap ine-treated</w>
clon al</w>
clo sed-
clipp ing</w>
clas s.</w>
clas s,</w>
circumst ances</w>
cho w</w>
ch ori
cephal ic</w>
cefotet an</w>
caudate- putamen</w>
catarac t</w>
carbach ol-induced</w>
carbach ol,</w>
ca st
c olic</w>
c .)</w>
but yr
bur den</w>
bupivaca ine-
bul im
bu b
bronchospas m</w>
breast ,</w>
br ush
bo vine</w>
bleph aro
ble ,</w>
bis phosphonates</w>
bir th,</w>
bicalut amide</w>
bi ventricular</w>
bi periden</w>
bi ochemical,</w>
bi as</w>
beta- blockers.</w>
beta- adrenoreceptor</w>
beta- 2</w>
beta ine</w>
beta (2)-
benzoyl ecgonine</w>
benzodiazep ine,</w>
bam buterol</w>
b -
aver sive</w>
audi ometry</w>
audi ograms</w>
atr an</w>
ation s)</w>
ati pame
atherosclero sis,</w>
ather ogenic</w>
at re
assess ment,</w>
aspar tic</w>
ase- positive</w>
ascorb ate</w>
asc icular</w>
as pect
as e
art an,</w>
ari e-
arcot -M
arb ox
arabino side.</w>
ar ia</w>
aquapor in-
ap rine</w>
ap r
antipsycho tic-like</w>
antipsycho tic,</w>
antidepress ant-induced</w>
anticoagul ation,</w>
antibod y.</w>
anti- parkinsonian</w>
anti oxidative</w>
antagonist ),</w>
ant en
ant )</w>
anhydr ase</w>
aneurysm s.</w>
anaphyl actoid</w>
an oids</w>
amitriptyl ine.</w>
amine ;</w>
amine :</w>
amin ol
amant adine.</w>
alpha-methyl- p-
alpha 3</w>
all idal</w>
alg or
alfentan il.</w>
aldehy de,</w>
al t
ag en</w>
advant age
adrenocept ors,</w>
adren erg
adju v
adipon ectin</w>
addi tionally</w>
add- on</w>
adap tations</w>
acade mic</w>
ab users,</w>
a ul
[ 3-
YM 430</w>
X- ray</w>
Wee kly</w>
WR-27 21</w>
VT A</w>
V ig
V F.</w>
V CM</w>
V 2</w>
U I</w>
Trimethop rim-sulfamethox
To oth</w>
Time -
TT P/
TH E</w>
T O
T E</w>
T C
Syst em
Suc cin
Subst ance</w>
Struct ural</w>
Sch iz
ST ),</w>
SE ARCH</w>
SE ).</w>
SAM e</w>
S cre
S cop
S CN
S ;</w>
S 14
Ring er's</w>
Ri ght</w>
Recur rence</w>
Re action</w>
R at
R AL
Prolong ation</w>
Pro ximal</w>
Perio perative</w>
Pa O2</w>
PA -induced</w>
P y
P ir
P al
P ER
Ou t</w>
OA B</w>
Neuro psychiatric</w>
NSAID -induced</w>
NO ,</w>
NB QX</w>
NA S</w>
N-nitrosodiethyl amine</w>
N-methyl- d-aspartate</w>
N ov
N G</w>
N CE:</w>
Met o
MPT P-
MM C</w>
MA O
M olecular</w>
M SA</w>
Lind ane</w>
Li pos
Levo dopa</w>
Lang endor
LT ),</w>
L- dopa.</w>
L ymph
L A
K E
Intra ocular</w>
Inter mittent</w>
Inhib itory</w>
Individu als</w>
In tram
In dic
Impres sions</w>
II I/
I mat
I HD</w>
Hyper baric</w>
Hy dr
Hunting ton's</w>
Hospit al.</w>
HUS ,</w>
HBsAg -positive</w>
HBeAg -negative</w>
H Y
GA G</w>
G ab
Forty- three</w>
Fifty- four</w>
FE AT
F ast
F ascicul
F U</w>
F G</w>
Ex trac
Epi rub
Ep inephr
Endo thel
Elect romyo
EC M</w>
EC G
E rec
E phed
E N</w>
E -17
Dose -related</w>
Don epe
Do pa
DBA/2 J</w>
D2 R</w>
D er
D G
D CE</w>
D 1/
Cs A.</w>
Creat ine</w>
Cor tis
Contr ary</w>
Con di
Clop ido
Clin ical,</w>
Cl assi
Cl ar
Cl -</w>
Ch ec
Ch arcot-M
Celec oxib</w>
Ceftriax one</w>
Ce bus</w>
Cd A</w>
Cana dian</w>
CT ,</w>
CR H</w>
C ushing's</w>
C 57</w>
BoNT -A</w>
Bi opsy</w>
Benz odi
BZ D</w>
B P.</w>
B P,</w>
B MI</w>
B C</w>
B ;</w>
Appro priate</w>
An y</w>
Al b
Ace tazol
Ac tivity</w>
Ac cumulation</w>
AR F,</w>
AL )</w>
AF- DX</w>
AE D</w>
ADR +
AD R,</w>
A dequ
> =</w>
8 9.
8 ,
7 9-year-old</w>
6- thioguanine</w>
6 50</w>
6 0)</w>
50- mg</w>
5- M
5 7.
5 3,</w>
4-amin opyridine</w>
4 5)</w>
39 ).</w>
3. 6
3. 5%</w>
3-mercapto propionic</w>
3,4- D
3 6-
3 00-
3 )
23 4</w>
2- hour</w>
2- adrenoceptors</w>
2 9-
2 2).</w>
2 17
2 1
2 )
199 3,</w>
198 9</w>
198 6</w>
19 8</w>
19 80
19 5</w>
16 ),</w>
141716 A</w>
100 %,</w>
1, 6
1 20-
1 1.0</w>
1 0.3</w>
00 /
0.7 5%</w>
0.0 6
0.0 4)</w>
0.0 %</w>
0 +/-
/ P
-1 20</w>
-- -
- I</w>
) ]
(S R)</w>
(S )</w>
(R R)</w>
(P a
(P R)</w>
(N R
(N P
(N H
(N A)</w>
(MA P),</w>
(H A
(F S)</w>
(E AC
(8 00</w>
(5 6%)</w>
(5 5</w>
(3 2</w>
(3 2%)</w>
(3 /
(3 ,</w>
(2 4%</w>
(2 .0
(1 1)</w>
(0. 7</w>
(0. 5,</w>
(0. 25-
( s.c.)</w>
( patient</w>
( more</w>
( left</w>
( high</w>
( heart</w>
( difference</w>
( 50%</w>
( 0-1
z imel
yridox ine</w>
yr amine</w>
yol k</w>
ym path
year )</w>
yc in-
y aw
y al</w>
worl d</w>
work up</w>
work ers</w>
whole- body</w>
wat er
vis ited</w>
verapam il
ver theless</w>
ventric ulography</w>
ve ter
ve ins.</w>
valu e,</w>
v ular</w>
v im
uter us</w>
use ful
urticar ia,</w>
uro toxicity</w>
urg e</w>
ur ate</w>
upri ght</w>
understo od</w>
unc oupl
un treated,</w>
un predict
ulo pathy,</w>
udi l</w>
ub ital</w>
u )</w>
trypt amine</w>
tretino in</w>
treatment- resistant</w>
transfer ase,</w>
tran su
transu rethral</w>
trac ts</w>
trac tive</w>
tra vel
toler ability,</w>
to gen
tissu e-
tis h</w>
ticlop idine,</w>
ticar c
tic /
tic )</w>
thy smo
throm bi
threshol ds.</w>
th s</w>
th in</w>
th ick</w>
ten sion
ten -
teicoplan in</w>
tauro ursodeoxycholate</w>
tan dem</w>
tachy cardiac</w>
ta u</w>
t one,</w>
t apping</w>
syndrome )</w>
sympath o-
swell ing,</w>
sup rac
summ ary</w>
sumatript an,</w>
sulph on
suc h,</w>
subsequ ently,</w>
sub optimal</w>
stud y;</w>
stra ins,</w>
stra i
sti tial</w>
ster on
st y
st upor</w>
st -induced</w>
spectro metry</w>
spectro metry.</w>
specific ,</w>
sol ut
slic es.</w>
sigma (1)</w>
shock -induced</w>
sex u
sequ encing</w>
sensor y-
seizure- inducing</w>
second arily</w>
se as
scre ens</w>
scot omas</w>
sco re
scaveng er,</w>
scal ene</w>
sc en
satis factor
saline- injected</w>
s -induced</w>
run -in</w>
rt- PA</w>
rit uxim
ricket s</w>
retrospecti vely.</w>
retard ation.</w>
resp ect
resid ents</w>
rescu e.</w>
requi red,</w>
reporte dly</w>
replic ation.</w>
replac ement,</w>
relax ations</w>
reinforce ment.</w>
reg im
refrac tive</w>
recogn ized,</w>
radi ocon
rad icular</w>
quin april</w>
quarter s</w>
pur su
public ations</w>
prote oglyc
prot ective.</w>
propylthio uracil-induced</w>
prophylac tically</w>
prolong ed.</w>
program ,</w>
profoun dly</w>
prob able
pro of</w>
pro l</w>
pro convulsive</w>
preven tion.</w>
precl uded</w>
prece des</w>
pre hospital</w>
pos ing</w>
por tions</w>
poison ing,</w>
ple thysmo
plasi a,</w>
plac ing</w>
phot osensi
perman ently</w>
perm it</w>
pericardi tis.</w>
pericardi tis,</w>
perf usate</w>
pe dic
paradig ms</w>
papaver ine.</w>
pal ate,</w>
pal atal</w>
pac ing,</w>
pa in)</w>
pa di
pa d</w>
p assi
p 75
oxcarb azep
over drive</w>
ov agal</w>
ou se</w>
ot oxin</w>
ost er</w>
osmolal ity.</w>
os pinal</w>
origin ally</w>
ore x</w>
or um</w>
or al,</w>
opportun istic</w>
oplas mo
om edullary</w>
olg i</w>
ol in
occurren ces</w>
oc ent
oc al
obj ectively</w>
o estradiol</w>
o edema.</w>
non- significant</w>
nocicep tion,</w>
ng/ kg/
neurolep tic,</w>
neuro vascular</w>
neuro peptides</w>
neuro biological</w>
nephro lith
neoplas ms.</w>
necessit ate</w>
ne fir
n ac
n NOS</w>
n ;</w>
mydri asis</w>
myalg ia.</w>
multi organ</w>
mucos a,</w>
mono hydrate</w>
moi ety</w>
mode s</w>
modal ities</w>
minocycl ine.</w>
micrograms.kg-1. min-1</w>
mibefradi l</w>
mi um</w>
metoclopram ide,</w>
methylprednisol one.</w>
methylphenid ate.</w>
methyl transferase</w>
methyl glutar
mesi al</w>
mes alaz
mefloqu ine.</w>
medic ine,</w>
medi ated,</w>
mean ing
mas ked</w>
mar mo
mapro tiline</w>
male ate,</w>
mala ise</w>
mRNA .</w>
mL/ min/
mE q</w>
m mol
m ia;</w>
m ass
m Ab</w>
m ),</w>
luk ast</w>
lograph y.</w>
locomo tion.</w>
lobe .</w>
lo t
ligi bility</w>
lig ation.</w>
leth an
length ened</w>
leng th,</w>
lenal idom
le ish
leish man
l en
kallikre in</w>
k ling</w>
iz ers</w>
iterpen e</w>
isol ated,</w>
io -
intrag astric</w>
intest inal,</w>
intersti tium</w>
inter scalene</w>
inter im</w>
inter acting</w>
integr in</w>
insul in-like</w>
institu tions</w>
institu tional</w>
insp iratory</w>
inflammat ory,</w>
infiltr ating</w>
infer i
inf using</w>
inf ra
in ous</w>
in determin
in amide</w>
implic it</w>
imipr amine-induced</w>
imidaz enil</w>
ido pa
ic- tonic</w>
ic hi
i vermectin</w>
hypox ia.</w>
hypox ia,</w>
hypomagnesem ia,</w>
hypocalce mia,</w>
hypo gly
hyper sensitivity,</w>
hydroxy toluene</w>
hy ster
hour s;</w>
hol ding</w>
hexachloro cyclohex
her nia</w>
hepat omegal
hemo therapy</w>
heigh t,</w>
haloperid ol-treated</w>
haemodi lution</w>
haemat oma</w>
habit uation</w>
h os
h old</w>
guan fac
grav ity</w>
granulocy te-
go es</w>
glycos uria</w>
glybur ide</w>
glucose-6- phosphate</w>
gluc agon
gl and.</w>
gangli a.</w>
gadol inium-
g inning</w>
g ent</w>
fron t
flur azepam</w>
flest olol</w>
fl us
first- episode</w>
fibrill atory</w>
fashi on,</w>
far .</w>
fai led.</w>
extub ated</w>
extrem ities,</w>
ext ent.</w>
expect ed.</w>
ex per
evid ence
event s:</w>
eti olog
eth acrynic</w>
est er,</w>
es un
es in</w>
erythro cytes.</w>
epirub icin.</w>
epilep sy-
epididy mal</w>
environ ment.</w>
entr y.</w>
enthix ol</w>
ent ation</w>
ent )</w>
ent 's</w>
encounte red.</w>
encephal on</w>
en op
en able</w>
emis sions</w>
embry onal</w>
electro retino
electr onic</w>
edar av
dysph or
dys functions.</w>
drom ic</w>
dou bling</w>
dose- depend
dobut amine.</w>
distribu tion.</w>
disten sion</w>
disru ptive</w>
dis rupt
dis appeared,</w>
diethylstilbestro l.</w>
diaph or
di ents</w>
dex verapamil</w>
desogest rel</w>
dens ity,</w>
demyel in
del usional</w>
degre e.</w>
def ining</w>
dec lines</w>
deb riso
de :</w>
da z
cyclohex yl
cyclo- oxygenase</w>
cur ve.</w>
cult ures.</w>
cri sis.</w>
cre ate</w>
cr yo
cour ses,</w>
convol uted</w>
controver sy</w>
control s).</w>
control ).</w>
contracep tion</w>
contra st-induced</w>
contra indication</w>
conjug ate</w>
cong estion</w>
conf ocal</w>
condi tional</w>
conclu sive</w>
concent ric</w>
concent rate</w>
con i
con flu
comorbidi ties</w>
comorb idity</w>
communic ation</w>
colon y</w>
colchic ine.</w>
clobaz am</w>
clinicopath ologic</w>
clar ified.</w>
cil astatin</w>
cid ofovir</w>
choro idal</w>
chlordiazep oxide</w>
chlor alo
chill s,</w>
chemotherap y:</w>
cer tain
cell ul
cefuro xime</w>
cav a</w>
catechol amine-
carrageen an-induced</w>
cardiomyo pathic</w>
carbox amide</w>
car mustine</w>
calcium- channel</w>
c ine</w>
bypas s.</w>
but olol</w>
bumet anide</w>
bp m</w>
bos entan</w>
bol us.</w>
biomark ers</w>
bin alt
binalt orph
between- group</w>
bas ed,</w>
bacter ium</w>
b one-
b amate</w>
b abo
azot emic</w>
azathiop rine,</w>
auto antibody</w>
auth or
audi ometric</w>
ati ve-
atazana vir</w>
at ric
at or-
ascit es.</w>
artic ular</w>
arth ritic</w>
art esun
arie- Tooth</w>
ar yl</w>
ar yl
ap se</w>
antr one</w>
antipyre tic</w>
antioxid ants,</w>
anti-HB s</w>
anti tuberculosis</w>
anti fibrinolytic</w>
anten atal</w>
ant -
anem ia:</w>
anatom y</w>
anand amide</w>
ana erobic</w>
an other.</w>
an il
amygdal a.</w>
aminonucleo side.</w>
amino guanidine</w>
amide /
ameth yl
alph a.</w>
aggreg ation.</w>
ag o
ag inal</w>
ag al
adul t.</w>
adenos ine,</w>
addic ted</w>
ad ded.</w>
actin omycin</w>
act u
act s,</w>
aconit ine</w>
acetyl ated</w>
accumul ating</w>
accid ents</w>
ac tions,</w>
ac com
abecarn il</w>
ab ut
ab ri
ab ic
a prost</w>
] :</w>
X- 2)</w>
W IN
V A</w>
UPD RS</w>
Treatment -related</w>
Tramad ol</w>
Thiop ental</w>
Th rough</w>
Tac rolim
Ta q
TUNE L-
TR AC
TRAC TION:</w>
TP M</w>
TMP-SM X</w>
T ur
T l</w>
T T</w>
T M</w>
T /
Syn thesis</w>
Surg ery</w>
Secon d,</w>
SV R</w>
ST ,</w>
SN S</w>
SN HL</w>
SC T</w>
SA H.</w>
S us
S o</w>
S NA</w>
S LE</w>
S A),</w>
S 100
Res olution</w>
Repor ting</w>
Recomm end
Raniti dine</w>
Raloxif ene</w>
RE LE
RELE VAN
R ot
R R
R L
R K
R H</w>
R G
Q 10</w>
Propofol -
Prog ester
Pres ent</w>
Practi tion
Post ural</w>
Penicill amine</w>
Pe g
Path ologic</w>
Parad oxical</w>
Paracetam ol</w>
Pa ren
PT ,</w>
PIIIN P</w>
PG )</w>
PATIENT :</w>
PANS S</w>
P ;</w>
O vari
Not ably,</w>
Nephro genic</w>
Na+, K+-ATPase</w>
NT69 L</w>
NT D</w>
NO .</w>
NMDA- receptor</w>
N icardi
N et
N N
Myoclon ic</w>
MTX -induced</w>
MT X)</w>
MDMA /
M er</w>
M H
M F</w>
M F
Loc omotor</w>
Li /
Li -induced</w>
LI Ds</w>
LE ,</w>
L R</w>
L H
KE Y</w>
K- ATPase</w>
K- 3
Jap an</w>
J NK</w>
Inter stitial</w>
In jections</w>
IP ).</w>
II ).</w>
ICRF-1 8
I mag
I MA
I H
Hyponat remia</w>
His -P
Hal f</w>
HO E</w>
HIV -1-
HIT ,</w>
H all
Glut amate</w>
Ger man
Gab ap
GL EP
GLEP P1</w>
G olgi</w>
G ST-
G SP
G 6
Fos car
Flu oxet
Fascicul ations</w>
FEAT URES:</w>
F ree</w>
F am
Ep iso
Electro physiologic</w>
EX TRACTION:</w>
EMB A
EC o
E stim
E AD
E 2,</w>
E ).</w>
Di ure
Di hydro
DX R-induced</w>
DOX -treated</w>
D-penicill amine-induced</w>
D en
D PO
D I</w>
Cs A-
Cros s-
Con sec
Con genital</w>
Comp uter
Clin ic</w>
Cholest asis</w>
Chem ical</w>
Charcot-M arie-Tooth</w>
Cer tain</w>
Capecit abine</w>
Cal cit
Ca ro
CO PD</w>
CNS ,</w>
CM L</w>
CG S</w>
CG RP
CB F
CA T</w>
CA S</w>
CA ),</w>
C ou
C l.</w>
C ase-
C PAP</w>
C L</w>
C F</w>
Be ginning</w>
BZ D
B rown</w>
B iliary</w>
B ile</w>
B ay
Ap parent</w>
An alo
Amino glyco
Am mon
Altern atively,</w>
Alph a-
Adju vant</w>
AS P
AR I</w>
AP PRO
AM )</w>
AH -10
ADR- 5
AD HD.</w>
A mitript
A KI</w>
A -1</w>
A (2)</w>
> or=</w>
< 0.001).</w>
< /
8 9%</w>
7 8-year-old</w>
6- mercaptop
5-fluorourac il,</w>
5-HT(2 B)</w>
5-HT 2A</w>
5-FU ,</w>
5-1 5</w>
5 00,</w>
4. 3%</w>
4 2)</w>
39 )</w>
37 ).</w>
36 ),</w>
3. 6%</w>
3 7)</w>
3 3-
26 8</w>
25 ),</w>
25 %.</w>
24- year-old</w>
24- (OH)(2)
24 ),</w>
200 4,</w>
20 2</w>
20 1
2, 4
2 6-year-old</w>
2 50,</w>
199 9,</w>
16 %,</w>
15. 5</w>
15 7</w>
14 C-
10- min</w>
10(- 7)</w>
10 th</w>
1. 8%</w>
1. 00
1- selective</w>
1,25-dihydroxy vitamin</w>
1 0.8</w>
00 0/
0.6 9</w>
0. 40</w>
0. 27</w>
0 3</w>
-1 50</w>
-- ></w>
- G
- 0.7
+ ,</w>
(v )
(p -
(V TE)</w>
(V PA).</w>
(TM P-SM
(SP EC
(S p
(P I)</w>
(L M
(HC C)</w>
(E E)</w>
(D L
(CO X-2)</w>
(AL L)</w>
(A m
(8 4%)</w>
(6 7%)</w>
(6 4%)</w>
(5 /
(4 3%)</w>
(4 2%)</w>
(4 00
(2. 5,</w>
(2 7</w>
(2 6%)</w>
(100 %)</w>
(10 %),</w>
(1. 25</w>
(1 -10</w>
(0.0 3-
(0. 8</w>
(0. 8
( un
( two
( systolic</w>
( such</w>
( score</w>
( plasma</w>
( mainly</w>
( acute</w>
' )</w>
zom epirac</w>
zol amide/
yr .</w>
yl yl</w>
year- old,</w>
y- -
y ros
worth y</w>
whole- cell</w>
whe reas,</w>
well- described</w>
wean ed</w>
warm th</w>
warfar in-induced</w>
vulg aris.</w>
volum ic</w>
vol ati
visc osity</w>
vir us,</w>
vi b
verapam il-induced</w>
ven ular</w>
vasopress in,</w>
vascul itic</w>
vacuol ation</w>
vacc ine.</w>
urticar ial</w>
urin aly
unmas king</w>
univer sal</w>
un selected</w>
un intentional</w>
uc hen
uc cin
tur ning</w>
tumori genesis</w>
tum or,</w>
tuberculo sis,</w>
transmit ter</w>
transfu sions,</w>
transamin ase,</w>
tran sesophageal</w>
tract ,</w>
topo isomerase</w>
tis ation</w>
tinnit us,</w>
tim ed</w>
thyro trop
threshol ds,</w>
thi one
thi onate</w>
thi azine</w>
th ous
th enium</w>
tetrahydro -
tetrachlor ide</w>
test ;</w>
termin als.</w>
ter 's</w>
tension -type</w>
te .</w>
t ),</w>
syn ergy</w>
symptom s;</w>
sympath ectomy</w>
sym pathe
supplement ary</w>
sup ratentorial</w>
substanti ate</w>
sube pithelial</w>
strom al</w>
streptozotoc in.</w>
stra in.</w>
stereot ax
stat es,</w>
st ut
sper mine</w>
spec ially</w>
son -
slow- release</w>
sk in-
simul ate</w>
sim vastatin.</w>
sim pl
sildenaf il.</w>
short- lasting</w>
sevoflur ane,</w>
sett ings,</w>
ses ;</w>
sertral ine.</w>
sequ ence.</w>
separ ately,</w>
selectiv ity.</w>
seg reg
secre ted</w>
se man
seman tic</w>
se m</w>
sclero tic</w>
scinti graphic</w>
sarcolem mal</w>
sal ine;</w>
run s</w>
rot ations</w>
rilmen idine</w>
rig id</w>
retri e
retic ular
resul t.</w>
rest en
resp i
respi rat
resol ves</w>
reser pin
research .</w>
res veratrol</w>
reproduc i
remodel ing.</w>
relap se-
regul ator</w>
regener ation.</w>
red ness</w>
recur red.</w>
rectom ized</w>
recor ded,</w>
rec alled</w>
reb oun
re medi
re j
re introduction</w>
re al
re admitted</w>
rauwol sc
rapid ,</w>
rang es.</w>
ra rely,</w>
r ut
qu ired</w>
q .
pyrrolid inyl)
pyri dos
pyr one</w>
py ram
puber tal</w>
psoriatic s</w>
protocol s,</w>
prot ection,</w>
proper ty,</w>
pronoun ce
prolong ed,</w>
progres sive,</w>
progest ins</w>
profil es,</w>
produc t,</w>
princ i
prim id
pri mi
pressure- volume</w>
pre emptive</w>
pre cautions</w>
pran dial</w>
pr ud
post traumatic</w>
posi tions</w>
poly godi
poly arteritis</w>
pollic is</w>
pol icy</w>
pmol )</w>
plast y,</w>
plaqu es</w>
piperid ine</w>
pilocarp ine-
phenyleth yl
phentol amine,</w>
ph obia</w>
ph ases.</w>
perf u
per mitting</w>
per g
penicill amine-induced</w>
pelle ts</w>
peculi ar</w>
pector is,</w>
pat h</w>
participat es</w>
partic le</w>
parti ally,</w>
para esthe
par ame
pair -fed</w>
paclitaxel /
pac ed</w>
p antop
oxybutyn in</w>
oxy morphone</w>
ox amine,</w>
ot ap
osi s:</w>
orphenad rine</w>
ori e</w>
organ el
orbitof rontal</w>
or ide</w>
or chi
opioid -
ophyl line
ophthalmop legia</w>
ophthalmo log
on /
ol der,</w>
ol ).</w>
oin t
od al</w>
ocap nia</w>
oc u
oc tap
observ ations,</w>
ob t
ob liter
o k
o be
numer ical</w>
noreth ind
nor- binaltorph
nitrate/ nitrite</w>
nigh t.</w>
nigh t,</w>
nicardi pine.</w>
nic ergoline</w>
ng/ d
newbor n.</w>
neo plasia</w>
natriure sis</w>
n-Whit ney</w>
n ul
muscim ol,</w>
mum ol
multi factorial</w>
mu -
moric izine</w>
mofe til
mmol/ l)</w>
mmol/ L.</w>
ml ;</w>
mit ogen
mist ak
min (-1))</w>
mictur i
microsph ere</w>
microsom es</w>
microscop e</w>
micrograms/ mL</w>
microgram/kg/ min</w>
microgram/ kg</w>
microgram )</w>
micro liters</w>
micro globulin</w>
micro emulsion</w>
micro bub
mic e)</w>
mg/kg/ h</w>
mg/K g</w>
mg /</w>
mg %</w>
membran es,</w>
medull a,</w>
medi um,</w>
mat ter.</w>
mat ter,</w>
mat ory</w>
margin ally</w>
manage able.</w>
man son
mL/ kg</w>
m id</w>
m A</w>
m 2.</w>
m ).</w>
lymph omas</w>
low- frequency</w>
lor azepam,</w>
lob ar</w>
lipo philic</w>
lig ation,</w>
li er</w>
lev ome
lef tward</w>
le ast
labour .</w>
labetal ol.</w>
lab our</w>
kynuren ine</w>
kynuren ic</w>
knoc k-
kg .
ketoro lac
keto profen</w>
ket amine-
kappa -opioid</w>
kP a</w>
k ing,</w>
it ching</w>
iso volumic</w>
iso quinol
is ation.</w>
irt ine</w>
irrit ability</w>
ir regular
ir on-
ip ,</w>
iome prol</w>
invari ably</w>
introduc ed.</w>
intravenous ly)</w>
intram yocardial</w>
intr al
inte rest.</w>
insul t.</w>
inst ances,</w>
innoc uous</w>
influenz a</w>
infer red</w>
induc ibility</w>
individu alized</w>
indic ations,</w>
indetermin ate</w>
inco ordination</w>
incl ined</w>
in- clavulanic</w>
in- 4-
in g/
in ess.</w>
if i
id ze
ic ro
i.m .,</w>
i se
hypothalam us,</w>
hypos padi
hypop ar
hypopar athyro
hypokal aemia</w>
hypo prote
hypertensi ves</w>
hyperten sive,</w>
hyperten sion
hyperprolactine mia,</w>
hyper active</w>
hydrox ylation</w>
hydrocephal us</w>
hydr ated</w>
hippocamp i</w>
highligh ted</w>
hepat oblast
hepat o
hepat ectomy</w>
he xim
he ating</w>
haplo type</w>
haloperid ol-
half- lives</w>
group s)</w>
gro oming</w>
gra de
glomer ulopathy</w>
ginsen osides</w>
gang rene</w>
galact osid
galact os
gal lium</w>
ga str
g/ kg,</w>
g/ 24</w>
g ap
ful min
frusem ide</w>
frequ ent.</w>
four- hour</w>
foscar ne
for ce
flunitraz ep
fluc loxacill
flox uridine</w>
fl am
fif teen</w>
fibrin ogen
fentan yl-
feno profen</w>
famil y.</w>
f its</w>
extrem ity.</w>
extr asystol
extr act.</w>
expl oring</w>
excit ability.</w>
exci sion</w>
ex plic
evo kes</w>
evalu ated,</w>
euphor ia</w>
etid oca
ethyn ylestradiol</w>
estrogen s.</w>
esc ence</w>
es --
erythro dysesthesia</w>
erythematos us,</w>
erythemat ous</w>
erm ally</w>
erg ometr
epid er
epiandro sterone</w>
ent ac
enroll ment</w>
enox im
endocannabin oid</w>
encour aging</w>
encephalo pathy:</w>
en in</w>
em ed</w>
ell ation</w>
electrophysi ologically</w>
ejac ulatory</w>
edroph onium</w>
ear .</w>
dysrhythmi as,</w>
dysph oric</w>
dy ing</w>
dulox et
duct openia</w>
drug- eluting</w>
dri ving</w>
dose- limiting.</w>
dose ).</w>
dn ess,</w>
distres sing</w>
distres s,</w>
disp ens
disor gan
diseas e)</w>
disabl ed</w>
dis ci
disci pl
direc t-
dimin ished.</w>
dilat ation,</w>
dig estive</w>
diarrho ea,</w>
diaphore sis,</w>
dialy sis,</w>
di pyrone</w>
di isopropyl
dev ic
deta il.</w>
design ated</w>
der ing</w>
deliri ous</w>
definit ely</w>
defici encies</w>
de stro
de emed</w>
datab ase,</w>
dan aparo
d ness</w>
d ine.</w>
d .
cyclo hexim
cult ure,</w>
cul ating</w>
crystall ine</w>
counter part
contrac tion,</w>
continu ously.</w>
constitu ent</w>
const ellation</w>
conside red,</w>
consequ ently</w>
consequ ence,</w>
condition ing.</w>
con fer
complic ate</w>
complain ts,</w>
coca ine:</w>
clu sters</w>
cit rulline</w>
chrom atin</w>
cholecyst ectomy</w>
cholec alc
cho ice.</w>
chloro zotoc
chloramphenic ol.</w>
chlor hexidine</w>
chill s</w>
chem osensi
ch or
ch .</w>
cent .</w>
cefotax ime</w>
cef ox
ce li
carmo fur
cardiover sion.</w>
cardi otonic</w>
car pal</w>
car ing</w>
capill ari
capac itance</w>
canal icul
calcul ate</w>
c es.</w>
bu tion</w>
bu il
br and</w>
br ac
bortezomib -induced</w>
bo ard</w>
block er)</w>
blo od
blast s</w>
bl u
bl in
biopsi es,</w>
bi ochemically</w>
beta- H
benz ofur
ben ign
behaviour ,</w>
be ha
be f</w>
basel ine).</w>
bas e-
b ucindo
b ox
b cl
azido thymidine</w>
axon s.</w>
awak e,</w>
aw ay</w>
autophag y</w>
audi ologic</w>
attention- deficit/hyperactivity</w>
ate d)</w>
ate -associated</w>
ate -</w>
at o</w>
at ase</w>
arc uate</w>
ar ic</w>
apr ind
approach ed</w>
appear ance.</w>
apne ic</w>
aph asia</w>
ap it
ap ath
anxiety- related</w>
antihist amin
antidot e</w>
anticonvuls ant,</w>
antibio tic.</w>
anti- oxidant</w>
anti dysrhythmic</w>
anti dyskinetic</w>
anorexi gen
angi ocardi
analy se</w>
an s
an ol,</w>
an of
an /
an 's</w>
amygdala- kindled</w>
amphet amine-</w>
amitriptyl ine,</w>
aminophyll ine-induced</w>
amant adine,</w>
alu minal</w>
alpha, 5alpha-
albu min.</w>
al ),</w>
aj maline</w>
agoraph obia</w>
agal us</w>
advantage ous</w>
adrenocor tical</w>
adenos ine-
acyclovir .</w>
acrole in</w>
acetylchol ine,</w>
acet one</w>
ac in-induced</w>
ac a</w>
abnormal iti
abnormal .</w>
ab ro
a ren
a .
[OR ]</w>
ZO -1</w>
X- 4</w>
W ell
Ver y</w>
V TE
UL- FS</w>
Thyro id</w>
Thrombo embolic</w>
Te trac
Tak otsubo</w>
TM Z</w>
TM X</w>
TLP R</w>
TGF- beta</w>
TGF- beta
TA C</w>
T ric
T c
T G
Swe den
Succin yl
Su xameth
Sou th
Seventy- two</w>
Sel f-
Schiz ophren
SU N
SUN -13
SUN-13 34
SR L-
SI ,</w>
SD BP</w>
SC 1</w>
SA P</w>
S pas
S il
S TI
S J
Rifamp icin</w>
Renograf in-
Remifentan il</w>
Recommend ations</w>
RA S</w>
R ati
Quin ine-induced</w>
Pul se</w>
Pub M
Pro pafen
Pre valence</w>
Practi ce</w>
Place bo</w>
Pergol ide</w>
Penicill amine-induced</w>
Paclitax el
PV N</w>
PT U.</w>
PR L,</w>
PR ,</w>
PH ,</w>
PE ,</w>
PA G</w>
P U
P PA
P NS</w>
Oxy toc
Out patient</w>
O d
Neuro lep
Na Cl
NH L</w>
N- [4-
N MR</w>
Mo od</w>
MgSO 4</w>
Mal ign
MT X-
MT ,</w>
MMP- 9</w>
MK-80 1,</w>
M isoprost
M CP
Life- threatening</w>
Lid oca
Le sions</w>
Lam otrig
Labet alol</w>
L-NOAR G</w>
L- 1</w>
L ethal</w>
L act
L CT/
L 5</w>
KCC 2</w>
K v
Intram uscular</w>
Intra vesical</w>
Intra ventricular</w>
In ten
In flam
IFN- alpha</w>
IF N/
ID V</w>
IC D</w>
I DA</w>
Histopath ology</w>
Histopath ologic</w>
Hist ology</w>
His-P urkinje</w>
Hepar in-associated</w>
Hemat ological</w>
HIP/ PAP</w>
HC C.</w>
HC ,</w>
H om
H ar
H F)</w>
H 1-
Gener ally,</w>
Gemcit abine</w>
Gabap entin</w>
GV HD.</w>
GS K-3
GR1389 50</w>
GR P)</w>
GM -induced</w>
GF ,</w>
G y</w>
G y
G li
G astric</w>
G all
Fluoro-J ade</w>
Fish er's</w>
Fifty- three</w>
Fact or</w>
FK- 506</w>
FANF T-
F ull</w>
F allo
F H
Ethambut ol</w>
Estradi ol</w>
Epirub icin</w>
Epilep sy</w>
Engl and</w>
Endo genous</w>
En ox
Electr ical</w>
EE -treated</w>
ECo G</w>
E-17 G</w>
E van
E c
E L</w>
E 1-induced</w>
Dop aminergic</w>
DE HP</w>
D uchen
D IC
D D</w>
D 6</w>
Cortis ol</w>
Cor tico
Consec utive</w>
Con tri
Citalop ram</w>
Cimeti dine</w>
Chemo therapy-induced</w>
Ch ar
Ce phal
Car vedi
Capsa icin-induced</w>
CT GF</w>
CR P</w>
CR F
CO X
CM RO
CI S</w>
CA 1,</w>
C3 H/
C ranial</w>
C an</w>
By J</w>
Bic ucul
Be sides</w>
BM D</w>
B D</w>
Atten tion</w>
Aqu eous</w>
An ter
Amne sia</w>
Al lo
Ac ut
AP AC
APAC HE</w>
AE s.</w>
AD H</w>
AD ).</w>
AC I</w>
A str
A ortic</w>
A mil
A II</w>
A H</w>
99 )</w>
80- year-old</w>
8- week,</w>
8- hydroxy-2-
8- fold</w>
8 1)</w>
7 0,</w>
6-keto- PG
6 35</w>
6 2.
6 1-
5826 1</w>
5-hydroxytrypt ophan</w>
5-HT(1 B/
5-HT TLPR</w>
5-HT P</w>
5-HT (3)</w>
5- 6</w>
5 7,</w>
5 -</w>
5 );</w>
4. 2%</w>
4- mg</w>
4- hydroxy
30 .</w>
3. 7
3- methyl
3, 000</w>
3', 5'-
3 :
3 1)</w>
3 1
3 );</w>
3 '
28 ),</w>
28 %,</w>
25 3</w>
24 ,
23 7</w>
200 3.</w>
200 1.</w>
20 4</w>
2-chloro procaine</w>
2 80</w>
2 30</w>
199 6.</w>
198 5</w>
17 4</w>
17 %,</w>
15. 0</w>
15- minute</w>
13 /
13 %,</w>
1.0 5</w>
1. 75</w>
1. 4%)</w>
1,25 (OH)2D3</w>
1 18</w>
1 1,
0.6 2</w>
0.5 6</w>
0. 8,</w>
0. 4%</w>
0. 3-
0. 125</w>
/- )</w>
/ c</w>
-1 45
- plantar</w>
)- based</w>
(r 2</w>
(c Tn
(TGF- beta
(SSR Is)</w>
(SE M)</w>
(S NP
(S ER
(PT Z)</w>
(PT Z),</w>
(PR A)</w>
(P< 0.01)</w>
(P N)</w>
(O P
(LD H)</w>
(L )</w>
(I B
(DOX )-induced</w>
(DO PAC
(D el
(C D)</w>
(B rd
(Ara- C)</w>
(ADH D)</w>
(ACh E)</w>
(A ST)</w>
(A IN)</w>
(8 8%)</w>
(8 3%)</w>
(8 2%)</w>
(8 %),</w>
(7 6%)</w>
(6-OHD A)</w>
(6 2.
(5 5%)</w>
(4 8%)</w>
(4 6.
(4 3.
(3 80</w>
(3 4%)</w>
(2. 3</w>
(2- chloroethyl
(2 8</w>
(2 3.
(2 00-
(10 /
(1 80</w>
(1 60</w>
(1 00-
(1 0.0</w>
(0.0 4</w>
(0.0 2</w>
(-1 ).</w>
( week</w>
( on</w>
( nine</w>
( ip)</w>
( except</w>
( blood</w>
( beta-
( anti-
" off"</w>
xen obio
win dow
wa ve,</w>
w t,</w>
voltage- gated</w>
vide otap
verapam il-
ve -induced</w>
vasospas tic</w>
vasodil ation,</w>
vasoconstric t
vaso depressor</w>
v oid</w>
v ill
v ap
utili z
us u
us er
uro protective</w>
ur o</w>
ur ines</w>
un differentiated</w>
um- deficient</w>
two- thirds</w>
twic e,</w>
tw in</w>
tur n,</w>
tubul in</w>
tro vafloxacin</w>
tro pi
tric hloro
tri iodo
tremor s.</w>
transl ational</w>
transcrip tional</w>
trans- retinoic</w>
tr yp
tr unc
tr on
tr al</w>
toxic ologic</w>
tol azoline</w>
tim es)</w>
tic tal</w>
tic "</w>
ti bi
tibi alis</w>
thym ocyte</w>
thym ia</w>
thrombo ses</w>
thir ty</w>
thiopent al.</w>
thick ness,</w>
thiaz ide-induced</w>
thi ou
therap y).</w>
tetr aben
tetan ic</w>
termin ate</w>
terbutal ine-induced</w>
te am</w>
te a</w>
tadal afil</w>
tachy p
t yramine</w>
t le
t ard
tard a</w>
system ic,</w>
symptomat ology.</w>
symptom -free</w>
suxameth onium-induced</w>
surve y.</w>
subst ance.</w>
subject s)</w>
subject ,</w>
sub- Ten
sub population</w>
sub icul
strychn ine-induced</w>
stre et</w>
strati fication</w>
stimul ator</w>
stav ud
st ay.</w>
st ains</w>
sprout ing.</w>
splen omegaly</w>
spi ren
spectr a</w>
spas m,</w>
som no
so ver,</w>
so a
sleep- wake</w>
sl er</w>
sin o-
signal- regulated</w>
sigma 1</w>
sib lings</w>
sib ling</w>
show n.</w>
she ep</w>
sex ually</w>
sex es.</w>
ses )</w>
seroton inergic</w>
seri ous,</w>
separ ately.</w>
semi quantitative</w>
second s,</w>
sec ,</w>
se mic
scienti f
sc an,</w>
saralas in</w>
saliv ary</w>
s ap
ru p
ru bell
rota -
rofecoxi b,</w>
ro ll
rit anserin</w>
ris ks.</w>
ri se,</w>
ri ol</w>
resuscit ation.</w>
restless ness</w>
response )</w>
repolar ization.</w>
remo ve</w>
relapse- free</w>
rej ection.</w>
reflex es.</w>
reflex es,</w>
recurren t,</w>
recogn iz
rec essive</w>
reason ably</w>
re new
re dox
re d;</w>
rat s'</w>
ras ag
rapid -
radio therapy,</w>
radic als.</w>
ra ising</w>
qu ick</w>
prurit us.</w>
proper ly</w>
program me</w>
proce eded</w>
proce ed</w>
pro collagen</w>
primat es</w>
primat es.</w>
pri min
prevent able</w>
pressure ;</w>
pressu res.</w>
prednisol one,</w>
pre requisite</w>
pre pon
prepon der
pre optic</w>
pre morbid</w>
pre medication.</w>
pre load</w>
pram ipexole</w>
potenti als.</w>
post- SE</w>
post injection</w>
post er
post anesthesia</w>
possibil ities</w>
popul arity</w>
polygodi al</w>
pituit aries</w>
pir arubicin</w>
phospholip ids,</w>
phenyl acetic</w>
ph otoc
peroxis omal</w>
perme ability.</w>
perm its</w>
periton itis</w>
peri -
per is
pent adec
paw ,</w>
pattern s,</w>
patch -
pass age</w>
paroxet ine,</w>
parenchy ma</w>
paren tal</w>
parano ia.</w>
parac ellular</w>
papill a</w>
pan ic
painf ul
pac kage</w>
pa uses</w>
pa use</w>
oxid ation,</w>
ox ac
out weigh</w>
out growth</w>
other s,</w>
otec an,</w>
ost at</w>
os al</w>
orth opa
oro pharyngeal</w>
ornith ine</w>
ore p
optim ize</w>
open ,</w>
on y</w>
ol iv
ol ine-induced</w>
ol d-
ol :</w>
occurren ce.</w>
o val
o ds</w>
novel ,</w>
non- alcoholic</w>
non treated</w>
nit raz
neuro toxicity:</w>
neuro psych
nerv ous
neon atally</w>
neg ligible.</w>
nec k.</w>
ne d.</w>
nam ely,</w>
n ia.</w>
myo pathy:</w>
mus cul
mon o-
mode lling</w>
mmol/ kg)</w>
mmol/ L,</w>
mm 3)</w>
mix ed-
minut e.</w>
minoxidi l-induced</w>
minim ized</w>
min -1),</w>
mil nac
mil i
micrograms/kg/ min)</w>
micrograms/ kg.</w>
micro l,</w>
micro globul
mg/ l,</w>
mg. kg-1)</w>
methylglutar yl</w>
methyl- 6-
methodo logy</w>
methi azole</w>
meth asone</w>
meperid ine.</w>
meglum ine</w>
mar -plantar</w>
man eu
malignanc y,</w>
mal e.</w>
main tains</w>
mac h
ma y
ma -like</w>
mL/ min</w>
m U/
m L.</w>
lyso zyme</w>
ly :</w>
lob es</w>
lit ter</w>
libit um</w>
li st
li ber
levonorgest rel
levof loxacin,</w>
leuk aemia.</w>
left- ventricular</w>
leak y</w>
lay er.</w>
lat ter,</w>
labetal ol,</w>
l s,</w>
l :</w>
kg(-1 )
ke eping</w>
kain ate-induced</w>
kP a)</w>
k y</w>
k ed.</w>
k ary
isoflur ane-
iso propyl</w>
ism :</w>
is sure</w>
ir on,</w>
ip uncture</w>
iohex ol.</w>
iohex ol,</w>
intrat ubular</w>
intrane ural</w>
intram ural</w>
interven tions.</w>
insul in-dependent</w>
input s</w>
innerv ated</w>
inj ected.</w>
initi ation,</w>
ing in</w>
ing ham</w>
ing ent</w>
ine- dependent</w>
indole acetic</w>
indic ation.</w>
ind ing</w>
in organic</w>
in es,</w>
in -1-
impoten ce.</w>
impl ies</w>
immunohistochemistr y,</w>
immunohist ochemically</w>
immun olab
immun o-
im pression</w>
im pac
illnes ses.</w>
ific ation.</w>
ifenpro dil</w>
idiosyn c
idiosync rati
idi lol</w>
identifi es</w>
ide ),</w>
ic v)</w>
ic idal</w>
ic -induced</w>
ia- reperfusion</w>
i pr
i let
hypoparathyro idis
hypom an
hypoalbum inemia,</w>
hypo algesia</w>
hypertriglyceride mia</w>
hyperten sion;</w>
hyperreflex ia</w>
hypernat remia</w>
hyperlipide mia.</w>
hydroxy zine</w>
hormon es,</w>
hom o
hom e.</w>
hist amine,</w>
hiccup s.</w>
hepatocarcin ogenesis.</w>
hepati c,</w>
health ,</w>
he d,</w>
har ms</w>
hand- foot</w>
haemo dynam
haemat uria</w>
h ope</w>
h im
h an
guide lines.</w>
gu id
grad ing</w>
gonad otrop
go als</w>
glycos amino
glycer ol</w>
glucocortico id-
gli omas</w>
gl icl
gl ab
geu sia</w>
gen u
gen omic</w>
ganciclo vir
gamma-glutam yl</w>
gamma- hydroxybut
gall amine</w>
galant amine</w>
gal anin</w>
g/m 2,</w>
g/m 2)</w>
g over
g e</w>
g aro
garo toxin</w>
g -1</w>
further .</w>
fre e,</w>
formul ation.</w>
formul ation,</w>
form ance</w>
fore brain.</w>
follow up</w>
foc uses</w>
flut ter,</w>
fluo rop
fl at
fl are
five- year</w>
fil ter</w>
fibroblast s.</w>
fi er</w>
fen oterol</w>
fa ec
f icially</w>
exclu ded,</w>
exacerb ating</w>
ex change,</w>
ev acu
etid ocaine</w>
ethan olic</w>
ethambut ol.</w>
et uses</w>
est rus</w>
es sel</w>
erro r
ergotamine/ caffeine</w>
epirub icin,</w>
epilepsy- prone</w>
ep it
ent ries</w>
ent eral</w>
enflur ane.</w>
endoscop y</w>
end s</w>
end ings</w>
en s,</w>
en em</w>
en anth
empir ically</w>
embry otoxic</w>
embol ization</w>
elucid ating</w>
electro diagnostic</w>
el ess</w>
effect or</w>
ecti ve
e.g .,</w>
dyst oni
dysp nea,</w>
duc ts,</w>
du e,</w>
drug- specific</w>
dose ;</w>
dose ),</w>
dofe tili
diure tic,</w>
disulfir am-induced</w>
disul fi
disopyram ide,</w>
dis k</w>
diphenyl hydanto
dimen hydr
dihydro- 5H-
diarrhe a.</w>
diabe tics</w>
di propyl
di lev
di acetyl
dex razox
desi pramine.</w>
desferri oxamine.</w>
desat uration</w>
derang ements</w>
depart ment,</w>
denerv ation.</w>
demeclo cycline</w>
del ay,</w>
degener ated</w>
deep- vein</w>
de serves</w>
de hydration,</w>
de afferen
dd i</w>
day s/
dam aging</w>
da idze
d4 T</w>
d ]
cyto protective</w>
cyt openia,</w>
crypt ococcal</w>
cross- tolerance</w>
cros sover,</w>
cow s</w>
counsel ing</w>
coumar in</w>
cot inine</w>
contro ll
contrac tion.</w>
contr adic
constric tion,</w>
constitu ents</w>
confoun ders,</w>
conduc ting</w>
computer -
compon ent.</w>
complex es,</w>
complete ly,</w>
compl ain</w>
collo idal</w>
collagen ase</w>
coca ine/
clon ic-tonic</w>
cle f
cle avage</w>
ciprof loxacin,</w>
cin nar
chore iform</w>
chore a.</w>
chlor dec
child 's</w>
character izes</w>
channe l.</w>
ch ose</w>
cephalospor in</w>
cent )</w>
cells/ mm3</w>
caver nous</w>
caver nos
cau tion,</w>
catheter s.</w>
cardiomyo pathy:</w>
cardio -
cardiac ,</w>
carcin ogenesis.</w>
carbo prost</w>
carb idopa
carb ap
calbind in-
caffe ic</w>
c ine
but yl</w>
bronchodi lation</w>
bran ches</w>
br af
blo t
bisphosph onate</w>
birth weight</w>
biomark er</w>
bio avail
bi otrans
bi le.</w>
beta (1)-
benz trop
be red</w>
basel ine),</w>
b.i. d.)</w>
b it
b h</w>
b are</w>
awa iting</w>
avir ,</w>
autoradi ographic</w>
auto regulatory</w>
aut onom
attempt .</w>
atri um.</w>
ate br
at oxin</w>
astro cytic</w>
astro cyt
ast roph
as sign
arti ficially</w>
arterio graphy.</w>
arrhythmi as
arac ter</w>
ar ization</w>
ar ding</w>
ar )</w>
aprot inin</w>
appropri ate.</w>
ap ram</w>
ap point
ap eptide</w>
aorta .</w>
antimicro bi
anticonvuls ants,</w>
antibody -positive</w>
anti- platelet</w>
anti social</w>
anter i
anomal ies.</w>
an z
an osine</w>
an astro
amplitu de.</w>
amin al</w>
am o
am niqu
alpha 2-adrenergic</w>
alkalin ization</w>
alfa- 2a</w>
agon al</w>
aggres siveness</w>
age ).</w>
ag o,</w>
after war
advis able</w>
adrenocortic otropic</w>
aden omas.</w>
ad sorption</w>
actu arial</w>
activ ity:</w>
activ ations</w>
acti ve-
acr yl
achi ev
accumul ation,</w>
accom mod
accid ent</w>
acc es
abuse :</w>
abo ve-
abl ative</w>
aber r
a rec
[3H] spiperone</w>
[ 11
[ 1-
ZD V</w>
Z ol
Z TP</w>
Wilc oxon</w>
W at
Vincrist ine-induced</w>
Ven lafax
Vas cul
V III</w>
Un usual</w>
Top ir
Th io
Ter at
TTP- HUS</w>
TR (-)</w>
TN F
T- positive</w>
T yr
T i
T Q</w>
Sul piride</w>
South west</w>
Ser vice</w>
Scre ening</w>
SE M</w>
SA C</w>
S P-
Reg arding</w>
Re ye</w>
RELEVAN CE:</w>
RE G
R- (+)-
R emission</w>
R a
R M</w>
R CT
R A,</w>
R ).</w>
Qu ality</w>
Propofol- Lip
Progester one</w>
Prob able</w>
Prin z
Phenylpropan olamine</w>
Per formance</w>
Per cutaneous</w>
PO THESIS:</w>
PL C</w>
PF S</w>
PF 4/
PB -treated</w>
PAR P</w>
PA H</w>
P< 0.001),</w>
P- 2</w>
P u
P entam
P em
P S)</w>
P CI</w>
P B.</w>
P :</w>
Ophthal mo
OX C</w>
O me
O ddi</w>
O at
Non hematologic</w>
Netherl ands</w>
Na(+ ),</w>
NS -
NRA0 160</w>
NC r</w>
N- desmethyl
N ot</w>
N orep
N -induced</w>
N (
Mo de
Mg(2 +)</w>
Mg(2 +
Mex ilet
Methyl dopa</w>
Me perid
Man ual</w>
Malign ant</w>
MT EP</w>
MP H</w>
MMP- 2</w>
MI D</w>
Low -
LQT S</w>
LMW H</w>
LCT/ MCT</w>
L- Dopa
L ear
L d
K ir
K O
Ir reversible</w>
Indi a.</w>
Inc id
Imat inib</w>
IL- 6,</w>
IL -17</w>
III/ IV</w>
IF S</w>
I s-
I ll
I Q</w>
I -induced</w>
I (K
Hz ,</w>
Hor ner's</w>
His panic</w>
Hex abri
Haemat ological</w>
HY POTHESIS:</w>
HR P</w>
HCO 3</w>
H er
H ]</w>
H D)</w>
H +</w>
Grou p-
Gol d
GTN -induced</w>
Further more</w>
Fifty- five</w>
F enflur
F UD
F HF</w>
Erec tile</w>
Elev ation</w>
Ei ther</w>
Eff ectiveness</w>
EP S.</w>
ED ,</w>
E w
E ti
E NT</w>
E H
Dyst onia</w>
Diethyl stilbestrol</w>
Dap sone</w>
DR D2</w>
DH T</w>
DH P</w>
DE )</w>
D aun
D CE
D C</w>
D A,</w>
D (2
Cyclospor in</w>
Coca ine-related</w>
Chec k
Character is
Cardi oprotective</w>
Can di
CaCl (2)-
Ca esarean</w>
CYP2C 19</w>
CS F,</w>
CS .</w>
CONCLUSION S</w>
CNS .</w>
CL O
CD 50</w>
CB F)</w>
C- fibers</w>
C yc
C remophor</w>
C am
C V</w>
Bupren orphine</w>
Behavi or</w>
Be zol
Bac lofen
BO O</w>
BH A</w>
B- cell</w>
B S
B R</w>
B CN
B B</w>
Aripi prazole</w>
Ap nea</w>
Anti bodies</w>
Angio graphy</w>
Anaesthe sia</w>
Amil oride</w>
All -
Ak athi
Adequ ate</w>
Acet aminophen
Ac quired</w>
Ac ce
AED s</w>
ACTH -induced</w>
ACTH -
ACE i</w>
A me
A B</w>
>/ =</w>
9 9%</w>
9 5.
9 4
9 1%</w>
80 )</w>
8 8.
8 7)</w>
7- year</w>
7 H
7 79</w>
7 61</w>
7 6,</w>
7 5)</w>
60 %,</w>
6- h</w>
6 th</w>
6 5.
59 3</w>
55 %,</w>
5. 0,</w>
5-hydroxy indoleacetic</w>
5- min</w>
5- mg</w>
5 ]</w>
5 7)</w>
5 5)</w>
5 48</w>
5 40</w>
48 ).</w>
40 /
4. 6%</w>
4- point</w>
4 2-
4 2,</w>
35 %,</w>
3- hydroxy-
3- hydroxy
3- O-
3 K
3 7,</w>
3 2,</w>
28 .</w>
25 00</w>
24 ).</w>
23 5</w>
200 1,</w>
200 0,</w>
20 9</w>
20 %.</w>
2. 0,</w>
2-amino- 7-
2- mercapto
2- deoxyglucose</w>
2 h</w>
2 C
2 13</w>
2 12</w>
198 4</w>
19- year-old</w>
18 7</w>
18 5</w>
18 0
17 3</w>
16 3</w>
15 ;</w>
15 8</w>
15 2</w>
14. 5</w>
11. 2</w>
10-1 5</w>
1. 1%</w>
1- adrenergic</w>
1- 5</w>
1, 500</w>
1, 4-
1 7.5</w>
0.6 6</w>
0.6 5</w>
0.6 3</w>
0.5 7</w>
0.4 6</w>
0.05 .</w>
0.00 6).</w>
0.00 3)</w>
0.0 25</w>
0.0 25).</w>
0. 7,</w>
0. 4,</w>
0. 36</w>
0. 35</w>
0. 31</w>
0. 29</w>
0. 25%</w>
0. 21</w>
0. 2-
/ SM
-1, 4-
-1 2
-1 000</w>
- 2.
)- ATPase</w>
(p< 0.05)</w>
(W B
(Vi agra
(R V)</w>
(R R,</w>
(R -
(QT c)</w>
(PG I
(P K
(P I
(P A)</w>
(P =.0
(N AC)</w>
(M MP
(LDH ),</w>
(IC U)</w>
(HB I
(H M
(H C)</w>
(DX R)</w>
(D VT)</w>
(CR F)</w>
(CM V)</w>
(C GRP)</w>
(BUN )</w>
(AI DS)</w>
(AE s)</w>
(A Q
(8 /
(6 1%)</w>
(6 /
(5- nitro-
(4 7%)</w>
(4 %),</w>
(3 7.
(3 50</w>
(3 2.
(3 1.
(2. 5-
(2. 4</w>
(2 ,</w>
(19 66-
(1. 9</w>
(1. 8</w>
(1 25
(0. 25,</w>
(0. 2-
(0. 1,</w>
( using</w>
( rh
( protocol</w>
( pre
( phase</w>
( not</w>
( level</w>
( alpha</w>
( R</w>
( A</w>
' off'</w>
" on"</w>
zolamide/ timolol</w>
z ero
y ing,</w>
y -</w>
world wide
withdraw ing</w>
w .</w>
w )</w>
vo ice</w>
vis its.</w>
vis it
vis ,</w>
vide o</w>
vi bration</w>
ves ti
vertig o,</w>
ver a</w>
ve rex
verex pression</w>
ve red,</w>
vasodilat ation,</w>
vancom ycin,</w>
valer ate</w>
val idation</w>
val idate</w>
vagotom ized</w>
vacuol ated</w>
use :</w>
urticaria/ angioedema</w>
ure )</w>
urap idil</w>
urac il,</w>
une qu
under score</w>
un suspected</w>
un described</w>
un aware</w>
u d</w>
u -
twice- weekly</w>
tro pic
trimethoprim-sulfamethox azole.</w>
trimethop rim
trimethadi one</w>
trime ster
tricho sis</w>
treatment -induced</w>
treat ed)</w>
treat able</w>
tre s</w>
tre moro
transl ated</w>
transfer rin</w>
transf used</w>
tramad ol.</w>
trac e</w>
tr ast</w>
toxic o
tox oplasmo
tom ography.</w>
tolter odine</w>
tobram ycin.</w>
thromb ocy
thro at</w>
thir teen</w>
thione in</w>
thio guan
thick ened</w>
thi gh</w>
thi amyl
thalam us.</w>
th yl
tetrazol ium</w>
tetr alin</w>
test ),</w>
temperat ures</w>
telmis artan</w>
tech nical</w>
taxan es</w>
tartr ate</w>
tac rine-induced</w>
syst olic,</w>
synth ase,</w>
synchron ized</w>
synaptos omal</w>
synap se</w>
swe at</w>
sw allowing</w>
surfac e.</w>
supra threshold</w>
suppres sed.</w>
support ,</w>
super nat
sup pressor</w>
sup posed</w>
sulfon amide</w>
successful ly.</w>
sub types,</w>
sub side
sub convulsive</w>
su stain</w>
su nit
strate g
stor age</w>
stimul us,</w>
stent ing</w>
st oc
spike- wave</w>
soun d-induced</w>
solitari us</w>
so y
sleep iness</w>
sk ill
six ,</w>
sis -induced</w>
sim vastatin,</w>
sildenaf il,</w>
signal ing.</w>
short- ter
shor test</w>
she ath</w>
ses sions,</w>
ses sion,</w>
seroton in.</w>
seri ously</w>
ser a
sera dish</w>
sep sis,</w>
sem ati
sel f</w>
sel eni
sel ected.</w>
sel ect</w>
sco red.</w>
scaveng ers</w>
scan s.</w>
scal es,</w>
scal e)</w>
samp le,</w>
saliv ation,</w>
salicyl ates</w>
sac ro
sa c</w>
rubell a</w>
rout es.</w>
rota- rod</w>
ropini role</w>
rol idine</w>
rocur onium.</w>
rocur onium,</w>
ro se
ro cortisone</w>
ris t</w>
rib os
rh in
rever sal
revascular ization.</w>
retro viral</w>
responder s,</w>
respon sib
reserp ine-treated</w>
research ers</w>
renin- angiotensin-
remifentan il-based</w>
regener ating</w>
record s,</w>
record ings,</w>
reci procal</w>
rec umb
reat ment</w>
read ings</w>
re appearance</w>
rapid ly.</w>
rap idity</w>
ran ular</w>
ran ol
rac lon
r ural</w>
quar ter</w>
qual ity-
pyrid ine-
pyri methamine</w>
pyri din
pyrazin amide</w>
purpo ses</w>
prud ent</w>
provoc ative</w>
provi ded.</w>
protein )</w>
prote as
prost one</w>
propofol :</w>
prop eptide</w>
proj ect</w>
progester one.</w>
progenit ors</w>
produc t.</w>
pro cycl
pre menopausal</w>
pre junctional</w>
pre ganglionic</w>
post- mortem</w>
post partum
post operatively,</w>
posses sed</w>
por e</w>
polydip sia,</w>
poin ting</w>
po grel
platinum- based</w>
pl u
pl it
pl ates</w>
piperazin -1-
pill s.</w>
pig ment</w>
pi ed</w>
phosphatidyl serine</w>
phosph oc
phosphoc reat
pher ic</w>
phenyto in-induced</w>
phenoxy benz
phenacet in,</w>
phen ol</w>
ph ob
ph ase-
pestic ides</w>
pergol ide.</w>
percent ).</w>
penicill ins</w>
pen is</w>
peg filgrastim</w>
pea k-
particip ant</w>
parallel- group,</w>
pancre atitis.</w>
pancre ati
palpit ations,</w>
pallid otomy</w>
p un
p end
p en</w>
oxaliplat in,</w>
ox ia</w>
overl apping</w>
overex pressing</w>
over sho
ov ary</w>
out ine</w>
ou ts</w>
oter minal</w>
ot es</w>
osteoporo sis.</w>
oscill ation</w>
organ s,</w>
or der.</w>
op es</w>
one- way</w>
on- off</w>
on gest
omime tics</w>
omega )-
oly mer
oligonucle otide</w>
olig uria.</w>
ol der.</w>
ol amine-induced</w>
oid ,</w>
ograph ical</w>
offspr ing,</w>
odi lat
ocyte -
och lear</w>
occu pied</w>
oc utaneous</w>
obes ity.</w>
obac ter</w>
ob long
o protein</w>
o il.</w>
o .)</w>
notice able</w>
normother mic</w>
normal ised</w>
normal -
norethind rone</w>
noradrenal ine.</w>
nor cocaine</w>
non- Hodgkin</w>
nmol/ kg</w>
nio s</w>
nicot ine's</w>
ng/ml ).</w>
new ,</w>
neurotransmis sion,</w>
neurolep tic
neuro sensory</w>
neuro pharmacological</w>
neur al-
nephrocalcin osis.</w>
neon ate.</w>
neocor tical</w>
neocor tex</w>
nefazod one</w>
ne d,</w>
nar ingin</w>
na il</w>
n ame</w>
n M),</w>
n )</w>
myocardi opathy</w>
myo- inositol</w>
my otonia</w>
my ocytes,</w>
mu tis
mu star
msec .</w>
msec ,</w>
morph ology.</w>
mo tion.</w>
mmHg ),</w>
mixt ure.</w>
mis ul
minim al.</w>
microliter )</w>
micrograms. kg-1</w>
microgram/ ml,</w>
microgram s.</w>
microgram s),</w>
micro l/
micro biological</w>
mi pramine</w>
mi metic</w>
mg/m2/ week</w>
mg/m (2)
mg/kg/ d)</w>
mg./ kg.</w>
mg./ kg
methadone- maintained</w>
meth anolic</w>
metalloprotein ases</w>
medi an,</w>
mechan o
mechan ics</w>
mat che
mas ses</w>
mannit ol-induced</w>
malignanc ies,</w>
macro cytic</w>
mOsm /kg</w>
mL/ min,</w>
mGluR s</w>
m ia-induced</w>
m ated</w>
m aps</w>
m V</w>
m L)</w>
lymph oproliferative</w>
lop in
long standing</w>
local ize</w>
loc ations</w>
loc ation,</w>
lo l-induced</w>
liver -
live do</w>
liter ,</w>
lit re
lisinopri l.</w>
ligh tly</w>
lig ated</w>
leukotri ene</w>
leukopen ia.</w>
leu pro
lethal ity,</w>
leg s.</w>
leg s,</w>
lear ning.</w>
le st
lat ter.</w>
lat est</w>
las er-
lact one</w>
l one</w>
l ity</w>
l ingu
l ess,</w>
l ens</w>
l ase</w>
l ability</w>
kg/ min</w>
kg/ day</w>
ket amine-induced</w>
ker ato
ke ys</w>
iso enzymes</w>
ip ec
investig ated,</w>
inver ted</w>
intr aluminal</w>
intest ine,</w>
interleukin -1
inter cal
inter active</w>
inten tion</w>
insul in.</w>
instrum ental</w>
ino ic</w>
influenz ae</w>
ine x
indinavir -associated</w>
indic ations.</w>
inde s
increas es.</w>
incid ents</w>
incid ental</w>
incid ence.</w>
inc h</w>
in consistent</w>
impoten ce,</w>
implic ates</w>
imp ending</w>
immunocyt ochemistry</w>
immuno prophylaxis</w>
immuno assay</w>
ime tic</w>
imag es,</w>
ifen acin</w>
idine di
id- stimulating</w>
ia sis:</w>
i.v .
i ro
hypoten sion
hypokal em
hypo thyroidism.</w>
hypercalci uria.</w>
hyper vitaminosis</w>
hyper uric
hydro lase</w>
hydro las
hydro cortis
hydram nios</w>
hospit als.</w>
hor seradish</w>
homogene ous</w>
homogen ate</w>
ho c</w>
her al
hemo phil
hemi parkinsonian</w>
hematocrit ,</w>
he d
hallucin ation</w>
half- life,</w>
grow th
graph ically</w>
graph ic,</w>
grade ly</w>
gonad otropin</w>
gn aw
glycosamino glyc
gh relin</w>
genu ine</w>
gener ation.</w>
gene sis,</w>
gen der.</w>
gastro enter
gall stones,</w>
g/d l,</w>
g/ day)</w>
full -term</w>
fre e.</w>
fr ucto
fore arm.</w>
foc ally</w>
fo pam</w>
flush ing,</w>
fluor idate</w>
flumazen il,</w>
fl ash
fl a
find ing,</w>
fe el</w>
fast ed</w>
fal se</w>
fail ures</w>
f um
f ra
f issure</w>
extr as
expan sion,</w>
excit ability,</w>
exchang er</w>
ex -
evidence -based</w>
evid ent.</w>
evalu able.</w>
eu tic
eu glycemic</w>
ethyl- beta-carboline-3-
eth nic
estim ated.</w>
erythro der
ergonov ine</w>
ergol ine,</w>
er t</w>
er ine</w>
er :</w>
er -dose</w>
equ ina</w>
epitheli um,</w>
ep ime</w>
ent ine</w>
ent ;</w>
ent -
enlarg ement,</w>
encour age</w>
enabl ed</w>
en ure
en n
en ly</w>
embry otoxicity</w>
embry ol
embran ous</w>
elev ating</w>
electromyo gram</w>
electroencephalo grams</w>
electro shock-induced</w>
ele mental</w>
ele ment</w>
el in</w>
el astic</w>
eigh teen</w>
eh n</w>
ede matous</w>
ed ronic</w>
ear ly,</w>
e dic
e .
dysphag ia</w>
dys functional</w>
dur ation)</w>
drug -treated</w>
drin k</w>
dre am
down regulated</w>
doses )</w>
dose "</w>
dors i</w>
dor sum</w>
don ors.</w>
do x</w>
distor tion</w>
distinc tly</w>
distinc tion</w>
discharge d.</w>
difficul t.</w>
differen t,</w>
differen ce
diff use
diagno ses.</w>
di phosphate</w>
di methyl</w>
di le
di hydrochloride</w>
desi red</w>
derivati ve.</w>
der -
depres ses</w>
deple tions</w>
dep ren
dep olymer
deoxy uridine</w>
delay ed.</w>
defect ,</w>
def ini
decompens ation</w>
decom pression</w>
deci sion-
deaf ness.</w>
de liver</w>
dang ers</w>
dail y),</w>
da ugh
d l-
cys tic
cyclo hept
cycl es;</w>
cy stin
cup s</w>
counterpart s.</w>
control led.</w>
contribut ory</w>
contribut or</w>
contrast- enhanced</w>
contra indications</w>
consul tation</w>
constitu tive</w>
conf ers</w>
concer n.</w>
con temporary</w>
collater als</w>
col i</w>
cochle a</w>
cocaine- ethanol</w>
coca ine;</w>
co-trimox azole</w>
closu re.</w>
clon azepam,</w>
clear -
clear- cut</w>
clear ,</w>
cl aims</w>
circuit ry</w>
ciga ret
cholest asi
chol ed
chi -square</w>
chec k</w>
ch aracter</w>
cer uleus</w>
cer ti
cer iv
cefac lor</w>
ce iling</w>
cav ity.</w>
cas ca
caro ten
cardiomy ocytes.</w>
carcin oma:</w>
carbim azole.</w>
caps ular</w>
cann ulated</w>
can al</w>
calcin osis</w>
calci uria</w>
cal lo
c ation
c DNA</w>
bun garotoxin</w>
bul lous</w>
brush -evoked</w>
brimon idine</w>
bridg e</w>
br y
both ).</w>
bodi es.</w>
blun ting</w>
biosyn the
biopsi es.</w>
bilater ally.</w>
bige min
bicarbon ate,</w>
bethan idine</w>
bethan echol</w>
beta- oxidation</w>
beta- hydroxy
beg un
bec lo
be sides</w>
be am</w>
baro receptors</w>
avir /
aver sion</w>
autoradi ography</w>
autop sy.</w>
autom atic
aur anof
atten tional</w>
attac h
atri a.</w>
ate ).</w>
at tractive</w>
at ing.</w>
at -
asymptom atic,</w>
associ ation,</w>
as cer
as ak
as -
artic le,</w>
arti caine</w>
aris ch</w>
apy ri
appreci ated</w>
appear ance,</w>
app end
aph ere
ap raclon
aor t
antinocicep tion,</w>
antigen .</w>
anticholinerg ics</w>
antiarrhyth mic
anti- tumor</w>
anti- hyperalgesic</w>
anti diabetic</w>
anti cholinesterase</w>
anti amnesic</w>
anthracyclin es,</w>
ano ic</w>
ang er</w>
androgen -independent</w>
analgesic s,</w>
an y
an uria,</w>
an do
ampl ification</w>
amine- associated</w>
am ostat</w>
alpha (2)</w>
all s</w>
alkalo ids</w>
alfentan il,</w>
alf uz
aler tness</w>
aler ted</w>
alcohol ism</w>
alb en
al ;</w>
akine sia.</w>
air ways</w>
air s</w>
agre ed</w>
agranulocyto sis,</w>
after no
aff in
aff ect
adv ances</w>
adriamyc in-
acit retin</w>
acetyl amino
accompan ies</w>
acceler ates</w>
ac in
ac ,</w>
abol ishing</w>
abo ve.</w>
abnormal ity,</w>
abl ation.</w>
ab ine-induced</w>
a uro
a phosphor
a hr</w>
a dis
[ 4,
Y et,</w>
Y ahr</w>
W M</w>
W I</w>
Vascul itis</w>
Valpro ate-induced</w>
V max</w>
V E</w>
V CR
Uni variate</w>
Unex pected</w>
Treat ments</w>
Trans genic</w>
Tr x
Toxic ology</w>
Tim m</w>
Thirty- nine</w>
Th en,</w>
Th ail
Ter but
TUNEL- positive</w>
TR I</w>
TP O</w>
TP MT</w>
T ubular</w>
T ro
T X</w>
T DH
T CP</w>
Sub stitution</w>
Sub acute</w>
Streptozotoc in</w>
Ster oids</w>
Spir onolact
Sixty- seven</w>
Ser ologic</w>
Sc hedul
SW V</w>
SN Ps</w>
SI )</w>
SH )</w>
SG O
SA L</w>
S9 788</w>
S, 3
S ham
S ha
S aline</w>
S a
S Z</w>
S M</w>
Ret inoic</w>
Repe at</w>
Reg ression</w>
Re active</w>
RO C</w>
RN A-
RN 23
RAL H</w>
R outine</w>
R oc
Queti apine</w>
QT L</w>
Q .</w>
Pro j
Pro gram</w>
Por tal</w>
Phenyleph rine-induced</w>
Ph il
Pericardi tis</w>
Per son
Per man
PROCED URE:</w>
PR 3-
PPAR alpha</w>
PON V</w>
PO D</w>
PK C</w>
PG ,</w>
PF4/ heparin</w>
PD TC</w>
PB O</w>
P< 0.05</w>
P reg
P NP</w>
P IP
P 2-
Ox carb
On dan
Oc ca
OP ID
OLT .</w>
OD E</w>
O verexpression</w>
O AT
O A</w>
Nimesul ide</w>
Niger ian</w>
Na prox
NT G-induced</w>
NO- deficient</w>
NI K-
N-acetyl-beta-D- glucosaminidase</w>
N- terminal</w>
N- acetyl</w>
N rf
N P,</w>
N DE
N ),</w>
More over</w>
Modi fication</w>
Mil rinone</w>
Me tron
Mc N-
Mannit ol</w>
Man n-Whitney</w>
MPTP- lesioned</w>
ME S</w>
MB C</w>
MA PK</w>
MA P.</w>
M ain</w>
M H</w>
M ;</w>
Line ar</w>
Lif e</w>
Lear ning</w>
Lamotrig ine</w>
LE ),</w>
L ung</w>
L F</w>
L AM-
L A)</w>
King dom</w>
KG F</w>
K- 2</w>
K ine
K W-
